



(51) International Patent Classification:

*A61K 39/00* (2006.01) *A61P 13/06* (2006.01)  
*A61K 38/00* (2006.01) *C12N 9/16* (2006.01)

(21) International Application Number:

PCT/US2012/039004

(22) International Filing Date:

22 May 2012 (22.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/549,047 19 October 2011 (19.10.2011) US  
61/649,717 21 May 2012 (21.05.2012) US

(71) Applicants (for all designated States except US): **ENO-BIA CANADA LIMITED PARTNERSHIP** [CA/CA]; 2901 Rachel Street East, Suite 23, Montreal, Quebec, H1W 4A4 (CA). **VANDERBIL T UNIVERSITY** [US/US]; 305 Kirkland Hall, Nashville, TN 37240 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CRINE, Philippe** [CA/CA]; 28 Avenue Claude-champagne, Outremont, Quebec, H2V 2X1 (CA). **ELEFTERIOU, Florent** [FR/US]; 4110 Westlawn Drive, Nashville, TN 37209 (US).

(74) Agents: **BIEKER-BRADY, Kristina** et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF

(57) Abstract: The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. Polypeptides having an alkaline phosphatase peptide fused to an Fc domain of an immunoglobulin or a natriuretic peptide fused to an Fc domain of an immunoglobulin can be administered to subjects, e.g., subcutaneously, to treat a neurocutaneous syndromes. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating neurocutaneous syndromes.



## COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF

### 5 CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of priority to U.S. Provisional Application No. 61/549,047, filed October 19, 2011, and U.S. Provisional Application No. 61/649,717, filed May 21, 2012, each of which is hereby incorporated by reference.

### 10 REFERENCE TO A SEQUENCE LISTING

A Sequence Listing is provided in this patent document as a .txt file entitled, "50694\_039WO3\_ST25\_Seq\_Listing.txt," created May 21, 2012 (file size 716 kB). The content of this file is hereby incorporated by reference.

### 15 BACKGROUND OF THE INVENTION

In general, this invention relates to the treatment of various diseases using alkaline phosphatase and/or natriuretic peptide.

Numerous diseases and conditions involve abnormal skeletal function, structure, or growth of bone or cartilage. For some diseases, the etiology of these skeletal manifestations is known, such as in  
20 hypophosphatasia (HPP) and achondroplasia (ACH), but treatment options are limited. In other diseases, the etiology is unknown. For example, neurofibromatosis type I (NF1 or Von Recklinghausen disease) is an autosomal dominant genetic disorder having an incidence of approximately 1 in 3,500 live births. NF1 encodes neurofibromin, a member of the GTPase Activating Protein (GAP) family known to suppress the Ras kinase. Neurofibromin is a specific suppressor of p21-RAS, and mutations in the NF1 gene cause  
25 unsuppressed activation of RAS that lead to abnormal cell growth and differentiation. Accordingly, the clinical features of NF1 include various oncogenic transformations, such as neurocutaneous neurofibromas and optic pathway tumors, and other non-cancer manifestations, such as cognitive defects and skeletal abnormalities. Some of the NF1 skeletal manifestations have high morbidity (e.g., dystrophic scoliosis, long bone bowing, and pseudarthrosis) and unsatisfactory treatment options, which  
30 has been complicated by the fact that the etiology of these manifestations is unclear.

Many skeletal diseases arise from loss of function of one or more proteins. For example, hypophosphatasia (HPP) is a rare, heritable disease caused by one or more loss-of-function mutations in the gene *ALPL*, which encodes tissue-nonspecific alkaline phosphatase (TNALP; a.k.a. liver/bone/kidney type ALP). Alkaline phosphatase deficiency in osteoblasts and chondrocytes impairs skeletal  
35 mineralization, leading to symptoms of varying severity, from rickets or osteomalacia to almost complete absence of bone mineralization *in utero*. However, enzyme replacement therapy with unmodified alkaline phosphatase (e.g., infusion of native alkaline phosphatase) has been largely unsuccessful.

In another example, achondroplasia (ACH) is the most common form of short limb dwarfism in human beings, affecting more than 250,000 individuals worldwide, and is caused by mutations in the gene encoding fibroblast growth factor receptor 3 (FGFR3), which cause gain of FGFR3 function. The severity of the clinical phenotype is related to the capacity of the mutation to overactivate FGFR3 signaling pathways in chondrocytes, such as the MAP-kinase pathway. This pathway can be inhibited by activating the natriuretic peptide receptor B (NPR-B), which produces the second messenger cGMP, and cGMP, in turn, inhibits the MAP-kinase pathway inside the cell. In the cellular environment, the immature and mature forms of C-type natriuretic peptide (CNP), such as CNP53 and CNP22, bind to NPR-B and induce cGMP production in a dose-dependent and similar fashion. Thus, use of CNP or a CNP analog that could activate the NPR-B signaling pathway for the treatment of skeletal dysplasia has been considered. However, a major drawback of the therapeutic use of CNP is its extremely short half-life.

There is thus a need in the art to develop therapeutic molecules and methods for treating diseases having skeletal manifestations, such as neurofibromatosis. In addition, more therapeutic molecules are needed that have an appreciable half-life and/or other favorable pharmacokinetic and therapeutic properties, and these molecules can be used to treat a variety of disorders that would benefit from their underlying mode of action, such as neurofibromatosis, hypophosphatasia, and achondroplasia.

#### SUMMARY OF THE INVENTION

It has surprisingly been discovered that neurofibromatosis, a neurocutaneous syndrome resulting in tumors in the nervous system, results in bone manifestations that arise from accumulation of inorganic pyrophosphate (PP<sub>i</sub>). As alkaline phosphatase-Fc fusion proteins (either with or without a bone-targeting moiety) can reduce PP<sub>i</sub> accumulation, the present invention provides a polypeptide including a soluble alkaline phosphatase (sALP) domain (i.e., an sALP polypeptide), as well as compositions and uses thereof. In addition, bone manifestations in neurofibromatosis may also arise from overactivation of the MAP-kinase pathway, and a natriuretic peptide (NP) or NP analog could be used to inhibit this pathway. Accordingly, the present invention provides a polypeptide including an NP (e.g., a CNP) domain (i.e., an NP polypeptide) and compositions and uses thereof.

Furthermore, the present invention includes a combination of an sALP polypeptide and an NP polypeptide, where these polypeptides can be administered separately or together. This combination would be particularly useful in diseases that would benefit from increased ALP levels (e.g., disorders associated with increased levels of PP<sub>i</sub>, such as neurofibromatosis, or disorders associated with ALP deficiency, such as hypophosphatasia) and/or diseases that would benefit from inactivation of a signaling pathway involving FGFR3 (e.g., disorders associated with overactivation of the MAP-kinase pathway, such as neurofibromatosis or achondroplasia, or disorders associated with overactivation of FGFR3, such as achondroplasia or craniosynostosis or cancer) and/or diseases that would benefit from increased NP levels (e.g., disorders associated with CNP deficiency, such as skeletal dysplasia, or vascular smooth

muscle disorders). The polypeptides of the invention can also be provided in kits, either separately or together.

In a first aspect, the invention features a method of treating a neurocutaneous syndrome in a subject, the method including administering to the subject a therapeutically effective amount of a pharmaceutical composition including: (a) a polypeptide including the structure A-sALP-B; and (b) a pharmaceutically acceptable excipient, where sALP is the extracellular domain of an alkaline phosphatase, A is absent or is an amino acid sequence of at least one amino acid, and B is absent or is an amino acid sequence of at least one amino acid. In some embodiments, the syndrome in the subject is thereby treated.

In some embodiments, the amino acid sequence of the sALP includes or consists of amino acid residues 23-508 of SEQ ID NO: 1215, amino acid residues 18-498 of SEQ ID NO: 1216, amino acid residues 23-508 of SEQ ID NO: 1218, or amino acid residues 18-498 of SEQ ID NO: 1219, or the amino acid sequence of the sALP includes or consists of amino acid residues 23-512 of SEQ ID NO: 1215, amino acid residues 18-502 of SEQ ID NO: 1216, amino acid residues 23-512 of SEQ ID NO: 1218, or amino acid residues 18-502 of SEQ ID NO: 1219. In some embodiments, the amino acid sequence of the sALP includes an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 1205. In some embodiments, the amino acid sequence of the sALP includes or consists of the amino acid sequence of SEQ ID NO: 1205.

In some embodiments, the amino acid sequence of the sALP includes or consists of amino acid residues 1-497, 1-498, 1-499, 1-500, 1-501, 1-502, 1-503, 1-504, 1-505, 1-506, 1-507, 1-508, 1-509, 1-510, 1-511, 1-512, 23-497, 23-498, 23-499, 23-500, 23-501, 23-502, 23-503, 23-504, 23-505, 23-506, 23-507, 23-508, 23-509, 23-510, 23-511, or 23-512 of SEQ ID NO: 1218, where X is any amino acid but is not an amino acid corresponding to a pathogenic mutation at that position of human TNALP, e.g., not an amino acid corresponding to a pathogenic mutation provided in Table 1. In some embodiments, the amino acid sequence of the sALP includes or consists of amino acid residues 18-497, 18-498, 18-499, 18-500, 18-501, 18-502, 18-503, 18-504, 18-505, 18-506, 18-507, 18-508, 18-509, 18-510, 18-511, or 18-512 of SEQ ID NO: 1219, where X is any amino acid but is not an amino acid corresponding to a pathogenic mutation at that position of human TNALP, e.g., not an amino acid corresponding to a pathogenic mutation provided in Table 1.

In some embodiments, the amino acid sequence of the sALP includes an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NOs: 1218 or 1219, where X is any amino acid but is not an amino acid corresponding to a pathogenic mutation at that position of human TNALP, e.g., not an amino acid corresponding to a pathogenic mutation provided in Table 1. In some embodiments, the amino acid sequence of the sALP includes or consists of an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to amino acid residues 23-508 of SEQ ID NO: 1215, amino acid residues 18-498 of SEQ ID NO: 1216, amino acid residues 23-508 of SEQ ID NO: 1218, or amino acid residues 18-498 of SEQ ID NO: 1219, or the amino acid sequence of the sALP

consists of an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to amino acid residues 23-512 of SEQ ID NO: 1215, amino acid residues 18-502 of SEQ ID NO: 1216, amino acid residues 23-512 of SEQ ID NO: 1218, or amino acid residues 18-502 of SEQ ID NO: 1219, where X in SEQ ID NO: 1218 or 1219 is any amino acid but is not an amino acid corresponding to a pathogenic mutation at that position of human TNALP, e.g., not an amino acid corresponding to a pathogenic mutation provided in Table 1.

In some embodiments, A and/or B are absent.

In some embodiments, A and/or B includes a fragment crystallizable region (Fc). In some embodiments, the Fc includes a C<sub>H2</sub> domain, a C<sub>H3</sub> domain, and a hinge region, or the Fc is a constant domain of an immunoglobulin selected from the group consisting of IgG-1, IgG-2, IgG-3, and IgG-4, e.g., IgG-1. In some embodiments, the amino acid sequence of the Fc includes an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 401. In some embodiments, the amino acid sequence of the Fc includes or consists of the amino acid sequence of SEQ ID NO: 401.

In some embodiments, A and/or B includes I<sub>n</sub>, where I represents an aspartic acid or a glutamic acid and n=10 to 16, e.g., n is 10, 11, 12, 13, 14, 15, or 16. In some embodiments, the I<sub>n</sub> is E<sub>10</sub>, E<sub>11</sub>, E<sub>12</sub>, E<sub>13</sub>, E<sub>14</sub>, E<sub>15</sub>, E<sub>16</sub>, D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub>, D<sub>13</sub>, D<sub>14</sub>, D<sub>15</sub>, or D<sub>16</sub>, e.g., E<sub>10</sub> or D<sub>10</sub>.

In some embodiments, A and/or B includes a bone-targeting moiety, e.g., including 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 consecutive acidic residues, e.g., aspartic acid or glutamic acid. In some embodiments, the bone-targeting moiety includes or consists of E<sub>6</sub>, E<sub>7</sub>, E<sub>8</sub>, E<sub>9</sub>, E<sub>10</sub>, E<sub>11</sub>, E<sub>12</sub>, E<sub>13</sub>, E<sub>14</sub>, E<sub>15</sub>, E<sub>16</sub>, D<sub>6</sub>, D<sub>7</sub>, D<sub>8</sub>, D<sub>9</sub>, D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub>, D<sub>13</sub>, D<sub>14</sub>, D<sub>15</sub>, or D<sub>16</sub>, e.g., E<sub>6</sub>, E<sub>10</sub>, D<sub>6</sub>, or D<sub>10</sub>. In some embodiments, the polypeptide does not include a polyaspartic acid or polyglutamic acid region longer than three consecutive aspartic acid or glutamic acid residues, or the polypeptide does not include a polyaspartic acid or polyglutamic acid region longer than two consecutive aspartic acid or glutamic acid residues.

In some embodiments, the polypeptide does not include a bone-targeting moiety.

In some embodiments, the polypeptide includes the structure C-sALP-D-Fc-E or the structure C-Fc-D-sALP-E, where C is absent or is an amino acid sequence of at least one amino acid, D is absent or is an amino acid sequence of at least one amino acid, and E is absent or is an amino acid sequence of at least one amino acid.

In some embodiments, C and/or E are absent. In some embodiments, D is two amino acid residues, e.g., leucine-lysine or aspartic acid-isoleucine. In some embodiments, D is any linker described herein, e.g., the amino acid sequence of any one of SEQ ID NOS: 301-391.

In some embodiments, the polypeptide includes the structure C-sALP-D-Fc-G-I<sub>n</sub>-H or the structure C-Fc-D-sALP-G-I<sub>n</sub>-H, where C is absent or is an amino acid sequence of at least one amino acid, D is absent or is an amino acid sequence of at least one amino acid, G is absent or is an amino acid sequence of at least one amino acid, H is absent or is an amino acid sequence of at least one amino acid, I represents an aspartic acid or a glutamic acid, and n=10 to 16, e.g., n is 10, 11, 12, 13, 14, 15, or 16. In

some embodiments, the  $I_n$  is  $E_{10}$ ,  $E_{11}$ ,  $E_{12}$ ,  $E_{13}$ ,  $E_{14}$ ,  $E_{15}$ ,  $E_{16}$ ,  $D_{10}$ ,  $D_{11}$ ,  $D_{12}$ ,  $D_{13}$ ,  $D_{14}$ ,  $D_{15}$ , or  $D_{16}$ , e.g.,  $E_{10}$  or  $D_{10}$ .

In some embodiments, C and/or H are absent. In some embodiments, G is two amino acid residues, e.g., leucine-lysine or aspartic acid-isoleucine, e.g., aspartic acid-isoleucine. In some  
 5       embodiments, I is an aspartic acid or a glutamic acid and  $n=10$  to 16, e.g.,  $n$  is 10, 11, 12, 13, 14, 15, or 16, e.g., I is aspartic acid and  $n=10$ . In some embodiments, D is two amino acid residues, e.g., leucine-lysine or aspartic acid-isoleucine, e.g., leucine-lysine. In some embodiments, D or G is any linker described herein, e.g., the amino acid sequence of any one of SEQ ID NOs: 301-391.

In some embodiments, the amino acid sequence of the polypeptide includes an amino acid  
 10       sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity of any one of SEQ ID NOs: 1201, 1204, 1220, or 1221, e.g., SEQ ID NO: 1204. In some embodiments, the amino acid sequence of the polypeptide includes or consists of the amino acid sequence of any one of SEQ ID NOs: 1201, 1204, 1220, or 1221, e.g., SEQ ID NO: 1204. In some embodiments, the amino acid sequence of the polypeptide consists of the amino acid sequence of SEQ ID NO: 1204.

In a second aspect, the invention features a method of treating a neurocutaneous syndrome in a subject, the method including administering to the subject a therapeutically effective amount of a pharmaceutical composition including: (a) a polypeptide including the structure V-NP-W; and (b) a pharmaceutically acceptable excipient, where NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), V is absent or is an amino acid sequence of at least one amino acid, and W  
 20       is absent or is an amino acid sequence of at least one amino acid. In some embodiments, the syndrome in the subject is thereby treated.

In some embodiments, the NP includes the structure: [N-terminal extension]-[short segment]-[ring domain]-[C-terminal extension], where the ring domain includes the amino acid sequence of SEQ ID NO: 6, amino acid residues 11-27 of SEQ ID NO: 30, or SEQ ID NO: 95, and each of the N-terminal  
 25       extension, short segment, and C-terminal extension is, independently, absent or is an amino acid sequence of at least one amino acid. In some embodiments, the ring domain includes amino acid residues 6-22 of SEQ ID NO: 126. In some embodiments, the amino acid at position 17 of SEQ ID NO: 126 is Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, Asp, Gly, Ala, Ser, Val, Trp, Asn, Gln, His, or Lys, e.g., Phe, Leu, Ile, Thr, Val, Ala, Ser, Glu, Arg, Tyr, Cys, Pro, or Asp, e.g., Phe, Leu, Ile, Thr, Val, Ala, or Ser, e.g., Phe or  
 30       Leu, e.g., Phe, e.g., Leu. In some embodiments, the ring domain includes the amino acid sequence of SEQ ID NO: 12. In some embodiments, the short segment and the ring domain together include the amino acid sequence of any one of SEQ ID NOs: 4, 13-30, 119-122, 126, or 156-161, e.g., SEQ ID NOs: 4 or 13-30. In some embodiments, the amino acid sequence of the short segment includes or consists of amino acid residues 1-5, 2-5, 3-5, 4-5, or 5, e.g., consists of amino acid residues 1-5, of SEQ ID NO: 4;  
 35       amino acid residues 1-10 of SEQ ID NO: 17; amino acid residues 1-5 of SEQ ID NO: 19; amino acid residues 1-3 of SEQ ID NO: 20; amino acid residues 1-5 of SEQ ID NO: 21; or amino acid residues 1-6 of SEQ ID NO: 29. In some embodiments, the amino acid sequence of the short segment and the ring

domain together includes or consists of the amino acid sequence of SEQ ID NO: 4. In some embodiments, the amino acid sequence of the short segment and the ring domain together includes or consists of the amino acid sequence of any one of SEQ ID NOs: 119-122, 126, or 156-161 (e.g., where X in SEQ ID NO: 126 is Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, Asp, Gly, Ala, Ser, Val, Trp, Asn, Gln, His, or Lys, e.g., Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, or Asp, e.g., Phe, Leu, Ile, Thr, Val, Ala, or Ser, e.g., Phe or Leu, e.g., Phe, e.g., Leu).

In some embodiments, the amino acid sequence of the N-terminal extension includes amino acid residues 1-31 or 17-31 of SEQ ID NO: 11. In some embodiments, the amino acid sequence of the N-terminal extension includes amino acid residues 17-31 of SEQ ID NO: 11. In some embodiments, the amino acid sequence of the N-terminal extension includes KGANKK (SEQ ID NO: 314) or KGANQK (SEQ ID NO: 315). In some embodiments, the N-terminal extension, short segment, and ring domain together include the amino acid sequence of SEQ ID NO: 11. In some embodiments, the C-terminal extension includes the amino acid sequence of SEQ ID NOs: 117 or 118 or includes amino acid residues 23-37 selected from any one of SEQ ID NOs: 101-116. In some embodiments, the amino acid sequence of the NP consists of SEQ ID NOs: 4 or 11, or the amino acid sequence of any one of SEQ ID NOs: 31-94, or a fragment thereof including at least a ring domain, or the amino acid sequence of any one of SEQ ID NOs: 13-29, 100-116, 119-125, 127-233, or 1001-1155.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Phe.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Leu.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Ile.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Thr.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Glu.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Arg.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Tyr.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Cys.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Pro.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Asp.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Gly.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Ala.

5 In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Ser.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Val.

10 In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Trp.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Asn.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Gln.

15 In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be His.

In any of the aspects described herein, the amino acid sequence of the NP may include amino acids 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 may be Lys.

In some embodiments, V and/or W are absent.

20 In some embodiments, V and/or W includes a fragment crystallizable region (Fc). In some embodiments, the Fc includes a C<sub>H2</sub> domain, a C<sub>H3</sub> domain, and a hinge region, or the Fc is a constant domain of an immunoglobulin selected from the group consisting of IgG-1, IgG-2, IgG-3, and IgG-4, e.g., IgG-1. In some embodiments, the amino acid sequence of the Fc includes an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 401. In some  
25 embodiments, the amino acid sequence of the Fc includes or consists of the amino acid sequence of SEQ ID NO: 401.

In some embodiments, V and/or W includes a glycine-rich region.

In some embodiments, the amino acid sequence of V or W consists of one or more glycines and one or more serines. In some embodiments, the amino acid sequence of V or W includes  
30 [(Gly)<sub>m</sub>(Ser)]<sub>n</sub>(Gly)<sub>p</sub> or (Gly)<sub>p</sub>[(Ser)(Gly)<sub>m</sub>]<sub>n</sub>, where each of m, n, and p is, independently, between 0 and 20. In some embodiments, m is between 1 and 6; n is between 1 and 10; and p is between 0 and 4, e.g., m is 4 and n is 1-6. In some embodiments, combinations of m, n, and p are selected from a single row of Table 2, or the amino acid sequence of V or W includes the amino acid sequence of any one of SEQ ID  
35 NOs: 301-391.

In some embodiments, V and/or W does not include a bone-targeting moiety.

In some embodiments, V and/or W includes a bone-targeting moiety, e.g., including 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 consecutive acidic residues, e.g., aspartic acid or glutamic acid. In some

embodiments, the bone-targeting moiety includes or consists of E<sub>6</sub>, E<sub>7</sub>, E<sub>8</sub>, E<sub>9</sub>, E<sub>10</sub>, E<sub>11</sub>, E<sub>12</sub>, E<sub>13</sub>, E<sub>14</sub>, E<sub>15</sub>, E<sub>16</sub>, D<sub>6</sub>, D<sub>7</sub>, D<sub>8</sub>, D<sub>9</sub>, D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub>, D<sub>13</sub>, D<sub>14</sub>, D<sub>15</sub>, or D<sub>16</sub>, e.g., E<sub>6</sub>, E<sub>10</sub>, D<sub>6</sub>, or D<sub>10</sub>.

In some embodiments, V and/or W includes a cathepsin (e.g., cathepsin K) cleavage sequence. In some embodiments, the cathepsin cleavage sequence is HGPQG (SEQ ID NO: 374) or HKLRG (SEQ ID NO: 375).

In some embodiments, the polypeptide includes the structure V-NP-W, where NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), each of V and W is, independently, absent or is an amino acid sequence of at least one amino acid, and the NP includes the amino acid sequence of any one of SEQ ID NOs: 17-29, 31-40, 42-94, 101-116, 119-122, 128-161, or 163-233, or V or W includes the amino acid sequence of any one of SEQ ID NOs: 304-313, 322-333, or 337-391.

In some embodiments, the polypeptide includes the structure V-NP or NP-W, where NP is the natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), and each of V and W includes, independently, the amino acid sequence of any one of SEQ ID NOs: 304-313, 322-333, or 337-391.

In some embodiments, the polypeptide includes the structure X-Fc-Y-NP-Z or the structure X-NP-Y-Fc-Z, where NP is the natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B) (e.g., any NP described herein), and each of X, Y, and Z is, independently, absent or is an amino acid sequence of at least one amino acid. In some embodiments, Y includes a glycine-rich region. In some embodiments, the amino acid sequence of Y consists of one or more glycines and one or more serines. In some embodiments, the amino acid sequence of Y includes [(Gly)<sub>m</sub>(Ser)]<sub>n</sub>(Gly)<sub>p</sub> or (Gly)<sub>p</sub>[(Ser)(Gly)<sub>m</sub>]<sub>n</sub>, where each of m, n, and p is, independently, between 0 and 20. In some embodiments, m is between 1 and 6; n is between 1 and 10; and p is between 0 and 4, e.g., m is 4 and n is 1-6. In some embodiments, combinations of m, n, and p are selected from a single row of Table 2, or the amino acid sequence of Y includes the amino acid sequence of any one of SEQ ID NOs: 301-389. In some embodiments, the amino acid sequence of Y consists of [(Gly)<sub>m</sub>(Ser)]<sub>n</sub>(Gly)<sub>p</sub> or (Gly)<sub>p</sub>[(Ser)(Gly)<sub>m</sub>]<sub>n</sub>, wherein combinations of m, n, and p are selected from a single row of Table 2, or the amino acid sequence of Y consists of the amino acid sequence of any one of SEQ ID NOs: 301-389. In some embodiments, X is absent, Z is absent, or X and Z are both absent. In some embodiments, X, Y, or Z includes a bone-targeting moiety, e.g., including 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 consecutive acidic residues, e.g., aspartic acid or glutamic acid. In some embodiments, the bone-targeting moiety includes or consists of E<sub>6</sub>, E<sub>7</sub>, E<sub>8</sub>, E<sub>9</sub>, E<sub>10</sub>, E<sub>11</sub>, E<sub>12</sub>, E<sub>13</sub>, E<sub>14</sub>, E<sub>15</sub>, E<sub>16</sub>, D<sub>6</sub>, D<sub>7</sub>, D<sub>8</sub>, D<sub>9</sub>, D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub>, D<sub>13</sub>, D<sub>14</sub>, D<sub>15</sub>, or D<sub>16</sub>, e.g., E<sub>6</sub>, E<sub>10</sub>, D<sub>6</sub>, or D<sub>10</sub>.

In some embodiments, X, Y, or Z includes a cathepsin (e.g., cathepsin K) cleavage sequence. In some embodiments, the cathepsin cleavage sequence includes or consists of HGPQG (SEQ ID NO: 374) or HKLRG (SEQ ID NO: 375).

In some embodiments, the amino acid of the polypeptide includes or consists of the amino acid sequence of any one of SEQ ID NOs: 501-608, e.g., SEQ ID NOs: 502, 504, 506, 512, 514, 516, 530, 560, 562, 564, 572, 574, 576, 584, 586, 588, 596, 598, 600, or 608, e.g., SEQ ID NOs: 504, 512, 530,

554, 572, or 578, e.g., SEQ ID NO: 512. In some embodiments, the amino acid of the polypeptide includes a bone-targeting moiety, e.g., E<sub>6</sub>, E<sub>7</sub>, E<sub>8</sub>, E<sub>9</sub>, E<sub>10</sub>, E<sub>11</sub>, E<sub>12</sub>, E<sub>13</sub>, E<sub>14</sub>, E<sub>15</sub>, E<sub>16</sub>, D<sub>6</sub>, D<sub>7</sub>, D<sub>8</sub>, D<sub>9</sub>, D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub>, D<sub>13</sub>, D<sub>14</sub>, D<sub>15</sub>, or D<sub>16</sub>, e.g., E<sub>6</sub>, E<sub>10</sub>, D<sub>6</sub>, or D<sub>10</sub>.

In some embodiments, the amino acid sequence of the polypeptide includes an amino acid  
 5 sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to any one of SEQ ID NOs: 504, 512, 530, 554, 572, or 578, e.g., SEQ ID NOs: 504, 512, 530, or 572, e.g., SEQ ID NO: 512. In some embodiments, the amino acid sequence of the polypeptide includes or consists of the amino acid sequence of any one of SEQ ID NOs: 504, 512, 530, 554, 572, or 578, e.g., SEQ ID NOs: 504, 512, 530, or 572, e.g., SEQ ID NO: 512. In some embodiments, the amino acid sequence of the polypeptide  
 10 consists of the amino acid sequence of SEQ ID NOs: 504, 512, 530, or 572, e.g., SEQ ID NO: 512.

In some embodiments, the polypeptide includes the structure X-Fc-Y-NP-Z or the structure X-NP-Y-Fc-Z, wherein NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), and wherein either: (i) NP includes amino acids 6-22 of SEQ ID NO: 126, wherein the amino acid at position 17 is not Met; and each of X, Y, and Z is, independently, absent or is an amino acid sequence of  
 15 at least one amino acid; or (ii) each of X and Z is, independently, absent or is an amino acid sequence of at least one amino acid; and the amino acid sequence of Y includes [(Gly)<sub>4</sub>(Ser)]<sub>n</sub>(Gly)<sub>p</sub> or (Gly)<sub>p</sub>[(Ser)(Gly)<sub>4</sub>]<sub>n</sub>, wherein n is between 1 and 10 and p is between 0 and 4 or wherein combinations of m, n, and p are selected from a single row of Table 2, or wherein the amino acid sequence of Y includes the amino acid sequence of any one of SEQ ID NOs: 304-313, 322-333, or 337-391.

20 In some embodiments, the polypeptide includes the structure X-Fc-Y-NP-Z.

In some embodiments, (i) NP includes amino acids 6-22 of SEQ ID NO: 126, wherein the amino acid at position 17 is not Met; and each of X, Y, and Z is, independently, absent or is an amino acid sequence of at least one amino acid. In some embodiments, the amino acid at position 17 of SEQ ID NO: 126 is Phe, Leu, Ile, Thr, Val, Ala, or Ser. In some embodiments, the amino acid at position 17 of SEQ  
 25 ID NO: 126 is Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, Asp, Gly, Ala, Ser, Val, Trp, Asn, Gln, His, or Lys, e.g., Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, or Asp, e.g., Phe or Leu, e.g., Phe, e.g., Leu. In some embodiments, the NP includes the structure: [N-terminal extension]-[short segment]-[ring domain]-[C-terminal extension], wherein said ring domain comprises amino acids 6-22 of SEQ ID NO: 126, wherein the amino acid at position 17 is not Met, and each of said N-terminal extension, short segment,  
 30 and C-terminal extension is, independently, absent or is an amino acid sequence of at least one amino acid. In some embodiments, the amino acid sequence of said NP includes or consists of the amino acid sequence of any one of SEQ ID NOs: 119-125 or 156-220, wherein position 17 relative to SEQ ID NO: 126 is not Met, or the amino acid sequence of any one of SEQ ID NOs: 221-233.

In some embodiments, (ii) each of X and Z is, independently, absent or is an amino acid sequence  
 35 of at least one amino acid; and the amino acid sequence of Y comprises [(Gly)<sub>4</sub>(Ser)]<sub>n</sub>(Gly)<sub>p</sub> or (Gly)<sub>p</sub>[(Ser)(Gly)<sub>4</sub>]<sub>n</sub>, wherein n is between 1 and 10 and p is between 0 and 4, or wherein the amino acid sequence of Y comprises the amino acid sequence of any one of SEQ ID NOs: 304-313, 322-333, or 337-

391. In some embodiments, the NP includes the structure: [N-terminal extension]-[short segment]-[ring domain]-[C-terminal extension], wherein the ring domain includes the amino acid sequence of SEQ ID NO: 6, amino acids 11-27 of SEQ ID NO: 30, or SEQ ID NO: 95, and each of the N-terminal extension, short segment, and C-terminal extension is, independently, absent or is an amino acid sequence of at least one amino acid. In some embodiments, the ring domain includes amino acids 6-22 of SEQ ID NO: 126. In some embodiments, the amino acid at position 17 of SEQ ID NO: 126 is Phe, Leu, Ile, Thr, Val, Ala, or Ser. In some embodiments, the amino acid at position 17 of SEQ ID NO: 126 is Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, Asp, Gly, Ala, Ser, Val, Trp, Asn, Gln, His, or Lys, e.g., Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, or Asp, e.g., Phe or Leu, e.g., Phe, e.g., Leu. In some embodiments, the ring domain includes the amino acid sequence of SEQ ID NO: 12. In some embodiments, the short segment and the ring domain together include the amino acid sequence of any one of SEQ ID NOs: 4 or 13-30. In some embodiments, the amino acid sequence of the short segment and the ring domain together consists of the amino acid sequence of SEQ ID NO: 4. In some embodiments, the amino acid sequence of the short segment and the ring domain together consists of the amino acid sequence of any one of SEQ ID NOs: 119-122, 126, or 156-161 (e.g., where X in SEQ ID NO: 126 is Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, Asp, Gly, Ala, Ser, Val, Trp, Asn, Gln, His, or Lys, e.g., Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, or Asp, e.g., Phe or Leu, e.g., Phe, e.g., Leu). In some embodiments, the N-terminal extension, short segment, and ring domain together include the amino acid sequence of SEQ ID NO: 11. In some embodiments, the amino acid sequence of the NP consists of SEQ ID NO: 4. In some embodiments, the amino acid sequence of the NP consists of SEQ ID NO: 11. In some embodiments, the amino acid sequence of the NP consists of the amino acid sequence of any one of SEQ ID NOs: 31-94, or a fragment thereof including at least a ring domain. In some embodiments, the amino acid sequence of the NP includes or consists of the amino acid sequence of any one of SEQ ID NOs: 13-29, 100-116, 119-125, 127-233, or 1001-1155.

In some embodiments, the amino acid sequence of the short segment consists of amino acids 1-5 of SEQ ID NO: 4. In some embodiments, the amino acid sequence of the short segment consists of amino acids 1-5, 2-5, 3-5, 4-5, or 5 of SEQ ID NO: 4, amino acids 1-10 of SEQ ID NO: 17, amino acids 1-5 of SEQ ID NO: 19, amino acids 1-3 of SEQ ID NO: 20, amino acids 1-5 of SEQ ID NO: 21, or amino acids 1-6 of SEQ ID NO: 29. In some embodiments, the amino acid sequence of the N-terminal extension includes amino acids 1-31 of SEQ ID NO: 11. In some embodiments, the amino acid sequence of the N-terminal extension includes amino acids 17-31 of SEQ ID NO: 11. In some embodiments, the amino acid sequence of the N-terminal extension includes KGANKK (SEQ ID NO: 314) or KGANQK (SEQ ID NO: 315). In some embodiments, the C-terminal extension includes the amino acid sequence of SEQ ID NO: 118, SEQ ID NO: 117, or amino acids 23-37 selected from any one of SEQ ID NOs: 101-116.

In some embodiments, the NP is selective for NPR-B over NPR-A, wherein the  $EC_{50(NPR-B)}/EC_{50(NPR-A)}$  ratio for the NP, as determined in an *in vivo* pharmacokinetic assay, is at least 30.

In some embodiments, the Fc includes a C<sub>H2</sub> domain, a C<sub>H3</sub> domain, and a hinge region. In some embodiments, the Fc is a constant domain of an immunoglobulin selected from the group consisting of IgG-1, IgG-2, IgG-3, IgG-3 and IgG-4. In some embodiments, the Fc includes the amino acid sequence of SEQ ID NO: 401. In some embodiments, the immunoglobulin is IgG-1. In some embodiments, the amino acid sequence of the Fc includes an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 401, or includes or consists of the amino acid sequence of SEQ ID NO: 401.

In some embodiments, Y includes a glycine-rich region, or the amino acid sequence of Y consists of one or more glycines and one or more serines. For example, the amino acid sequence of Y may include [(Gly)<sub>m</sub>(Ser)]<sub>n</sub>(Gly)<sub>p</sub> or (Gly)<sub>p</sub>[(Ser)(Gly)<sub>m</sub>]<sub>n</sub>, wherein each of m, n, and p is, independently, between 0 and 20. In some embodiments, m is 0-20 (e.g., m is 3-6, 3-7, 3-8, 3-9, 3-10, 3-11, 3-12, 3-14, 3-15, 3-16, 3-17, 3-18, 3-19, 3-20, 4-6, 4-7, 4-8, 4-9, 4-10, 4-11, 4-12, 4-14, 4-15, 4-16, 4-17, 4-18, 4-19, 4-20, 5-6, 5-7, 5-8, 5-9, 5-10, 5-11, 5-12, 5-14, 5-15, 5-16, 5-17, 5-18, 5-19, 5-20, 6-7, 6-8, 6-9, 6-10, 6-11, 6-12, 6-14, 6-15, 6-16, 6-17, 6-18, 6-19, 6-20, 7-8, 7-9, 7-10, 7-11, 7-12, 7-14, 7-15, 7-16, 7-17, 7-18, 7-19, 7-20, 8-9, 8-10, 8-11, 8-12, 8-14, 8-15, 8-16, 8-17, 8-18, 8-19, 8-20, 9-10, 9-11, 9-12, 9-14, 9-15, 9-16, 9-17, 9-18, 9-19, 9-20, 10-11, 10-12, 10-14, 10-15, 10-16, 10-17, 10-18, 10-19, or 10-20). In some embodiments, m is 4 and n is 1-6. In some embodiments, combinations of m, n, and p are selected from a single row of Table 2, or the amino acid sequence of Y includes the amino acid sequence of any one of SEQ ID NOs: 304-313, 322-333, or 337-391. In some embodiments, the amino acid sequence of Y consists of [(Gly)<sub>m</sub>(Ser)]<sub>n</sub>(Gly)<sub>p</sub> or (Gly)<sub>p</sub>[(Ser)(Gly)<sub>m</sub>]<sub>n</sub>, wherein combinations of m, n, and p are selected from a single row of Table 2, or the amino acid sequence of Y consists of the amino acid sequence of any one of SEQ ID NOs: 304-313, 322-333, or 337-391.

In some embodiments, X is absent, Z is absent, or X and Z are both absent.

In some embodiments, X, Y, or Z includes a bone-targeting moiety, e.g., including 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 consecutive acidic residues, e.g., aspartic acid or glutamic acid. In some embodiments, the bone-targeting moiety includes or consists of E<sub>6</sub>, E<sub>7</sub>, E<sub>8</sub>, E<sub>9</sub>, E<sub>10</sub>, E<sub>11</sub>, E<sub>12</sub>, E<sub>13</sub>, E<sub>14</sub>, E<sub>15</sub>, E<sub>16</sub>, D<sub>6</sub>, D<sub>7</sub>, D<sub>8</sub>, D<sub>9</sub>, D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub>, D<sub>13</sub>, D<sub>14</sub>, D<sub>15</sub>, or D<sub>16</sub>, e.g., E<sub>6</sub>, E<sub>10</sub>, D<sub>6</sub>, or D<sub>10</sub>.

In some embodiments, X, Y, or Z includes a cathepsin (e.g., cathepsin K) cleavage sequence. In some embodiments, the cathepsin cleavage sequence includes or consists of HGPQG (SEQ ID NO: 374) or HKLRG (SEQ ID NO: 375).

In some embodiments, the polypeptide includes or consists of the amino acid sequence of any one of SEQ ID NOs: 501-608, e.g., SEQ ID NOs: 502, 504, 506, 512, 514, 516, 530, 560, 562, 564, 572, 574, 576, 584, 586, 588, 596, 598, 600, or 608. In some embodiments, the polypeptide includes a bone-targeting moiety, e.g., E<sub>6</sub>, E<sub>7</sub>, E<sub>8</sub>, E<sub>9</sub>, E<sub>10</sub>, E<sub>11</sub>, E<sub>12</sub>, E<sub>13</sub>, E<sub>14</sub>, E<sub>15</sub>, E<sub>16</sub>, D<sub>6</sub>, D<sub>7</sub>, D<sub>8</sub>, D<sub>9</sub>, D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub>, D<sub>13</sub>, D<sub>14</sub>, D<sub>15</sub>, or D<sub>16</sub>, e.g., E<sub>6</sub>, E<sub>10</sub>, D<sub>6</sub>, or D<sub>10</sub>.

In some embodiments, the polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 504.

In some embodiments, the polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 512.

In some embodiments, the polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 530.

5 In some embodiments, the polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 554.

In some embodiments, the polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 572.

10 In some embodiments, the polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 578.

In some embodiments, the polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 560.

In some embodiments, the polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 566.

15 In some embodiments, the polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 538 (e.g., where X in SEQ ID NO: 538 can be any amino acid, e.g., Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, Asp, Gly, Ala, Ser, Val, Trp, Asn, Gln, His, or Lys, e.g., Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, or Asp, e.g., Phe or Leu, e.g., Phe, e.g., Leu).

In some embodiments, the polypeptide includes the structure V-NP.

20 In some embodiments, any of the NPs or polypeptides described herein may be used in conjunction with the method (e.g., NPs or polypeptides described in any of the aspects described herein). In some embodiments, the amino acid sequence of V or W includes  $[(\text{Gly})_m(\text{Ser})]_n(\text{Gly})_p$  or  $(\text{Gly})_p[(\text{Ser})(\text{Gly})_m]_n$ , wherein each of m, n, and p is, independently, between 0 and 20. In some embodiments, m is 4 and n is 1-6. In some embodiments, V is absent, W is absent, or V and W are both  
25 absent. In some embodiments, V and/or W includes a bone-targeting moiety, e.g., E<sub>6</sub>, E<sub>7</sub>, E<sub>8</sub>, E<sub>9</sub>, E<sub>10</sub>, E<sub>11</sub>, E<sub>12</sub>, E<sub>13</sub>, E<sub>14</sub>, E<sub>15</sub>, E<sub>16</sub>, D<sub>6</sub>, D<sub>7</sub>, D<sub>8</sub>, D<sub>9</sub>, D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub>, D<sub>13</sub>, D<sub>14</sub>, D<sub>15</sub>, or D<sub>16</sub>, e.g., E<sub>6</sub>, E<sub>10</sub>, D<sub>6</sub>, or D<sub>10</sub>. In some embodiments, V and/or W includes a cathepsin (e.g., cathepsin K) cleavage sequence, e.g., HGPQG (SEQ ID NO: 374) or HKLRG (SEQ ID NO: 375).

30 In some embodiments of any of the aspects described herein, the polypeptide of the invention, e.g., the sALP polypeptide and/or the NP polypeptide, is in dimeric form. In some embodiments, the polypeptide is glycosylated or pegylated.

In some embodiments of any of the aspects described herein, the pharmaceutical composition is administered in a dosage between about 0.2 mg/kg to about 20 mg/kg of the polypeptide of the invention, e.g., the sALP polypeptide and/or the NP polypeptide, e.g., the sALP polypeptide. In some embodiments,  
35 the pharmaceutical composition is administered to the subject in a dosage between about 0.2 mg/kg to about 20 mg/kg once, twice, three times, or four times daily. The dosage may be between, e.g., about 0.5 mg/kg to about 10 mg/kg, e.g., about 1 mg/kg to about 5 mg/kg, once, twice, three times, or four times

daily. In some embodiments, the dosage is about 1 mg/kg, about 2 mg/kg, or about 3 mg/kg once, twice, or three times daily. In some embodiments, the pharmaceutical composition is administered to the subject in a dosage between about 0.2 mg/kg to about 20 mg/kg once, twice, three times, or four times weekly. The dosage may be between, e.g., about 0.5 mg/kg to about 10 mg/kg, e.g., about 1 mg/kg to  
5 about 5 mg/kg, once, twice, three times, or four times weekly. In some embodiments, the dosage is about 1 mg/kg, about 2 mg/kg, or about 3 mg/kg once, twice, or three times weekly.

In some embodiments of any of the aspects described herein, the pharmaceutical composition is administered in a dosage between about 0.5 mg/kg to about 500 mg/kg of the polypeptide of the invention, e.g., the sALP polypeptide and/or the NP polypeptide, e.g., the NP polypeptide. In some  
10 embodiments, the pharmaceutical composition is administered to the subject in a dosage between about 0.5 mg/kg to about 500 mg/kg once, twice, three times, or four times daily. The dosage may be between, e.g., about 5 mg/kg to about 200 mg/kg, e.g., about 10 mg/kg to about 100 mg/kg, once, twice, three times, or four times daily. In some embodiments, the dosage is about 10 mg/kg or about 100 mg/kg twice daily. In some embodiments, the pharmaceutical composition is administered to the subject in a dosage  
15 between about 0.5 mg/kg to about 500 mg/kg once, twice, three times, or four times weekly. The dosage may be between, e.g., about 5 mg/kg to about 200 mg/kg, e.g., about 10 mg/kg to about 100 mg/kg, e.g., about 20 mg/kg to about 40 mg/kg, once, twice, three times, or four times weekly. In some embodiments, the dosage is about 10 mg/kg, about 30 mg/kg, or about 100 mg/kg, once, twice, or three times weekly.

In some embodiments of any of the aspects described herein, the pharmaceutical composition is administered in a dosage between about 10 µg/kg to about 1,000 µg/kg of the polypeptide of the invention, e.g., the sALP polypeptide and/or the NP polypeptide, e.g., the NP polypeptide. In some  
20 embodiments, the pharmaceutical composition is administered to the subject in a dosage between about 10 µg/kg to about 1,000 µg/kg once, twice, three times, or four times weekly. The dosage may be between, e.g., about 20 µg/kg to about 800 µg/kg, e.g., about 30 µg/kg to about 600 µg/kg, e.g., about 50 µg/kg to about 500 µg/kg, e.g., about 100 µg/kg to about 400 µg/kg, e.g., about 200 µg/kg to about 300  
25 µg/kg, once, twice, three times, or four times weekly. In some embodiments, the dosage is about 30 µg/kg, about 100 µg/kg, about 300 µg/kg, or about 500 µg/kg, once, twice, or three times weekly.

In some embodiments of any of the aspects described herein, the pharmaceutical composition is administered subcutaneously. In some embodiments, the pharmaceutical composition is administered one  
30 time, two times, or three times per week.

In a third aspect, the invention features a composition including a first polypeptide and a second polypeptide, where a) the first polypeptide includes the structure A-sALP-B, where i) sALP is the extracellular domain of an alkaline phosphatase, ii) A is absent or is an amino acid sequence of at least one amino acid, and iii) B is absent or is an amino acid sequence of at least one amino acid; and b) the  
35 second polypeptide includes the structure V-NP-W, where i) NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), ii) V is absent or is an amino acid sequence of at least one amino acid, and iii) W is absent or is an amino acid sequence of at least one amino acid.

In some embodiments, the first polypeptide is any sALP polypeptide described herein, e.g., as described for the first aspect. In some embodiments, the amino acid sequence of the first polypeptide includes an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity of any one of SEQ ID NOs: 1201, 1204, 1220, or 1221, e.g., SEQ ID NO: 1204. In some embodiments, the amino acid sequence of the first polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 1204.

In some embodiments, the second polypeptide is any NP polypeptide described herein, e.g., as described for the second aspect. In some embodiments, the amino acid sequence of the second polypeptide includes an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to any one of SEQ ID NOs: 504, 512, 530, 554, 572, or 578, e.g., SEQ ID NO: 512. In some embodiments, the amino acid sequence of the second polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 512.

In some embodiments, the amino acid sequence of the first polypeptide includes or consists of the amino acid sequence of SEQ ID NOs: 1204 or 1221, and the amino acid sequence of the second polypeptide includes or consists of the amino acid sequence of SEQ ID NOs: 504, 512, 530, or 572.

In some embodiments, the first polypeptide and/or the second polypeptide are in dimeric form. In some embodiments, the first polypeptide and/or the second polypeptide are glycosylated or pegylated.

In some embodiments, the composition is a pharmaceutical composition including a pharmaceutically acceptable excipient, e.g., saline. In some embodiments, the composition is lyophilized.

In some embodiments, the first polypeptide is present in a dosage between about 0.2 mg/kg to about 20 mg/kg and the second polypeptide is present in a dosage between about 0.5 mg/kg to about 500 mg/kg. In some embodiments, the first polypeptide is present in a dosage between about 0.2 mg/kg to about 20 mg/kg, e.g., about 0.5 mg/kg to about 10 mg/kg, e.g., about 1 mg/kg to about 5 mg/kg, for once daily, twice daily, three times daily, four times daily, once weekly, twice weekly, three times weekly, or four times weekly administration, e.g., about 1 mg/kg, about 2 mg/kg, or about 3 mg/kg for once daily, twice daily, four times daily, once weekly, twice weekly, or three times weekly administration; and the second polypeptide is present in a dosage between about 0.5 mg/kg to about 500 mg/kg, e.g., about 5 mg/kg to about 200 mg/kg, e.g., about 10 mg/kg to about 100 mg/kg, e.g., about 20 mg/kg to about 40 mg/kg, for once daily, twice daily, three times daily, four times daily, once weekly, twice weekly, three times weekly, or four times weekly administration, e.g., about 10 mg/kg, about 30 mg/kg, or about 100 mg/kg, for once daily, twice daily, three times daily, once weekly, twice weekly, or three times weekly administration.

In some embodiments, the amino acid sequence of the first polypeptide includes the amino acid sequence of SEQ ID NO: 1204 and the amino acid sequence of the second polypeptide includes the amino acid sequence of SEQ ID NO: 512.

In a fourth aspect, the invention features a method of treating a disease or a condition in a subject, the method including administering to the subject a therapeutically effective amount of a first polypeptide

and a second polypeptide, where a) the first polypeptide includes the structure A-sALP-B, where i) sALP is the extracellular domain of an alkaline phosphatase, ii) A is absent or is an amino acid sequence of at least one amino acid, and iii) B is absent or is an amino acid sequence of at least one amino acid; and b) the second polypeptide includes the structure V-NP-W, where i) NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), ii) V is absent or is an amino acid sequence of at least one amino acid, and iii) W is absent or is an amino acid sequence of at least one amino acid; and the disease or the condition is selected from the group consisting of a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, a vascular smooth muscle disorder, and a condition for elongation of bone. In some embodiments, the disease or the condition in the subject is thereby treated.

In some embodiments, the first polypeptide is any polypeptide described herein including sALP, e.g., any sALP polypeptide described herein, e.g., as described for the first or third aspect. In some embodiments, the amino acid sequence of the first polypeptide includes an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity of any one of SEQ ID NOs: 1201, 1204, 1220, or 1221, e.g., SEQ ID NO: 1204. In some embodiments, the amino acid sequence of the first polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 1204.

In some embodiments, the second polypeptide is any polypeptide described herein including NP, e.g., any NP polypeptide described herein, e.g., as described for the second or third aspect. In some embodiments, the amino acid sequence of the second polypeptide includes an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to any one of SEQ ID NOs: 504, 512, 530, 554, 572, or 578, e.g., SEQ ID NO: 512. In some embodiments, the amino acid sequence of the second polypeptide includes or consists of the amino acid sequence of SEQ ID NO: 512.

In some embodiments, the first polypeptide and the second polypeptide are administered within ten days, five days, or twenty-four hours of each other, e.g., within ten, nine, eight, seven, six, five, four, three, or two days of each other or within twenty-four, twelve, eleven, ten, nine, eight, seven, six, five, four, three, two, or one hour(s) of each other.

In some embodiments, the first polypeptide and the second polypeptide are administered simultaneously. In some embodiments, the first polypeptide and the second polypeptide are formulated together in a composition or each separately in a composition. In some embodiments, the composition is a pharmaceutical composition comprising a pharmaceutically acceptable excipient, e.g., saline. In some embodiments, the composition is lyophilized. In some embodiments, the composition is any composition, e.g., a pharmaceutical composition, described herein, e.g., as described for the first, second, or third aspect.

In a fifth aspect, the invention features a kit including: a) a first polypeptide including the structure A-sALP-B, where i) sALP is the extracellular domain of an alkaline phosphatase, ii) A is absent or is an amino acid sequence of at least one amino acid, and iii) B is absent or is an amino acid sequence of at least one amino acid; and b) instructions for administering the first polypeptide to a patient

diagnosed with or at risk of developing a neurocutaneous syndrome. In some embodiments, the first polypeptide is any polypeptide described herein including sALP, e.g., any sALP polypeptide described herein, e.g., as described in any of the above aspects.

In some embodiments, the kit further includes (c) a second polypeptide including the structure V-NP-W, where i) NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), ii) V is absent or is an amino acid sequence of at least one amino acid, and iii) W is absent or is an amino acid sequence of at least one amino acid. In some embodiments, the second polypeptide is any polypeptide described herein including NP, e.g., any NP polypeptide described herein, e.g., as described in any of the above aspects.

In a sixth aspect, the invention features a kit including: a) a polypeptide including the structure V-NP-W, where i) NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), ii) V is absent or is an amino acid sequence of at least one amino acid, and iii) W is absent or is an amino acid sequence of at least one amino acid; and b) instructions for administering the polypeptide to a patient diagnosed with or at risk of developing a neurocutaneous syndrome. In some embodiments, the polypeptide is any polypeptide described herein including NP, e.g., any NP polypeptide described herein, e.g., as described in any of the above aspects.

In a seventh aspect, the invention features a kit including: a) a first polypeptide including the structure A-sALP-B, where i) sALP is the extracellular domain of an alkaline phosphatase, ii) A is absent or is an amino acid sequence of at least one amino acid, and iii) B is absent or is an amino acid sequence of at least one amino acid; and b) a second polypeptide including the structure V-NP-W, where i) NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), ii) V is absent or is an amino acid sequence of at least one amino acid, and iii) W is absent or is an amino acid sequence of at least one amino acid. In some embodiments, the first polypeptide is any polypeptide described herein including sALP, e.g., any sALP polypeptide described herein, e.g., as described in any of the above aspects; and the second polypeptide is any polypeptide described herein including NP, e.g., any NP polypeptide described herein, e.g., as described in any of the above aspects. In some embodiments, the first polypeptide and the second polypeptide are formulated together. In some embodiments, the first polypeptide and the second polypeptide are formulated separately and in individual dosage amount.

In any of the aspects described herein, the amino acid sequence of the sALP includes an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to any one of SEQ ID NOs: 1202, 1205, 1218, or 1219.

In any of the aspects described herein, the amino acid sequence of the sALP includes or consists of an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to amino acid residues 23-508 of SEQ ID NO: 1215, amino acid residues 18-498 of SEQ ID NO: 1216, amino acid residues 23-508 of SEQ ID NO: 1218, amino acid residues 18-498 of SEQ ID NO: 1219, amino acid residues 23-512 of SEQ ID NO: 1215, amino acid residues 18-502 of SEQ ID NO: 1216, amino acid residues 23-512 of SEQ ID NO: 1218, or amino acid residues 18-502 of SEQ ID NO: 1219, where X in

SEQ ID NO: 1218 or 1219 is any amino acid but is not an amino acid corresponding to a pathogenic mutation at that position of human TNALP, e.g., not an amino acid corresponding to a pathogenic mutation provided in Table 1.

In any of the aspects described herein, the amino acid sequence of the NP includes or consists of amino acid residues 6-22 of SEQ ID NO: 126, and the amino acid at position 17 of SEQ ID NO: 126 is Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, Asp, Gly, Ala, Ser, Val, Trp, Asn, Gln, His, or Lys, e.g., Phe, Leu, Ile, Thr, Val, Ala, Ser, Glu, Arg, Tyr, Cys, Pro, or Asp, e.g., Phe, Leu, Ile, Thr, Val, Ala, or Ser, e.g., e.g., Phe, Leu, Arg, Tyr, e.g., Phe or Leu, e.g., Phe, e.g., Leu.

In any of the aspects described herein, the amino acid sequence of the NP comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 13-29, 100-116, 119-125, 127-233, or 1001-1155.

In any of the aspects described herein, the NP is selective for NPR-B over NPR-A, where the  $EC_{50(NPR-A)}/EC_{50(NPR-B)}$  ratio for the NP, as determined in an *in vivo* pharmacokinetic assay, is at least 30, e.g., at least 35, 40, 35, 50, 55, or 60.

In any of the aspects described herein, the Fc includes a  $C_{H2}$  domain, a  $C_{H3}$  domain, and a hinge region, or where the Fc is a constant domain of an immunoglobulin selected from the group consisting of IgG-1, IgG-2, IgG-3, and IgG-4, e.g., IgG-1. In some embodiments, the amino acid sequence of the Fc includes an amino acid sequence having at least 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 401. In some embodiments, the amino acid sequence of the Fc includes or consists of SEQ ID NO: 401.

In any of the aspects described herein, the amino acids sequence of D or Y includes a glycine-rich region, or the amino acid sequence of D or Y consists of one or more glycines and one or more serines. For example, the amino acid sequence of D or Y may include or consist of  $[(Gly)_m(Ser)]_n(Gly)_p$  or  $(Gly)_p[(Ser)(Gly)_m]_n$ , where each of m, n, and p is, independently, between 0 and 20. In some embodiments, m is between 1 and 6; n is between 1 and 10; and p is between 0 and 4, e.g., m is 4 and n is 1-6. In some embodiments, combinations of m, n, and p are selected from a single row of Table 2, or the amino acid sequence of D or Y includes or consists of the amino acid sequence of any one of SEQ ID NOs: 301-391.

In any of the aspects described herein, the amino acids sequence of D, G, or Y is optionally two amino acid residues (e.g., leucine-lysine or aspartic acid-isoleucine). In some embodiments of an sALP polypeptide, C and E may both be absent, and D may be absent or may be an amino acid sequence of at least one amino acid. For example, the polypeptide may consist of the structure sALP-D-Fc or the structure Fc-D-sALP, where D may be any linker described herein or may optionally consist of two amino acid residues, e.g., leucine-lysine. For example, the polypeptide may consist of the structure sALP-D-Fc. Optionally, the amino acid sequence of sALP is the amino acid sequence of SEQ ID NO: 1205, the amino acid sequence of D is leucine-lysine, and/or the amino acid sequence of Fc is the amino acid sequence of SEQ ID NO: 401. In other embodiments of an sALP polypeptide, C may be absent, and

D and E may both be absent or may be an amino acid sequence of at least one amino acid. For example, the polypeptide may include the structure sALP-D-Fc-E or the structure Fc-D-sALP-E. In other embodiments of an sALP polypeptide, C may be absent, and D, G, and H may all be absent or may be an amino acid sequence of at least one amino acid. For example, the polypeptide may include the structure sALP-D-Fc-G-I<sub>n</sub>-H. In some embodiments of an NP polypeptide, X and Z may both be absent, and Y may be absent or may be an amino acid sequence of at least one amino acid. For example, the polypeptide may consist of the structure NP-Y-Fc or the structure Fc-Y-NP, where Y may be any linker described herein or may optionally consist of two amino acid residues, e.g., leucine-lysine. For example, the polypeptide may consist of the structure NP-Y-Fc.

In any of the aspects described herein, one or more of A, B, C, D, E, G, H, V, W, X, Y, or Z are absent. In some embodiments, A is absent, B is absent, or A and B are both absent. In some embodiments, C is absent, E is absent, or C and E are both absent. In some embodiments, C is absent, H is absent, or C and H are both absent. In some embodiments, X is absent, Z is absent, or X and Z are both absent.

In any of the aspects described herein, the polypeptide of the invention, e.g., the sALP polypeptide and/or the NP polypeptide, may include a bone-targeting moiety, e.g., including 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 consecutive acidic residues, e.g., aspartic acid or glutamic acid, e.g., E<sub>6</sub>, E<sub>7</sub>, E<sub>8</sub>, E<sub>9</sub>, E<sub>10</sub>, E<sub>11</sub>, E<sub>12</sub>, E<sub>13</sub>, E<sub>14</sub>, E<sub>15</sub>, E<sub>16</sub>, D<sub>6</sub>, D<sub>7</sub>, D<sub>8</sub>, D<sub>9</sub>, D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub>, D<sub>13</sub>, D<sub>14</sub>, D<sub>15</sub>, or D<sub>16</sub>, e.g., E<sub>6</sub>, E<sub>10</sub>, D<sub>6</sub>, or D<sub>10</sub>. In some embodiments of any of the above aspects, one or more of A, B, C, D, E, V, W, X, Y, or Z includes a bone-targeting moiety, e.g., including 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 consecutive acidic residues, e.g., aspartic acid or glutamic acid, e.g., E<sub>6</sub>, E<sub>7</sub>, E<sub>8</sub>, E<sub>9</sub>, E<sub>10</sub>, E<sub>11</sub>, E<sub>12</sub>, E<sub>13</sub>, E<sub>14</sub>, E<sub>15</sub>, E<sub>16</sub>, D<sub>6</sub>, D<sub>7</sub>, D<sub>8</sub>, D<sub>9</sub>, D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub>, D<sub>13</sub>, D<sub>14</sub>, D<sub>15</sub>, or D<sub>16</sub>, e.g., E<sub>6</sub>, E<sub>10</sub>, D<sub>6</sub>, or D<sub>10</sub>.

In any of the aspects described herein, the polypeptide of the invention optionally does not include a bone-targeting moiety (e.g., a polyaspartic acid or polyglutamic acid region longer than two consecutive aspartic acid or glutamic acid residues).

In any of the aspects described herein, the polypeptide of the invention may include a cathepsin (e.g., cathepsin K) cleavage sequence, e.g., HGPQG (SEQ ID NO: 374) or HKLRG (SEQ ID NO: 375). In some embodiments of any of the above aspects, A, B, C, D, E, G, H, V, W, X, Y, or Z includes a cathepsin (e.g., cathepsin K) cleavage sequence.

In some embodiments of any of the above aspects, the polypeptide of the invention may include a polypeptide having reduced (e.g., by about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) degradation (e.g., by neutral endopeptidase (NEP), insulin degrading enzyme (IDE), or any other enzyme that cleaves a natriuretic peptide *in vivo*), as compared to a control (e.g., CNP22, CNP53, or any polypeptide described herein, such as a peptide described in International Application Pub. No. WO2010/135541 or U.S. Application Pub. No. 2010-0331256).

In some embodiments of any of the above aspects, the polypeptide of the invention may have increased (e.g., by about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or more) efficacy and/or reduced (e.g.,  
5 by about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) dose-dependent side effects (e.g., decreased adverse hemodynamic effects, such as decreased lowering of blood pressure), as compared to a control (e.g., any polypeptide described herein, such as a peptide described in International Application Pub. No.

10 WO2010/135541 or U.S. Application Pub. No. 2010-0331256).

In any of the aspects described herein, the polypeptide of the invention (e.g., an sALP polypeptide or an NP polypeptide) is glycosylated or pegylated. In some embodiments, the pharmaceutical composition includes a dimer of one or more of the polypeptides of the invention. In some embodiments, the pharmaceutically acceptable excipient includes saline. In some embodiments, the  
15 pharmaceutical composition is lyophilized. In some embodiments, the pharmaceutical composition is administered subcutaneously, intravenously, orally, nasally, intramuscularly, sublingually, intrathecally, or intradermally, e.g., subcutaneously.

In some embodiments, the pharmaceutical composition is administered to the subject in a dosage between about 0.5 mg/kg to about 500 mg/kg once, twice, three times, or four times daily. The dosage  
20 may be between, e.g., about 5 mg/kg to about 200 mg/kg, e.g., about 10 mg/kg to about 100 mg/kg, once, twice, three times, or four times daily. In some embodiments, the dosage is about 10 mg/kg or about 100 mg/kg twice daily.

In some embodiments, the pharmaceutical composition is administered to the subject in a dosage between about 0.5 mg/kg to about 500 mg/kg once or twice weekly. The dosage may be between, e.g.,  
25 about 5 mg/kg to about 200 mg/kg, e.g., about 10 mg/kg to about 100 mg/kg, e.g., about 20 mg/kg to about 40 mg/kg, once or twice weekly. In some embodiments, the dosage is about 10 mg/kg, about 30 mg/kg, or about 100 mg/kg, once or twice weekly.

In some embodiments, the pharmaceutical composition is administered to the subject in a dosage between about 10 µg/kg to about 1,000 µg/kg once or twice weekly. The dosage may be between, e.g.,  
30 about 20 µg/kg to about 800 µg/kg, e.g., about 30 µg/kg to about 600 µg/kg, e.g., about 50 µg/kg to about 500 µg/kg, e.g., about 100 µg/kg to about 400 µg/kg, e.g., about 200 µg/kg to about 300 µg/kg, once or twice weekly. In some embodiments, the dosage is about 30 µg/kg, about 100 µg/kg, about 300 µg/kg, or about 500 µg/kg, once or twice weekly.

In any of the aspects described herein, the pharmaceutical composition is administered to the  
35 subject in a dosage between about 0.1 mg/kg to about 500 mg/kg of one or more of the polypeptides of the invention in a dosage regimen of once, twice, three times, or four times daily. The dosage may be between, e.g., about 1 mg/kg to about 200 mg/kg, e.g., about 2 mg/kg to about 100 mg/kg or about 10

mg/kg to about 100 mg/kg of one or more of the polypeptides of the invention in a dosage regimen of once, twice, three times, or four times daily. In some embodiments, the dosage is about 10 mg/kg or about 100 mg/kg of one or more of the polypeptides of the invention in a dosage regimen of twice daily. For example, the methods of the invention may optionally include administering a pharmaceutical composition including the polypeptides of the invention (e.g., an sALP polypeptide and/or an NP polypeptide) to the subject in a dosage of about 0.5 mg/kg/day to about 10 mg/kg/day (e.g., about 2 mg/kg/day to about 3 mg/kg/day).

In any of the aspects described herein, the pharmaceutical composition is administered to the subject between one and fourteen times a week, or is administered at least once daily for at least one month. In some embodiments, the pharmaceutical composition is administered to the subject once weekly for at least one month. In some embodiments, the pharmaceutical composition is administered one time, two times, three times, or four times a week, e.g., three times a week.

Any of the pharmaceutical compositions of the invention may optionally be formulated for treating a disease or condition (e.g., any described herein) in a subject.

Any of the pharmaceutical composition of the invention featuring an isolated nucleic acid may optionally include a recombinant expression vector (e.g., a lentiviral vector) including the isolated nucleic acid. In some embodiments, the pharmaceutical composition includes about 0.1 mg to about 10 mg of the isolated nucleic acid.

In any embodiment described herein, the polypeptide may or may not be isolated.

In any embodiment described herein, the subject may be human.

In any of the aspects described herein, the combination of two or more polypeptides of the invention (e.g., any sALP polypeptide and/or any NP polypeptide described herein) or two or more compositions of the invention provides a synergistic effect. In particular embodiments, the synergistic effect is a therapeutic effect that is observed for the combination of two or more polypeptides of the invention, wherein one or more of the polypeptides of the invention is present at a dose that is normally non-therapeutic; or a therapeutic effect that results in an unexpected decrease in one or more adverse events (e.g., hemodynamic effects, such as a decrease in blood pressure, such as systolic arterial blood pressure, diastolic arterial blood pressure, or mean arterial blood pressure, that results in adverse hypotensive effects); or a therapeutic effect that results in reduced dose-dependent side effects, as compared to the level of dose-dependent side effects observed for a single polypeptide of the invention at a therapeutic dose.

In some embodiments of any of the methods described herein, the disease is the neurocutaneous syndrome (e.g., neurofibromatosis (e.g., classic von Recklinghausen type (type I), either with gastrointestinal stromal tumors (i.e., as in intestinal neurofibromatosis (type 3B)) or without such tumors; an acoustic neuroma type (type II); a mixed type that combines the features of types I and II with predominant features, such as bilateral acoustic neuromas, posterior fossa and upper cervical meningiomas, and spinal/paraspinal neurofibromas (type III, Riccardi type or type 3A); an atypical type

that is distinguished from by the lack of iris Lisch nodules that are characteristic of type I (type VI); segmental neurofibromatosis, which is a variant of type I having lesions affecting a specific area of the body, such as a single segment of the body or an area that crosses the midline (type V); a type having only the symptoms of café au lait spots without other manifestations of neurofibromatosis (type VI);

5 familial spinal neurofibromatosis, which is caused by mutation in the neurofibromin gene NF1 and considered a distinguishable variant of type I; other variants of type I, such as neurofibromatosis-pheochromocytoma-duodenal carcinoid syndrome; neurofibromatosis with manifestations of Noonan syndrome, such as short stature, ptosis, midface hypoplasia, webbed neck, learning disabilities, and muscle weakness; and schwannomatosis, where any of these disorders can include or exclude one or

10 more bone manifestations); tuberous sclerosis; Sturge-Weber disease; ataxia telangiectasia; von Hippel-Lindau disease; incontinentia pigmenti; epidermal nevus syndromes, such as linear sebaceous nevus of Jadassohn; nevoid basal cell carcinoma syndrome; hypomelanosis of Ito; neurocutaneous melanosis; Klippel-Trenaunay syndrome; and Waardenburg syndrome, including types I, II, III, and IV). In some embodiments, the neurocutaneous syndrome has one or more bone manifestations. In some

15 embodiments, the neurocutaneous syndrome is neurofibromatosis type I. In some embodiments of any of the methods described herein, the disease is any syndrome (e.g., a neurocutaneous syndrome) with overactivated RAS and/or ERK signaling (e.g., Noonan syndrome, Costello syndrome, Noonan syndrome with multiple lentigines/LEOPARD syndrome, neurofibromatosis type 1, hereditary gingival fibromatosis type 1, NF1-Noonan syndrome, capillary malformation-AV malformation syndrome, Legius syndrome,

20 Noonan syndrome-like disorder with loose anagen hair, Noonan syndrome-like disorder with juvenile myelomonocytic leukemia (JMML), cardio-facio-cutaneous syndrome, or autoimmune lymphoproliferative syndrome, where any of these disorders can include or exclude one or more bone manifestations). In some embodiments of any of the methods described herein, the disorder associated with overactivation of FGFR3 is a bone or cartilage disorder, e.g., a skeletal dysplasia, such as any

25 described herein, e.g., achondroplasia or craniosynostosis. In some embodiments of any of the methods described herein, the disorder is a bone or cartilage disorder, e.g., a skeletal dysplasia, such as any described herein. In some embodiments, the bone or cartilage disorder is a skeletal dysplasia, e.g., achondroplasia, homozygous achondroplasia, heterozygous achondroplasia, achondrogenesis, acrodysostosis, acromesomelic dysplasia, atelosteogenesis, camptomelic dysplasia, chondrodysplasia

30 punctata, rhizomelic type of chondrodysplasia punctata, cleidocranial dysostosis, congenital short femur, craniosynostosis (e.g., Muenke syndrome, Crouzon syndrome, Apert syndrome, Jackson-Weiss syndrome, Pfeiffer syndrome, or Crouzonodermoskeletal syndrome), dactyly, brachydactyly, camptodactyly, polydactyly, syndactyly, diastrophic dysplasia, dwarfism, dyssegmental dysplasia, enchondromatosis, fibrochondrogenesis, fibrous dysplasia, hereditary multiple exostoses,

35 hypochondroplasia, hypophosphatasia, hypophosphatemic rickets, Jaffe-Lichtenstein syndrome, Kniest dysplasia, Kniest syndrome, Langer-type mesomelic dysplasia, Marfan syndrome, McCune-Albright syndrome, micromelia, metaphyseal dysplasia, Jansen-type metaphyseal dysplasia, metatrophic dysplasia,

Morquio syndrome, Nievergelt-type mesomelic dysplasia, neurofibromatosis (e.g., type 1, e.g., with bone manifestations or without bone manifestations; type 2; schwannomatosis; or any described herein), osteoarthritis, osteochondrodysplasia, osteogenesis imperfecta, perinatal lethal type of osteogenesis imperfecta, osteopetrosis, osteopoikilosis, peripheral dysostosis, Reinhardt syndrome, Roberts syndrome, Robinow syndrome, short-rib polydactyly syndromes, short stature, spondyloepiphyseal dysplasia congenita, spondyloepimetaphyseal dysplasia, or thanatophoric dysplasia. In some embodiments, the bone or cartilage disorder is optionally hypophosphatasia (e.g., infantile HPP, childhood HPP, perinatal HPP, adult HPP, or odontohypophosphatasia). In some embodiments, the pharmaceutical composition is administered in an amount that is therapeutically effective to treat an achondroplasia phenotype selected from the group consisting of growth retardation, skull deformities, and orthodontic defects. In some embodiments, the pharmaceutical composition is administered in an amount that is therapeutically effective to treat an achondroplasia phenotype selected from the group consisting of cervical cord compression, spinal stenosis, hydrocephalus, hearing loss due to chronic otitis, cardiovascular disease, neurological disease, and obesity. In some embodiments of any of the methods described herein, the disorder associated with overactivation of FGFR3 is cancer, e.g., multiple myeloma, myeloproliferative syndrome, leukemia, plasma cell leukemia, lymphoma, glioblastoma, prostate cancer, bladder cancer, or mammary cancer. In some embodiments of any of the methods described herein, the vascular smooth muscle disorder is hypertension, restenosis, arteriosclerosis, acute decompensated heart failure, congestive heart failure, cardiac edema, nephredema, hepatic edema, acute renal insufficiency, or chronic renal insufficiency. In some embodiments of any of the methods described herein, the condition for elongation of bone is insufficient or impaired bone growth arising from fractures, renal failure or insufficiency, poor diet, vitamin deficiency, hormone deficiency, or any skeletal dysplasia described herein.

In any method described herein, the neurocutaneous syndrome, disorder associated with overactivation of FGFR3, bone or cartilage disorder, vascular smooth muscle disorder, or condition for elongation of bone in the subject is thereby treated.

In some embodiments of any of the methods described herein, one or more polypeptides of the invention or one or more compositions of the invention is optionally administered in an amount that is therapeutically effective to treat a HPP phenotype selected from the group consisting of HPP-related seizure, premature loss of deciduous teeth, incomplete bone mineralization, elevated blood and/or urine levels of inorganic pyrophosphate ( $PP_i$ ), elevated blood and/or urine levels of phosphoethanolamine (PEA), elevated blood and/or urine levels of pyridoxal 5'-phosphate (PLP), inadequate weight gain, rickets, bone pain, calcium pyrophosphate dihydrate crystal deposition, aplasia, hypoplasia, and dysplasia of the dental cementum. In some embodiments, the incomplete bone mineralization is incomplete femoral bone mineralization, incomplete tibial bone mineralization, incomplete metatarsal bone mineralization, or incomplete rib bone mineralization.

*Definitions*

As used herein, the term “about” means  $\pm 10\%$  of the recited value.

By “area under the curve” or “AUC” in the context of an *in vivo* pharmacokinetic assay is meant the area under the serum concentration vs. time curve after administration in an animal.

5 By “bone or cartilage disorder” is meant any disorder, disease, or other abnormality that affects the function, structure, or growth of bone or cartilage.

By “bone-targeting moiety” is meant an amino acid sequence of between 6 and 20 amino acid residues in length having a sufficient affinity to the bone matrix such that the bone-targeting moiety, taken alone, has an *in vivo* binding affinity to the bone matrix that is at least  $10^{-6}$  M or better (e.g.,  $10^{-7}$  M,  
10  $10^{-8}$  M,  $10^{-9}$  M, or better).

By “cathepsin cleavage sequence” is meant an amino acid sequence having a site that can be cleaved by cathepsin with a  $k_{cat}/K_M$  rate constant of at least  $10^3 \text{ M}^{-1}\text{s}^{-1}$  (e.g.,  $10^4 \text{ M}^{-1}\text{s}^{-1}$ ,  $10^5 \text{ M}^{-1}\text{s}^{-1}$ ,  $10^6 \text{ M}^{-1}\text{s}^{-1}$ ,  $10^7 \text{ M}^{-1}\text{s}^{-1}$ , or  $10^8 \text{ M}^{-1}\text{s}^{-1}$ ) at  $30^\circ\text{C}$  or higher (e.g.,  $37^\circ\text{C}$ ). In particular embodiments, the cathepsin cleavage sequence is specific for cathepsin K. Exemplary cathepsin cleavage sequences are P2-P1-P1',  
15 where cleavage by the enzyme would occur at the P1-P1' peptide bond; P2 is preferentially composed of Pro, Leu, Ile, but could also be Val, Norleucine, Met, or Ala; P1 is preferentially Arg, Lys, Gln, but could also be Met, Norleucine, Leu, Ile, or Thr; and P1' can be any amino acid but is preferentially Gly. Additional cathepsin cleavage sequences are provided in Choe et al., J. Biol. Chem. 281(18):12824-832, 2006, which is incorporated herein by reference.

20 By “CNP22” is meant human CNP22 (SEQ ID NO: 4), unless a different meaning is expressly indicated.

By “CNP53” is meant human CNP53 (SEQ ID NO: 11), unless a different meaning is expressly indicated.

By “condition for elongation of bone” is meant any disorder, disease, or other abnormality that  
25 would benefit from lengthening of one or more segments of bone. After administration of any polypeptide described herein, the lengthening of one or more segments of bone can be increased by more than about 1%, about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about  
30 100%, or more.

By “disorder associated with overactivation of FGFR3” is meant any disorder, disease, or other abnormality that is caused by, or is associated with, overactivation of FGFR3, e.g., stemming from a gain-of-function FGFR3 mutation.

By “efficacy” is meant the  $E_{max}$  value of a compound in a dose-response assay.

35 By “Fc” is meant a fragment crystallizable region of an immunoglobulin, e.g., IgG-1, IgG-2, IgG-3, IgG-3 or IgG-4, including the  $C_{H2}$  and  $C_{H3}$  domains of the immunoglobulin heavy chain. Fc may also include any portion of the hinge region joining the Fab and Fc regions. The Fc can be of any mammal,

including human, and may be post-translationally modified (e.g., by glycosylation). In a non-limiting example, Fc can be the fragment crystallizable region of human IgG-1 having the amino acid sequence of SEQ ID NO: 401.

By “fragment” is meant a portion of a polypeptide or nucleic acid molecule that contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain, e.g., 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 500, 600, 700, 800, 900, 1,000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, or more nucleotides, up to the entire length of the nucleic acid molecule, or 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 400, 500, 600, 700, or more amino acid residues, up to the entire length of the polypeptide. Exemplary sALP fragments have amino acid residues 18-498, 18-499, 18-500, 18-501, 18-502, 18-503, 18-504, 18-505, 18-506, 18-507, 18-508, 18-509, 18-510, 18-511, or 18-512 of an consensus sequence for ALP (e.g., SEQ ID NOs: 1215, 1216, 1218, or 1219), and may include additional N-terminal and/or C-terminal portions. Exemplary NP fragments have at least a consensus ring domain, e.g., of SEQ ID NOs: 6, 30, or 95, and may include additional N-terminal and/or C-terminal portions.

By “homolog” is meant a polypeptide or nucleic acid molecule exhibiting at least 50% identity to a reference amino acid sequence or nucleic acid sequence. Such a sequence is generally at least, e.g., 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical at the amino acid level or nucleic acid to a reference sequence. In general, for polypeptides, the length of comparison sequences can be at least five amino acid residues, e.g., 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 400, 500, 600, 700, or more amino acid residues, up to the entire length of the polypeptide. For nucleic acids, the length of comparison sequences can generally be at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, or more nucleotides, up to the entire length of the nucleic acid molecule. It is understood that for the purposes of determining sequence identity when comparing a DNA sequence to an RNA sequence, a thymine nucleotide is equivalent to a uracil nucleotide.

As used herein, when a polypeptide or nucleic acid sequence is referred to as having “at least X% sequence identity” to a reference sequence, it is meant that at least X percent of the amino acid residues or nucleotides in the polypeptide or nucleic acid are identical to those of the reference sequence when the sequences are optimally aligned. An optimal alignment of sequences can be determined in various ways that are within the skill in the art, for instance, the Smith Waterman alignment algorithm (Smith et al., J. Mol. Biol. 147:195-7, 1981) and BLAST (Basic Local Alignment Search Tool; Altschul et al., J. Mol. Biol. 215: 403-10, 1990). These and other alignment algorithms are accessible using publicly available computer software such as “Best Fit” (Smith and Waterman, Advances in Applied Mathematics, 482-489,

1981) as incorporated into GeneMatcher Plus™ (Schwarz and Dayhof, Atlas of Protein Sequence and Structure, Dayhoff, M.O., Ed pp 353-358, 1979), BLAST, BLAST-2, BLAST-P, BLAST-N, BLAST-X, WU-BLAST-2, ALIGN, ALIGN-2, CLUSTAL, or Megalign (DNASTAR). In addition, those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve optimal alignment over the length of the sequences being compared.

By "hybridize" is meant to pair to form a double-stranded molecule between complementary polynucleotides, or portions thereof, under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) *Methods Enzymol.* 152:399; Kimmel, A. R. (1987) *Methods Enzymol.* 152:507.) For example, high stringency salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, less than about 500 mM NaCl and 50 mM trisodium citrate, or less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide or at least about 50% formamide. High stringency temperature conditions will ordinarily include temperatures of at least about 30°C, 37°C, or 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In one embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In an alternative embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a further alternative embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

For most applications, washing steps that follow hybridization will also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, high stringency salt concentrations for the wash steps may be, e.g., less than about 30 mM NaCl and 3 mM trisodium citrate, or less than about 15 mM NaCl and 1.5 mM trisodium citrate. High stringency temperature conditions for the wash steps will ordinarily include a temperature of, e.g., at least about 25°C, 42°C, or 68°C. In one embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In an alternative embodiment, wash steps will occur at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a further alternative embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (*Science* 196:180, 1977); Grunstein and Hogness (*Proc. Natl. Acad. Sci., USA* 72:3961, 1975); Ausubel et al. (*Current Protocols in Molecular Biology*, Wiley Interscience, New York, 2001); Berger and Kimmel (*Guide to Molecular*

Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.

By “isolated” or “purified” is meant separated from other naturally accompanying components. Typically, a compound (e.g., polypeptide, nucleic acid, or small molecule), factor, cell, or other component is considered isolated when it is at least, e.g., 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or even 99%, by weight, free from proteins, antibodies, naturally-occurring organic molecules, and other components with which it is naturally associated. In some instances, the component is at least 75%, 90%, or even 99%, by weight, pure. An isolated component may be obtained by chemical synthesis, separation of the factor from natural sources, or production of the component in a recombinant host cell that does not naturally produce the component. Proteins and small molecules may be purified by one skilled in the art using standard techniques such as those described by Ausubel *et al.* (Current Protocols in Molecular Biology, John Wiley & Sons, New York, 2000). The component is preferably at least, e.g., 2, 5, or 10 times as pure as the starting material, as measured using, e.g., polyacrylamide gel electrophoresis, column chromatography, optical density, HPLC analysis, or Western analysis (Ausubel *et al., supra*). Exemplary methods of purification are column chromatography, immunoprecipitation, and magnetic bead immunoaffinity purification.

By “natriuretic peptide that is an agonist of natriuretic peptide receptor B” (abbreviated “NP”) is meant a natriuretic peptide as described herein, e.g., human CNP22 (SEQ ID NO: 4), or variant thereof, that is capable of agonizing NPR-B, e.g., human NPR-B, with at least 0.000001, 0.000005, 0.00001, 0.00005, 0.0001, 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 0.9, or 1 times the potency, and at least 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 95%, or even 100% times the efficacy of CNP22 as measured in a standard NPR-B activation assay, e.g., a membrane assay or whole cell assay, as described herein. Variant NPs may include one or more substitutions, additions or deletions relative to CNP22 and have the ability to agonize NPR-B. An NP as described herein may include any other sequence or moiety, attached covalently or non-covalently, provided that the NP has the ability to agonize NPR-B.

By “neurocutaneous syndrome” is meant a neurological disorder with one or more cutaneous manifestations, such as lesions on the skin and/or the eye. Such syndromes can optionally be accompanied by benign or malignant tumors in multiple sites of the body.

By “NP polypeptide” is meant any sequence including an NP sequence, as defined herein. Exemplary NP polypeptides include those having the structure V-NP-W, wherein each of V and W is absent or is an amino acid sequence of at least one amino acid (e.g., any NP fusion polypeptide described herein).

By “nucleic acid molecule” is meant a molecule, e.g., RNA or DNA, having a sequence of two or more covalently bonded, naturally occurring or modified nucleotides. The nucleic acid molecule may be, e.g., single or double stranded, and may include modified or unmodified nucleotides, or mixtures or combinations thereof. Various salts, mixed salts, and free acid forms are also included.

The terms “peptide,” “polypeptide,” and “protein” are used interchangeably and refer to any chain of two or more natural or unnatural amino acid residues, regardless of post-translational modification (e.g., glycosylation or phosphorylation), constituting all or part of a naturally-occurring or non-naturally occurring polypeptide or peptide, as is described herein.

5 As used herein, a natural amino acid is a natural  $\alpha$ -amino acid having the L-configuration, such as those normally occurring in natural polypeptides. Unnatural amino acid refers to an amino acid that normally does not occur in polypeptides, e.g., an epimer of a natural  $\alpha$ -amino acid having the L configuration, that is to say an amino acid having the unnatural D-configuration; or a (D,L)-isomeric mixture thereof; or a homolog of such an amino acid, for example, a  $\beta$ -amino acid, an  $\alpha,\alpha$ -disubstituted  
10 amino acid, or an  $\alpha$ -amino acid wherein the amino acid side chain has been shortened by one or two methylene groups or lengthened to up to 10 carbon atoms, such as an  $\alpha$ -amino alkanolic acid with 5 up to and including 10 carbon atoms in a linear chain, an unsubstituted or substituted aromatic ( $\alpha$ -aryl or  $\alpha$ -aryl lower alkyl), for example, a substituted phenylalanine or phenylglycine.

By “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” is meant a  
15 carrier or excipient that is physiologically acceptable to the treated patient while retaining the therapeutic properties of the compound with which it is administered. One exemplary pharmaceutically acceptable carrier substance is physiological saline. Other physiologically acceptable carriers and their formulations are known to those skilled in the art and described, for example, in Remington’s Pharmaceutical Sciences, (20th edition), ed. A. Gennaro, 2000, Lippincott, Williams & Wilkins, Philadelphia, PA.

20 By “pharmaceutical composition” is meant a composition containing a polypeptide or nucleic acid molecule as described herein formulated with a pharmaceutically acceptable excipient, and manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment or prevention of a disease or event in a subject. Pharmaceutical compositions can be formulated, for example, for subcutaneous administration, intravenous administration (e.g., as a  
25 sterile solution free of particulate emboli and in a solvent system suitable for intravenous use), for oral administration (e.g., a tablet, capsule, caplet, gelcap, or syrup), or any other formulation described herein, e.g., in unit dosage form.

By “potency” is meant the reciprocal of the  $EC_{50}$  value of a compound in a dose-response assay. When comparing potency between a compound and a control or between an assay and a control assay,  
30 decreased potency indicates an increased  $EC_{50}$  value, and increased potency indicates a decreased  $EC_{50}$  value, as compared to the  $EC_{50}$  value for the control or the control assay.

By “reduced degradation” is meant having a lower percentage of degraded peptide after exposure to an enzyme for at least 5, 10, 15, 20, 25, 30, 60, 120, 180, or 240 minutes, or higher, or any range between any two of these values, as compared to a percentage of degraded control, such as CNP22,  
35 CNP53, or any polypeptide described herein, such as a peptide described in International Application Pub. No. WO2010/135541 or U.S. Application Pub. No. 2010-0331256. The percentage of degraded peptide can be lower by about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about

50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%, where the percentage of degraded peptide can be determined by measuring the percentage of degraded peptide directly or indirectly by measuring the percentage of remaining peptide after exposure to an enzyme (e.g., neutral endopeptidase, insulin degrading enzyme, and any other enzyme that cleaves a natriuretic peptide *in vivo*) and subtracting this percentage of remaining peptide from 100%. Percentage of degraded peptide or remaining peptide can be measured by any useful method, such as liquid chromatography (e.g., high performance liquid chromatography (HPLC)), mass spectrometry (MS), or combined analytic techniques (e.g., LC-MS).

By “reduced dose-dependent side effect” is meant a decrease in one or more adverse effects as a function of a dosage of a compound, as compared to a control (e.g., any polypeptide described herein, such as a peptide described in International Application Pub. No. WO2010/135541 or U.S. Application Pub. No. 2010-0331256). The decrease in one or more adverse effects can be by about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%, as determined by any useful assay for detecting the adverse effect. Exemplary adverse effects include hemodynamic effects, such as a decrease in blood pressure, such as systolic arterial blood pressure, diastolic arterial blood pressure, or mean arterial blood pressure, that results in adverse hypotensive effects, and assays to detect such hemodynamic effects include a sphygmomanometer or an implanted pressure transducer.

The terms “sALP,” “soluble alkaline phosphatase,” and “extracellular domain of an alkaline phosphatase” are used interchangeably and mean a soluble, non-membrane-bound alkaline phosphatase or a domain, biologically active fragment, or biologically active variant thereof. sALPs include, for example, an alkaline phosphatase lacking a C-terminal GPI signal sequence, e.g., a polypeptide including or consisting of the amino acid residues 18-502 of human TNALP (SEQ ID NO: 1208). sALPs further include, for example, soluble, non-membrane-bound forms of mammalian orthologs of human TNALP (e.g., polypeptides including or consisting of amino acid residues 16-502 or 18-502 of SEQ ID NO: 1206, amino acid residues 18-502 of SEQ ID NO: 1207, amino acid residues 18-502 of SEQ ID NO: 1209, amino acid residues 18-502 of SEQ ID NO: 1210, or amino acid residues 1-480 of SEQ ID NO: 1211), soluble, non-membrane-bound forms of human IALP, GALP, and PLALP (e.g., polypeptides including or consisting of amino acid residues 20-503 of SEQ ID NO: 1212, amino acid residues 20-503 of SEQ ID NO: 1213, or amino acid residues 23-506 of SEQ ID NO: 1214), and additional variants and analogs thereof which retain alkaline phosphatase activity, e.g., the ability to hydrolyze  $PP_i$ .

By “sALP polypeptide” is meant any sequence including an sALP sequence, as defined herein. Exemplary sALP polypeptides include those having the structure A-sALP-B, wherein each of A and B is absent or is an amino acid sequence of at least one amino acid (e.g., any sALP fusion polypeptide described herein).

By “selective for NPR-B over NPR-A” is meant having an  $EC_{50(NPR-A)}/EC_{50(NPR-B)}$  ratio that is at least 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 125, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,100, 1,200, 1,250, 1,300, 1,400, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, 10,000, or higher, or any range between any two of these values, in an *in vivo* or *in vitro* dose-response assay, e.g., measuring cGMP production, as described herein.

Alternatively, or in addition, the term “selective for NPR-B over NPR-A” means having an  $AUC_{(NPR-B)}/AUC_{(NPR-A)}$  ratio that is at least 1.1, 1.2, 1.25, 1.3, 1.4, 1.5, 1.6, 1.7, 1.75, 1.8, 1.9, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 125, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,100, 1,200, 1,250, 1,300, 1,400, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, 10,000, or higher, or any range between any two of these values, as described herein.

By “signal peptide” or “signal sequence” is meant an amino acid sequence that directs a polypeptide to the cellular membrane such that the polypeptide is secreted. Alternatively, the signal sequence may direct the polypeptide to an intracellular compartment or organelle, such as the Golgi apparatus. A signal sequence may be identified by homology, or biological activity, to a peptide sequence with the known function of targeting a polypeptide to a particular region of the cell. One of ordinary skill in the art can identify a signal sequence by using readily available software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705, BLAST, or PILEUP/PRETTYBOX programs). A signal sequence can be one that is, for example, substantially identical to amino acid residues 1-25 of SEQ ID NO: 501 or to amino acid residues 1-17 of SEQ ID NO: 1201.

By “skeletal dysplasia” is meant a bone or cartilage disorder characterized by short stature or dwarfism.

By “subject” is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline.

By a “synergistic” effect is meant a therapeutic effect observed following administration of two or more agents that is greater than the sum of the therapeutic effects observed following the administration of each single agent. In one example of synergy, a therapeutic effect is observed for the combination of two or more agents, wherein one or more of the agents is present at a dose that is normally non-therapeutic. In another example of synergy, the combination of two or more agents results in an unexpected decrease in one or more adverse events (i.e., a level or number of adverse events that is less than the sum of adverse events observed following administration of the single agents). In another example, the combination of two or more agents at a therapeutic dose results in reduced dose-dependent side effects, as compared to the level of dose-dependent side effects observed for a single agent at a therapeutic dose.

By “therapeutically effective amount” is meant an amount of a polypeptide or nucleic acid molecule described herein that is sufficient to substantially treat, prevent, delay, suppress, or arrest any symptom of a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder (e.g., achondroplasia), or a vascular smooth muscle disorder, or that is sufficient to substantially elongate bone. A therapeutically effective amount of a composition described herein may depend on the severity of the disorder being treated and the condition, weight, and general state of the subject and can be determined by an ordinarily-skilled artisan with consideration of such factors. A therapeutically effective amount of a composition described herein can be administered to a subject in a single dose or in multiple doses administered over a period of time.

By “treating,” “treat,” or “treatment” is meant the medical management of a patient with the intent to cure, ameliorate, stabilize, reduce the likelihood of, or prevent a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder (e.g., achondroplasia), or a vascular smooth muscle disorder, or management of a healthy subject with the intent to elongate bone, e.g., by administering a pharmaceutical composition. This term includes active treatment, that is, treatment directed specifically toward the improvement or associated with the cure of a disease, pathological condition, disorder, or event, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, disorder, or event. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, disorder, or event; symptomatic treatment, that is, treatment directed toward constitutional symptoms of the associated disease, pathological condition, disorder, or event; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, disorder, or event, e.g., in a patient who is not yet ill, but who is susceptible to, or otherwise at risk of, a particular disease, pathological condition, disorder, or event; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, disorder, or event.

By “vascular smooth muscle disorder” is meant any disorder, disease, or other abnormality that affects the function, structure, or growth of vascular smooth muscle.

By “vector” is meant a DNA molecule, usually derived from a plasmid or bacteriophage, into which fragments of DNA may be inserted or cloned. A recombinant vector will contain one or more unique restriction sites, and may be capable of autonomous replication in a defined host or vehicle organism such that the cloned sequence is reproducible. A vector contains a promoter operably linked to a gene or coding region such that, upon transfection into a recipient cell, an RNA is expressed.

Other features and advantages of the invention will be apparent from the detailed description and from the claims.

### BRIEF DESCRIPTION OF THE DRAWINGS

In figures showing a multiple sequence alignment, “\*” represents identity; “:” represents a conserved substitution; and “.” represents a semi-conserved substitution.

Fig. 1A is a graph showing levels of pyrophosphate (PP<sub>i</sub>) in osteoblasts from wild-type mice (left) and NF1<sub>col2</sub><sup>-/-</sup> mice (right).

Fig. 1B is a graph showing levels of progressive ankylosis gene (*Ank*) mRNA expression in osteoblasts from wild-type mice (labeled “WT”) and NF1<sub>col2</sub><sup>-/-</sup> mice (labeled “KO”). Osteoblasts were treated with vehicle, a MEK1/MEK2 kinase inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene), or bone morphogenetic protein 2 (BMP2).

Fig. 2 is a schematic showing a non-limiting, hypothetical working model for defective bone matrix mineralization in NF1<sub>col2</sub><sup>-/-</sup> mice.

Fig. 3A shows the effect of recombinant human bone morphogenetic protein 2 (rhBMP2) in osteoblasts from wild-type mice (labeled “WT”) and NF1<sub>col2</sub><sup>-/-</sup> mice. Cell plates are shown with histological staining for alkaline phosphatase (ALP) alone or in combination with alizarin red S (ALP/Alizarin) and for cell number with crystal violet.

Fig. 3B shows the effect of an sALP fusion polypeptide (sTNALP-FcD<sub>10</sub>, SEQ ID NO: 1204) in bone marrow stromal cells from wild-type mice (labeled “WT”) and NF1<sub>col2</sub><sup>-/-</sup> mice. Cells were then treated for 8 days with increasing doses of sTNALP-FcD<sub>10</sub>. Cell plates are shown with histological staining for alizarin red S to determine the presence of calcific deposition (top), and the relative intensity of staining with alizarin red S was quantified (bottom).

Fig. 3C shows the effect of an sALP fusion polypeptide (sTNALP-FcD<sub>10</sub>, SEQ ID NO: 1204) in bone marrow stromal cells (BMSCs) from wild-type mice (labeled “WT”) and NF1<sub>col2</sub><sup>-/-</sup> mice. BMSCs were plated in culture and differentiation was induced for 14 days using vitamin C and beta-glycerophosphate. Cells were then treated with 0.5 μg/mL of sTNALP-FcD<sub>10</sub> and stained with alizarin red to assess level of mineralization, with picrosirius red to demonstrate presence of extracellular matrix, or with crystal violet to stain cells.

Fig. 3D shows the effect of an sALP fusion polypeptide (sTNALP-FcD<sub>10</sub>, SEQ ID NO: 1204) in bone marrow stromal cells (BMSCs) from floxed NF1 gene mice. BMSCs were plated in culture, and differentiation was induced for 14 days using vitamin C and beta-glycerophosphate. Cells were treated for 8 days with an adenovirus coding for GFP (“Ad-GFP,” as control) or an adenovirus coding for CRE recombinase (“Ad-Cre”) either with vehicle or with 0.5 μg/mL of sTNALP-FcD<sub>10</sub>. Cells were then stained with alizarin red to assess level of mineralization (first and second columns) or with picrosirius red to demonstrate presence of extracellular matrix (third and fourth columns).

Fig. 3E shows the *in vivo* effect of an sALP fusion polypeptide (sTNALP-FcD<sub>10</sub>, SEQ ID NO: 1204) in wild-type mice (labeled “WT”) and NF1<sub>col2</sub><sup>-/-</sup> mice. NF1<sub>col2</sub><sup>-/-</sup> mice were treated from day 1 to day 18 with 8.2 mg/kg of sTNALP-FcD<sub>10</sub> and compared to untreated or WT mice. Mice were sacrificed

at day 19, and vertebrae were analysed with micro-CT imaging to measure bone volume over total volume (BV/TV). Treatment of mice with sTNALP-FcD<sub>10</sub> increased bone mineral density deficit in NF1<sub>col2</sub><sup>-/-</sup> mice compared to vehicle (\* p < 0.5).

Fig. 4A shows the expression of the *NPR-B* gene in NF1<sub>col2</sub><sup>-/-</sup> mice. Bone marrow stromal cells were cultured for 3 weeks under osteogenic conditions (with ascorbate acetate) and lysed. RT-PCR was performed using *NPR-B* and housekeeping gene *GAPDH* primers.

Fig. 4B shows the effect of an NP fusion polypeptide (NC2-KGANKK, SEQ ID NO: 512) in chondrocytes from wild-type mice (labeled "WT") and NF1<sub>col2</sub><sup>-/-</sup> mice. Western blot analysis provides levels of ERK and phosphorylated ERK (p-ERK) for chondrocytes from wild-type mice or from NF1<sub>col2</sub><sup>-/-</sup> mice. Primary chondrocytes extracted from ribs of newborn NF1<sub>col2</sub><sup>-/-</sup> mice or WT mice were cultured and then treated for 30 minutes with increasing concentrations of NC2-KGANKK. Cells were then lysed, and western blotting was performed on lysates using anti-ERK or anti-phospho-ERK specific antibodies.

Fig. 4C shows the *in vivo* effect of an NP fusion polypeptide (NC2B, SEQ ID NO: 504) on naso-anal length in wild-type mice (labeled "WT") and NF1<sub>col2</sub><sup>-/-</sup> mice. NF1<sub>col2</sub><sup>-/-</sup> mice were treated from day 1 to day 18 with 100 or 300 mg/kg of NC2B and compared to vehicle-treated or WT mice. Mice were measured for naso-anal length at day 19.

Fig. 4D shows the *in vivo* effect of an NP fusion polypeptide (NC2B, SEQ ID NO: 504) on tibia length in wild-type mice (labeled "WT") and NF1<sub>col2</sub><sup>-/-</sup> mice. NF1<sub>col2</sub><sup>-/-</sup> mice were treated from day 1 to day 18 with 100 or 300 mg/kg of NC2B and compared to vehicle-treated or WT mice. Mice were measured for tibia length at day 19.

Fig. 4E shows the *in vivo* effect of an NP fusion polypeptide (NC2B, SEQ ID NO: 504) on growth plates in wild-type mice (labeled "WT") and NF1<sub>col2</sub><sup>-/-</sup> mice. NF1<sub>col2</sub><sup>-/-</sup> mice were treated from day 1 to day 18 with 300 mg/kg of NC2B and compared to vehicle-treated or WT mice. At day 19, tibias were used to analyze proximal growth plates in histology and to measure the size of chondrocyte zones.

Fig. 5A is a schematic diagram of the structure of human tissue nonspecific alkaline phosphatase (hsTNALP) as described herein, which includes a polypeptide having a TNALP ectodomain, an N-terminal signaling sequence, and a GPI signal sequence (top); a hsTNALP-FcD<sub>10</sub> having a TNALP ectodomain, an N-terminal signaling sequence, an IgG<sub>1</sub>-Fc sequence, and a bone-targeting D<sub>10</sub> moiety (middle); and a hsTNALP-FcD<sub>10</sub> without a signal sequence having a TNALP ectodomain, an IgG<sub>1</sub>-Fc sequence, and a bone-targeting D<sub>10</sub> moiety (bottom).

Fig. 5B shows the amino acid sequence of hsTNALP-FcD<sub>10</sub> (SEQ ID NO: 1201), including the N-terminal signal sequence (the first 17 amino acid residues, underlined and italicized; position 2, a valine, differs from the wild-type residue in that position, isoleucine); and the amino acid sequence of secreted hsTNALP-FcD<sub>10</sub> (SEQ ID NO: 1204), which lacks the N-terminal signal sequence. Amino acid residues of the hsTNALP portion of the polypeptides, which correspond to amino acid residues 18-502 of hsTNALP (SEQ ID NO: 1205), are italicized. The signal sequence in SEQ ID NO: 1201 is italicized and underlined. The Fc portions of the polypeptides (SEQ ID NO: 401) are underlined. A dipeptide leucine-

lysine (LK) linker between the hsTNALP and Fc portions and a dipeptide aspartic acid-isoleucine (DI) linker between the hsTNALP and bone-targeting moiety are shown in bold.

Fig. 5C shows the amino acid sequence of sALP fusion proteins lacking a bone-targeting moiety: hsTNALP-Fc (SEQ ID NO: 1220) and secreted hsTNALP-FcD<sub>10</sub> (SEQ ID NO: 1221), which lacks the N-terminal signal sequence. Amino acid residues of the hsTNALP portion of the polypeptides, which correspond to amino acid residues 18-502 of hsTNALP (SEQ ID NO: 1205), are italicized. The signal sequence in SEQ ID NO: 1201 is italicized and underlined. The Fc portions of the polypeptides (SEQ ID NO: 401) are underlined. A dipeptide leucine-lysine (LK) linker between the hsTNALP and Fc portions are shown in bold.

Fig. 5D shows a nucleic acid sequence (SEQ ID NO: 1217) encoding the hsTNALP-Fc polypeptide depicted in Fig. 5B.

Fig. 6 shows amino acid sequences for human soluble tissue nonspecific alkaline phosphatase (hsTNALP), including the sequence of hsTNALP having the N-terminal signal sequence (amino acid residues 1-502) (SEQ ID NO: 1202) and the sequence of secreted hsTNALP lacking the signal sequence (amino acid residues 18-502) (SEQ ID NO: 1205). The signal sequence is underlined.

Fig. 7 is a listing of the amino acid sequence of an exemplary Fc from human IgG-1 (SEQ ID NO: 401).

Fig. 8 shows a CLUSTAL™ W (1.82) multiple sequence alignment of mammalian tissue nonspecific alkaline phosphatase (TNALP) orthologs. Mammalian TNALP orthologs include cow TNALP ("P09487|PPBT\_BOVIN"; Accession No. P09487; SEQ ID NO: 1206); cat TNALP ("Q29486|PPBT\_FELCA"; Accession No. Q29486; SEQ ID NO: 1207), human TNALP ("P05186|PPBT\_HUMAN"; Accession No. P05186; SEQ ID NO: 1208), mouse TNALP ("P09242|PPBT\_MOUSE"; Accession No. P09242; SEQ ID NO: 1209), rat TNALP ("P08289|PPBT\_RAT"; Accession No. P08289; SEQ ID NO: 1210), and a partial sequence of dog TNALP ("Q9N0V0|Q9N0V0\_CANFA"; Accession No. Q9N0V0; SEQ ID NO: 1211). A consensus sequence is derived from this alignment ("Consensus"; SEQ ID NO: 1216), where X denotes degenerate positions and can be any amino acid.

Fig. 9 shows a CLUSTAL™ (2.0.5) multiple sequence alignment of mammalian tissue nonspecific alkaline phosphatase (TNALP) orthologs and human alkaline phosphatase (ALP) isozymes. Mammalian TNALP orthologs include those shown in Fig. 8, including rat TNALP ("TNALPrn," SEQ ID NO: 1210), mouse TNALP ("TNALPmm," SEQ ID NO: 1209), human TNALP ("TNALPhs," SEQ ID NO: 1208), a partial sequence of dog TNALP ("TNALPcf," SEQ ID NO: 1211), cat TNALP ("TNALPfc," SEQ ID NO: 1207), and cow TNALP ("TNALPbt," SEQ ID NO: 1206). Human ALP isozymes include a human gastrointestinal ALP ("GALPhs"; Accession No. P10696; SEQ ID NO: 1213), a human placental ALP ("PLALPhs"; Accession No. 05187; SEQ ID NO: 1214), and a human intestinal ALP ("IALPhs"; Accession No. P09923; SEQ ID NO: 1212). A consensus sequence is derived from this

alignment (“Consensus”; SEQ ID NO: 1215), where X denotes degenerate positions and can be any amino acid.

Fig. 10 is a consensus sequence (SEQ ID NO: 1218) for mammalian tissue nonspecific alkaline phosphatase (TNALP) orthologs and human alkaline phosphatase (ALP) isozymes excluding pathogenic mutations, where X can be any amino acid but not an amino acid corresponding to one or more pathogenic mutations provided in Table 1.

Fig. 11 is a consensus sequence (SEQ ID NO: 1219) for mammalian tissue nonspecific alkaline phosphatase (TNALP) orthologs excluding pathogenic mutations, where X can be any amino acid but not an amino acid corresponding to one or more pathogenic mutations provided in Table 1.

Fig. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5). The 17-amino acid ring domain for each natriuretic peptide is shown in bold and enclosed in a box. A consensus sequence (SEQ ID NO: 6) is shown below, wherein each X represents any amino acid, or optionally represents any amino acid at the corresponding position in one of SEQ ID NOs: 1-5.

Fig. 13 is an alignment of human CNP53 (SEQ ID NO: 11), human CNP22, and human CNP (ring domain only) (SEQ ID NO: 12).

Fig. 14 is a multiple sequence alignment of various CNP22 homologs. The 17-amino acid ring domain for each NP is shown in bold and enclosed in a box. A consensus sequence (SEQ ID NO: 30) is shown below, wherein each X within the ring domain represents any amino acid, or optionally represents any amino acid at the corresponding position in one of SEQ ID NOs: 4 and 13-29. Each X outside the ring domain represents any amino acid or may be absent, or optionally represents any amino acid at the corresponding position in one of SEQ ID NOs: 4 and 13-29.

Figs. 15A-15G are a multiple sequence alignment of various CNP homologs, in some cases including the N-terminal pre- and pro-sequences. The 17-amino acid ring domain for each NP is shown in bold and enclosed in a box. A consensus sequence (SEQ ID NO: 95) is shown below, wherein each X represents any amino acid, or optionally represents any amino acid at the corresponding position in one of SEQ ID NOs: 31-94.

Fig. 16 is a schematic diagram of the structure of a natriuretic peptide as described herein, which includes an optional N-terminal extension, an optional short segment, a required ring domain, and an optional C-terminal extension.

Figs. 17A-17E are schematic diagrams of exemplary Fc-NP or NP-Fc constructs. Fig. 17A depicts an Fc-NP dimer. Fig. 17B depicts an NP-Fc dimer. Fig. 17C depicts an Fc:Fc-NP monomer-dimer hybrid. Fig. 17D depicts an NP-Fc:Fc monomer-dimer hybrid. Fig. 17E depicts an NP-Fc:Fc-NP hybrid dimer.

Fig. 18A is a listing of the amino acid sequence of the immature NC2 Streptag (“NC2st”) fusion protein (SEQ ID NO: 501), together with a table providing a summary of protein regions. The N-terminal signal sequence, which is cleaved during translation, is underlined. Various linker sequences are shown

in italics. The Fc domain is shown in bold. The CNP domain is shown in gray highlighting. Fig. 18B is a listing of the amino acid sequence of the NC2st fusion protein (SEQ ID NO: 502) without the signal sequence. Fig. 18C is a listing of the nucleic acid sequence (SEQ ID NO: 801) encoding the NC2st fusion protein.

5 Fig. 19A is a listing of the NC2B amino acid sequence, both with the signal sequence (SEQ ID NO: 503) and without the signal sequence (SEQ ID NO: 504), and the D10-NC2 amino acid sequence having a D<sub>10</sub> tag, both with the signal sequence (SEQ ID NO: 607) and without the signal sequence (SEQ ID NO: 608).

Fig. 19B is a listing of a nucleic acid sequence (SEQ ID NO: 802) encoding NC2B.

10 Fig. 20A is a listing of amino acid sequences for NC2B-22, NC2B-28, and NC2B-34, both with the signal sequence (SEQ ID NOs: 505, 507, and 509, respectively) and without the signal sequence (SEQ ID NOs: 506, 508, and 510, respectively). Signal sequences are underlined. The Fc domain is shown in bold. Linker sequences are shown in italics. The CNP domain is shown in gray highlighting. Fig. 20B is a listing of a nucleic acid sequence (SEQ ID NO: 803) encoding NC2B-22. Fig. 20C is a  
15 listing of a nucleic acid sequence (SEQ ID NO: 804) encoding NC2B-28. Fig. 20D is a listing of a nucleic acid sequence (SEQ ID NO: 805) encoding NC2B-34.

Fig. 21 is a listing of amino acid sequences for NC2-KGANKK and NC2-KGANQK, both with the signal sequence (SEQ ID NOs: 511 and 513, respectively) and without the signal sequence (SEQ ID NOs: 512 and 514, respectively). Signal sequences are underlined. The Fc domain is shown in bold.

20 Linker sequences are shown in italics. The CNP domain is shown in gray highlighting.

Fig. 22 is a listing of amino acid sequences for NC2-CNP53mut2, both with the signal sequence (SEQ ID NO: 515) and without the signal sequence (SEQ ID NOs: 516). Signal sequence is underlined. The Fc domain is shown in bold. Linker sequences are shown in italics. The CNP domain is shown in gray highlighting.

25 Fig. 23 is a listing of amino acid sequences for Fc-CNP53-A (also referred to as Fc-CNP53wt) and Fc-CNP53-AAA (also referred to as Fc-CNP53mut), both with the signal sequence (SEQ ID NOs: 517 and 519, respectively) and without the signal sequence (SEQ ID NOs: 518 and 520, respectively). Signal sequences are underlined. The Fc domain is shown in bold. Linker sequences are shown in italics. The CNP domain is shown in gray highlighting.

30 Fig. 24 is a multiple sequence alignment of various NPs and homologs, including CDNP. The boxed region is the most conserved region of the DNP tail among NPRA-binding peptides. The sequences of numerous CDNP variants are shown in the bottom half of the figure, and a consensus sequence (SEQ ID NO: 118) for the DNP C-terminal tail is also shown. Each X in the consensus sequence represents any amino acid, or optionally represents any amino acid at the corresponding  
35 position in one of SEQ ID NOs: 100-116.

Fig. 25A is a listing of amino acid sequences for CNP-16AAlinker-Fc-His10 (NC1) (SEQ ID NO: 521), CNP-6AAlinker-Fc-His10 (NC3) (SEQ ID NO: 522), CNP-6AAlinker-Fc (SEQ ID NO: 523),

CDNP-Fc (SEQ ID NO: 524), CDNP-A17saa-Fc (SEQ ID NO: 525), and CDNP-A17sra-Fc (SEQ ID NO: 526). The CNP domain is shown in gray highlighting. Linker sequences are shown in italics. The Fc domain is shown in bold. Fig. 25B is a listing of the nucleic acid sequence (SEQ ID NO: 806) of NC1.

5 Fig. 26 is a listing of various point mutants (SEQ ID NOs: 119-125) each having a mutation at position 17 of CNP22, together with a consensus sequence (SEQ ID NO: 126). X represents any amino acid, or optionally represents any amino acid at the corresponding position in one of SEQ ID NOs: 119-125.

10 Fig. 27 is a listing of amino acid sequences for several CNP variants (SEQ ID NOs: 4 and 127-150). The 17-amino acid ring domain for each variant is shown in bold. The linker region is shown in italics.

Figs. 28A-28E are a listing of amino acid sequences for additional CNP variants (SEQ ID NOs: 1001-1155).

15 Fig. 29 is a listing of amino acid sequences for CNP22 (SEQ ID NO: 4), CNP-L17 (SEQ ID NO: 120), CNP-F17 (SEQ ID NO: 119), CNP-T17 (SEQ ID NO: 122), D6-14AAlinker-CNP [C3] (SEQ ID NO: 147), CNP-14AAlinker-D6 [C4] (SEQ ID NO: 148), CNP-Nterm2 [C5] (SEQ ID NO: 150), CDNP-S3A4A5R6 [C13] (SEQ ID NO: 115), CDNP29-S3A4A5R6 [C14] (SEQ ID NO: 151), C1(E6) [BC1] (SEQ ID NO: 129), C2(E6) [BC2] (SEQ ID NO: 130), C3 (E6) [BC3] (SEQ ID NO: 131), C4(E6) [BC4] (SEQ ID NO: 132), C5(E6) [BC5] (SEQ ID NO: 133), C6(E6) [BC6] (SEQ ID NO: 134), C7(E6) [BC7] (SEQ ID NO: 135), C8(E6) [BC8] (SEQ ID NO: 136), C9(E6) [BC9] (SEQ ID NO: 137), C10(E6) [BC10] (SEQ ID NO: 138), C11(E6) [BC11] (SEQ ID NO: 139), PGCNP37(E6) (SEQ ID NO: 128), KA1 (SEQ ID NO: 152), KA1(E6) (SEQ ID NO: 153), KB1 (SEQ ID NO: 154), and KB1(E6) (SEQ ID NO: 155). The 17-amino acid ring domain for each variant is shown in bold. The linker sequences are shown in italics. The cathepsin cleavage sequences are shown in underline.

25 Fig. 30 is a listing of amino acid sequences for CNP variants having a point mutation at position 17 relative to CNP22 (SEQ ID NOs: 126, 119-122, and 156-172). For SEQ ID NOs: 126 and 162, X can be any amino acid, including but not limited to F, L, I, T, E, R, Y, C, P, or D. The 17-amino acid ring domain for each variant is shown in bold. The linker sequences are shown in italics.

30 Figs. 31A-31B are listings of amino acid sequences for additional CNP variants having a point mutation at position 17 relative to CNP22 (SEQ ID NOs: 173-220). X can be any amino acid, including but not limited to F, L, I, T, E, R, Y, C, P, or D. The 17-amino acid ring domain for each variant is shown in bold. The linker sequences are shown in italics. The cathepsin cleavage sequences are shown in underline.

35 Fig. 32 is a listing of amino acid sequences for CNP variants having a point mutation at position 17 relative to CNP22, where the methionine at position 17 has been substituted with a leucine (SEQ ID NOs: 221-233). The 17-amino acid ring domain for each variant is shown in bold. The linker sequences are shown in italics. The cathepsin cleavage sequences are shown in underline.

Figs. 33A-33E are listings of amino acid sequences for constructs having a point mutation at position 17 relative to CNP22 (SEQ ID NOs: 527-552). X can be any amino acid, including but not limited to F, L, I, T, E, R, Y, C, P, or D. Signal sequences are underlined. The Fc domain is shown in bold. Linker sequences are shown in italics. The CNP domain is shown in gray highlighting.

Figs. 34A-34J are listings of amino acid sequences for NC2 variants (SEQ ID NOs: 511-516 and 553-606) with or without the signal sequence and either with or without a D<sub>10</sub> bone-targeting moiety at the N-terminal. Signal sequences are underlined. The Fc domain is shown in bold. Linker sequences are shown in italics. The CNP domain is shown in gray highlighting.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention features soluble alkaline phosphatase (sALP) polypeptides, e.g., fused to an Fc domain of an immunoglobulin, nucleic acid encoding such, and their uses to treat any disease or condition described herein (e.g., neurocutaneous syndromes (e.g., neurofibromatosis, e.g., type 1), disorders associated with overactivation of FGFR3, bone or cartilage disorders (e.g., hypophosphatasia or achondroplasia), vascular smooth muscle disorders, as well as to elongate bone). The present invention also features natriuretic (NP) polypeptides, e.g., fused to an Fc domain of an immunoglobulin, nucleic acid encoding such, and their uses to treat any disease or condition described herein (e.g., neurocutaneous syndromes (e.g., neurofibromatosis, e.g., type 1), disorders associated with overactivation of FGFR3, bone or cartilage disorders (e.g., hypophosphatasia or achondroplasia), vascular smooth muscle disorders, as well as to elongate bone). The present invention also features a combination of such sALP polypeptides with such NP polypeptides, as described herein, and uses of this combination to treat any disease or condition described herein (e.g., neurocutaneous syndromes, disorders associated with overactivation of FGFR3, bone or cartilage disorders (e.g., hypophosphatasia or achondroplasia), vascular smooth muscle disorders, as well as to elongate bone). Additional details of the invention are provided below.

### Alkaline phosphatase

Alkaline phosphatases encompass a group of enzymes that share the property of being able to cleave phosphate in a variety of contexts (e.g., hydrolysis of pyrophosphate, PP<sub>i</sub>). There are four known mammalian alkaline phosphatase (ALP) isozymes: tissue nonspecific alkaline phosphatase (TNALP; described further below), placental alkaline phosphatase (PLALP) (e.g., Accession Nos. P05187, NP\_112603, and NP\_001623), germ cell alkaline phosphatase (GALP) (e.g., Accession No. P10696), and intestinal alkaline phosphatase (IALP) (e.g., Accession Nos. P09923 and NP\_001622). These isozymes possess very similar three dimensional structures. Each of their catalytic sites contains four metal binding domains that bind to metal ions necessary for enzymatic activity, including two zinc ions and one magnesium ion. These enzymes catalyze the hydrolysis of monoesters of phosphoric acid and also catalyze a transphosphorylation reaction in the presence of high concentrations of phosphate acceptors. It

has been shown that PLALP is physiologically active toward phosphoethanolamine (PEA), inorganic pyrophosphate (PP<sub>i</sub>), and pyridoxal 5'-phosphate (PLP), all three being known natural substrate for TNALP (Whyte, 1995). An alignment between these isozymes is shown in Fig. 9. Additional alkaline phosphatases are described, e.g., in WO 2008/138131 and in U.S. Publication No. 2006/0014687, which

5 are hereby incorporated by reference.

Tissue nonspecific phosphatases are a family of proteins, encoded by a single gene, that differ from each other by post-translational modification. TNALPs are present predominantly in the liver, kidneys, and bone, but can occur throughout the body. Known TNALPs in mammals include, e.g., human TNALP (Accession Nos. NP\_000469, AAI10910, AAH90861, AAH66116, AAH21289, and

10 AAI26166); rhesus TNALP (Accession No. XP\_01109717); rat TNALP (Accession No. NP\_037191); dog TNALP (Accession No. AAF64516); pig TNALP (Accession No. AAN64273), mouse (Accession No. NP\_031457), cow TNALP (Accession Nos. NP\_789828, NP\_776412, AAM 8209, and AAC33858), and cat TNALP (Accession No. NP\_001036028), in addition to other examples provided herein.

### 15 Soluble alkaline phosphatase

The soluble alkaline phosphatases (sALP) of the invention include, for example, soluble (e.g., extracellular or non membrane-bound) forms of any of the alkaline phosphatases described herein. The soluble alkaline phosphatase of the invention can be, for example, a soluble form of human TNALP. A schematic representation of the domains of human TNALP (hTNALP) is shown in Fig. 5A (top).

20 TNALP is a membrane-bound protein anchored through a glycolipid bound to its C-terminal (Swiss-Prot, P05186). This glycolipid anchor (GPI) is added post translationally after the removal of a hydrophobic C-terminal end, which serves both as a temporary membrane anchor and as a signal for the addition of the GPI. This GPI anchor is buried in the cell membrane, and the remaining portions of the protein are extracellular. TNALP, including hTNALP, can be engineered to replace the first amino acid of the

25 hydrophobic C-terminal sequence (an alanine) with a stop codon. The engineered hTNALP so formed contains all amino acid residues of the native anchored form of TNALP but lacks the GPI membrane anchor. An hTNALP which is soluble is herein referred to as "hsTNALP." One skilled in the art will appreciate that the position of the GPI membrane anchor will vary in different alkaline phosphatases and may include, for example, the last 10, 12, 14, 16, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36,

30 38, 40, 45, 50, or more amino acid residues on the C-terminus of the polypeptide. For example, the GPI membrane anchor of the hTNALP (SEQ ID NO: 1208) is amino acid residues 503-524. The amino acid sequence of this hsTNALP (with one variation at position 2 of the signal sequence), as fused to Fc, is shown in Fig. 5B. The sequence of a nucleic acid encoding this hsTNALP-Fc fusion polypeptide is shown in Fig. 5D (SEQ ID NO: 1217).

35 In addition to the C-terminal GPI anchor, TNALP also has an N-terminal signal peptide sequence. The N-terminal signal peptide is initially present on the protein when it is synthesized, but is cleaved after translocation into the ER. Thus, the N-terminal signal peptide is absent from the secreted

form of TNALP. The sALPs of the invention include both secreted (i.e., lacking the N-terminal signal) and non-secreted (i.e., having the N-terminal signal) forms thereof. One skilled in the art will appreciate that the position of the N-terminal signal peptide will vary in different alkaline phosphatases and may include, for example, the first 5, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 30, or more amino acid residues on the N-terminus of the polypeptide. For example, the N-terminal signal peptide of the hTNALP of SEQ ID NO: 1208 is its first 17 amino acid residues, as shown in Fig. 6. Thus, a secreted, soluble form of this hTNALP is amino acid residues 18-502 of SEQ ID NO: 1208 (SEQ ID NO: 1205), as shown in Fig. 6. The amino acid sequence of this secreted hsTNALP, as fused to Fc, is shown in Fig. 5B. The sALPs of the invention include both secreted and non-secreted forms thereof.

One of skill in the art can predict the position of a signal sequence cleavage site, e.g., by an appropriate computer algorithm such as that described in Bendtsen et al. (*J. Mol. Biol.* 340(4):783-795, 2004) and available on the Web at <http://www.cbs.dtu.dk/services/SignalP/>.

The sALPs of the invention also include, for example, polypeptide sequences satisfying a consensus sequence derived from the ALP extracellular domain of human ALP isozymes and of mammalian TNALP orthologs (human, mouse, rat, cow, cat, and dog) (SEQ ID NO: 1215, as shown in Fig. 9), or a consensus derived from the ALP extracellular domain of just mammalian TNALP orthologs (human, mouse, rat, cow, cat, and dog) (SEQ ID NO: 1216, as shown in Fig. 8). In some embodiments, the sALP includes amino acid residues 18-498, 18-499, 18-500, 18-501, 18-502, 18-503, 18-504, 18-505, 18-506, 18-507, 18-508, 18-509, 18-510, 18-511, or 18-512 of SEQ ID NO: 1216. In some embodiments, the sALP includes amino acid residues 23-498, 23-499, 23-500, 23-501, 23-502, 23-503, 23-504, 23-505, 23-506, 23-507, 23-508, 23-509, 23-510, 23-511, or 23-512 of SEQ ID NO: 1215.

The sALPs of the invention also include those which satisfy similar consensus sequences derived from various combinations of these TNALP orthologs or human ALP isozymes. Such consensus sequences are given, for example, in WO 2008/138131, herein incorporated by reference.

Furthermore, it has been shown that recombinant hsTNALP retaining original amino acid residues 1 to 501 (18 to 501 when secreted) (Oda et al., *J. Biochem.* 126: 694-699, 1999), amino acid residues 1 to 502 (18 to 502 when secreted) (WO 2008/138131), amino acid residues 1 to 504 (18 to 504 when secreted) (U.S. Pat. No. 6,905,689, which is herein incorporated by reference), and amino acid residues 1 to 505 (18-505 when secreted) (U.S. Pat. Pub. No. 2007/0081984, which is herein incorporated by reference), are enzymatically active. This indicates that certain amino acid residues can be truncated from the C-terminal end of the soluble hsTNALP polypeptide without affecting its enzymatic activity. This also indicates that certain amino acid residues of the GPI membrane anchor, when present, do not significantly affect the solubility of the polypeptide. Hence, the sALPs of the invention also include those where, e.g., up to five (e.g., one, two, three, four, or five) amino acid residues are truncated on its C-terminal end, and those where, e.g., up to five (e.g., one, two, three, four, or five) amino acid residues of the GPI membrane anchor are present. For example, non-secreted sALPs of the invention include those containing amino acid residues 1-497, 1-498, 1-499, 1-500, 1-501, 1-502, 1-503, 1-504, 1-505, 1-

506, or 1-507 of SEQ ID NO: 1208, as well as variants thereof where the amino acid at position 2 is a valine, and secreted sALPs of the invention include those containing amino acid residues 18-497, 18-498, 18-499, 18-500, 18-501, 18-502, 18-503, 18-504, 18-505, 18-506, or 18-507 of SEQ ID NO: 1208.

One skilled in the art will appreciate that many mutations in the amino acid sequence of an enzyme will not significantly disrupt the catalytic function of the enzyme. In some cases, certain mutation may even benefit the catalytic function of the enzyme in the context of therapy for any disorder or condition described herein (e.g., a neurocutaneous syndrome or a bone or cartilage disorder).

Therefore, the sALPs of the invention include not only the wild-type sequence of the alkaline phosphatases described above, but also include any polypeptide having at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity to these alkaline phosphatases. It is known, however, that specific mutations in TNALP are known to cause HPP. Such pathogenic mutations are preferably absent in the sALPs of the invention. Thus, the sALPs of the invention include those having an amino acid sequence including a consensus sequence for multiple mammalian TNALP orthologs and human ALP isozymes that lack pathogenic mutations (SEQ ID NO: 1218, as shown in Fig. 10) or including a consensus sequence for multiple mammalian TNALP orthologs that lack pathogenic mutations (SEQ ID NO: 1219, as shown in Fig. 11). Exemplary sALPs of the invention include those containing amino acid residues 1-497, 1-498, 1-499, 1-500, 1-501, 1-502, 1-503, 1-504, 1-505, 1-506, 1-507, 1-508, 1-509, 1-510, 1-511, 1-512, 23-497, 23-498, 23-499, 23-500, 23-501, 23-502, 23-503, 23-504, 23-505, 23-506, 23-507, 23-508, 23-509, 23-510, 23-511, or 23-512 of SEQ ID NO: 1218, and secreted sALPs of the invention include those containing amino acid residues 18-497, 18-498, 18-499, 18-500, 18-501, 18-502, 18-503, 18-504, 18-505, 18-506, 18-507, 18-508, 18-509, 18-510, 18-511, or 18-512 of SEQ ID NO: 1219. In these consensus sequences (SEQ ID NOs: 1218 and 1219), X is any amino acid but is not an amino acid corresponding to a pathogenic mutation at that position of human TNALP. Examples of such pathogenic mutations are listed below and provided in Table 1.

Table 1. Pathogenic mutations for human TNALP\*

Total number of mutations 188										
Exon	Base change	Amino acid change		Reference	Clinical form in patient	Genotype of patient	% WT	ref.	E. coli	
		Non-standardized nomenclature	Standardized nomenclature							
1	c.-195C>T			Taillandier et al. 2000	perinatal	c.-195C>T/C184Y			na	Affects transcription start site
2	c.17T>A	L-12X	p.L6X	Taillandier et al. 2000	childhood	L-12X/?			na	Nonsense mutation
2	c.50C>T	S-1F	p.S17F	Mornet et al. 1998	infantile	S-1F/G58S	19.0	1	na	
3	c.83A>G	Y11C	p.Y28C	Taillandier et al. 2001	infantile	Y11C/R119H	7.2	2	-	
3	c.98C>T	A16V	p.A33V	Henthorn et al. 1992	childhood	A16V/Y419H			-	
3	c.110T>C	L20P	p.L37P	Versailles lab oct. 2003	perinatal	L20P/L20P			+	
3	c.119C>T	A23V	p.A40V	Mornet et al. 1998	perinatal	A23V/G456S	2.3	1	+	
3	c.132C>T	Q27X	p.Q44X	Mornet E, unpublished	perinatal	Q27X/c.662in <sub>SG</sub>			na	Nonsense mutation
3	c.151G>T	A34S	p.A51S	Mumm et al. 2002	infantile	A34S/T117H			+	
3	c.152G>T	A34V	p.A51V	Taillandier et al. 2001	infantile	A34V/V442M			+	
4	c.184A>T	M45L	p.M62L	Taillandier et al. 1999	infantile	M45L/c.1172delC	27.4	1	+	
4	c.184A>G	M45V	p.M62V	Spentchian et al. 2003	infantile	M45V/M45V			+	
4	c.186G>C	M45I	p.M62I	Taillandier et al. 2005	childhood	M45I/E174K	0	16	+	
4	c.187G>C	G46R	p.G63R	Spentchian et al. 2003	infantile	G46R/G46R			+	
4	c.188G>T	G46V	p.G63V	Lia-Baldini et al. 2001	infantile	G46V/N	0.8	3	+	
4	c.203C>T	T51M	p.T68M	Orino et al. 2002	childhood	T51M/A160T	5.2	4	+	
4	c.211C>T	R54C	p.R71C	Henthorn et al. 1992	infantile	R54C/D277A	0	17	+	
4	c.211C>A	R54S	p.R71S	Orino et al. 2002	childhood	R54S/?	2.9	4	+	

\* In the column labeled "Non-standardized nomenclature" under "Amino acid change," the position of the mutation is provided with respect to mature human TNALP lacking the N-terminal signal sequence. In the column labeled "Standardized nomenclature" under "Amino acid change," the position is provided with respect to full length human TNALP having the 17-amino acid N-terminal signal sequence (SEQ ID NO: 1208).

4	c.212G>C	R54P	p.R71P	Henthorn et al. 1992	perinatal	R54P/Q190P			+		
4	c.212G>A	R54H	p.R71H	Taillandier et al. 2001	perinatal	A23V/R54H			+		
4	c.219T>C	I55T	p.I72T	Versailles lab oct. 2004	odonto	I55T/N			-		
4	c.223G>A	G58S	p.G75S	Mornet et al. 1998	infantile	S-1F/G58S	3.5	1	+		
4	c.227A>G	Q59R	p.Q76R	Mornet et al. 2001	infantile	Q59R/T117N			-		
IVS4	c.298-2A>G			Taillandier et al. 2000	perinatal	c.298-2A>G/c.997+3A>C			na		This mutation affects splicing and not coding sequence
5	c.299C>T	T83M	p.T100M	Mornet et al. 2001	infantile	T83M/E174K			+		
5	c.303_311del	N85_N87del	p.N102_N104del	Versailles lab Jul 2007	perinatal	c.303_311del/G474R			na		Deletion
5	c.323C>T	P91L	p.P108L	Herasse et al. 2003	odonto	P91L/N	0.4	unp.	-		
5	c.331G>A	A94T	p.A111T	Goseki-Sone et al. 1998	odonto	A94T/?			+		
5	c.334G>A	G95S	p.G112S	Witters et al. 2004	infantile	G95S/R374C			-		
5	c.340G>A	A97T	p.A114T	Mumm et al. 2001	infantile	A97T/D277A			+		
5	c.341C>G	A97G	p.A114G	Draguet et al. 2004	perinatal	A97G+c.348_349insACCGT C/G309R			+		
5	c.348_349insA CCGTC			Draguet et al. 2004	perinatal	A97G+c.348_349insACCGT C/G309R			na		Two missense mutations and insertion
5	c.346G>T	A99S	p.A116S	Versailles lab Jul 2007	adult	A99S/N400S			+		
5	c.346G>A	A99T	p.A116T	Hu et al. 2000	adult	A99T/N	0.8	3	+		
5	c.358G>A	G103R	p.G120R	Mornet et al. 1998	perinatal	G103R/G48+1 G>A			+		
5	c.368C>A	A106D	p.A123D	Spentchian et al. 2006	perinatal	A106D/S249_H250del			-		

5	c.382G>A	V111M	p.V128M	Mumm et al. 2002	perinatal	V111M/R206W			-	
5	c.385G>A	G112R	p.G129R	Mornet et al. 1998	perinatal	G112R/G474R			+	
5	c.388_391delG TAA			Spentchian et al. 2003	perinatal	E294K/388_391delGTAA			na	Frameshift mutation
5	c.389delT			Spentchian et al. 2003	perinatal	c.389delT/c.389delT			na	Frameshift mutation
5	c.392delG			Mumm et al. 2002	perinat/infant	c.392delG/A331T			na	Frameshift mutation
5	c.394G>A	A115T	p.A132T	Versailles lab Jul 2006	adult	A115T/E174K				
5	c.395C>T	A115V	p.A132V	Watanabe et al. 2001	adult	A115V/?	16.9	14	-	
5	c.400_401AC>CA	T117H	p.T134H	Mumm et al. 2002	perinatal	T117H/F310del			-	
5	c.401C>A	T117N	p.T134N	Taillandier et al. 2000	perinatal	T117N/T117N	20.5	5	-	
5	c.406C>T	R119C	p.R136C	Versailles lab oct. 2003	odonto	R119C/R119H			-	
5	c.407G>A	R119H	p.R136H	Taillandier et al. 1999	infantile	R119H/G145V	33.4	1	-	
5	c.442A>G	T131A	p.T148A	Michigami et al. 2005	perinatal	T131A/?			-	
5	c.443C>T	T131I	p.T148I	Spentchian et al. 2003	infantile	T131I/G145S			-	
6	c.480delT			Versailles lab. Jan. 2008	perinatal	c.480delT/R206W			na	deletion
6	c.484G>A	G145S	p.G162S	Spentchian et al. 2003	infantile	T131I/G145S			+	
6	c.485G>T	G145V	p.G162V	Taillandier et al. 1999	infantile	R119H/G145V	1.3	1	+	
6	c.500C>T	T150M	p.T167M	Versailles lab oct. 2003	infantile	T150M/E174K	0		+	
6	c.508A>G	N153D	p.N170D	Mornet et al. 1998	perinatal	N153D/N153D	0	13	-	
6	c.511C>T	H154Y	p.H171Y	Taillandier et al. 1999	infantile	H154Y/E174K	2.1	1	-	

6	c.512A>G	H154R	p.H171R	Mornet E, unpublished	adult								
6	c.526G>A	A159T	p.A176T	Taillandier et al. 2000	childhood			45.4	5	+			
6	c.529G>A	A160T	p.A177T	Goseki-Sone et al. 1998	adult			83.8	4	-			
6	c.535G>A	A162T	p.A179T	Weiss et al. 1988	perinatal			18	6	+			
6	c.542C>T	S164L	p.S181L	Lia-Baldini et al. 2001	infantile			1.3	3	-			
6	c.544delG			Taillandier et al. 1999	perinatal					na			Frameshift mutation
6	c.550C>T	R167W	p.R184W	Mornet et al. 1998	perinatal			0.6	3	+			
6	c.567C>A	D172E	p.D189E	Spentchian et al. 2003	perinatal					-			
6	c.568_570delA AC	N173del	p.N190del	Michigami et al. 2005	perinatal					-			Deletion of 1 a.a.
6	c.571G>A	E174K	p.E191K	Henthorn et al. 1992	infantile			88.0	1	-			
6	c.572A>G	E174G	p.E191G	Goseki-Sone et al. 1998	odonto					-			
6	c.575T>C	M175T	p.M192T	Versailles lab Jul 2007	infantile					-			
6	c.577C>G	P176A	p.P193A	Mumm et al. 2002	adult					+			
6	c.602G>A	C184Y	p.C201Y	Taillandier et al. 1999	perinatal					-			
6	c.609C>G	D186E	p.D203E	Versailles lab oct. 2004	perinatal					-			
6	c.620A>C	Q190P	p.Q207P	Henthorn et al. 1992	perinatal					+			
6	c.631A>G	N194D	p.N211D	Taillandier et al. 2001	infantile					+			
6	c.634A>T	I195F	p.I212F	Souka et al. 2002	perinatal					-			
IVS6	c.648+1G>T			Brun-Heath et al. 2005	perinatal								Affects splicing
IVS6	c.648+1G>A			Mornet et al. 1998	perinatal					na			Affects splicing

IVS6	c.649-1_3delinsAA		Versailles lab Jul 2006	perinatal	c.649-1_3delinsAA/c.649-1_3delinsAA				Frameshift mutation
7	c.653T>C	I201T	p.I218T	Utsch et al., 2005, contact	perinatal	I201T/R374C	3.7	unp.	-
7	c.659G>T	G203V	p.G220V	Taillandier et al. 2001	odonto	E174K/G203V			+
7	c.659G>C	G203A	p.G220A	Spentchian et al. 2003	perinatal	G203A/G203A			+
7	c.662insG			Mornet E, unpublished	perinatal	Q27X/662insG			na
7	c.662delG			Spentchian et al. 2003	perinatal	R255L/c.662delG			na
7	c.662G>T	G204V	p.G221V	Versailles lab oct. 2004	perinatal	G204V/M338T			+
7	c.667C>T	R206W	p.R223W	Mornet et al. 1998	perinatal	R206W/?	2.8	3	-
7	c.668G>A	R206Q	p.R223Q	Mumm et al. 2002	perinatal	R206Q/deletion			-
7	c.670A>G	K207E	p.K224E	Mochizuki et al. 2000	infantile	K207E/G409C	43	15	+
7	c.677T>C	M209T	p.M226T	Baumgartner-Sigl et al. 2007	infantile	M209T/T354I			-
7	c.704A>G	E218G	p.E235G	Taillandier et al. 2001	adult	E218G/A382S	3.6	7	+
7	c.738G>T	R229S	p.R246S	Taillandier et al. 2000	childhood	A159T/R229S	4.4	5	-
7	c.746G>T	G232V	p.G249V	Fedde et al. 1996	perinatal	G232V/N	34.5	3	+
7	c.971A>G	K247R	p.K264R	Versailles lab Jan.2007	perinatal	K247R/D361V			-
8	c.797_802del	S249_H250del	p.S266_H267del	Spentchian et al. 2006	perinatal	A106D/S249_H250del			Deletion of 2 a.a.
8	c.809G>A	W253X	p.W270X	Mornet et al. 1998	perinatal	R167W/W253X			na
8	c.814C>T	R255C	p.R272C	Spentchian et al. 2006	perinatal	R255C/T117H			-

8	c.815G>T	R255L	p.R272L	Spentchian et al. 2003	perinatal	R255L/c.662delG			-	
8	c.815G>A	R255H	p.R272H	Brun-Heath et al. 2005	infantile	R255H/R255H	6.8	16	-	
8	c.824T>C	L258P	p.L275P	Orimo et al. 2002	childhood	L258P/A160T	3.3	4	-	
8	c.853_854insG ATC	Y268X	p.Y285X	Michigami et al. 2005	perinatal	c1559delT/Y268X			na	Nonsense mutation
IVS8	c.862+5G>A			Taillandier et al. 1999	infantile	c.862+5G>A/c.862+5G>A			na	Affects splicing
9	c.865C>T	L272F	p.L289F	Sugimoto et al. 1998	infantile	L272F/?	50	8	-	
9	c.871G>A	E274K	p.E291K	Mornet et al. 1998	infantile	E174K/E274K	8.3	1	-	
9	c.871G>T	E274X	p.E291X	Taillandier et al. 2000	perinatal	A94T/E274X			-	Nonsense mutation
9	c.874C>A	P275T	p.P292T	Brun-Heath et al. 2005	infantile	P275T/A16V	4.0	16	+	
9	c.876_881delA GGGA	G276_D277del		Spentchian et al. 2003	perinatal	G276_D277del/c.962delG			na	
9	c.880G>T	D277Y	p.D294Y	Taillandier et al. 2001	infantile	A159T/D277Y			-	
9	c.881A>C	D277A	p.D294A	Henthorn et al. 1992	infantile	R54C/D277A	0	17	-	
9	c.883A>G	M278V	p.M295V	Mornet et al. 2001	childhood	E174K/M278V			-	
9	c.884T>C	M278T	p.M295T	Brun-Heath et al. 2005	perinatal	M278T/R206W	8.5	16	-	
9	c.885G>A	M278I	p.M295I	Michigami et al. 2005	perinatal	M278I/c.1559delT			-	
9	c.889T>G	Y280D	p.Y297D	Brun-Heath et al. 2005	childhood	R119HY/280D	1.3	16	-	
9	c.892G>A	E281K	p.E298K	Orimo et al. 1994	infantile	E281K/1559delT			-	
9	c.896T>C	L282P	p.L299P	Versailles lab oct. 2003	infantile	L282P/L282P	9.7	15	-	
9	c.917A>T	D289V	p.D306V	Taillandier et al. 1999	infantile	D289V/D289V	0	12	-	
9	c.919C>T	P290S	p.P307S	Versailles lab oct. 2004	infantile	P290S/M450T			+	
9	c.920C>T	P290L	p.P307L	Versailles lab Jul. 2006	childhood	P290L/S164L				

9	c.928_929delT C			Brun-Heath et al. 2005	perinatal	T394A/c.928_929delTTC					Frameshift mutation
9	c.931G>A	E294K	p.E311K	Spentchian et al. 2003	perinatal	E294K/c.388_391delGTAA			-		
9	c.962delG			Spentchian et al. 2003	perinatal	G276_D277del/c.962delG			na		Frameshift mutation
9	c.976G>C	G309R	p.G326R	Litmanovitz et al. 2002	perinatal	G309R/E274K			+		
9	c.981_983delTT	F310del	p.F327del	Orimo et al. 1997	infantile	F310del/c.155_9delT	-10	15	+		Amino acid deletion
9	c.979T>G	F310C	p.F327C	Mornet et al. 2001	perinatal	T117N/F310C			+		
9	c.979_980TT>GG	F310G	p.F327G	Taillandier et al. 2001	adult	E174K/F310G			+		
9	c.979T>C	F310L	p.F327L	Ozono et al. 1996	infantile	F310L/G439R	72	9	+		
9	c.982T>A	F311L	p.F328L	Michigami et al. 2005	perinatal non-lethal	F311L/T83M	-10	15	+		
IVS9	c.997+2T>A			Taillandier et al. 2000	perinatal	c.997+2T>A/C472S			na		Affects splicing
IVS9	c.997+2T>G			Brun-Heath et al. 2005	perinatal	c.997+2T>G/c.997+2T>G					Affects splicing
IVS9	c.997+3A>C			Mornet et al. 1998	perinatal	c.997+3A>C/c.997+3A>C			na		Affects splicing
IVS9	c.998-1G>T			Taillandier et al. 2001	perinatal	E174K/c.998-1G>T			na		Affects splicing
10	c.1001G>A	G317D	p.G334D	Greenberg et al. 1993	perinatal	G317D/G317D	0	10	-		
10	c.1015G>A	G322R	p.G339R	Mumm et al. 2002	perinatal	G322R/A159T			-		
10	c.1016G>A	G322E	p.G339E	Versailles lab oct. 2004	infantile	G322E/V111M			-		
10	c.1042G>A	A331T	p.A348T	Taillandier et al. 2000	infantile	E174K/A331T	33.2	5	-		
10	c.1044_1055del	L332_A335del	p.L349_A352del	Spentchian et al. 2006	perinatal	L332_A335del/G474R					Deletion of 4 a.a.

10	c.1062G>C	E337D	p.E354D	Souka et al. 2002	perinatal	I195F/E337D		+		
10	c.1064A>C	M338T	p.M355T	Versailles lab oct. 2004	perinatal	G204V/M338T		-		
10	c.1065G>A	M338I	p.M355I	Versailles lab. Jan. 2008	infantile	M338I/R374C		-		
10	c.1101_1103deICTC	S351del	p.S368del	Versailles lab oct. 2004	perinatal	c.1101_1103deICTC/T372I				Deletion of 1 a.a.
10	c.1112C>T	T354I	p.T371I	Baumgartner-Sigl et al. 2007	infantile	M209T/T354I		-		
10	c.1120G>A	V357M	p.V374M	Versailles lab oct. 2004	adult	V357M/E281K		+		
10	c.1130C>T	A360V	p.A377V	Mornet et al. 2001	perinatal	A360V/A360V		+		
10	c.1133A>T	D361V	p.D378V	Henthorn et al. 1992	infantile	E174K/D361V	1.2	3		
10	c.1142A>G	H364R	p.H381R	Taillandier et al. 2000	infantile	A23V/H364R		+		
10	c.1144G>A	V365I	p.V382I	Goseki-Sone et al. 1998	childhood	F310L/V365I	0	11	+	
10	c.1166C>T	T372I	p.T389I	Versailles lab oct. 2004	perinatal	T372I/S351de		-		
10	c.1171C>T	R374C	p.R391C	Zurutza et al. 1999	childhood	E174K/R374C	10.3	1	-	
10	c.1172G>A	R374H	p.R391H	Orimo et al. 2002	childhood	R374H/?	3.7	4	-	
10	c.1172delC			Taillandier et al. 1999	infantile	M45L/c.1172delC		na		Frameshift mutation
10	c.1175G>C	G375A	p.G392A	Versailles lab. Jan. 2008	perinatal	G375A/R119C		-		
10	c.1182T>C	I378T	p.I395T	Versailles lab. Jul. 2006	perinatal	I378T/E174K				
11	c.1195G>T	A382S	p.A399S	Taillandier et al. 2001	adult	E218G/A382S		-		
11	c.1196C>T	A382V	p.A399V	Spentchian et al. 2006	adult	A392V/A16V		-		
11	c.1199C>T	P383L	p.P400L	Spentchian et al. 2006	infantile	P383L/P383L		+		
11	c.1214_1215deICA			Versailles lab. Jul. 2006	adult	c.1214_1215deICA/E174K				Frameshift mutation
11	c.1216 1218de			Brun-Heath et al. 2005	perinatal	c.1216 1219d				

	IGACA						eIGACA?					
11	c.1217A>G	D389G	p.D406G	Taillandier et al. 2000	odonto.		D389G/R433 H	14.9	5	+		
11	c.1228T>C	F393L	p.F410L	Versailles lab oct. 2004	infantile		F393L/E174K			-		
11	c.1231A>G	T394A	p.T411A	Brun-Heath et al. 2005	perinatal		T394A/c.926_927delTC	0.3	16	-		
11	c.1240C>A	L397M	p.L414M	Mumm et al. 2002	perinatal		L397M/D277A			-		
11	c.1250A>G	N400S	p.N417S	Sergi et al. 2001	perinatal		N400S/c.648+1G>A	3	unp.	+		
11	c.1256delC			Taillandier et al. 2000	perinatal		c.1256delC/?			na		Frameshift mutation
11	c.1258G>A	G403S	p.G420S	Glaser et al. 2004	perinatal		G403S/G403S	0.4	unp.	-		
11	c.1268T>C	V406A	p.V423A	Taillandier et al. 2001	perinatal		A99T/V406A	15.7	2	-		
11	c.1270G>A	V407M	p.V424M	Versailles lab jan. 2007	adult		V407M/V407M			-		
11	c.1276G>T	G409C	p.G426C	Mochizuki et al. 2000	infantile		K207A/G409C	18.5	15	-		
11	c.1277G>A	G409D	p.G426D	Mumm et al. 2002	childhood		G409D/E174K			-		
11	c.1282C>T	R411X	p.R428X	Taillandier et al. 1999	perinatal		R411X/R411X			na		Nonsense mutation
11	c.1283G>C	R411P	p.R428P	Spentchian et al. 2006	perinatal		R411P/c.997+2T>A			-		
11	c.1285G>A	E412K	p.E429K	Versailles lab Jul. 2006	odonto.		E412K/?					
11	c.1306T>C	Y419H	p.Y436H	Henthorn et al. 1992	childhood		A16V/Y419H			na		
12	c.1333T>C	S428P	p.S445P	Mornet et al. 1998	infantile		S428P/?	2.1	1	-		
12	c.1349G>A	R433H	p.R450H	Taillandier et al. 2000	odonto.		D389G/R433H			-		
12	c.1348C>T	R433C	p.R450C	Mornet et al. 1998	infantile		R433C/R433C	4.0	1	-		
12	c.1354G>A	E435K	p.E452K	Spentchian et al. 2003	perinatal		A94T/E435K			+		
12	c.1361A>G	H437R	p.H454R	Versailles lab oct. 2003	childhood		E174K/H437R			+		

12	c.1363G>A	G438S	p.G455S	<u>Draguet et al. 2004</u>	adult	G438S/G474R	-	-	-	
12	c.1364G>A	G438D	p.G455D	<u>Versailles lab jan. 2007</u>	perinatal	G438D/G438D	-	-	-	
12	c.1366G>T	G439W	p.G456W	<u>Versailles lab oct. 2003</u>	childhood	G439W/?	+	+	+	
12	c.1366G>A	G439R	p.G456R	<u>Ozono et al. 1996</u>	infantile	G439R/?	unp.	1.5	+	
12	c.1375G>A	V442M	p.V459M	<u>Taillandier et al. 2000</u>	infantile	A34V/V442M	+		+	
12	c.1375G>T	V442L	p.V459L	<u>Versailles lab oct. 2004</u>	perinatal	V442L/E435K	-		-	
12	c.1396C>T	P449L	p.P466L	<u>Versailles lab oct. 2003</u>	perinatal	P449L/?	+		+	
12	c.1400T>C	M450T	p.M467T	<u>Versailles lab oct. 2004</u>	infantile	M450T/P290S	-		-	
12	c.1402G>A	A451T	p.A468T	<u>Spentchian et al. 2003</u>	perinatal	A451T/A451T	+		+	
12	c.1417G>A	G456S	p.G473S	<u>Mornet et al. 1998</u>	perinatal	A23V/G456S	+		+	
12	c.1426G>A	E459K	p.E476K	<u>Taillandier et al. 1999</u>	perinatal	A94T/E459K	+		+	
12	c.1427A>G	E459G	p.E476G	<u>Mornet et al. 2001</u>	perinatal	E459G/E459G	+		+	
12	c.1433A>T	N461I	p.N478I	<u>Taillandier et al. 2000</u>	childhood	N461I/N	3	1.1	-	
12	c.1444_1445insC			<u>Brun-Heath et al. 2005</u>	perinatal	c.1444_1445insC/G317D				Frameshift mutation
12	c.1456G>C	C472S	p.C489S	<u>Taillandier et al. 2000</u>	perinatal	C472S/c.997+2T>A	5	9.4	-	
12	c.1468A>T	I473F	p.I490F	<u>Lia-Baldini et al. 2001</u>	adult	I473F/?	3	37.1	-	
12	c.1471G>A	G474R	p.G491R	<u>Mornet et al. 1998</u>	perinatal	G112R/G474R	-		-	
12	c.1471delG			<u>Brun-Heath et al. 2005</u>	odonto	c.1471delG/R119H				Frameshift mutation
12	c.1559delT			<u>Orimo et al. 1994</u>	infantile	E281K/c.1559delT	18	28	na	Frameshift mutation
<b>Large deletions</b>										
deletion of exons 3-5				<u>Spentchian et al. 2006</u>	perinatal	homozygote				
deletion of exon 12 (3' part)				<u>Spentchian et al. 2006</u>	infantile	compound heterozygote with S164L				

In some embodiments, the sALP polypeptides of the invention do not include any of the mutations provided in Table 1. In particular, the sALP polypeptides of the invention, using the numbering of the consensus sequence of SEQ ID NO: 1218 (Fig. 10), the amino acid at position 22 is not a phenylalanine residue; the amino acid at position 33 (position 11 in the sequence without signal peptide) is not a cysteine residue; the amino acid at position 38 (position 16 in the sequence without signal peptide) is not a valine residue; the amino acid at position 42 (position 20 in the sequence without signal peptide) is not a proline residue; the amino acid at position 45 (position 23 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 56 (position 34 in the sequence without signal peptide) is not a serine or a valine residue; the amino acid residue at position 67 (position 45 in the sequence without signal peptide) is not a leucine, an isoleucine or a valine residue; the amino acid residue at position 68 (position 46 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 73 (position 51 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 76 (position 54 in the sequence without signal peptide) is not a cysteine, a serine, a proline or a histidine residue; the amino acid residue at position 77 (position 55 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 80 (position 58 in the sequence without signal peptide) is not a serine residue; the amino acid residue at position 81 (position 59 in the sequence without signal peptide) is not an asparagine residue; the amino acid residue at position 105 (position 83 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 113 (position 89 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 116 (position 94 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 117 (position 95 in the sequence without signal peptide) is not a serine residue; the amino acid residue at position 119 (position 97 in the sequence without signal peptide) is not a glycine residue; the amino acid residue at position 121 (position 99 in the sequence without signal peptide) is not a serine or a threonine residue; the amino acid residue at position 125 (position 103 in the sequence without signal peptide) is not an arginine residue; the amino acid residue at position 128 (position 106 in the sequence without signal peptide) is not an aspartic acid residue; the amino acid residue at position 133 (position 111 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 134 (position 112 in the sequence without signal peptide) is not an arginine residue; the amino acid residue at position 137 (position 115 in the sequence without signal peptide) is not a threonine or a valine residue; the amino acid residue at position 139 (position 117 in the sequence without signal peptide) is not a histidine or an asparagine residue; the amino acid residue at position 141 (position 119 in the sequence without signal peptide) is not a histidine residue; the amino acid residue at position 153 (position 131 in the sequence without signal peptide) is not an alanine or an isoleucine residue; the amino acid residue at position 167 (position 145 in the sequence without signal peptide) is not a serine or a valine residue; the amino acid residue at position 172 (position 150 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 175 (position 153 in the sequence without signal peptide) is not an aspartic acid residue; the

amino acid residue at position 176 (position 154 in the sequence without signal peptide) is not a tyrosine or an arginine residue; the amino acid residue at position 181 (position 159 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 182 (position 160 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 184 (position 162 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 186 (position 164 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 189 (position 167 in the sequence without signal peptide) is not a tryptophan residue; the amino acid residue at position 194 (position 172 in the sequence without signal peptide) is not a glutamate residue; the amino acid residue at position 196 (position 174 in the sequence without signal peptide) is not a lysine or a glycine residue; the amino acid residue at position 197 (position 175 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 198 (position 176 in the sequence without signal peptide) is not an alanine residue; the amino acid residue at position 206 (position 184 in the sequence without signal peptide) is not a tyrosine residue; the amino acid residue at position 208 (position 186 in the sequence without signal peptide) is not a glutamate residue; the amino acid residue at position 207 (position 190 in the sequence without signal peptide) is not a proline residue; the amino acid residue at position 216 (position 194 in the sequence without signal peptide) is not a aspartic acid residue; the amino acid residue at position 217 (position 195 in the sequence without signal peptide) is not a phenylalanine residue; the amino acid residue at position 223 (position 201 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 225 (position 203 in the sequence without signal peptide) is not a valine or an alanine residue; the amino acid residue at position 226 (position 204 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 228 (position 206 in the sequence without signal peptide) is not a tryptophan or a glutamine residue; the amino acid residue at position 229 (position 207 in the sequence without signal peptide) is not a glutamate residue; the amino acid residue at position 231 (position 209 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 240 (position 218 in the sequence without signal peptide) is not a glycine residue; the amino acid residue at position 251 (position 229 in the sequence without signal peptide) is not a serine residue; the amino acid residue at position 254 (position 232 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 269 (position 247 in the sequence without signal peptide) is not an arginine residue; the amino acid residue at position 277 (position 255 in the sequence without signal peptide) is not a cysteine, a leucine or a histidine residue; the amino acid residue at position 280 (position 258 in the sequence without signal peptide) is not a proline residue; the amino acid residue at position 295 (position 273 in the sequence without signal peptide) is not a phenylalanine residue; the amino acid residue at position 297 (position 275 in the sequence without signal peptide) is not a lysine residue; the amino acid residue at position 298 (position 276 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 300 (position 278 in the sequence without signal peptide) is not a tyrosine or an alanine residue; the amino acid residue at position 301 (position 279 in the sequence

without signal peptide) is not a valine, a threonine or an isoleucine residue; the amino acid residue at position 303 (position 281 in the sequence without signal peptide) is not an aspartate residue; the amino acid residue at position 304 (position 282 in the sequence without signal peptide) is not a lysine residue; the amino acid residue at position 305 (position 283 in the sequence without signal peptide) is not a proline residue; the amino acid residue at position 312 (position 290 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 313 (position 291 in the sequence without signal peptide) is not a serine or a leucine residue; the amino acid residue at position 317 (position 295 in the sequence without signal peptide) is not a lysine residue; the amino acid residue at position 332 (position 310 in the sequence without signal peptide) is not an arginine residue; the amino acid residue at position 333 (position 311 in the sequence without signal peptide) is not a cysteine, a glycine or a leucine residue; the amino acid residue at position 334 (position 312 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 340 (position 318 in the sequence without signal peptide) is not an aspartic acid residue; the amino acid residue at position 345 (position 323 in the sequence without signal peptide) is not an arginine or a glutamate residue; the amino acid residue at position 354 (position 332 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 360 (position 338 in the sequence without signal peptide) is not an aspartic acid residue; the amino acid residue at position 361 (position 339 in the sequence without signal peptide) is not a threonine or an isoleucine residue; the amino acid residue at position 377 (position 355 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 380 (position 358 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 383 (position 361 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 384 (position 362 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 387 (position 365 in the sequence without signal peptide) is not an arginine residue; the amino acid residue at position 388 (position 366 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 395 (position 373 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 397 (position 375 in the sequence without signal peptide) is not a cysteine or a histidine residue; the amino acid residue at position 398 (position 376 in the sequence without signal peptide) is not an alanine residue; the amino acid residue at position 401 (position 379 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 405 (position 383 in the sequence without signal peptide) is not a serine or a valine residue; the amino acid residue at position 406 (position 384 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 412 (position 390 in the sequence without signal peptide) is not a glycine residue; the amino acid residue at position 416 (position 394 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 417 (position 395 in the sequence without signal peptide) is not an alanine residue; the amino acid residue at position 420 (position 398 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 423 (position 401 in the sequence without signal peptide) is not a serine

residue; the amino acid residue at position 426 (position 404 in the sequence without signal peptide) is not a serine residue; the amino acid residue at position 429 (position 407 in the sequence without signal peptide) is not an alanine residue; the amino acid residue at position 430 (position 408 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 432 (position 410 in the sequence without signal peptide) is not a cysteine or an aspartic acid residue; amino acid residue at position 434 (position 412 in the sequence without signal peptide) is not a proline residue; amino acid residue at position 435 (position 413 in the sequence without signal peptide) is not a lysine residue; amino acid residue at position 442 (position 420 in the sequence without signal peptide) is not a histidine residue; amino acid residue at position 451 (position 429 in the sequence without signal peptide) is not a proline residue; amino acid residue at position 456 (position 434 in the sequence without signal peptide) is not a histidine or a cysteine residue; amino acid residue at position 458 (position 436 in the sequence without signal peptide) is not a lysine residue; amino acid residue at position 460 (position 438 in the sequence without signal peptide) is not an arginine residue; amino acid residue at position 461 (position 439 in the sequence without signal peptide) is not a serine or an aspartic acid residue; amino acid residue at position 462 (position 440 in the sequence without signal peptide) is not a tryptophan or an arginine residue; amino acid residue at position 465 (position 443 in the sequence without signal peptide) is not a methionine or a leucine residue; amino acid residue at position 472 (position 450 in the sequence without signal peptide) is not a leucine residue; amino acid residue at position 473 (position 451 in the sequence without signal peptide) is not a threonine residue; amino acid residue at position 474 (position 452 in the sequence without signal peptide) is not a threonine residue; amino acid residue at position 479 (position 457 in the sequence without signal peptide) is not a serine residue; amino acid residue at position 482 (position 460 in the sequence without signal peptide) is not a lysine or a glycine residue; amino acid residue at position 484 (position 462 in the sequence without signal peptide) is not a leucine residue; amino acid residue at position 495 (position 473 in the sequence without signal peptide) is not a serine residue; amino acid residue at position 496 (position 474 in the sequence without signal peptide) is not a phenylalanine residue; and amino acid residue at position 497 (position 475 in the sequence without signal peptide) is not an arginine residue.

Also more specifically, when a sTNALP is used in the bone targeted sALPs of the present invention, using the numbering of the human TNALP sequence, the amino acid at position 17 is not a phenylalanine residue; the amino acid at position 28 (position 11 in the sequence without signal peptide) is not a cysteine residue; the amino acid at position 33 (position 16 in the sequence without signal peptide) is not a valine residue; the amino acid at position 37 (position 20 in the sequence without signal peptide) is not a proline residue; the amino acid at position 40 (position 23 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 51 (position 34 in the sequence without signal peptide) is not a serine or a valine residue; the amino acid residue at position 62 (position 45 in the sequence without signal peptide) is not a leucine, an isoleucine or a valine residue; the amino acid residue at position 63 (position 46 in the sequence without signal peptide) is not a valine residue; the amino acid

residue at position 68 (position 51 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 71 (position 54 in the sequence without signal peptide) is not a cysteine, a serine, a proline or a histidine residue; the amino acid residue at position 72 (position 55 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 75 (position 58 in the sequence without signal peptide) is not a serine residue; the amino acid residue at position 76 (position 59 in the sequence without signal peptide) is not an asparagine residue; the amino acid residue at position 100 (position 83 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 108 (position 89 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 111 (position 94 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 112 (position 95 in the sequence without signal peptide) is not a serine residue; the amino acid residue at position 114 (position 97 in the sequence without signal peptide) is not a glycine residue; the amino acid residue at position 116 (position 99 in the sequence without signal peptide) is not a serine or a threonine residue; the amino acid residue at position 120 (position 103 in the sequence without signal peptide) is not an arginine residue; the amino acid residue at position 123 (position 106 in the sequence without signal peptide) is not an aspartic acid residue; the amino acid residue at position 128 (position 111 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 129 (position 112 in the sequence without signal peptide) is not an arginine residue; the amino acid residue at position 132 (position 115 in the sequence without signal peptide) is not a threonine or a valine residue; the amino acid residue at position 134 (position 117 in the sequence without signal peptide) is not a histidine or an asparagine residue; the amino acid residue at position 136 (position 119 in the sequence without signal peptide) is not a histidine residue; the amino acid residue at position 148 (position 131 in the sequence without signal peptide) is not an alanine or an isoleucine residue; the amino acid residue at position 162 (position 145 in the sequence without signal peptide) is not a serine or a valine residue; the amino acid residue at position 167 (position 150 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 170 (position 153 in the sequence without signal peptide) is not an aspartic acid residue; the amino acid residue at position 171 (position 154 in the sequence without signal peptide) is not a tyrosine or an arginine residue; the amino acid residue at position 176 (position 159 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 177 (position 160 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 179 (position 162 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 181 (position 164 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 184 (position 167 in the sequence without signal peptide) is not a tryptophan residue; the amino acid residue at position 189 (position 172 in the sequence without signal peptide) is not a glutamate residue; the amino acid residue at position 191 (position 174 in the sequence without signal peptide) is not a lysine or a glycine residue; the amino acid residue at position 192 (position 175 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 193 (position 176 in

the sequence without signal peptide) is not an alanine residue; the amino acid residue at position 201 (position 184 in the sequence without signal peptide) is not a tyrosine residue; the amino acid residue at position 203 (position 186 in the sequence without signal peptide) is not a glutamate residue; the amino acid residue at position 207 (position 190 in the sequence without signal peptide) is not a proline residue;

5 the amino acid residue at position 211 (position 194 in the sequence without signal peptide) is not a aspartic acid residue; the amino acid residue at position 212 (position 195 in the sequence without signal peptide) is not a phenylalanine residue; the amino acid residue at position 218 (position 201 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 220 (position 203 in the sequence without signal peptide) is not a valine or an alanine residue; the amino acid

10 residue at position 221 (position 204 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 223 (position 206 in the sequence without signal peptide) is not a tryptophan or a glutamine residue; the amino acid residue at position 224 (position 207 in the sequence without signal peptide) is not a glutamate residue; the amino acid residue at position 226 (position 209 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 235

15 (position 218 in the sequence without signal peptide) is not a glycine residue; the amino acid residue at position 246 (position 229 in the sequence without signal peptide) is not a serine residue; the amino acid residue at position 249 (position 232 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 264 (position 247 in the sequence without signal peptide) is not an arginine residue; the amino acid residue at position 272 (position 255 in the sequence without signal peptide) is

20 not a cysteine, a leucine or a histidine residue; the amino acid residue at position 275 (position 258 in the sequence without signal peptide) is not a proline residue; the amino acid residue at position 289 (position 272 in the sequence without signal peptide) is not a phenylalanine residue; the amino acid residue at position 291 (position 274 in the sequence without signal peptide) is not a lysine residue; the amino acid residue at position 292 (position 275 in the sequence without signal peptide) is not a threonine residue;

25 the amino acid residue at position 294 (position 277 in the sequence without signal peptide) is not a tyrosine or an alanine residue; the amino acid residue at position 295 (position 278 in the sequence without signal peptide) is not a valine, a threonine or an isoleucine residue; the amino acid residue at position 297 (position 280 in the sequence without signal peptide) is not an aspartate residue; the amino acid residue at position 298 (position 281 in the sequence without signal peptide) is not a lysine residue;

30 the amino acid residue at position 299 (position 282 in the sequence without signal peptide) is not a proline residue; the amino acid residue at position 306 (position 289 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 307 (position 290 in the sequence without signal peptide) is not a serine or a leucine residue; the amino acid residue at position 311

(position 294 in the sequence without signal peptide) is not a lysine residue; the amino acid residue at

35 position 326 (position 309 in the sequence without signal peptide) is not an arginine residue; the amino acid residue at position 327 (position 310 in the sequence without signal peptide) is not a cysteine, a glycine or a leucine residue; the amino acid residue at position 328 (position 311 in the sequence without

signal peptide) is not a leucine residue; the amino acid residue at position 334 (position 317 in the sequence without signal peptide) is not an aspartic acid residue; the amino acid residue at position 339 (position 322 in the sequence without signal peptide) is not an arginine or a glutamate residue; the amino acid residue at position 348 (position 331 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 354 (position 337 in the sequence without signal peptide) is not an aspartic acid residue; the amino acid residue at position 355 (position 338 in the sequence without signal peptide) is not a threonine or an isoleucine residue; the amino acid residue at position 371 (position 354 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 374 (position 357 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 377 (position 360 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 378 (position 361 in the sequence without signal peptide) is not a valine residue; the amino acid residue at position 381 (position 364 in the sequence without signal peptide) is not an arginine residue; the amino acid residue at position 382 (position 365 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 389 (position 372 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 391 (position 374 in the sequence without signal peptide) is not a cysteine or a histidine residue; the amino acid residue at position 392 (position 375 in the sequence without signal peptide) is not an alanine residue; the amino acid residue at position 395 (position 378 in the sequence without signal peptide) is not a threonine residue; the amino acid residue at position 399 (position 382 in the sequence without signal peptide) is not a serine or a valine residue; the amino acid residue at position 400 (position 383 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 406 (position 389 in the sequence without signal peptide) is not a glycine residue; the amino acid residue at position 410 (position 393 in the sequence without signal peptide) is not a leucine residue; the amino acid residue at position 411 (position 394 in the sequence without signal peptide) is not an alanine residue; the amino acid residue at position 414 (position 397 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 417 (position 400 in the sequence without signal peptide) is not a serine residue; the amino acid residue at position 420 (position 403 in the sequence without signal peptide) is not a serine residue; the amino acid residue at position 423 (position 406 in the sequence without signal peptide) is not an alanine residue; the amino acid residue at position 424 (position 407 in the sequence without signal peptide) is not a methionine residue; the amino acid residue at position 426 (position 409 in the sequence without signal peptide) is not a cysteine or an aspartic acid residue; amino acid residue at position 428 (position 411 in the sequence without signal peptide) is not a proline residue; amino acid residue at position 429 (position 412 in the sequence without signal peptide) is not a lysine residue; amino acid residue at position 436 (position 419 in the sequence without signal peptide) is not a histidine residue; amino acid residue at position 445 (position 428 in the sequence without signal peptide) is not a proline residue; amino acid residue at position 450 (position 433 in the sequence without signal peptide) is not a histidine or a cysteine residue; amino acid residue at position 452 (position 435 in the sequence

without signal peptide) is not a lysine residue; amino acid residue at position 454 (position 437 in the sequence without signal peptide) is not an arginine residue; amino acid residue at position 455 (position 438 in the sequence without signal peptide) is not a serine or an aspartic acid residue; amino acid residue at position 456 (position 439 in the sequence without signal peptide) is not a tryptophan or an arginine residue; amino acid residue at position 459 (position 442 in the sequence without signal peptide) is not a methionine or a leucine residue; amino acid residue at position 466 (position 449 in the sequence without signal peptide) is not a leucine residue; amino acid residue at position 467 (position 450 in the sequence without signal peptide) is not a threonine residue; amino acid residue at position 468 (position 451 in the sequence without signal peptide) is not a threonine residue; amino acid residue at position 473 (position 456 in the sequence without signal peptide) is not a serine residue; amino acid residue at position 476 (position 459 in the sequence without signal peptide) is not a lysine or a glycine residue; amino acid residue at position 478 (position 461 in the sequence without signal peptide) is not a leucine residue; amino acid residue at position 489 (position 472 in the sequence without signal peptide) is not a serine residue; amino acid residue at position 490 (position 473 in the sequence without signal peptide) is not a phenylalanine residue; and amino acid residue at position 491 (position 474 in the sequence without signal peptide) is not an arginine residue. In other specific embodiments, one or more Xs are defined as being any of the amino acid residues found at that position in the sequences of the alignment or a residue that constitutes a conserved or semi-conserved substitution of any of these amino acid residues. In other specific embodiments, X's are defined as being any of the amino acid residues found at that position in the sequences of the alignment. For instance, the amino acid residue at position 51 (position 34 in the sequence without signal peptide) is an alanine or a valine residue; the amino acid residue at position 177 (position 160 in the sequence without signal peptide) is an alanine or a serine residue; the amino acid residue at position 212 (position 195 in the sequence without signal peptide) is an isoleucine or a valine residue; the amino acid residue at position 291 (position 274 in the sequence without signal peptide) is a glutamic acid or an aspartic acid residue; and the amino acid residue at position 374 (position 357 in the sequence without signal peptide) is a valine or an isoleucine residue.

An sALP may optionally be glycosylated at any appropriate one or more amino acid residues.

In addition, an sALP may have at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity to any of the sALPs described herein.

An sALP may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more additions, deletions, or substitutions relative to any of the sALPs described herein.

## NPs

Any natriuretic peptide or variant thereof that is an agonist of natriuretic peptide receptor B ("NPR-B"), e.g., human NPR-B, may be used in any of the methods and compositions described herein.

Natriuretic peptides as described herein are peptides that are capable of agonizing NPR-B. Natriuretic peptides include atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). These peptides bind to three types of receptors that signal intracellularly to modulate physiological functions. ANP and BNP bind preferentially to natriuretic peptide receptor A (NPR-A) (also known as guanylyl cyclase A (GC-A)), and CNP binds preferentially to natriuretic peptide receptor B (NPR-B) (also known as guanylyl cyclase B (GC-B)). All three peptides have similar affinity for natriuretic peptide receptor C (NPR-C), which has both signaling and peptide clearance functions. Clearance of natriuretic peptides also occurs through the action of membrane-bound neutral endopeptidase (NEP). Peptide binding to NPR-A or NPR-B activates the intracellular guanylyl cyclase domain of these receptors, which produces the second messenger cGMP. cGMP activates or inhibits multiple signaling pathways inside the cell.

Natriuretic peptides, including CNP, which primarily agonizes NPR-B, and ANP and BNP, which primarily agonize NPR-A, have important roles in multiple biological processes. Multiple sequence alignments of various NP family members and consensus sequences are shown in Figs. 12-14 and 15A-15G.

A key downstream effect of CNP22 and CNP53, and variants thereof as described herein, in agonizing NPR-B is endochondral ossification. Thus, the NPs described herein are useful, e.g., for treating a wide array of disorders associated with overactivation of FGFR3 and vascular smooth muscle disorders.

NPs include the schematic structure shown in Fig. 16, wherein the ring domain is required and each of the N-terminal extension, short segment, and C-terminal extension is optional. The ring domain is 17 amino acid residues long, with cysteine residues at each terminus of the ring domain (positions 1 and 17) that form a disulfide bond. In some embodiments, the ring domain has an amino acid sequence that falls within one of the consensus sequences shown in Figs. 12, 14, or 15A-15G (SEQ ID NO: 6, amino acid residues 11-27 of SEQ ID NO: 30, or SEQ ID NO: 95, respectively). Any of the ring domains shown in Figs. 12-14 and 15A-15G may be used in an NP as described herein.

The short segment is a segment immediately N-terminal to the ring domain that is between 0 and 10 amino acid residues (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues) in length. Exemplary short segments are shown immediately N-terminal to the boxed region in Fig. 12 or Fig. 14, e.g., residues 1-5 of SEQ ID NO: 4, or the 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues immediately N-terminal to the conserved ring domain in any of the species shown in Figs. 14 and 15A-15G. In some embodiments, the short segment consists of the 5-amino acid portion immediately N-terminal to the conserved ring domain in any of the species shown in Figs. 12, 14, or 15A-15G. In some embodiments, the short segment confers increased selectivity for NPR-B relative to NPR-A.

The N-terminal extension is a region immediately N-terminal to the short segment (if the short segment is present) or the ring domain (if the short segment is not present) and may be of any length, e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,

31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, or even more amino acid residues. This region is absent in CNP22 but is present in CNP53 (residues 1-31 of SEQ ID NO: 11). Exemplary N-terminal extensions are the 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, or more residues immediately N-terminal to the short segment, e.g., of 5 amino acid residues (if short segment is present), or immediately N-terminal to the ring domain (if short segment is not present), of any of the species shown in Figs. 15A-15G. In some embodiments, the N-terminal extension provides increased selectivity for NPR-B relative to NPR-A.

The C-terminal extension is a region immediately C-terminal to the ring domain and may be of any length, e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, or even more amino acid residues. This region is absent in CNP22 and CNP53 but is present in the hybrid peptide CDNP (SEQ ID NO: 100, Fig. 24). Additional variants of CDNP include those that have one or more mutations that provide reduced NEP degradation, such as those provided in Fig. 24: CDNP-N1 (SEQ ID NO: 101), CDNP-G1 (SEQ ID NO: 102), CDNP-H1 (SEQ ID NO: 103), and CDNP-K1 (SEQ ID NO: 104).

Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in Fig. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5. In some embodiments, the C-terminal tail includes, or consists of, the DNP C-terminal tail (SEQ ID NO: 117), or a variant thereof having one or more addition, deletion, or substitution mutations (e.g., SEQ ID NO: 118). For example, a C-terminal tail of an NP may include any of the DNP C-terminal tail mutations shown in Fig. 24. In particular, residues 1, 3, 4, 5, 6, and/or 7 of the DNP C-terminal tail (SEQ ID NO: 117) may be mutated, e.g., as in any of the mutations shown in Fig. 24. In some embodiments, the C-terminal extension confers increased selectivity for NPR-B relative to NPR-A.

An NP may optionally be glycosylated at any appropriate one or more amino acid residues.

In addition, an NP may have at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity to any of the NPs described herein, or to one or more of the ring domain, the short segment, the C-terminal extension, or the N-terminal extension.

An NP may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more additions, deletions, or substitutions relative to any of the NPs described herein, or to one or more of the ring domain, the short segment, the C-terminal extension, or the N-terminal extension.

In one example, the NP can have one or more mutations that are less sensitive to oxidation without substantially reducing potency or efficacy. For example, residue 17 of CNP22 is one of the less well-conserved positions in CNP22, with naturally-occurring homologs having (without limitation) Phe, Leu, Ile, Thr, Val, or Ser at this position (see, e.g., Fig. 14). Exemplary CNP22 variants include CNP-F17 (SEQ ID NO: 119); CNP-L17 (SEQ ID NO: 120); CNP-I17 (SEQ ID NO: 121); CNP-T17 (SEQ ID NO: 122); CNP-V17 (SEQ ID NO: 123); CNP-A17 (SEQ ID NO: 124); CNP-S17 (SEQ ID NO: 125); CNP-E17 (SEQ ID NO: 156); CNP-R17 (SEQ ID NO: 157); and CNP-Y17 (SEQ ID NO: 158), where the consensus sequence is shown in SEQ ID NO: 126 (where X can be any amino acid, including, without limitation, Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, Asp, Val, Ala, or Ser) (Fig. 26). Additional exemplary CNP22 variants include those having a point mutation at position 17, as shown in Fig. 30 (SEQ ID NOs: 126, 119-122, and 156-172), where X in SEQ ID NOs: 126 or 162 can be any amino acid, e.g., F, L, I, T, E, R, Y, C, P, or D.

In another example, the NP can have one or more mutations that provide increased resistance to one or more enzymes that cleave CNP *in vivo* (e.g., neutral endopeptidase (NEP) and/or insulin degrading enzyme (IDE)). Exemplary molecules are shown in Fig. 27 (SEQ ID NOs: 127-150), Figs. 28A-28E (SEQ ID NOs: 1001-1155), and Fig. 29 (SEQ ID NOs: 4, 115, 119, 120, 122, 128-139, 147, 148, and 150-155).

An NP as described herein may include any other sequence or moiety, attached covalently or non-covalently, provided that the NP has the ability to agonize NPR-B.

In some embodiments, an NP as described herein may be no more than 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 70, 80, 90, 100, 110, or 120 amino acid residues in length.

Furthermore, in some embodiments, an NP as described herein may be no more than 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, 4.8, 5.0, 5.2, 5.4, 5.6, 5.8, 6.0, 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.4, 7.6, 7.8, 8.0, 8.2, 8.4, 8.6, 8.8, 9.0, 9.2, 9.4, 9.6, 9.8, or 10.0 kilodaltons (kDa) in molecular weight.

NPs that are suitable for use in the compositions and methods described herein include those described, e.g., in U.S. Patent Nos. 5,352,770; 5,434,133; 6,020,168; 6,034,231; 6,407,211; 6,743,425; 6,818,619; 7,276,481; 7,384,917; and 7,754,852; U.S. Application Pub. Nos. 2007-0197434; 2008-0181903; 2008-0312142; 2009-0170756; 2010-0055150; and 2010-0297021; International Application Pub. Nos. WO 94/20534; WO 02/047871; WO 2004/047871; WO 2005/098490; WO 2008/154226; and WO 2009/067639; European Application Pub. Nos. EP 0497368 and EP 0466174; Furuya et al., Biochem. Biophys. Res. Comm. 183: 964-969 (1992); Takano et al., Zool. Sci., 11: 451-454 (1994); Plater et al., Toxicon., 36(6): 847-857 (1998); and Inoue et al., Proc. Nat. Acad. Sci., 100(17): 10079-10084 (2003), each of which is hereby incorporated by reference in its entirety, including all formulas, structures, and sequences for natriuretic peptides and variants thereof. In alternative embodiments, the NPs referenced in the present paragraph are excluded from the compositions and methods described herein.

In some embodiments, any of the NPs described or incorporated by reference herein may be used in the compositions and methods described herein without fusion to an Fc domain or to a linker, or alternatively may be fused to any of the linkers described herein but not to an Fc domain. Such NPs may be used to treat a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, e.g.,  
 5 achondroplasia, a bone or cartilage disorder, a vascular smooth muscle disorder, or a condition for elongation of bone, as described herein.

In other embodiments, any of the NPs described or incorporated by reference herein may include a point mutation at position 17 relative to CNP22. Wild-type CNP22 has a methionine at position 17 relative to CNP22, which can be oxidized *in vivo* and/or which can provide a peptide that is degradable  
 10 by a protease. As described herein, point mutations at position 17 relative to CNP22 could provide polypeptides having decreased degradation, while maintaining potency. Exemplary amino acid residues at position 17 relative to CNP22 are Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, Asp, Gly, Ala, Ser, Val, Trp, Asn, Gln, His, or Lys, e.g., Phe, Leu, Ile, Thr, Glu, Arg, Tyr, Cys, Pro, or Asp, e.g., Phe or Leu, e.g., Phe, e.g., Leu. For example, the amino acid at position 17 relative to CNP22 could be Phe, Leu, Ile, Thr,  
 15 Glu, Arg, Tyr, Cys, Pro, and Asp, e.g., Phe or Leu, e.g., Phe, e.g., Leu. In another example, the amino acid at position 17 relative to CNP22 could be Phe, Leu, Ile, Thr, Val, Ala, or Ser. Alternatively, exemplary amino acid residues at position 17 relative to CNP22 are Gly, Ala, Ser, Val, Trp, Asn, Gln, His, or Lys.

Furthermore, included in the compositions and methods described herein are nucleic acid  
 20 molecules encoding any of the NPs and fusion polypeptides described herein, as well as nucleic acid molecules that hybridize under high stringency conditions to at least a portion, e.g., to 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or even 100%, of a nucleic acid molecule that encodes any of the NPs or fusion polypeptides described herein.

## 25 **Fragment crystallizable region (Fc) fragments**

The fusion polypeptides of the invention may include an N-terminal or C-terminal domain such as Fc, a fragment crystallizable region of an immunoglobulin. For example, an sALP polypeptide and/or an NP polypeptide of the invention can be a fusion polypeptide including an Fc. An immunoglobulin molecule has a structure that is well known in the art. It includes two light chains (~23 kD each) and two  
 30 heavy chains (~50-70 kD each) joined by inter-chain disulfide bonds. Immunoglobulins are readily cleaved proteolytically (e.g., by papain cleavage) into Fab (containing the light chain and the VH and CH1 domains of the heavy chain) and Fc (containing the C<sub>H2</sub> and C<sub>H3</sub> domains of the heavy chain, along with adjoining sequences). Cleavage typically occurs in a flexible hinge region joining the Fab and Fc regions. For example, papain cleaves the hinge region immediately before the disulfide bonds joining the  
 35 two heavy chains.

Useful Fc fragments as described herein include the Fc fragment of any immunoglobulin molecule, including IgG, IgM, IgA, IgD, or IgE, and their various subclasses (e.g., IgG-1, IgG-2, IgG-3,

IgG-4, IgA-1, IgA-2), taken from any mammal (e.g., human). The Fc fragments of the invention may include, for example, the C<sub>H2</sub> and C<sub>H3</sub> domains of the heavy chain, as well as any portion of the hinge region. Furthermore, the Fc region may optionally be glycosylated at any appropriate one or more amino acid residues, e.g., various amino acid residues known to those skilled in the art. In some embodiments, the Fc fragment is of human IgG-1. In particular embodiments, the Fc fragment of the fusion polypeptide has the amino acid sequence of SEQ ID NO: 401, or has at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity to SEQ ID NO: 401 (Fig. 7).

In some embodiments, engineered, e.g., non-naturally occurring, Fc regions may be utilized in the compositions and methods of the invention, e.g., as described in International Application Pub. No. WO2005/007809, which is hereby incorporated by reference.

An Fc fragment as described herein may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, or more additions, deletions, or substitutions relative to any of the Fc fragments described herein.

### Linkers

The fusion proteins described herein may include a peptide linker region between the Fc fragment and the sALP or between the Fc fragment and the NP. In addition, a peptide linker region may be included between the Fc fragment and the optional bone-targeting moiety. The linker region may be of any sequence and length that allows the sALP or the NP to remain biologically active, e.g., not sterically hindered. Exemplary linker lengths are between 1 and 200 amino acid residues, e.g., 1-5, 6-10, 11-15, 16-20, 21-25, 26-30, 31-35, 36-40, 41-45, 46-50, 51-55, 56-60, 61-65, 66-70, 71-75, 76-80, 81-85, 86-90, 91-95, 96-100, 101-110, 111-120, 121-130, 131-140, 141-150, 151-160, 161-170, 171-180, 181-190, or 191-200 amino acid residues. Additional exemplary linker lengths are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 amino acid residues. Additional exemplary linker lengths are 14-18, 20-24, 26-30, 32-36, 38-42, and 44-48 amino acid residues.

In some embodiments, linkers include or consist of flexible portions, e.g., regions without significant fixed secondary or tertiary structure. Exemplary flexible linkers are glycine-rich linkers, e.g., containing at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or even 100% glycine residues. Linkers may also contain, e.g., serine residues. In some cases, the amino acid sequence of linkers consists only of glycine and serine residues.

In some cases, the amino acid sequence of the linker sequence includes or consists of a sequence according to the formula [(Gly)<sub>m</sub>(Ser)]<sub>n</sub>(Gly)<sub>p</sub>, where each of m, n, and p is, independently, 0, 1, 2, 3, 4, 5,

6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments,  $m = 1, 2, 3, 4, 5$ , or 6;  $n = 1, 2, 3, 4, 5, 6, 7, 8, 9$ , or 10; and  $p = 0, 1, 2, 3$ , or 4. Alternatively, the linker sequence includes or consists of a sequence according to the formula  $(\text{Gly})_p[(\text{Ser})(\text{Gly})_m]_n$ , where each of  $m, n$ , and  $p$  is, independently, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments,  $m = 1, 2, 3, 4, 5$ , or 6;  $n = 1, 2, 3, 4, 5, 6, 7, 8, 9$ , or 10; and  $p = 0, 1, 2, 3$ , or 4.

Exemplary combinations of  $m, n$ , and  $p$  values for either of the preceding two formulae are listed in Table 2.

A

Table 2.

m	n	p	m	n	p	m	n	p	m	n	p	m	n	p	m	n	p
N/A	0	1	5	8	0	5	5	1	5	2	2	4	9	3	4	6	4
N/A	0	2	5	9	0	5	6	1	5	3	2	4	10	3	4	7	4
N/A	0	3	5	10	0	5	7	1	5	4	2	5	1	3	4	8	4
N/A	0	4	6	1	0	5	8	1	5	5	2	5	2	3	4	9	4
N/A	0	5	6	2	0	5	9	1	5	6	2	5	3	3	4	10	4
N/A	0	6	6	3	0	5	10	1	5	7	2	5	4	3	5	1	4
N/A	0	7	6	4	0	6	1	1	5	8	2	5	5	3	5	2	4
N/A	0	8	6	5	0	6	2	1	5	9	2	5	6	3	5	3	4
N/A	0	9	6	6	0	6	3	1	5	10	2	5	7	3	5	4	4
N/A	0	10	6	7	0	6	4	1	6	1	2	5	8	3	5	5	4
1	1	0	6	8	0	6	5	1	6	2	2	5	9	3	5	6	4
1	2	0	6	9	0	6	6	1	6	3	2	5	10	3	5	7	4
1	3	0	6	10	0	6	7	1	6	4	2	6	1	3	5	8	4
1	4	0	1	1	1	6	8	1	6	5	2	6	2	3	5	9	4
1	5	0	1	2	1	6	9	1	6	6	2	6	3	3	5	10	4
1	6	0	1	3	1	6	10	1	6	7	2	6	4	3	6	1	4
1	7	0	1	4	1	1	1	2	6	8	2	6	5	3	6	2	4
1	8	0	1	5	1	1	2	2	6	9	2	6	6	3	6	3	4
1	9	0	1	6	1	1	3	2	6	10	2	6	7	3	6	4	4
1	10	0	1	7	1	1	4	2	1	1	3	6	8	3	6	5	4
2	1	0	1	8	1	1	5	2	1	2	3	6	9	3	6	6	4
2	2	0	1	9	1	1	6	2	1	3	3	6	10	3	6	7	4
2	3	0	1	10	1	1	7	2	1	4	3	1	1	4	6	8	4
2	4	0	2	1	1	1	8	2	1	5	3	1	2	4	6	9	4
2	5	0	2	2	1	1	9	2	1	6	3	1	3	4	6	10	4
2	6	0	2	3	1	1	10	2	1	7	3	1	4	4	1	5	4
2	7	0	2	4	1	2	1	2	1	8	3	1	5	4	1	6	4
2	8	0	2	5	1	2	2	2	1	9	3	1	6	4	1	7	4
2	9	0	2	6	1	2	3	2	1	10	3	1	7	4	1	8	4
2	10	0	2	7	1	2	4	2	2	1	3	1	8	4	1	9	4
3	1	0	2	8	1	2	5	2	2	2	3	1	9	4	1	10	4
3	2	0	2	9	1	2	6	2	2	3	3	2	1	4	2	1	4
3	3	0	2	10	1	2	7	2	2	4	3	2	2	4	2	2	4
3	4	0	3	1	1	2	8	2	2	5	3	2	3	4	2	3	4
3	5	0	3	2	1	2	9	2	2	6	3	2	4	4	2	4	4
3	6	0	3	3	1	2	10	2	2	7	3	2	5	4	2	5	4
3	7	0	3	4	1	3	1	2	2	8	3	2	6	4	2	6	4
3	8	0	3	5	1	3	2	2	2	9	3	2	7	4	2	7	4
3	9	0	3	6	1	3	3	2	2	10	3	2	8	4	2	8	4
3	10	0	3	7	1	3	4	2	3	1	3	2	9	4	2	9	4
4	1	0	3	8	1	3	5	2	3	2	3	3	10	4	3	1	4
4	2	0	3	9	1	3	6	2	3	3	3	3	1	4	3	2	4
4	3	0	3	10	1	3	7	2	3	4	3	3	2	4	3	3	4
4	4	0	4	1	1	3	8	2	3	5	3	3	3	4	3	4	4
4	5	0	4	2	1	3	9	2	3	6	3	3	4	4	3	5	4
4	6	0	4	3	1	3	10	2	3	7	3	3	5	4	3	6	4
4	7	0	4	4	1	4	1	2	3	8	3	3	6	4	3	7	4
4	8	0	4	5	1	4	2	2	3	9	3	3	7	4	3	8	4
4	9	0	4	6	1	4	3	2	4	1	3	3	8	4	3	9	4
4	10	0	4	7	1	4	4	2	4	2	3	3	9	4	3	10	4
5	1	0	4	8	1	4	5	2	4	3	3	4	1	4	4	1	4
5	2	0	4	9	1	4	6	2	4	4	3	4	2	4	4	2	4
5	3	0	4	10	1	4	7	2	4	5	3	4	3	4	4	3	4
5	4	0	5	1	1	4	8	2	4	6	3	4	4	4	4	4	4
5	5	0	5	2	1	4	9	2	4	7	3	4	5	4	4	5	4
5	6	0	5	3	1	4	10	2	4	8	3	4	6	4	4	6	4
5	7	0	5	4	1	5	1	2	4	8	3	4	7	4	4	7	4

In some embodiments, the amino acid sequence of the linker (e.g., between the Fc and the sALP, or between the Fc and the NP, or between the Fc and the optional bone-targeting moiety) includes or consists of a sequence in Table 3.

5

**Table 3.**

Linker sequence	SEQ ID NO.
G	301
GG	302
GGG	303
GGGG	304
GGGGS	305
GGGGSG	306
GGGGSGGGGSGGGG	307
GGGGSGGGGSGGGGSG	308
GGGGSGGGGSGGGGSGGGGSGG	309
GGGGSGGGGSGGGGSGGGGSGGGGSGGG	310
GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGG	311
GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSG	312
GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSG	313
KGANKK	314
KGANQK	315
KGANKQ	316
KGANQQ	317
QGANKK	318
QGANKQ	319
QGANKQ	320
QGANQQ	321
GGGGSGGGGSKGANKK	322
GGGGSGGGGSKGANQK	323
GGGGSGGGGSKGANKQ	324
GGGGSGGGGSKGANQQ	325
GGGGSGGGGSQGANKK	326
GGGGSGGGGSQGANKQ	327
GGGGSGGGGSQGANKQ	328
GGGGSGGGGSQGANKQ	329
GGGDLQVDTQSQAAWAQLLQEHNAQQYKGANKK	330
GGGGSGGGGSGGGGSGGGGSGGGGSGGGGKGANKK	331
GGGGSGGGGSGGGGSGGGGSGGGGSGGGGKGANKQ	332
GGGGSGGGGSGGGGSGGGGSGGGGSGGGGQGANKQ	333
QEHPNARKYKGANKK	334
GQEHPNARKYKGANKK	335
PGQEHPNARKYKGANKK	336
SGGGGSGGGGSGGGG	337
ASTSPANPQPAASSP	338
PSSAAPQPNAPSTA	339
SGGGGSGGGKGANKK	340
SGGGGSGGGQGANKQ	341
SGGGGSGGGKGANKQ	342
SGGGGSGGGKGANKQ	343
SGGGGSGGGQGANKK	344
SGGGGSGGGKGANKQ	345
SGGGGSGGGQGANKQ	346
SGGGGSGGGQGANKQ	347
ASTSPANPQPAASSG	348

GSSAAPQPNAPSTSA	349
GSSAAPRPNAPSTSAGLSKG	350
ASTSPANPRPAASSG	351
HGPPQGEHPNARKYKGANKK	352
HKLRGQGEHPNARKYKGANKK	353
GHGPPQGEHPNARKYKGANKK	354
GHLRGQGEHPNARKYKGANKK	355
GGHPPQGEHPNARKYKGANKK	356
GGHLRGQGEHPNARKYKGANKK	357
GGGHPPQGEHPNARKYKGANKK	358
GGGHLRGQGEHPNARKYKGANKK	359
GGGGHPPQGEHPNARKYKGANKK	360
GGGGHLRGQGEHPNARKYKGANKK	361
GGGGGHPPQGEHPNARKYKGANKK	362
GGGGGHLRGQGEHPNARKYKGANKK	363
HGPQSGGGGSGGGKGANKK	364
HKLRGSGGGGSGGGKGANKK	365
GGGHPPQSGGGGSGGGKGANKK	366
GGGHLRGSGGGGSGGGKGANKK	367
SGGGGQGEHPNARKYKGANKK	368
GGSGGGGQGEHPNARKYKGANKK	369
SGGGGSGGGGSGGGKGANKK	370
SGGGGSGGGGSGGGGSGGGKGANKK	371
GGSGGGGSGGGGSGGGGSGGGKGANKK	372
GGSGGGGSGGGGSGGGGSGGGGSGGGKGANKK	373
HGPQG	374
HKLRG	375
GHGPQG	376
GGHGPQG	377
GGGHGPQG	378
GGGGHGPQG	379
GGGGGHGPQG	380
GHLRG	381
GHLRG	382
GGHLRG	383
GGGGHLRG	384
GGGGGHLRG	385
GGQEIPNARKYKGANKK	386
GGGQGEHPNARKYKGANKK	387
GGGGQGEHPNARKYKGANKK	388
GGGGGQGEHPNARKYKGANKK	389
LK	390
DI	391

In some embodiments, the linker may include or consist of a  $[(\text{Gly})_m(\text{Ser})_n(\text{Gly})_p \text{ or } (\text{Gly})_p[(\text{Ser})(\text{Gly})_m]_n$  linker as described above, followed by one of SEQ ID NOs: 314-321, e.g., one of SEQ ID NOs: 314, 315, or 321.

- 5 In other embodiments of polypeptides including an sALP, the linker may include or consist of all or a fragment of an sALP. For example, the 17-amino acid portion of human TNALP that is an N-terminal signal sequence, or homologs or variants or fragments thereof (e.g., residues 1-17 of SEQ ID NOs: 1202 or 1208), may be used as a linker. Homologs of this 17-amino acid region may be identified, e.g., by consulting a sequence alignment such as Fig. 8 (residues 1-17 of SEQ ID NO:

1216, where X can be any amino acid) or in Fig. 11 (residues 1-17 of SEQ ID NO: 1219, where X can be any amino acid but not a pathogenic mutation provided in Table 1). In another example, the C-terminal GPI anchor portion of human TNALP, or homologs or variants or fragments thereof (e.g., residues 503-524 of SEQ ID NO: 1208) may be used as a linker. Homologs of this C-terminal region may be identified, e.g., by consulting a sequence alignment such as Fig. 8 (residues 503-524 of SEQ ID NO: 1216, where X can be any amino acid) or in Fig. 11 (residues 503-524 of SEQ ID NO: 1219, where X can be any amino acid but not a pathogenic mutation provided in Table 1).

In other embodiments of polypeptides including an NP, the linker may include or consist of all or a fragment of an NP. For example, the 31-amino acid portion of human CNP53 that is N-terminal to CNP22, or homologs or variants thereof (e.g., residues 4-34 of SEQ ID NO: 320), may be used as a linker. Homologs of this 31-amino acid region may be identified, e.g., by consulting a sequence alignment such as Figs. 15A-15G and identifying the regions corresponding to the N-terminal 31 amino acid residues of human CNP53. Other suitable linkers may also be identified, e.g., by choosing any portion of an NP, optionally excluding a ring domain, as shown in Figs. 15A-15G, or in any other NP or region of an NP not shown in Figs. 15A-15G. For example, the C-terminal extension of DNP (SEQ ID NO: 117), or fragments or variants thereof, may be used as a linker.

A linker may optionally be glycosylated at any appropriate one or more amino acid residues.

In addition, a linker may have at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity to any of the linkers described herein. In addition, a linker may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more additions, deletions, or substitutions relative to any of the linkers described herein.

A linker as described herein may include any other sequence or moiety, attached covalently or non-covalently.

In some embodiments, the linker is absent, meaning that the Fc fragment and the sALP are fused together directly or that the Fc fragment and the NP are fused together directly, with no intervening residues.

It should be noted that certain Fc-sALP or sALP-Fc fusion proteins may be viewed, according to the present disclosure, either as 1) having no linker, or as 2) having a linker which corresponds to a portion of the sALP. For example, Fc fused directly to hsTNALP (1-502) may be viewed, e.g., either as having no linker, wherein the NP is hsTNALP (1-502), or as having a 17-amino acid linker, wherein the NP is hsTNALP (18-502).

Further, it should be noted that certain Fc-NP or NP-Fc fusion proteins may be viewed, according to the present disclosure, either as 1) having no linker, or as 2) having a linker which corresponds to a portion of the NP. For example, Fc fused directly to CNP53 may be viewed, e.g., either as having no linker, wherein the NP is CNP53, or as having a 31-amino acid linker, wherein the NP is CNP22.

### sALP Polypeptides

Any of the sALPs and linkers described herein may be combined in an sALP polypeptide, e.g., an sALP polypeptide of A-sALP-B, wherein each of A and B is absent or is an amino acid sequence of at least one amino acid. When present, A and/or B can be any linker described herein (e.g., the amino acid sequence of any one of SEQ ID NOs: 301-391). In some embodiments, A is absent, B is absent, or A and B are both absent.

The sALP polypeptides of the invention can optionally include an Fc region to provide an sALP fusion polypeptide, as described herein.

The sALP polypeptide can optionally include a bone-targeting moiety (e.g., any described herein). In some embodiments, a linker, e.g., a flexible linker, may be included between the bone-targeting moiety and the sALP. For example, Fig. 5B provide polypeptides having both a bone-targeting moiety and a linker (shown in bold) between the Fc region and the bone-targeting moiety. In some embodiments, the linker is a dipeptide sequence (e.g., leucine-lysine or aspartic acid-isoleucine) or the amino acid sequence of any one of SEQ ID NOs: 301-391.

The sALP polypeptide can include any ALPs, mutations, N-terminal signal sequence, C-terminal GPI sequence, and/or linkers, or fragments thereof, described herein. For example, the italicized regions in Figs. 5B-5C and sequences provided in Figs. 6 or 8-11 may be used as for any of the sALPs disclosed herein (e.g., SEQ ID NOs: 1201, 1202, 1204-1216, 1218, and 1219).

### *sALP Fusion Polypeptides*

Any of the sALPs, linkers, and Fc regions described herein may be combined in a fusion polypeptide, e.g., a recombinant fusion polypeptide, that includes the structure C-sALP-D-Fc-E, C-Fc-D-sALP-E, C-sALP-D-Fc-G-I<sub>n</sub>-H, or C-Fc-D-sALP-G-I<sub>n</sub>-H, where each of C, D (the linker region), E, G (linker region), and H is absent or is an amino acid sequence of at least one amino acid; I represents an aspartic acid or a glutamic acid; and n=10 to 16. D and G can be absent or can optionally include any linker described herein (e.g., the amino acid sequence of any one of SEQ ID NOs: 301-391).

The polypeptides of the invention optionally include one or more additional amino acid residues 1) at the N-terminus of the polypeptide, 2) between the sALP and Fc regions of the polypeptide, and 3) at the C-terminus of the polypeptide. Thus, the invention includes, for example, polypeptides of the form C-sALP-D-Fc-E or the structure C-Fc-D-sALP-E, where C is one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 25, 30, 35, 40, 45, 50, or more) additional amino acid residues at the N-terminus of the polypeptide, D is one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 25, 30, 35, 40, 45, 50, or more) additional amino acid residues (i.e., a linker) between the sALP and Fc regions of the polypeptide, and E is one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 25, 30, 35, 40, 45, 50, or more) additional amino acid residues at

the C-terminus of the polypeptide. In a particular example, D is the dipeptide leucine-lysine.

Alternatively, any combination of C, D, and E may be present or absent. For example, in some embodiments, C and E are both absent, and D is absent or is an amino acid sequence of at least one amino acid. For example, the polypeptide may consist of the structure sALP-D-Fc or the structure Fc-D-sALP. In some embodiments of polypeptides consisting of the structure sALP-D-Fc or Fc-D-sALP, D may consist of two amino acid residues, e.g., leucine-lysine. For example, the polypeptide may consist of the structure sALP-D-Fc. Optionally, the amino acid sequence of sALP is the amino acid sequence of SEQ ID NO: 1205, the amino acid sequence of D is leucine-lysine, and/or the amino acid sequence of Fc is the amino acid sequence of SEQ ID NO: 401. In some embodiments, the amino acid sequence of the polypeptide consists of the amino acid sequence of SEQ ID NO: 1204. In some embodiments, polypeptide includes an amino acid sequence of at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity to the amino acid sequence of SEQ ID NOs: 1204 or 1221.

In some embodiments, the polypeptide includes a bone-targeting moiety, e.g., having a series of consecutive Asp or Glu residues, e.g., E<sub>6</sub>, E<sub>7</sub>, E<sub>8</sub>, E<sub>9</sub>, E<sub>10</sub>, E<sub>11</sub>, E<sub>12</sub>, E<sub>13</sub>, E<sub>14</sub>, E<sub>15</sub>, E<sub>16</sub>, D<sub>6</sub>, D<sub>7</sub>, D<sub>8</sub>, D<sub>9</sub>, D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub>, D<sub>13</sub>, D<sub>14</sub>, D<sub>15</sub>, or D<sub>16</sub>. The bone-targeting moiety, if present, may be positioned anywhere in the fusion polypeptide, e.g., at or near the N-terminal or C-terminal end, and/or in the linker region. For example, any one of C, D, and/or E may include a bone-targeting moiety. In some embodiments, the bone-targeting moiety is at the C-terminal end. For example, the polypeptide may comprise or consist of the structure C-sALP-D-Fc-G-I<sub>n</sub>-H or the structure C-Fc-D-sALP-G-I<sub>n</sub>-H, where each of C, D (the linker region), G (linker region), and H is absent or is an amino acid sequence of at least one amino acid, I represents an aspartic acid or a glutamic acid, and n=10 to 16. In some embodiments, C and H are both absent, and D and G can be absent or can optionally include any linker described herein (e.g., the amino acid sequence of any one of SEQ ID NOs: 301-391). For example, the polypeptide may comprise or consist of the structure sALP-D-Fc-G-I<sub>n</sub> or the structure Fc-D-sALP-G-I<sub>n</sub>.

In some embodiments, polypeptide does not include a bone-targeting moiety.

A fusion polypeptide as described herein may have at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity to any of the fusion polypeptides described herein, e.g., SEQ ID NOs: 1201, 1204, 1220, or 1221. In addition, a fusion polypeptide as described herein may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, or more additions, deletions, or substitutions relative to any of the fusion polypeptides described herein.

Furthermore, in some embodiments, a fusion polypeptide as described herein may be encoded by a nucleic acid molecule that hybridizes under high stringency conditions to at least a portion, e.g., to 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or even 100%,

of a nucleic acid molecule that encodes any of the polypeptides, e.g., fusion polypeptides, described herein.

In some embodiments, additional amino acid residues can be introduced into the polypeptide according to the cloning strategy used to produce the fusion polypeptides. In some embodiments, the additional amino acid residues do not provide an additional GPI anchoring signal so as to maintain the polypeptide in a soluble form. Furthermore, in some embodiments, any such additional amino acid residues, when incorporated into the polypeptide of the invention, do not provide a cleavage site for endoproteases of the host cell. The likelihood that a designed sequence would be cleaved by the endoproteases of the host cell can be predicted as described, e.g., by Ikezawa (*Biol. Pharm. Bull.* 25:409-417, 2002).

In certain embodiments, the polypeptides of the invention are associated into dimers or tetramers. For example, two sALP-Fc monomers can covalently be linked through two disulfide bonds located in the hinge regions of the Fc fragments.

## NP Polypeptides

Any of the NPs and linkers described herein may be combined in an NP polypeptide, e.g., an NP polypeptide of V-NP-W, wherein each of V and W is absent or is an amino acid sequence of at least one amino acid.

The NP polypeptides of the invention can optionally include an Fc region to provide an NP fusion polypeptide, as described herein.

The NP polypeptide can optionally include a bone-targeting moiety. In some embodiments, a linker, e.g., a flexible linker, may be included between the bone-targeting moiety and the NP. For example, Fig. 27 provides polypeptides having a linker or both a bone-targeting moiety and a linker (SEQ ID NOs: 128-150); Figs. 31A-31B provide polypeptides having a linker or both a bone-targeting moiety and a linker, where X in any one of SEQ ID NOs: 173-220 can be any amino acid, e.g., F, L, I, T, E, R, Y, C, P, or D; and Fig. 32 provides amino acid sequences for particular variants, where X in SEQ ID NOs: 186-198 is a leucine to provide the sequences in SEQ ID NOs: 221-233.

The NP polypeptide can include any NPs, N-terminal extensions, C-terminal extensions, and/or linkers described herein. For example, the italicized regions in Figs. 30, 31A-31B, and 32 may be used as for any of the NPs disclosed herein (see, e.g., SEQ ID NOs: 511-516 and 553-558).

## *NP Fusion Polypeptides*

Any of the NPs, linkers, and Fc regions described herein may be combined in a fusion polypeptide, e.g., a recombinant fusion polypeptide, that includes the structure X-Fc-Y-NP-Z or the structure X-NP-Y-Fc-Z, wherein each of X, Y (the linker region), and Z is absent or is an amino acid sequence of at least one amino acid.

Figs. 17A-17E depict several possible schematic structures of fusion polypeptides as described herein. Fc-NP or NP-Fc homodimers may be formed, e.g., due to disulfide bonds formed by Fc (Figs. 17A and 17B, respectively). Alternative, monomer-dimer hybrids are possible in which an NP-Fc or Fc-NP fusion polypeptide is joined to a free Fc domain (Figs. 17C and 17D, respectively). Furthermore, an NP-Fc monomer may be joined to an Fc-NP monomer, as shown in Fig. 17E. These configurations not intended to be exhaustive but are merely exemplary.

Exemplary fusion polypeptides having an N-terminal NP domain and a C-terminal Fc domain include those shown in Fig. 25A and include CNP-16AAlinker-Fc-His<sub>10</sub> (NC1) (SEQ ID NO: 521); CNP-6AAlinker-Fc-His<sub>10</sub> (NC3) (SEQ ID NO: 522); CNP-6AAlinker-Fc (SEQ ID NO: 523); CDNP-Fc (SEQ ID NO: 524), which has no linker between the CDNP and Fc moieties; CDNP-A17saa-Fc (SEQ ID NO: 525), which has a mutation to alanine at position 17 of the CNP22 region and mutations S3, A4, and A5 in the DNP tail region; and CDNP-A17sra-Fc (SEQ ID NO: 526), which has a mutation to alanine at position 17 of the CNP22 region and mutations S3 and A5 in the DNP tail region. Fig. 25B is a listing of the nucleic acid sequence (SEQ ID NO: 806) of NC1.

The NP domain in the fusion polypeptide can be any NP described herein. For example, any of the molecules shown in Figs. 30, 31A-31B, and 32, with or without the bone-targeting moiety, may be fused to an Fc domain and may optionally further include a linker region between the Fc and NP, as disclosed herein. For example, a CNP variant with M17X mutation can be fused to an Fc domain, e.g., as shown in Figs. 33A-33E, where X can be any amino acid, e.g., F, L, I, T, E, R, Y, C, P, D, G, A, S, V, W, N, Q, H, or K, e.g., F, L, I, T, E, R, Y, C, P, or D, e.g., F or L. In some embodiments, the sequence is SEQ ID NO: 530, and X is any amino acid described herein, e.g., F, L, I, T, E, R, Y, C, P, D, G, A, S, V, W, N, Q, H, or K, e.g., F, L, I, T, E, R, Y, C, P, or D, e.g., F or L.

In the structure X-Fc-Y-NP-Z or the structure X-NP-Y-Fc-Z, X may include one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or more) additional amino acid residues at the N-terminus of the polypeptide, and Z may independently include one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or more) additional amino acid residues at the C-terminus of the polypeptide.

In some embodiments, the polypeptide includes a bone-targeting moiety, e.g., having a series of consecutive Asp or Glu residues, e.g., E<sub>6</sub>, E<sub>7</sub>, E<sub>8</sub>, E<sub>9</sub>, E<sub>10</sub>, E<sub>11</sub>, E<sub>12</sub>, E<sub>13</sub>, E<sub>14</sub>, E<sub>15</sub>, E<sub>16</sub>, D<sub>6</sub>, D<sub>7</sub>, D<sub>8</sub>, D<sub>9</sub>, D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub>, D<sub>13</sub>, D<sub>14</sub>, D<sub>15</sub>, or D<sub>16</sub>. The bone-targeting moiety, if present, may be positioned anywhere in the fusion polypeptide, e.g., at or near the N-terminal or C-terminal end, and/or in the linker region. For example, any one of X, Y, and/or Z may include a bone-targeting moiety.

In some instances, one or more amino acid residues are introduced into the fusion polypeptide, e.g., within X, Y, or Z, as a result of the cloning strategy used. In some embodiments, any such additional amino acid residues, when incorporated into the polypeptide of the invention, do not provide a cleavage site for endoproteases of the host cell. The likelihood that a designed sequence

would be cleaved by the endoproteases of the host cell can be predicted as described, e.g., by Ikezawa (*Biol. Pharm. Bull.* 25:409-417, 2002), hereby incorporated by reference.

In certain embodiments, the fusion polypeptides of the invention are associated into dimers, e.g., through two disulfide bonds located in the hinge regions of the Fc fragments.

5 In some embodiments, the fusion polypeptides of the invention have at least, e.g., 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 12.5, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,500, 2,000, 3,000, 4,000, 5,000, 7,500, 10,000, 15,000, 20,000, 25,000, 30,000, 40,000, or 50,000 times the half-life of CNP22 *in vivo*.

10 Any NP fusion protein may be expressed with an N-terminal signal sequence to facilitate secretion, e.g., amino acid residues 1-25 of SEQ ID NO: 501, or any other signal sequence known in the art. Such sequences are generally cleaved co-translationally, resulting in secretion of the mature version of the protein.

A fusion polypeptide as described herein may have at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 15 96%, 97%, 98%, 99%, or more) sequence identity to any of the fusion polypeptides described herein, e.g., SEQ ID NOs: 501-608. In addition, a fusion polypeptide as described herein may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, or more additions, deletions, or substitutions relative to any of the fusion polypeptides described herein. Furthermore, in some embodiments, a fusion polypeptide as described herein may be encoded by a nucleic acid molecule 20 that hybridizes under high stringency conditions to at least a portion, e.g., to 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or even 100%, of a nucleic acid molecule that encodes any of the polypeptides, e.g., fusion polypeptides, described herein.

Fusion proteins include those having one or more modifications that are cleaved during expression. For example, an Fc-CNP fusion protein was designed as shown in Figs. 18A and 18B. 25 This protein, termed "NC2 Strep-tag" or "NC2st," has a 25-amino acid N-terminal signal sequence that is cleaved during expression. The mature protein has the following domain structure, from N terminus to C terminus: Strep-tag II sequence (to facilitate purification) flanked by short linker sequences; TEV protease cleavage sequence, followed by a short linker; Fc domain of human IgG-1; 16-amino acid glycine-rich linker; and CNP22. This protein can be produced by chemically 30 synthesizing the coding sequence (Fig. 18C, SEQ ID NO: 801) and inserting the coding sequence into a small cloning plasmid using standard techniques known in the art.

Fusion proteins may be varied in several respects. For example, NC2st can be varied by eliminating the sequence that is N-terminal to the Fc domain (resulting, e.g., in NC2B, as shown in Figs. 19A-19B), adding a bone-targeting moiety (resulting, e.g., in D10-NC2, as shown in Fig. 19A), 35 and/or altering of the length of the linker between Fc and CNP22 (e.g., NC2B-22 (also referred to as NC2-22), NC2B-28 (also referred to as NC2-28), and NC2B-34 (also referred to as NC2-34), as

shown in Figs. 20A-20D). Other exemplary NC2st variants are shown in Fig. 21 (NC2-KGANKK and NC2-KGANQK) and Fig. 22 (NC2-CNP53mut2).

NC2B may be varied in several respects, including having a point mutation, e.g., at position 17 relative to CNP22, having a bone-targeting moiety, and/or having modified or altered linker

5 regions. Exemplary fusion protein include any sequences having a modified or altered linker region (e.g., SEQ ID NOs: 511-516, as shown in Fig. 34A), as compared to NC2B (as shown in Figs. 16A-16B); any sequences having a bone-targeting moiety, e.g., a D<sub>10</sub> moiety (e.g., SEQ ID NOs: 553-558, as shown in Fig. 34B); any N-terminal extensions, C-terminal extensions, and/or linkers for any of the NPs disclosed herein (e.g., the italicized regions in SEQ ID NOs: 511-516 and 553-558, as shown in  
10 Figs. 30, 31A-31B, and 32); any sequences having a phenylalanine (Phe, F) substitution at position 17 relative to CNP22 (e.g., SEQ ID NOs: 559-564, as shown in Fig. 34C), including those sequences having a further modification of a D<sub>10</sub> bone-targeting moiety at the N-terminus (e.g., SEQ ID NOs: 565-570, as shown in Fig. 34D); any sequences having a leucine (Leu, L) substitution at position 17 relative to CNP22 (e.g., SEQ ID NOs: 571-576, as shown in Fig. 34E), including those sequences  
15 having a further modification of a D<sub>10</sub> bone-targeting moiety at the N-terminus (e.g., SEQ ID NOs: 577-582, as shown in Fig. 34F); any sequences having an arginine (Arg, R) substitution at position 17 relative to CNP22 (e.g., SEQ ID NOs: 583-588, as shown in Fig. 34G), including those sequences having a further modification of a D<sub>10</sub> bone-targeting moiety at the N-terminus (e.g., SEQ ID NOs: 589-594, as shown in Fig. 34H); and any sequences having a tyrosine (Tyr, Y) substitution at position  
20 17 relative to CNP22 (e.g., SEQ ID NOs: 595-600, as shown in Fig. 34I), including those sequences having a further modification of a D<sub>10</sub> bone-targeting moiety at the N-terminus (e.g., SEQ ID NOs: 601-606, as shown in Fig. 34J).

Additional constructs include fusion proteins in which an N-terminal Fc domain is fused to a variant of CNP53 with a short Gly<sub>3</sub> linker region. An alternative way to analyze these fusion  
25 polypeptides is that the linker region is Gly<sub>3</sub> followed by amino acid residues 1-31 of CNP53 (or variants thereof); viewed in this way, the linker region connects the Fc domain to CNP22 and is 34 amino acid residues in length. For Fc-CNP53-A (also referred to as "Fc-CNP53wt") (SEQ ID NOs: 517 (with signal sequence) and 518 (without signal sequence); Fig. 23), position 48 of CNP53, corresponding to position 17 of CNP22, was mutated to alanine. Fc-CNP53-AAA (also referred to as  
30 "Fc-CNP53mut") (SEQ ID NOs: 519 (with signal sequence) and 520 (without signal sequence); Fig. 23) has the same sequence as Fc-CNP53-A with the exception that residues 30 and 31 of CNP53, the two residues immediately before CNP22, are mutated to alanine in order to reduce the likelihood of proteolytic cleavage. In some cases, modifying the linker region of an Fc-CNP22 fusion to include the first 31 amino acid residues of CNP53 could result in constructs having even greater potency and  
35 efficacy than NC2st in *in vitro* membrane and whole cell assays.

### Additional Polypeptide Features

The polypeptides of the invention also include any polypeptide having one or more post-translational modifications such as glycosylation (e.g., mannosylation and other forms of glycosylation discussed herein), acetylation, amidation, blockage, formylation, gamma-carboxyglutamic acid hydroxylation, methylation, ubiquitination, phosphorylation, pyrrolidone carboxylic acid modification, and sulfation. Artificial modifications, e.g., pegylation, may also be made.

### Production of Nucleic Acids and Polypeptides

The nucleic acids and polypeptides of the invention can be produced by any method known in the art. Typically, a nucleic acid encoding the desired fusion protein is generated using molecular cloning methods, and is generally placed within a vector, such as a plasmid or virus. The vector is used to transform the nucleic acid into a host cell appropriate for the expression of the fusion protein. Representative methods are disclosed, for example, in Maniatis et al. (Cold Springs Harbor Laboratory, 1989). Many cell types can be used as appropriate host cells, although mammalian cells are preferable because they are able to confer appropriate post-translational modifications. For example, Human Embryonic Kidney 293 (HEK293) cells have been used as a host for expressing the fusion proteins of the present invention, as described in more detail in the Examples below.

The polypeptides of the invention can be produced under any conditions suitable to effect expression of the polypeptide in the host cell. Such conditions include appropriate selection of a media prepared with components such as a buffer, bicarbonate and/or HEPES, ions like chloride, phosphate, calcium, sodium, potassium, magnesium, iron, carbon sources like simple sugars, amino acids, potentially lipids, nucleotides, vitamins and growth factors like insulin; regular commercially available media like alpha-MEM, DMEM, Ham's-F12, and IMDM supplemented with 2-4 mM L-glutamine and 5% Fetal bovine serum; regular commercially available animal protein free media like Hyclone™ SFM4CHO, Sigma CHO DHFR, Cambrex POWER™ CHO CD supplemented with 2-4 mM L-glutamine. These media are desirably prepared without thymidine, hypoxanthine and L-glycine to maintain selective pressure, allowing stable protein-product expression.

Additional details of the production of the polypeptides and nucleic acids of the invention are given in the Examples.

### Therapeutic Applications

The polypeptides and nucleic acid molecules described herein can have a wide variety of therapeutic applications, e.g., in the fields of neurocutaneous syndromes (e.g., neurofibromatosis) or disorders associated with overactivation of FGFR3 (e.g., bone and cartilage disorders, e.g., achondroplasia, or cancers, e.g., multiple myeloma) or bone or cartilage disorders (e.g., that are not associated with overactivation of FGFR3) or vascular smooth muscle disorders. In addition, the

polypeptides and nucleic acid molecules described herein can be used for any condition or disorder that would benefit from elongation of bone.

### *Neurocutaneous Syndromes*

5       The polypeptides and nucleic acid molecules described herein can be used to treat any disorder, disease, or other abnormality associated with elevated blood and/or urine levels of inorganic pyrophosphate (PP<sub>i</sub>) and/or overactivation of MAP kinase, such as neurocutaneous syndromes. In particular embodiments, the polypeptide and nucleic acid molecules are used to treat a neurocutaneous syndrome either with or without a bone manifestation. Exemplary neurocutaneous  
10       syndromes include neurofibromatosis (e.g., any type described herein, such as type I or type II); Noonan syndrome-like disorder with loose anagen hair; Noonan syndrome-like disorder with juvenile myelomonocytic leukemia (JMML); tuberous sclerosis; Sturge-Weber disease; ataxia telangiectasia; von Hippel-Lindau disease; incontinentia pigmenti; epidermal nevus syndromes, such as linear sebaceous nevus of Jadassohn; nevoid basal cell carcinoma syndrome; hypomelanosis of Ito;  
15       neurocutaneous melanosis; Klippel-Trenaunay syndrome; and Waardenburg syndrome, including types I, II, III, and IV.

### *Neurofibromatosis*

Neurofibromatosis is an autosomal dominant neurocutaneous syndrome characterized by  
20       abnormal growth or proliferation of nerve tissue, such as to produce tumors (or neurofibromas) or abnormal pigmentation (e.g., café au lait spots). In particular, neurofibromatosis can be accompanied by bone manifestations (e.g., manifestations arising from hypophosphatasia), such as short stature, scoliosis, osteomalacia, osseous fibrous dysplasia (e.g., one or more lesions at the ends of or within one or more bones, such as the femur, tibia, or fibula), pseudarthrosis (e.g., tibial pseudarthrosis),  
25       and/or skeletal dysplasia (e.g., tibial dysplasia, orbital dysplasia, and/or sphenoid wing dysplasia).

Neurofibromatosis, or any of its manifestations or phenotypes, can be treated using the compositions and methods described herein. Examples of such disorders, manifestations, and phenotypes include the classic von Recklinghausen type (type I), either with gastrointestinal stromal tumors (i.e., as in intestinal neurofibromatosis (type 3B)) or without such tumors; an acoustic neuroma  
30       type (type II); a mixed type that combines the features of types I and II with predominant features, such as bilateral acoustic neuromas, posterior fossa and upper cervical meningiomas, and spinal/paraspinal neurofibromas (type III, Riccardi type or type 3A); an atypical type that is distinguished from by the lack of iris Lisch nodules that are characteristic of type I (type VI); segmental neurofibromatosis, which is a variant of type I having lesions affecting a specific area of  
35       the body, such as a single segment of the body or an area that crosses the midline (type V); a type having only the symptoms of café au lait spots without other manifestations of neurofibromatosis (type VI); familial spinal neurofibromatosis, which is caused by mutation in the neurofibromin gene

NF1 and considered a distinguishable variant of type I; other variants of type I, such as neurofibromatosis-pheochromocytoma-duodenal carcinoid syndrome; neurofibromatosis with manifestations of Noonan syndrome, such as short stature, ptosis, midface hypoplasia, webbed neck, learning disabilities, and muscle weakness; and schwannomatosis, where any of these disorders can include or exclude one or more bone manifestations.

***Disorders Associated with Overactivation of RAS and/or ERK***

Any disorder, disease, or other abnormality that is caused by, or is associated with, overactivation of RAS and/or ERK may be treated using the compositions and methods described herein. These disorders, diseases, and other abnormalities include, without limitation, Noonan syndrome, Costello syndrome, Noonan syndrome with multiple lentigines/LEOPARD syndrome, neurofibromatosis type 1, NF1-Noonan syndrome, hereditary gingival fibromatosis type 1, capillary malformation-AV malformation syndrome, Legius syndrome, Noonan syndrome-like disorder with loose anagen hair, Noonan syndrome-like disorder with juvenile myelomonocytic leukemia (JMML), cardio-facio-cutaneous syndrome, or autoimmune lymphoproliferative syndrome, where any of these disorders can include or exclude one or more bone manifestations.

***Disorders Associated with Overactivation of FGFR3***

Any disorder, disease, or other abnormality that is caused by, or is associated with, overactivation of FGFR3, e.g., stemming from a gain-of-function FGFR3 mutation, may be treated using the compositions and methods described herein. These disorders, diseases, and other abnormalities include, without limitation, bone or cartilage disorders and cancers, each of which is described in more detail below.

***Bone or Cartilage Disorders Associated with Overactivation of FGFR3***

Any disorder, disease, or other abnormality, e.g., skeletal dysplasia, that affects the function, structure, or growth of bone or cartilage, may be treated using the compositions and methods described herein. In particular, the disorder may be a skeletal dysplasia that is associated with overactivation of FGFR3, such as achondroplasia, including severe achondroplasia with developmental delay and acanthosis; Muenke syndrome (Muenke coronal craniosynostosis); Crouzonodermoskeletal syndrome; hypochondroplasia; thanatophoric dysplasia type I; and thanatophoric dysplasia type II. The compositions and methods of the invention can also be used to treat bone or cartilage disorders not associated with overactivation of FGFR3, and these disorders are described in more detail below.

### *Cancers*

Any cancer that is caused by, or is associated with, overactivation of FGFR3, may be treated using the compositions and methods described herein. These cancers include, e.g., multiple myeloma, myeloproliferative syndromes, leukemia (e.g., plasma cell leukemia), lymphomas, glioblastoma, prostate cancer, bladder cancer, and mammary cancer.

### *Bone or Cartilage Disorders*

The polypeptides and nucleic acid molecules described herein can be used to treat any disorder, disease, phenotype, or other abnormality that affects the function, structure, or growth of bone or cartilage. These bone or cartilage disorders may be, but do not necessarily have to be, associated with overactivation of FGFR3.

Exemplary bone or cartilage disorders include skeletal dysplasia and any other disorders, diseases, phenotypes, or other abnormalities related to the bone or cartilage, including achondroplasia (e.g., homozygous or heterozygous achondroplasia), achondrogenesis, acrodysostosis, acromesomelic dysplasia, atelosteogenesis, bone pain, calcium pyrophosphate dihydrate (CPPD) crystal deposition, camptomelic dysplasia, chondrodysplasia punctata (e.g., rhizomelic type of chondrodysplasia punctata), cleidocranial dysostosis, congenital short femur, craniosynostosis (e.g., Muenke syndrome, Crouzon syndrome, Apert syndrome, Jackson-Weiss syndrome, Pfeiffer syndrome, or Crouzonodermoskeletal syndrome), dactyly (e.g., brachydactyly, camptodactyly, polydactyly, or syndactyly), diastrophic dysplasia, dental disorders (e.g., decrease in teeth mineralization and premature loss of deciduous teeth, such as through aplasia, hypoplasia or dysplasia of the dental cementum), dwarfism, dyssegmental dysplasia, enchondromatosis, fibrochondrogenesis, fibrous dysplasia, hereditary multiple exostoses, hypochondroplasia, hypophosphatasia (HPP) (e.g., infantile HPP, childhood HPP, perinatal HPP, adult HPP, or odontohypophosphatasia), HPP-related seizure, hypophosphatemic rickets, incomplete bone mineralization, Jaffe-Lichtenstein syndrome, Kniest dysplasia, Kniest syndrome, Langer-type mesomelic dysplasia, Marfan syndrome, McCune-Albright syndrome, micromelia, metaphyseal dysplasia (e.g., Jansen-type metaphyseal dysplasia), metatrophic dysplasia, Morquio syndrome, Nievergelt-type mesomelic dysplasia, neurofibromatosis (e.g., type 1, e.g., with bone manifestations or without bone manifestations; type 2; or schwannomatosis), osteoarthritis, osteochondrodysplasia, osteogenesis imperfecta (e.g., perinatal lethal type of osteogenesis imperfecta), osteomalacia, osteopetrosis, osteopoikilosis, osteoporosis, peripheral dysostosis, Reinhardt syndrome, Roberts syndrome, Robinow syndrome, short-rib polydactyly syndromes, short stature, spondyloepiphyseal dysplasia congenita, spondyloepimetaphyseal dysplasia, or thanatophoric dysplasia. Bone or cartilage disorders also include those that can be diagnosed, for example, by elevated blood and/or urine levels of one or more clinical markers related to hypophosphatasia (e.g., elevated levels of inorganic pyrophosphate ( $PP_i$ ), phosphoethanolamine

(PEA), and/or pyridoxal 5'-phosphate (PLP)), growth retardation with a decrease of long bone length (such as femur, tibia, humerus, radius, ulna), a decrease of the mean density of total bone, or a decrease of bone mineralization in bones such as femur, tibia, ribs and metatarsi, and phalange.

Without being so limited, treatment of bone or cartilage disorders may be observed by one or more of the following: an increase of long bone length, an increase of mineralization in bone and/or teeth, a correction of bowing of the legs, a reduction of bone pain, and a reduction of CPPD crystal deposition in joints.

### *Skeletal Dysplasia*

Skeletal dysplasias are bone or cartilage disorders characterized by short stature or dwarfism. Skeletal dysplasias are typically congenital and may include numerous abnormalities in addition to short stature, e.g., short limbs and trunk; bowlegs; a waddling gait; skull malformations, e.g., a large head, cloverleaf skull, craniosynostosis (premature fusion of the bones in the skull), or wormian bones (abnormal thread-like connections between the bones in the skull); anomalies of the hands and feet, e.g., polydactyly (extra fingers), "hitchhiker" thumbs, and abnormal fingernails and toenails; or chest anomalies, e.g., pear-shaped chest or narrow thorax. Non-skeletal abnormalities may also be present in individuals having skeletal dysplasia, e.g., anomalies of the eyes, mouth, and ears, such as congenital cataracts, myopia, cleft palate, or deafness; brain malformations, such as hydrocephaly, porencephaly, hydranencephaly, or agenesis of the corpus callosum; heart defects, such as atrial septal defect, patent ductus arteriosus, or transposition of the great vessels; developmental delays; or mental retardation. Skeletal dysplasias associated with overactivation of FGFR3 include achondroplasia.

Skeletal dysplasias include achondroplasia (e.g., homozygous or heterozygous achondroplasia), achondrogenesis, acrodysostosis, acromesomelic dysplasia, atelosteogenesis, camptomelic dysplasia, chondrodysplasia punctata (e.g., rhizomelic type of chondrodysplasia punctata), cleidocranial dysostosis, congenital short femur, craniosynostosis (e.g., Muenke syndrome, Crouzon syndrome, Apert syndrome, Jackson-Weiss syndrome, Pfeiffer syndrome, or Crouzonodermoskeletal syndrome), dactyly (e.g., brachydactyly, camptodactyly, polydactyly, or syndactyly), diastrophic dysplasia, dwarfism, dyssegmental dysplasia, enchondromatosis, fibrochondrogenesis, fibrous dysplasia, hereditary multiple exostoses, hypochondroplasia, hypophosphatasia (HPP) (e.g., infantile HPP, childhood HPP, perinatal HPP, adult HPP, or odontohypophosphatasia), hypophosphatemic rickets, Jaffe-Lichtenstein syndrome, Kniest dysplasia, Kniest syndrome, Langer-type mesomelic dysplasia, Marfan syndrome, McCune-Albright syndrome, micromelia, metaphyseal dysplasia (e.g., Jansen-type metaphyseal dysplasia), metatrophic dysplasia, Morquio syndrome, Nievergelt-type mesomelic dysplasia, neurofibromatosis (e.g., type 1, e.g., with bone manifestations or without bone manifestations; type 2; or schwannomatosis), osteoarthritis, osteochondrodysplasia, osteogenesis imperfecta (e.g., perinatal lethal type of osteogenesis imperfecta), osteopetrosis, osteopoikilosis, peripheral dysostosis, Reinhardt syndrome, Roberts

syndrome, Robinow syndrome, short-rib polydactyly syndromes, short stature, spondyloepiphyseal dysplasia congenita, spondyloepimetaphyseal dysplasia, or thanatophoric dysplasia.

In particular, some forms of craniosynostosis are the result of mutations in one of the fibroblast growth factor receptors (e.g., one or more of FGFR1, FGFR2, or FGFR3) that cause the activation of the MAPK pathway. This is the case for Muenke (Muenke coronal craniosynostosis), Crouzon, Apert, Jackson-Weiss, Pfeiffer, and Crouzonodermoskeletal syndromes, for example. There is genetic and biochemical evidence in the scientific literature that agents that can prevent activation of the MAP-kinase (ERK 1/2) can prevent craniosynostosis in animal models. In particular, use of a MEK1/2 inhibitor (e.g., U0126), which prevents activation of ERK1/2 can prevent craniosynostosis in an animal model of Apert syndrome (Shukla et al., *Nat. Genet.* 39:1145, 2007). Accordingly, the compounds of the present invention, which can prevent activation of the MAP-kinase pathway, could be used to treat these forms of craniosynostosis.

#### *Achondroplasia*

Achondroplasia is an autosomal dominant skeletal dysplasia that is the most common cause of dwarfism in humans. Its incidence is approximately 1 in 20,000 live births. Skeletal manifestations include growth retardation (with an average adult height of 123-131 cm (4 feet ½ in. – 4 feet 3½ in.)), skull deformities, and orthodontic defects. Extraskelatal manifestations include cervical cord compression (with risk of death, e.g., from central apnea or seizures); spinal stenosis (e.g., leg and lower back pain); hydrocephalus (e.g., requiring cerebral shunt surgery); hearing loss due to chronic otitis; cardiovascular disease; neurological disease; higher frequency of accidents; and obesity.

Babies are often diagnosed at birth. While the homozygous form is usually lethal, individuals diagnosed with the heterozygous form have a life expectancy, on average, of 15 years less than the normal population.

Heterozygous or homozygous achondroplasia, or any of its manifestations or phenotypes, can be treated using the compositions and methods described herein. Treatment of either form may be started as early as possible in the patient's life, e.g., shortly after birth, or even *in utero*; this is particularly important for treatment of the homozygous form, which is typically much more severe and is often lethal if untreated.

#### *Hypophosphatasia (HPP)*

HPP is a matrix mineralization disorder that is historically classified according to age at diagnosis and includes (in order from most severe to least severe) perinatal, infantile, childhood, adult, and odontohypophosphatasia forms. The most severe form, perinatal (lethal) HPP, is manifest as an almost complete absence of bone mineralization *in utero* and can cause stillbirth. Some neonates with perinatal HPP may survive for several days, but suffer increased respiratory compromise due to hypoplastic and rachitic disease of the chest. In infantile HPP, diagnosed before 6

months-of-age, postnatal development seems normal until the onset of poor feeding, inadequate weight gain, and appearance of rickets. Infantile HPP has characteristic radiological features showing impaired skeletal mineralization, sometimes with progressive skeletal demineralization leading to rib fractures and chest deformity. Childhood HPP has highly variable clinical expression. One symptom of childhood HPP is the premature loss of deciduous teeth resulting from aplasia, hypoplasia or dysplasia of dental cementum that connects the tooth root with the periodontal ligament. Another symptom of childhood HPP is rickets, which causes short stature and skeletal deformities such as bowed legs and enlarged wrists, knees and ankles as a result of flared metaphysis. Adult HPP usually presents during middle age, but is frequently preceded by a history of rickets and/or early loss of teeth followed by good health during adolescence and young adult life. In adult HPP, recurrent metatarsal stress fractures are common, and calcium pyrophosphate dihydrate deposition can cause attacks of arthritis and pyrophosphate arthropathy. Finally, odontohypophosphatasia is diagnosed when the only clinical abnormality is dental disease, and radiological studies and even bone biopsies reveal no signs of rickets or osteomalacia.

The more severe clinical forms of HPP are usually inherited as autosomal recessive traits, with parents of such patients showing subnormal levels of serum AP activity. For the milder forms of HPP, i.e., adult HPP and odontohypophosphatasia, an autosomal dominant pattern of inheritance has also been documented.

In the healthy skeleton, TNALP is an ectoenzyme present on the surface of the plasma membrane of osteoblasts and chondrocytes, and on the membranes of their shed matrix vesicles (MVs), where the enzyme is particularly enriched. Deposition of hydroxyapatite during bone mineralization normally initiates within the lumen of these MVs. Electron microscopy has shown that TNALP-deficient MVs from severely affected HPP patients and *Akp2*<sup>-/-</sup> mice (a TNALP null mouse model, see below) contain hydroxyapatite crystals, but that extravesicular crystal propagation appears retarded. This defect is attributed to the extracellular accumulation of  $PP_i$ , a potent inhibitor of calcification, due to a deficiency of TNALP activity.

At physiological concentrations (0.01-0.1 mM),  $PP_i$  has the ability to stimulate mineralization. This has been demonstrated in organ-cultured chick femurs and in isolated rat MVs. However, at concentrations above 1 mM,  $PP_i$  inhibits calcium phosphate mineral formation by coating hydroxyapatite crystals, thus preventing mineral crystal growth and proliferative self-nucleation. Thus,  $PP_i$  has a dual physiological role: it functions as a promoter of mineralization at low concentrations but as an inhibitor of mineralization at higher concentrations. TNALP has been shown to hydrolyze the mineralization inhibitor  $PP_i$  to facilitate mineral precipitation and growth. Recent studies using the *Akp2*<sup>-/-</sup> mice have indicated that the primary role of TNALP *in vivo* is to restrict the size of the extracellular  $PP_i$  pool to allow proper skeletal mineralization.

The severity of hypophosphatasia depends on the nature of the TNALP mutation. Missense mutations at a variety of positions in TNALP, including the enzyme's active site vicinity, homodimer

interface, crown domain, amino-terminal arm, and calcium-binding site, have all been found to affect its catalytic activity. In addition, missense, nonsense, frame-shift, and splice site mutations have also been shown to lead to aberrant mutant proteins or intracellular trafficking defects that lead to subnormal activity on the cell surface. The multitude of mutations that cause HPP, and the fact that compound heterozygosity is a common occurrence in HPP, explain the variable expressivity and incomplete penetrance often observed in this disease.

Progress on the human form of HPP has benefited greatly from the existence of the TNALP null mice (*Akp2*<sup>-/-</sup>), an animal model of HPP. *Akp2*<sup>-/-</sup> mice phenocopy infantile HPP remarkably well: they are born with a normally mineralized skeleton but develop radiographically apparent rickets at about 6 days of age, and die between days 12-16 suffering severe skeletal hypomineralization and episodes of apnea and epileptic seizures attributable to disturbances in PLP (vitamin B<sub>6</sub>) metabolism.

Both PP<sub>i</sub> and PLP are confirmed natural substrates of TNALP, and some TNALP active site mutations have been shown to have different effects on the ability of the enzyme to metabolize PP<sub>i</sub> and PLP. Abnormalities in PLP metabolism explain the epileptic seizures observed in *Akp2*<sup>-/-</sup> mice, while abnormalities in PP<sub>i</sub> metabolism explain the skeletal phenotype in this mouse model of HPP.

In any of the methods of the invention, the pharmaceutical compositions described herein are optionally administered in an amount that is therapeutically effective to treat a HPP phenotype selected from the group consisting of HPP-related seizure, premature loss of deciduous teeth, incomplete bone mineralization, elevated blood and/or urine levels of PP<sub>i</sub>, elevated blood and/or urine levels of PEA, elevated blood and/or urine levels of PLP, inadequate weight gain, rickets, bone pain, calcium pyrophosphate dihydrate crystal deposition, aplasia, hypoplasia, and dysplasia of the dental cementum. In some embodiments, the incomplete bone mineralization is incomplete femoral bone mineralization, incomplete tibial bone mineralization, incomplete metatarsal bone mineralization, or incomplete rib bone mineralization.

### ***Vascular Smooth Muscle Disorders***

The polypeptides and nucleic acid molecules described herein can be used to treat any disorder, disease, or other abnormality that affects the function, structure, or growth of vascular smooth muscle. For example, natriuretic peptides modulate salt and water homeostasis in the body and in this way act as regulators of blood pressure. The peptides belonging to this family have varying amino acid sequences and are secreted through different mechanisms by various tissues in the body. For example, ANP is released by muscle cells in the upper chambers (atria) of the heart (atrial myocytes) and acts as a vasodilator; BNP is secreted by the lower chambers (ventricles) of the heart in response to cardiac stress; and CNP exerts natriuretic and natriuretic effect and regulates vessel tone, inhibits migration and proliferation of vascular smooth muscle cell. Accordingly, the polypeptides and compositions of the invention can be used to treat vascular smooth muscle disorders. Exemplary vascular smooth muscle disorders are hypertension, restenosis, arteriosclerosis, acute decompensated

heart failure, congestive heart failure, cardiac edema, nephredema, hepatic edema, acute renal insufficiency, and chronic renal insufficiency.

### ***Conditions for Elongation of Bone***

5 Any condition, disorder, disease, or other abnormality that would benefit from elongation of bone may be treated using the compositions and methods described herein. These conditions, disorders, diseases, and other abnormalities include, without limitation, insufficient or impaired bone growth arising from fractures, renal failure or insufficiency, poor diet, vitamin deficiency, or hormone deficiency. Healthy subjects, e.g., those without any conditions, disorders, diseases, or other  
10 abnormalities related to bone or cartilage, may also be treated using the compositions and methods described herein, e.g., for cosmetic purposes.

Skeletal dysplasias are also associated with shortened segments of long bones. Exemplary skeletal dysplasias include those associated with rhizomelia (or shortening in a proximal segment of a limb, e.g., in the humerus or femur), such as achondroplasia, atelosteogenesis, congenital short femur,  
15 diastrophic dysplasia, hypochondroplasia, Jansen type of metaphyseal dysplasia, rhizomelic type of chondrodysplasia punctata, spondyloepiphyseal dysplasia congenita, and thanatophoric dysplasia; mesomelia (or shortening in a middle segment of a limb, e.g., in the radius, ulna, tibia, or fibula), such as Langer and Nievergelt types of mesomelic dysplasias, Robinow syndrome, and Reinhardt syndrome; acromelia (or shortening in a distal segment of a limb, e.g., in the metacarpals or  
20 phalanges), such as acrodysostosis and peripheral dysostosis; acromesomelia (or shortening in the middle and distal segments of limbs, e.g., in the forearms and hands), such as acromesomelic dysplasia; micromelia (or shortening in the entire limb), such as achondrogenesis, fibrochondrogenesis, dyssegmental dysplasia, Kniest dysplasia, and Roberts syndrome; or short-trunk, such as Dyggve-Melchior-Clausen disease, Kniest syndrome, metatrophic dysplasia, Morquio  
25 syndrome, spondyloepimetaphyseal dysplasia, and spondyloepiphyseal dysplasia congenita.

### ***Combination Therapy***

The combinations of the polypeptides of the invention (e.g., a combination of an sALP polypeptide and an NP polypeptide, such as a combination of an sALP fusion protein and an NP  
30 fusion protein) are useful for the treatment of any disease or condition described herein. Therapy may be performed alone or in conjunction with another therapy (e.g., surgery, radiation therapy, immunotherapy, or gene therapy). Additionally, a person having a greater risk of developing a disease described herein (e.g., one who is genetically predisposed or one who previously had a neurocutaneous syndrome) may receive prophylactic treatment to inhibit or delay disease formation.  
35 The duration of the combination therapy depends on the type of disease or disorder being treated, the age and condition of the patient, the stage and type of the patient's disease, and how the patient

responds to the treatment. Therapy may be given in on-and-off cycles that include rest periods so that the patient's body has a chance to recovery from any as yet unforeseen side-effects.

The administration of a combination of the polypeptides of the present invention (e.g., a combination of an sALP polypeptide and an NP polypeptide) allows for the administration of lower doses of each polypeptide, providing similar efficacy and lower toxicity compared to administration of either polypeptide alone. Alternatively, such combinations result in improved efficacy in treating a disease described herein (e.g., a neurocutaneous syndrome, such as neurofibromatosis) with similar or reduced adverse events over the single agent alone, at moderate or high doses.

### *Formulation*

Formulation will depend on the route of administration, as well as on other therapeutic goals. The polypeptides and nucleic acid molecules described herein can be administered by any route known in the art, e.g., subcutaneous (e.g., by subcutaneous injection), intravenously, orally, nasally, intramuscularly, sublingually, intrathecally, or intradermally. By way of example, pharmaceutical compositions of the invention can be in the form of a liquid, solution, suspension, pill, capsule, tablet, gelcap, powder, gel, ointment, cream, nebulae, mist, atomized vapor, aerosol, or phytosome.

In some embodiments of the invention, the compositions of the invention can be administered subcutaneously. Subcutaneous administration is advantageous because it is relatively non-invasive and offers desirable pharmacokinetic profiles. Suitable volumes are known to those skilled in the art, and are typically 5 mL or smaller (e.g., 4 mL, 3.5 mL, 3 mL, 2.7 mL, 2.5 mL, 2.3 mL, 2.2 mL, 2.1 mL, 2.0 mL, 1.9 mL, 1.8 mL, 1.7 mL, 1.5 mL, 1.3 mL, 1.0 mL, 0.7 mL, 0.5 mL, 0.3 mL, 0.1 mL, 0.05 mL, 0.01 mL, or smaller). Typically, the compositions of the invention can be formulated at a concentration between 1 mg/mL and 500 mg/mL (e.g., between 10 mg/mL and 300 mg/mL, 20 mg/mL and 120 mg/mL, 40 mg/mL and 200 mg/mL, 30 mg/mL and 150 mg/mL, 40 mg/mL and 100 mg/mL, 50 mg/mL and 80 mg/mL, or 60 mg/mL and 70 mg/mL) for subcutaneous administration.

For oral administration, tablets or capsules can be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets can be coated by methods known in the art. Liquid preparations for oral administration can take the form of, for example, solutions, syrups, or suspension, or they can be presented as a dry product for constitution with saline or other suitable liquid vehicle before use. Compositions of the invention for oral administration also can contain pharmaceutically acceptable excipients such as suspending agents, emulsifying agents, non-aqueous vehicles, preservatives, buffer salts, flavoring, coloring, and sweetening agents as appropriate. Preparations for oral administration also can be suitably formulated to give controlled release of the active ingredients.

Enteric coatings can further be used on tablets of the present invention to resist prolonged contact with the strongly acidic gastric fluid, but dissolve in the mildly acidic or neutral intestinal environment. Without being so limited, cellulose acetate phthalate, Eudragit™ and hydroxypropyl

methylcellulose phthalate (HPMCP) can be used in enteric coatings of pharmaceutical compositions of the present invention. Cellulose acetate phthalate concentrations generally used are 0.5-9.0% of the core weight. The addition of plasticizers improves the water resistance of this coating material, and formulations using such plasticizers are more effective than when cellulose acetate phthalate is used alone. Cellulose acetate phthalate is compatible with many plasticizers, including acetylated monoglyceride; butyl phthalylbutyl glycolate; dibutyl tartrate; diethyl phthalate; dimethyl phthalate; ethyl phthalylethyl glycolate; glycerin; propylene glycol; triacetin; triacetin citrate; and tripropionin. It is also used in combination with other coating agents such as ethyl cellulose, in drug controlled-release preparations.

The compounds of the invention may be administered in combination with pharmaceutically acceptable, sterile, aqueous or non-aqueous solvents, suspensions or emulsions. Examples of nonaqueous solvents are propylene glycol, polyethylene glycol, vegetable oil, fish oil, and injectable organic esters. Aqueous carriers include water, water-alcohol solutions, emulsions or suspensions, including saline and buffered medical parenteral vehicles including sodium chloride solution, Ringer's dextrose solution, dextrose plus sodium chloride solution, Ringer's solution containing lactose, or fixed oils. Intravenous vehicles may include fluid and nutrient replenishers, electrolyte replenishers, such as those based upon Ringer's dextrose, and the like.

In some embodiments, the pharmaceutical compositions of the present invention can be delivered in a controlled release system. In some embodiments, polymeric materials including polylactic acid, polyorthoesters, cross-linked amphipathic block copolymers and hydrogels, polyhydroxy butyric acid and polydihydropyrans can be used (see also Smolen and Ball, *Controlled Drug Bioavailability, Drug product design and performance*, 1984, John Wiley & Sons; Ranade and Hollinger, *Drug Delivery Systems, pharmacology and toxicology series*, 2003, 2<sup>nd</sup> edition, CRC Press). In another embodiment, a pump may be used (Saudek et al., 1989, *N. Engl. J. Med.* 321: 574).

The compositions of the invention could be formulated in the form of a lyophilized powder using appropriate excipient solutions (e.g., sucrose) as diluents.

Furthermore, cells can be isolated from an individual having a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, e.g., achondroplasia, a bone or cartilage disorder, or a vascular smooth muscle disorder or from an individual that would benefit from bone elongation; transformed with a nucleic acid of the invention; and reintroduced to the afflicted individual (e.g., subcutaneous or intravenous injection). Alternatively, the nucleic acid can be administered directly to the afflicted individual, for example, by injection. The nucleic acid can also be delivered through a vehicle such as a liposome, which can be designed to be targeted to a specific cell type, and engineered to be administered through different routes.

The polypeptides or compositions of the present invention may also be used in combination with at least one other active ingredient to correct, e.g., an achondroplasia phenotype, neurofibromatosis, HPP, or any other disorder or condition described herein.

For combination therapy, two or more of the polypeptides of the present invention (e.g., an sALP polypeptide and an NP polypeptide) are formulated in a variety of ways that are known in the art. For example, the first and second polypeptides may be formulated together or separately. In some embodiments, the first and second polypeptides are formulated together for the simultaneous or  
5 near simultaneous administration of the polypeptides. Such co-formulated compositions can include the sALP polypeptide and the NP polypeptide formulated together in the same pill, capsule, liquid, etc.

Administration of each compound in controlled release formulations is useful where the sALP polypeptide or the NP polypeptide, has (i) a narrow therapeutic index (e.g., the difference between the  
10 plasma concentration leading to harmful side effects or toxic reactions and the plasma concentration leading to a therapeutic effect is small; generally, the therapeutic index, TI, is defined as the ratio of median lethal dose ( $LD_{50}$ ) to median effective dose ( $ED_{50}$ )); (ii) a narrow absorption window in the gastro-intestinal tract; (iii) a short biological half-life, such as by degradation *in vivo* by NEP and/or IDE; or (iv) the pharmacokinetic profile of each component must be modified to maximize the  
15 exposure of the neoplasm to an amount of each agent, together, that is therapeutically effective. Accordingly, a sustained release formulation may be used to avoid frequent dosing that may be required in order to sustain the plasma levels of both agents at a therapeutic level.

Many strategies can be pursued to obtain controlled release in which the rate of release outweighs the rate of metabolism of the therapeutic polypeptide. For example, controlled release can  
20 be obtained by the appropriate selection of formulation parameters and ingredients (e.g., appropriate controlled release compositions and coatings). Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticles, patches, and liposomes. The control release mechanism can be such that the compound of the sALP polypeptide is released first, followed by the NP polypeptide, or vice versa. The release  
25 mechanism can also be controlled that the two polypeptides are released at period intervals, the release could be simultaneous or a delayed release of one, when release of a particular drug is preferred over the other.

Controlled release formulations may include a degradable or nondegradable polymer, hydrogel, organogel, or other physical construct that modifies the bioabsorption, half life or  
30 biodegradation of the agent. The controlled release formulation can be a material that is painted or otherwise applied onto the afflicted site, either internally or externally. In one example, hydrogels, such as those described in U.S. Patent No. 5,626,863 can be used in controlled release formulations of compositions of the invention. These biodegradable polymers can be tailored to degrade at a desired rate and with a desired kinetics by selecting the appropriate monomers, method of preparation and  
35 molecular weight. Differences in crystallinity of the monomer can alter the polymeric degradation rate. Due to the relatively hydrophobic nature of most polymers, actual mass loss can begin with the

oligomeric fragments that are small enough to be water soluble; hence, even the initial molecular weight can influence the degradation rate.

The individually or separately formulated polypeptides can be packaged together as in a kit. Non-limiting examples include kits that contain, e.g., two pills, a pill and a powder, a suppository and a liquid in a vial, two topical creams, among others. The kit can include optional components that aid in the administration of the unit dose to patients, such as vials for reconstituting powder forms, syringes for injection or subcutaneous administration, customized IV delivery systems, inhalers, among others. Additionally, the unit dose kit can contain instructions for preparation and administration of the compositions. The kit may be manufactured as a single use unit dose for one subject, multiple uses for a particular subject (at a constant dose or in which the individual polypeptides may vary in potency as therapy progresses); or the kit may contain multiple doses suitable for administration to multiple subjects ("bulk packaging"). The kit components may be assembled in cartons, blister packs, bottles, tubes, and the like.

### **Gene Therapy**

The polypeptides described herein could also be advantageously delivered through gene therapy, where an exogenous nucleic acid encoding the proteins is delivered to tissues of interest and expressed *in vivo*. Gene therapy methods are discussed, e.g., in Verme et al. (*Nature* 389:239-242, 1997), Yamamoto et al. (*Molecular Therapy* 17:S67-S68, 2009), and Yamamoto et al., (*J. Bone Miner. Res.* 26:135-142, 2011), each of which is hereby incorporated by reference. Both viral and non-viral vector systems can be used. The vectors may be, for example, plasmids, artificial chromosomes (e.g., bacterial, mammalian, or yeast artificial chromosomes), virus or phage vectors provided with an origin of replication, and optionally, a promoter for the expression of the nucleic acid encoding the viral polypeptide and optionally, a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example, an ampicillin or kanamycin resistance gene in the case of a bacterial plasmid or a resistance gene for a fungal vector. Vectors may be used *in vitro*, for example, for the production of DNA, RNA, or the viral polypeptide, or may be used to transfect or transform a host cell, for example, a mammalian host cell, e.g., for the production of the viral polypeptide encoded by the vector. The vectors may also be adapted to be used *in vivo*, for example, in a method of vaccination or gene therapy.

Examples of suitable viral vectors include, retroviral, lentiviral, adenoviral, adeno-associated viral, herpes viral, including herpes simplex viral, alpha-viral, pox viral, such as Canarypox and vaccinia-viral based systems. Gene transfer techniques using these viruses are known in the art. Retrovirus vectors, for example, may be used to stably integrate the nucleic acids of the invention into the host genome. Replication-defective adenovirus vectors by contrast remain episomal and therefore allow transient expression. Vectors capable of driving expression in insect cells (e.g., baculovirus vectors), in human cells, yeast, or in bacteria may be employed in order to produce quantities of the

viral polypeptide(s) encoded by the nucleic acids of the invention, for example, for use in subunit vaccines or in immunoassays. Useful gene therapy methods include those described in WO 06/060641, U.S. Pat. No. 7,179,903 and WO 01/36620 (each of which is hereby incorporated by reference), which use an adenovirus vector to target a nucleic acid of interest to hepatocytes as protein  
5 producing cells.

In an additional example, a replication-deficient simian adenovirus vector may be used as a live vector. These viruses contain an E1 deletion and can be grown on cell lines that are transformed with an E1 gene. Examples of these replication-deficient simian adenovirus vectors are described in U.S. Patent No. 6,083,716 and WO 03/046124 (each of which is hereby incorporated by reference).

10 These vectors can be manipulated to insert a nucleic acid of the invention, such that the encoded viral polypeptide(s) may be expressed.

Promoters and other expression regulatory signals may be selected to be compatible with the host cell for which expression is designed. For example, mammalian promoters include the metallothionein promoter, which can be induced in response to heavy metals such as cadmium, and  
15 the  $\beta$ -actin promoter. Viral promoters, such as the SV40 large T antigen promoter, human cytomegalovirus (CMV) immediate early (1E) promoter, rous sarcoma virus LTR promoter, adenovirus promoter, or a HPV promoter, particularly the HPV upstream regulatory region (URR) may also be used. All these promoters, as well as additional promoters, are well-described in the art.

The nucleic acid molecules described herein may also be administered using non-viral based  
20 systems. For example, these administration systems include microsphere encapsulation, poly(lactide-co-glycolide), nanoparticle, and liposome-based systems. Non-viral based systems also include techniques facilitating the delivery of "naked" polynucleotides (such as electroporation, "gene gun" delivery and various other techniques used for the introduction of polynucleotides).

The introduced polynucleotide can be stably or transiently maintained in the host cell. Stable  
25 maintenance typically requires that the introduced polynucleotide either contains an origin of replication compatible with the host cell or integrates into a replicon of the host cell such as an extrachromosomal replicon (e.g., a plasmid) or a nuclear or mitochondrial chromosome.

### Dosage

30 Any amount of a polypeptide or a pharmaceutical composition of the invention can be administered to a subject. The dosages will depend on many factors, including the mode of administration and the age of the subject. Typically, the amount of the composition of the invention contained within a single dose will be an amount that is effective to treat a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth  
35 muscle disorder, or to elongate bone, without inducing significant toxicity. For example, the polypeptides described herein can be administered to subjects in individual doses ranging, e.g., from 0.01 mg/kg to 500 mg/kg (e.g., from 0.05 mg/kg to 500 mg/kg, from 0.2 mg/kg to 20 mg/kg, from 5

mg/kg to 500 mg/kg, from 0.1 mg/kg to 100 mg/kg, from 10 mg/kg to 100 mg/kg, from 0.1 mg/kg to 50 mg/kg, 0.5 mg/kg to 25 mg/kg, 1.0 mg/kg to 10 mg/kg, 1.5 mg/kg to 5 mg/kg, or 2.0 mg/kg to 3.0 mg/kg) or from 1 µg/kg to 1,000 µg/kg (e.g., from 5 µg/kg to 1,000 µg/kg, from 1 µg/kg to 750 µg/kg, from 5 µg/kg to 750 µg/kg, from 10 µg/kg to 750 µg/kg, from 1 µg/kg to 500 µg/kg, from 5 µg/kg to 500 µg/kg, from 10 µg/kg to 500 µg/kg, from 1 µg/kg to 100 µg/kg, from 5 µg/kg to 100 µg/kg, from 10 µg/kg to 100 µg/kg, from 1 µg/kg to 50 µg/kg, from 5 µg/kg to 50 µg/kg, or from 10 µg/kg to 50 µg/kg). Exemplary doses include, e.g., 0.01, 0.05, 0.1, 0.5, 1, 2, 2.5, 5, 10, 20, 25, 50, 100, 125, 150, 200, 250, or 500 mg/kg; or 1, 2, 2.5, 5, 10, 20, 25, 50, 100, 125, 150, 200, 250, 500, 750, 900, or 1,000 µg/kg. For all dosages or ranges recited herein, the term “about” may be used to modify these dosages by ±10% of the recited values or range endpoints.

Doses can also be adjusted when two or more polypeptides or compositions of the inventions are being administered. Exemplary doses include an sALP polypeptide (e.g., an sALP fusion protein) present in a dosage between about 0.2 mg/kg to about 20 mg/kg and an NP polypeptide (e.g., an NP fusion protein) present in a dosage of about 0.5 mg/kg to about 500 mg/kg. In particular embodiments, the dose of each individual polypeptide or composition is lower than the therapeutic dose of a single polypeptide or single composition when administered alone.

Doses can be administered, e.g., hourly, bihourly, daily, bidaily, twice a week, three times a week, four times a week, five times a week, six times a week, weekly, biweekly, monthly, bimonthly, or yearly. Alternatively, doses can be administered, e.g., twice, three times, four times, five times, six times, seven times, eight times, nine times, 10 times, 11 times, or 12 times per day. In particular embodiments, the dosing regimen is once weekly. The duration of the dosing regimen can be, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 day(s), week(s), or month(s), or even for the remaining lifespan of the subject. The amount, frequency, and duration of dosage will be adapted by the clinician in accordance with conventional factors such as the extent of the disease and different parameters from the subject.

The nucleic acids of the invention can be administered according the formulations described herein to a patient in dosages suitable for gene therapy. The amount of the nucleic acids administered will depend on a number of factors known to those skilled in the art, including: the length and nature of the nucleic acid, the vector (e.g., viral or non-viral) used, the activity of the polypeptide encoded, the presence of excipients, the route and method of administration, and the general condition and fitness of the subject. Exemplary dosages and routes of administration are described, e.g., in Melman et al. (*Isr. Med. Assoc. J.* 9:143-146, 2007; describing the intrapenile injection of 0.5 mg to 7.5 mg of a human cDNA in a plasmid for treating erectile dysfunction), Powell et al. (*Circulation* 118:58-65, 2008; describing the intramuscular injection of 0.4 mg to 4.0 mg of a hepatocyte growth factor plasmid to treat critical limb ischemia, Waddill et al. (*AJR Am. J. Roentgenol.* 169:63-67, 1997; describing the CT-guided intratumoral injection of 0.01 mg to 0.25 mg of plasmid DNA encoding an MHC antigen to treat melanoma), Kastrup et al. (*J. Am. Coll. Cardiol.* 45:982-988, 2005; describing

the intramyocardial injection of 0.5 mg of a VEGF plasmid to treat severe angina pectoris), and Romero et al. (*Hum. Gene. Ther.* 15:1065-1076, 2004; describing the intramuscular injection of 0.2 mg to 0.6 mg of a plasmid to treat Duchenne/Becker muscular dystrophy), each of which is hereby incorporated by reference.

5 In certain embodiments, the nucleic acids of the invention can be administered to the subject at a dose in the range from, e.g., 0.01 mg to 100 mg (e.g., from 0.05 mg to 50 mg, 0.1 mg to 10 mg, 0.3 mg to 3 mg, or about 1 mg) of nucleic acid. The total volume at which the nucleic acid can be administered will depend on its concentration, and can range from, e.g., 1  $\mu$ L to 10 mL (e.g. from 10  $\mu$ L to 1 mL, 50  $\mu$ L to 500  $\mu$ L, 70  $\mu$ L to 200  $\mu$ L, 90  $\mu$ L to 150  $\mu$ L, or 100  $\mu$ L to 120  $\mu$ L).

10 The nucleic acids can be administered, e.g., hourly, bihourly, daily, bidaily, twice a week, three times a week, four times a week, five times a week, six times a week, weekly, biweekly, monthly, bimonthly, or yearly. Alternatively, the nucleic acids can be administered, e.g., twice, three times, four times, five times, six times, seven times, eight times, nine times, 10 times, 11 times, or 12 times per day. The duration of the dosing regimen can be, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,  
15 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 day, weeks, or months, or even for the remaining lifespan of the subject.

These are guidelines, since the actual dose should be carefully selected and titrated by an attending physician or nutritionist based upon clinical factors unique to each subject. The optimal periodic dose will be determined by methods known in the art and will be influenced by factors such  
20 as the age of the subject, as indicated above, and other clinically relevant factors. In addition, subjects may be taking medications for other diseases or conditions. The other medications may be continued during the time that a polypeptide or nucleic acid of the invention is given to the subject, but it is advisable in such cases to begin with low doses to determine if adverse side effects are experienced.

25

## EXAMPLES

The following examples are provided for the purpose of illustrating the invention and are not meant to limit the invention in any way.

### Example 1. Characterization of Osteoblasts in Mice lacking NF1

30 To determine the effect of NF1 on bone matrix mineralization, mice lacking NF1 in osteochondroprogenitor cells were developed and characterized. These mice displayed skeletal dysplasia defects similar to patients with neurofibromatosis type I, where these defects included progressive scoliosis and kyphosis, tibial bowing and abnormalities in skull and anterior chest wall formation. In particular, NF1<sub>col2</sub><sup>-/-</sup> osteoblasts secreted increased levels of (PP<sub>i</sub>) as compared to  
35 osteoblasts from wild-type mice (Fig. 1A). Bone marrow adherent stromal cells (BMSCs) extracted from adult NF1<sub>col2</sub><sup>-/-</sup> mice and grown *in vitro* under osteogenic medium form less alkaline phosphatase (AP)-positive and less mineralized (alizarin red-positive) nodules compared to BMSCs extracted from

wild-type mice, which is accompanied by an increased amount of PP<sub>i</sub> released in the medium over 24 hours. Accumulation of PP<sub>i</sub> prevents proper bone matrix mineralization and likely contributes, at least in part, to defects observed in NF1<sub>col2</sub><sup>-/-</sup> mice. Thus, compounds that reduce PP<sub>i</sub> accumulation, such as sALP or an sALP analog, could be useful for treating NF1.

In addition, NF1<sub>col2</sub><sup>-/-</sup> osteoblasts expressed increased levels of mRNA for the progressive ankylosis gene (*Ank*) as compared to osteoblasts from wild-type mice (Fig. 1B). Treatment with a dual-specificity MEK1/MEK2 kinase inhibitor (U0126) provided decreased levels of *Ank* mRNA expression in NF1<sub>col2</sub><sup>-/-</sup> osteoblasts as compared to vehicle, and these observed levels were similar to that in wild-type osteoblasts (Fig. 1B, second and third bars). Thus, compounds that inhibit a kinase pathway, such as NP or an NP analog, could be useful for treating NF1.

Taken together, these data suggest that an sALP polypeptide alone, an NP polypeptide alone, or the combination of both an sALP polypeptide and an NP polypeptide could be useful for treating any neurocutaneous syndrome with bone manifestations, such as neurofibromatosis, or any other disorder described herein.

### Example 2. Combination Therapy for the Treatment of Neurofibromatosis

Fig. 2 provides a hypothetical working model for defective bone matrix mineralization in NF1<sub>col2</sub><sup>-/-</sup> mice, which can include multiple imbalances (e.g., increase of PP<sub>i</sub> or overactivation of one or more kinases, such as Ras or ERK) that contribute to the disease. Without wishing to be limited by theory, accumulation of PP<sub>i</sub> could be minimized by using any of the compositions and methods described herein including a soluble alkaline phosphatase (sALP) or sALP analog (see, e.g., the polypeptide of SEQ ID NO: 1204). Furthermore, overactivation of one or more kinases could be controlled by using any of the compositions and methods described herein including an NP or NP analog. As described herein, the intracellular production of cGMP resulting from NPR-B activation is known to inhibit the MAP-kinase pathway. Thus, an NP or NP analog that could activate the NPR-B signaling pathway can be used for the treatment of neurocutaneous syndromes, such as neurofibromatosis. Accordingly, the combination of an sALP or sALP analog (e.g., an sALP polypeptide) with an NP or NP analog (e.g., an NP polypeptide) could be particularly useful for treating such diseases.

### Example 3. *In vitro* and *In vivo* Effects of sTNALP-FcD<sub>10</sub> on NF1<sub>col2</sub><sup>-/-</sup> Phenotype

To assess the effect of sALP polypeptides on NF1 phenotype, cultures of osteoblasts from NF1<sub>col2</sub><sup>-/-</sup> mice were treated with either bone morphogenetic protein 2 (BMP2) or the sALP fusion polypeptide of sTNALP-FcD<sub>10</sub> (SEQ ID NO: 1204).

Both wild-type and NF1<sub>col2</sub><sup>-/-</sup> osteoblasts were treated with increasing concentrations of recombinant human BMP2 (rhBMP2, Fig. 3A). In NF1<sub>col2</sub><sup>-/-</sup> osteoblasts, rhBMP2 rescued the differentiation defect, as evidenced by an increased presence of alkaline phosphatase upon increasing

doses of rhBMP2 (Fig. 3A, second row). However, increased mineralization was not observed, as evidenced by the lack of calcium deposition (as indicated by the lack of alizarin red S staining) (Fig. 3A, fourth row).

In contrast, treatment with sTNALP-FcD<sub>10</sub> rescued the mineralization defect that is present in NF1<sub>col2</sub><sup>-/-</sup> osteoblasts (Fig. 3B). Increasing doses of sTNALP-FcD<sub>10</sub> provided increased calcific deposition in a dose-dependent manner (Fig. 3B, bottom, and Fig. 3C).

Furthermore, *in vitro* targeted deletion of the NF1 gene in BMSCs resulted in significant reduction of mineralization, which is at least partially rescued by treatment with 0.5 µg/mL of sTNALP-FcD<sub>10</sub> (Fig. 3D).

*In vivo* experiments were also conducted with sTNALP-FcD<sub>10</sub>. NF1<sub>col2</sub><sup>-/-</sup> mice were treated from day 1 to day 18 with 8.2 mg/kg of sTNALP-FcD<sub>10</sub>. Treatment of mice with sTNALP-FcD<sub>10</sub> increased bone mineral density deficit in NF1<sub>col2</sub><sup>-/-</sup> mice compared to vehicle (\* p < 0.5), as determined by the ratio of mineralized bone volume (BV) to total bone volume (TV) (Fig. 3E).

Accordingly, any sALP polypeptide described herein, either alone or in combination with any NP polypeptide described herein, could be particularly useful for treating neurofibromatosis or any neurocutaneous syndrome with bone manifestations.

#### **Example 4. *In vitro* and *In vivo* Effects of NC2-KGANKK on NF1<sub>col2</sub><sup>-/-</sup> Phenotype**

To assess the effect of NP polypeptides on NF1 phenotype, expression levels of the *NPR-B* gene were assessed in NF1<sub>col2</sub><sup>-/-</sup> mice (Fig. 4A). *NPR-B* was expressed in BMSCs at all stages of differentiation, where lack of *NF1* expression did not affect *NPR-B* expression.

Additional experiments were conducted in which cultures of chondrocytes from NF1<sub>col2</sub><sup>-/-</sup> mice were treated with the NP fusion polypeptide of NC2-KGANKK (SEQ ID NO: 512). Rib primary chondrocytes from P0 mice were obtained from wild-type mice and NF1<sub>col2</sub><sup>-/-</sup> mice and treated for 30 minutes with increasing concentrations of NC2-KGANKK. Without any treatment, increased levels of phosphorylated ERK (p-ERK) were observed in NF1<sub>col2</sub><sup>-/-</sup> chondrocytes, as compared to levels in wild-type chondrocytes (Fig. 4B). After treatment with NC2-KGANKK, decreased levels of p-ERK were observed in NF1<sub>col2</sub><sup>-/-</sup> chondrocytes. These results support the use of NP polypeptides, such as NC2-KGANKK, to inhibit the overactivation of one or more kinases, such as ERK.

*In vivo* experiments were also conducted. NF1<sub>col2</sub><sup>-/-</sup> mice were treated with NC2B (SEQ ID NO: 504). Treatment at least partially rescued the body length defect in NF1<sub>col2</sub><sup>-/-</sup> mice (Fig. 4C), the bone growth defect in NF1<sub>col2</sub><sup>-/-</sup> mice (Fig. 4D), and the proliferative and hypertrophic chondrocyte zone defects in NF1<sub>col2</sub><sup>-/-</sup> mice (Fig. 4E).

Accordingly, any NP polypeptide described herein, either alone or in combination with an sALP polypeptide described herein, could be particularly useful for treating disorders associated with

overactivation of one or more kinases, such as neurofibromatosis or any neurocutaneous syndrome with bone manifestations.

## References

5 The following documents are hereby incorporated by reference.

1. Wang et al., "Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I," *Hum. Mol. Genet.* 20:3910-24, 2011 (Epub 2011 Jul 14).
2. Ali et al., "Isolation and characterization of calcifying matrix vesicles from  
10 epiphyseal cartilage," *Proc. Natl. Acad. Sci. USA* 67:1513-20, 1970.
3. Anderson et al., "Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals," *Am. J. Pathol.* 151:1555-61, 1997.
4. Anderson et al., "The role of matrix vesicles in growth plate development and biomineralization," *Frontiers in Bioscience* 10:822-837, 2005.
- 15 5. Anderson et al., "Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice," *Am. J. Pathol.* 166:1711-1720, 2005.
6. Anderson et al., "Pyrophosphate stimulation of calcium uptake into cultured embryonic bones. Fine structure of matrix vesicles and their role in calcification," *Dev. Biol.* 34:211-  
20 227, 1973.
7. Anderson et al., "Impaired Calcification Around Matrix Vesicles of Growth Plate and Bone in Alkaline Phosphatase-Deficient Mice," *Am. J. Pathol.* 164:841-847, 2004.
8. Bernard, "Ultrastructural localization of alkaline phosphatase in initial intramembranous osteogenesis," *Clin. Orthop.* 218-25, 1978.
- 25 9. DiMaura et al., "Kinetic characterization of hypophosphatasia mutations with physiological substrates," *J. Bone Miner. Res.* 17:1383-1391, 2002.
10. Farley et al., "Effects of Tunicamycin, Mannosamine, and Other Inhibitors of Glycoprotein Processing on Skeletal Alkaline Phosphatase in Human Osteoblast-Like Cells," *Calcified Tissue International* 76:63-74, 2005.
- 30 11. Fedde et al., "Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia," *J. Bone Miner. Res.* 14:2015-2026, 1999.
12. Greenberg et al., "A homoallelic Gly317->Asp mutation in ALPL causes the perinatal (lethal) form of hypophosphatasia in Canadian mennonites," *Genomics* 17:215-217, 1993.
13. Harmey et al., "Elevated skeletal osteopontin levels contribute to the  
35 hypophosphatasia phenotype in Akp2(-/-) mice," *J. Bone Miner. Res.* 21:1377-1386, 2006.

14. Harmey et al., "Concerted Regulation of Inorganic Pyrophosphate and Osteopontin by Akp2, Enppi, and Ank: An Integrated Model of the Pathogenesis of Mineralization Disorders," *Am. J. Pathol.* 164:1199-1209, 2004.
15. Hawrylak et al., "The solubilization of tetrameric alkaline phosphatase from human  
5 liver and its conversion into various forms by phosphatidylinositol phospholipase C or proteolysis," *J. Biol. Chem.* 263:14368-14373, 1988.
16. Henthom et al., "Different missense mutations at the tissue-nonspecific alkaline phosphatase gene locus in autosomal recessively inherited forms of mild and severe hypophosphatasia," *Proc. Natl. Acad. Sci. USA* 89:9924-9928, 1992.
- 10 17. Henthom et al., "Missense mutations of the tissue-nonspecific alkaline phosphatase gene in hypophosphatasia," *Clin. Chem.* 38:2501-2505, 1992.
18. Hessle et al., "Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization," *Proc. Natl. Acad. Sci. USA* 99:9445-9449, 2002.
- 15 19. Ikezawa, "Glycosylphosphatidylinositol (GPI)-Anchored Proteins," *Biol. Pharm. Bull.* 25:409-417, 2002.
20. Jansson et al., "Structure, evolution and action of vitamin B6-dependent enzymes," *Curr. Opin. Struct. Biol.* 8:759-769, 1998.
21. Johnson et al., "Matrix vesicle plasma cell membrane glycoprotein-1 regulates  
20 mineralization by murine osteoblastic MC3T3 cells," *J. Bone Miner. Res.* 14:883-892, 1999.
22. Mahmood et al., "Selection of the First-Time Dose in Humans: Comparison of Different Approaches Based on Interspecies Scaling of Clearance," *J. Clin. Pharmacol.* 43:692-697, 2003.
23. Meyer, "Can biological calcification occur in the presence of pyrophosphate?" *Arch. Biochem. Biophys.* 231:1-8, 1984.
- 25 24. Millan, "Mammalian Alkaline Phosphatases. From Biology to Applications in Medicine and Biotechnology," Wiley-VCH Verlag GmbH & Co., Weinheim, Germany 1-322, 2006.
25. Morris et al., "Immunolocalization of alkaline phosphatase in osteoblasts and matrix vesicles of human fetal bone," *Bone Miner.* 19:287-98, 1992.
- 30 26. Murshed et al., "Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone," *Genes Dev.* 19:1093-1104, 2005.
27. Nasu et al., "Aberrant interchain disulfide bridge of tissue-nonspecific alkaline phosphatase with an Arg433Cys substitution associated with severe hypophosphatasia," *FEBS Journal* 273:5612-5624, 2006.
- 35 28. Narisawa et al., "Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia," *Developmental Dynamics* 208:432-446, 1997.

29. Narisawa et al., "Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization," *J. Pathol.* 193:125-133, 2001.
30. Nishioka et al., "Enhancement of drug delivery to bone: Characterization of human tissue-non specific alkaline phosphatase tagged with an acidic oligopeptide," *Mol. Genet. Metab.* 88:244-255, 2006.
31. Nosjean et al., "Human tissue non-specific alkaline phosphatases: Sugar-moiety-induced enzymic and antigenic modulations and genetic aspects," *Biochem. J.* 321:297-303, 1997.
32. Oda et al. "A General Method for Rapid Purification of Soluble Versions of Glycosylphosphatidylinositol-Anchored Proteins Expressed in Insect Cells: An Application for Human Tissue-Nonspecific Alkaline Phosphatase," *J. Biochem.* 126:694-699, 1999.
33. Rezende et al., "Inorganic pyrophosphate-phosphohydrolytic activity associated with rat osseous plate alkaline phosphatase," *Cell. Mol. Biol.* 44:293-302, 1998.
34. Urlaub et al., "Deletion of the Diploid Dihydrofolate-Reductase Locus from Cultured Mammalian-Cells," *Cell* 33:405-412, 1983.
35. Waymire et al., "Mice Lacking Tissue Nonspecific Alkaline-Phosphatase Die from Seizures Due to Defective Metabolism of Vitamin-B-6," *Nature Genet.* 11:45-51, 1995.
36. Weiss et al. "A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia," *Proc. Natl. Acad. Sci. USA* 85:7666-9, 1988.
37. Weninger et al., "Biochemical and Morphological Effects of Human Hepatic Alkaline-Phosphatase in A Neonate with Hypophosphatasia," *Acta. Paediatrica Scandinavica* 154-160, 1989.
38. Whyte, "Hypophosphatasia and the Role of Alkaline-Phosphatase in Skeletal Mineralization," *Endocrine Reviews* 15:439-461, 1994.
39. Whyte, "Alkaline Phosphatase: Placental and Tissue-nonspecific Isoenzymes hydrolyze Phosphoethanolamine, Inorganic Pyrophosphate, and Pyridoxal 5'-phosphate," *J. Clin. Invest.* 95:1440-1445, 1995.
40. Whyte, "Hypophosphatasia," in *The Metabolic and Molecular Bases of Disease*, edn 8th, pp 5313-5329. Eds CL Scriver, AL Beaudet, WS Sly, D Valle & B Vogelstein. New York: McGraw-Hill Book Company, 2001.
41. Whyte, "Hypophosphatasia. Nature's window on alkaline phosphatase function in man," In *Principle of Bone Biology*, edn Second, pp 1229-1248. Eds JP Bilezikian, LG Raisz & GA Rodan. London: Academic Press. 2002.
42. Whyte et al., "Marrow cell transplantation for infantile hypophosphatasia," *J. Bone Miner. Res.* 18:624-636, 2003.

43. Whyte et al., "Markedly Increased Circulating Pyridoxal-5'-Phosphate Levels in Hypophosphatasia - Alkaline- Phosphatase Acts in Vitamin-B6 Metabolism," *J. Clin. Invest.* 76:752-756, 1985.
44. Whyte et al., "Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: results in three additional patients," *J. Pediatr.* 105:926-933, 1984.
45. Whyte et al., "Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease," *J. Pediatr.* 101:379-386, 1982.
46. Zurutuza et al., "Correlations of genotype and phenotype in hypophosphatasia," *Human Molecular Genetics* 8:1039-1046, 1999.
47. Beertsen et al., "Root development in mice lacking functional tissue non-specific alkaline phosphatase gene: Inhibition of acellular cementum formation," *J. Dent. Res.* 78:1221-1229, 1999.
48. Potter et al., "Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions," *Endocr. Rev.* 27:47-72, 2006.
49. Hagiwara et al., "Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B," *J. Biol. Chem.* 269: 10729-33, 1994.
50. Hagiwara et al., "cGMP produced in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells," *Am. J. Physiol.* 270: C1311-8, 1996.
51. Suda et al., "C-type natriuretic peptide as an autocrine/paracrine regulator of osteoblast. Evidence for possible presence of bone natriuretic peptide system," *Biochem. Biophys. Res. Commun.* 223: 1-6, 1996.
52. Yasoda et al., "Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway," *J. Biol. Chem.* 273:11695-700, 1998.
53. Mericq et al., "Regulation of fetal rat bone growth by C-type natriuretic peptide and cGMP," *Pediatr. Res.* 47:189-93, 2000.
54. Daggubati et al., "Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators," *Cardiovasc. Res.* 36: 246-55, 1997.
55. Kalra et al., "The role of C-type natriuretic peptide in cardiovascular medicine," *Eur. Heart J.* 22:997-1007, 2001.
56. Pfeifer et al., "Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II," *Science* 274:2082-6, 1996.
57. Yasoda et al., "Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway," *Nat. Med.* 10:80-6, 2004.

58. Chusho et al., "Dwarfism and early death in mice lacking C-type natriuretic peptide," *Proc. Natl Acad. Sci. U S A* 98:4016-21, 2001.

59. Yoder et al., "Reduced ability of C-type natriuretic peptide (CNP) to activate natriuretic peptide receptor B (NPR-B) causes dwarfism in *lhab-/-* mice," *Peptides* 29:1575-1581, 2008.

60. Bocciardi et al., "Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation," *Hum. Mutat.* 28:724-31, 2007.

61. Tamura et al., "Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs," *Proc. Natl Acad. Sci. U S A* 101:17300-5, 2004.

62. Tsuji et al., "A loss-of-function mutation in natriuretic peptide receptor 2 (*Npr2*) gene is responsible for disproportionate dwarfism in *cn/cn* mouse," *J. Biol. Chem.* 280:14288-92, 2005.

63. Miyazawa et al., "Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification," *Endocrinology* 143: 3604-10, 2002.

64. Teixeira et al., "Nitric oxide, C-type natriuretic peptide and cGMP as regulators of endochondral ossification," *Develop. Biol.* 319:171-8, 2008.

65. Horton et al., "Achondroplasia," *Lancet* 370:162-72, 2007.

66. Nakao et al., "The pharmacokinetics of alpha-human atrial natriuretic polypeptide in healthy subjects," *Eur. J. Clin. Pharmacol.* 31:101-3, 1986.

67. Brenner et al., "Diverse biological actions of atrial natriuretic peptide," *Physiol. Rev.* 70:665-99, 1990.

68. Farnum et al., "In vivo delivery of fluoresceinated dextrans to the murine growth plate: Imaging of three vascular routes by multiphoton microscopy," *Anat. Rec. A Discov. Mol. Cell. Evol. Biol.*, 288A:91-103, 2006.

69. Williams et al., "Solute transport in growth plate cartilage: In vitro and in vivo," *Biophys. J.* 93:1039-50, 2007.

70. Chen et al., "Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis," *J. Clin. Invest.* 104:1517-25, 1999.

71. Yasoda et al., "Systemic Administration of C-Type Natriuretic Peptide as a Novel Therapeutic Strategy for Skeletal Dysplasias," *Endocrinology* 150:3138-44, 2009.

### Other Embodiments

All publications, patents, and patent applications mentioned in the above specification are hereby incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific

embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art are intended to be within the scope of the invention.

5           Other embodiments are in the claims.

**CLAIMS**

What is claimed is:

1. A method of treating a neurocutaneous syndrome in a subject, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising:

- (a) a polypeptide comprising the structure A-sALP-B; and
  - (b) a pharmaceutically acceptable excipient,
- wherein sALP is the extracellular domain of an alkaline phosphatase,  
A is absent or is an amino acid sequence of at least one amino acid, and  
B is absent or is an amino acid sequence of at least one amino acid,  
thereby treating said syndrome in said subject.

2. The method of claim 1, wherein the amino acid sequence of said polypeptide comprises the amino acid sequence of SEQ ID NOs: 1204 or 1221.

3. The method of claim 1, wherein  
the amino acid sequence of said sALP comprises amino acid residues 23-508 of SEQ ID NO: 1215, amino acid residues 18-498 of SEQ ID NO: 1216, amino acid residues 23-508 of SEQ ID NO: 1218, or amino acid residues 18-498 of SEQ ID NO: 1219, or  
the amino acid sequence of said sALP consists of amino acid residues 23-512 of SEQ ID NO: 1215, amino acid residues 18-502 of SEQ ID NO: 1216, amino acid residues 23-512 of SEQ ID NO: 1218, or amino acid residues 18-502 of SEQ ID NO: 1219.

4. The method of claim 1 or 3, wherein the amino acid sequence of said sALP comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 1205, or at least 95% sequence identity to SEQ ID NO: 1205, or at least 99% sequence identity to SEQ ID NO: 1205.

5. The method of claim 4, wherein the amino acid sequence of said sALP comprises or consists of the amino acid sequence of SEQ ID NO: 1205.

6. The method of any one of claims 1-5, wherein A and/or B are absent.

7. The method of any one of claims 1-6, wherein A or B comprises a fragment crystallizable region (Fc).

8. The method of any one of claims 1-7, wherein said Fc comprises a C<sub>H2</sub> domain, a C<sub>H3</sub> domain, and a hinge region, or wherein said Fc is a constant domain of an immunoglobulin selected from the group consisting of IgG-1, IgG-2, IgG-3, and IgG-4.

9. The method of claim 8, wherein the amino acid sequence of said Fc comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 401, or at least 95% sequence identity to SEQ ID NO: 401, or at least 99% sequence identity to SEQ ID NO: 401.

10. The method of claim 9, wherein the amino acid sequence of said Fc comprises or consists of the amino acid sequence of SEQ ID NO: 401.

11. The method of any one of claims 1-10, wherein A or B comprises I<sub>n</sub>, and wherein I represents an aspartic acid or a glutamic acid and n=10 to 16.

12. The method of any one of claims 1-10, wherein said polypeptide does not comprise a polyaspartic acid or polyglutamic acid region longer than three consecutive aspartic acid or glutamic acid residues, or wherein said polypeptide does not comprise a polyaspartic acid or polyglutamic acid region longer than two consecutive aspartic acid or glutamic acid residues.

13. The method of any one of claims 1-10, wherein said polypeptide does not comprise a bone-targeting moiety.

14. The method of any one of claims 1-10, wherein said polypeptide comprises the structure C-sALP-D-Fc-E or the structure C-Fc-D-sALP-E,

C is absent or is an amino acid sequence of at least one amino acid,

D is absent or is an amino acid sequence of at least one amino acid, and

E is absent or is an amino acid sequence of at least one amino acid.

15. The method of claim 14, wherein C and/or E are absent.

16. The method of any one of claims 1-10, wherein said polypeptide comprises the structure C-sALP-D-Fc-G-I<sub>n</sub>-H or the structure C-Fc-D-sALP-G-I<sub>n</sub>-H,  
C is absent or is an amino acid sequence of at least one amino acid,  
D is absent or is an amino acid sequence of at least one amino acid,  
G is absent or is an amino acid sequence of at least one amino acid,  
H is absent or is an amino acid sequence of at least one amino acid,  
I represents an aspartic acid or a glutamic acid, and n=10 to 16.
17. The method of claim 16, wherein C and/or H are absent.
18. The method of claim 16 or 17, wherein G is two amino acid residues.
19. The method of claim 18, wherein G is aspartic acid-isoleucine.
20. The method of any one of claims 16-19, wherein I is aspartic acid and n=10.
21. The method of any one of claims 14-20, wherein D is two amino acid residues.
22. The method of claim 21, wherein D is leucine-lysine.
23. The method of any one of claims 1-22, wherein the amino acid sequence of said polypeptide consists of the amino acid sequence of SEQ ID NOs: 1201, 1204, 1220, or 1221.
24. The method of claim 23, wherein the amino acid sequence of said polypeptide consists of the amino acid sequence of SEQ ID NO: 1204.
25. A method of treating a neurocutaneous syndrome in a subject, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising:
- (a) a polypeptide comprising the structure V-NP-W; and
  - (b) a pharmaceutically acceptable excipient,
- wherein NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B),  
V is absent or is an amino acid sequence of at least one amino acid, and  
W is absent or is an amino acid sequence of at least one amino acid,

thereby treating said syndrome in said subject.

26. The method of claim 25, wherein the amino acid sequence of said polypeptide comprises the amino acid sequence of SEQ ID NOs: 504, 512, 530, or 572.

27. The method of claim 25, wherein said NP comprises the structure:

[N-terminal extension]-[short segment]-[ring domain]-[C-terminal extension],

wherein said ring domain comprises the amino acid sequence of SEQ ID NO: 6, amino acid residues 11-27 of SEQ ID NO: 30, or SEQ ID NO: 95, and each of said N-terminal extension, short segment, and C-terminal extension is, independently, absent or is an amino acid sequence of at least one amino acid.

28. The method of claim 27, wherein said ring domain comprises amino acid residues 6-22 of SEQ ID NO: 126.

29. The method of claim 28, wherein the amino acid at position 17 of SEQ ID NO: 126 is Phe, Leu, Ile, Thr, Val, Ala, Ser, Glu, Arg, Tyr, Cys, Pro, or Asp.

30. The method of claim 27, wherein said ring domain comprises the amino acid sequence of SEQ ID NO: 12.

31. The method of any one of claims 27-30, wherein said short segment and said ring domain together comprise the amino acid sequence of any one of SEQ ID NOs: 4, 13-30, 119-122, 126, or 156-161.

32. The method of any one of claims 27-31, wherein the amino acid sequence of said short segment consists of amino acid residues 1-5, 2-5, 3-5, 4-5, or 5 of SEQ ID NO: 4, amino acid residues 1-10 of SEQ ID NO: 17, amino acid residues 1-5 of SEQ ID NO: 19, amino acid residues 1-3 of SEQ ID NO: 20, amino acid residues 1-5 of SEQ ID NO: 21, or amino acid residues 1-6 of SEQ ID NO: 29.

33. The method of any one of claims 27-32, wherein the amino acid sequence of said N-terminal extension comprises amino acid residues 1-31 or 17-31 of SEQ ID NO: 11.

34. The method of any one of claims 27-32, wherein the amino acid sequence of said N-terminal extension comprises KGANKK (SEQ ID NO: 314) or KGANQK (SEQ ID NO: 315).
35. The method of claim 27, wherein said N-terminal extension, short segment, and ring domain together comprise the amino acid sequence of SEQ ID NO: 11.
36. The method of any one of claims 27-35, wherein said C-terminal extension comprises the amino acid sequence of SEQ ID NOs: 117 or 118 or comprises amino acid residues 23-37 selected from any one of SEQ ID NOs: 101-116.
37. The method of claim 27, wherein the amino acid sequence of said NP consists of SEQ ID NOs: 4 or 11, or the amino acid sequence of any one of SEQ ID NOs: 31-94, or a fragment thereof comprising at least a ring domain, or the amino acid sequence of any one of SEQ ID NOs: 13-29, 100-116, 119-125, 127-233, or 1001-1155.
38. The method of any one of claims 27-37, wherein V and/or W are absent.
39. The method of any one of claims 27-38, wherein V or W comprises a fragment crystallizable region (Fc).
40. The method of claim 39, wherein said Fc comprises a C<sub>H2</sub> domain, a C<sub>H3</sub> domain, and a hinge region, or wherein said Fc is a constant domain of an immunoglobulin selected from the group consisting of IgG-1, IgG-2, IgG-3, and IgG-4.
41. The method of claim 40, wherein the amino acid sequence of said Fc comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 401, or at least 95% sequence identity to SEQ ID NO: 401, or at least 99% sequence identity to SEQ ID NO: 401.
42. The method of claim 41, wherein the amino acid sequence of said Fc comprises or consists of the amino acid sequence of SEQ ID NO: 401.
43. The method of any one of claims 27-42, wherein V or W comprises a glycine-rich region.

44. The method of claim 43, wherein the amino acid sequence of V or W consists of one or more glycines and one or more serines.

45. The method of claim 43 or 44, wherein the amino acid sequence of V or W comprises  $[(\text{Gly})_m(\text{Ser})]_n(\text{Gly})_p$  or  $(\text{Gly})_p[(\text{Ser})(\text{Gly})_m]_n$ , and wherein each of m, n, and p is, independently, between 0 and 20.

46. The method of claim 45, wherein m is between 1 and 6; n is between 1 and 10; and p is between 0 and 4.

47. The method of claim 46, wherein m is 4 and n is 1-6.

48. The method of claim 46, wherein combinations of m, n, and p are selected from a single row of Table 2, or wherein the amino acid sequence of V or W comprises the amino acid sequence of any one of SEQ ID NOs: 301-391.

49. The method of any one of claims 27-48, wherein V or W does not comprise a bone-targeting moiety.

50. The method of any one of claims 27-48, wherein V or W comprises a bone-targeting moiety.

51. The method of claim 50, wherein said bone-targeting moiety comprises six consecutive acidic residues.

52. The method of claim 51, wherein said bone-targeting moiety comprises ten consecutive acidic residues.

53. The method of claim 51 or 52, wherein said acidic residues are aspartic acid or glutamic acid.

54. The method of claim 53, wherein said bone-targeting moiety comprises E<sub>6</sub>, E<sub>10</sub>, D<sub>6</sub>, or D<sub>10</sub>.

55. The method of any one of claims 27-54, wherein V or W comprises a cathepsin cleavage sequence.

56. The method of claim 55, wherein said cathepsin cleavage sequence comprises a cathepsin K cleavage sequence.

57. The method of claim 55 or 56, wherein said cathepsin cleavage sequence is HGPQG (SEQ ID NO: 374) or HKLRG (SEQ ID NO: 375).

58. The method of any one of claims 27-57, wherein said polypeptide comprises the structure V-NP-W,

NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B),  
each of V and W is, independently, absent or is an amino acid sequence of at least one amino acid, and

said NP comprises the amino acid sequence of any one of SEQ ID NOs: 17-29, 31-40, 42-94, 101-116, 119-122, 128-161, or 163-233, or V or W comprises the amino acid sequence of any one of SEQ ID NOs: 304-313, 322-333, or 337-391.

59. The method of any one of claims 27-57, wherein said polypeptide comprises the structure V-NP or NP-W,

NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), and  
each of V and W comprises, independently, the amino acid sequence of any one of SEQ ID NOs: 304-313, 322-333, or 337-391.

60. The method of any one of claims 27-57, wherein said polypeptide comprises the structure X-Fc-Y-NP-Z or the structure X-NP-Y-Fc-Z,

NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), and  
each of X, Y, and Z is, independently, absent or is an amino acid sequence of at least one amino acid.

61. The method of claim 60, wherein Y comprises a glycine-rich region.

62. The method of claim 61, wherein the amino acid sequence of Y consists of one or more glycines and one or more serines.

63. The method of claim 62, wherein the amino acid sequence of Y comprises  $[(\text{Gly})_m(\text{Ser})_n](\text{Gly})_p$  or  $(\text{Gly})_p[(\text{Ser})(\text{Gly})_m]_n$ , and wherein each of m, n, and p is, independently, between 0 and 20.

64. The method of any one of claims 60-63, wherein X is absent, Z is absent, or X and Z are both absent.

65. The method of any one of claims 60-64, wherein X, Y, or Z comprises a bone-targeting moiety.

66. The method of claim 65, wherein said bone-targeting moiety comprises six or ten consecutive acidic residues.

67. The method of claim 66, wherein said acidic residues are aspartic acid or glutamic acid.

68. The method of any one of claims 65-67, wherein said bone-targeting moiety comprises E<sub>6</sub>, E<sub>10</sub>, D<sub>6</sub>, or D<sub>10</sub>.

69. The method of any one of claims 60-68, wherein X, Y, or Z comprises a cathepsin cleavage sequence.

70. The method of claim 69, wherein said cathepsin cleavage sequence comprises a cathepsin K cleavage sequence.

71. The method of any one of claims 25-70, wherein the amino acid sequence of said polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 501-608.

72. The method of claim 71, wherein the amino acid sequence of said polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 502, 504, 506, 512, 514, 516, 530, 560, 562, 564, 572, 574, 576, 584, 586, 588, 596, 598, 600, or 608.

73. The method of claim 72, wherein the amino acid sequence of said polypeptide comprises or consists of the amino acid sequence of SEQ ID NOs: 504, 512, 530, or 572.
74. The method of any one of claims 1-73, wherein said polypeptide is in dimeric form.
75. The method of any one of claims 1-74, wherein said polypeptide is glycosylated or pegylated.
76. The method of any one of claims 1-75, wherein said pharmaceutical composition is administered in a dosage between about 0.2 mg/kg to about 20 mg/kg of said polypeptide.
77. The method of any one of claims 1-75, wherein said pharmaceutical composition is administered in a dosage between about 0.5 mg/kg to about 500 mg/kg of said polypeptide.
78. The method of any one of claims 1-75, wherein said pharmaceutical composition is administered in a dosage between about 10 µg/kg to about 1,000 µg/kg of said polypeptide.
79. The method of any one of claims 1-78, wherein said pharmaceutical composition is administered subcutaneously.
80. The method of any one of claims 1-79, wherein said pharmaceutical composition is administered one time, two times, or three times per week.
81. The method of any one of claims 1-80, wherein said subject is human.
82. The method of any one of claims 1-81, wherein said neurocutaneous syndrome is neurofibromatosis type I.
83. A composition comprising a first polypeptide and a second polypeptide, wherein
- a) said first polypeptide comprises the structure A-sALP-B, wherein
    - i) sALP is the extracellular domain of an alkaline phosphatase,
    - ii) A is absent or is an amino acid sequence of at least one amino acid, and
    - iii) B is absent or is an amino acid sequence of at least one amino acid; and
  - b) said second polypeptide comprises the structure V-NP-W, wherein
    - i) NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B),

- ii) V is absent or is an amino acid sequence of at least one amino acid, and
- iii) W is absent or is an amino acid sequence of at least one amino acid.

84. The composition of claim 83, wherein the amino acid sequence of said first polypeptide comprises the amino acid sequence of SEQ ID NOs: 1204 or 1221 and the amino acid sequence of said second polypeptide comprises the amino acid sequence of SEQ ID NOs: 504, 512, 530, or 572.

85. The composition of claim 83, wherein the amino acid sequence of said sALP of said first polypeptide comprises amino acid residues 23-508 of SEQ ID NO: 1215, amino acid residues 18-498 of SEQ ID NO: 1216, amino acid residues 23-508 of SEQ ID NO: 1218, or amino acid residues 18-498 of SEQ ID NO: 1219, or

the amino acid sequence of said sALP of said first polypeptide consists of amino acid residues 23-512 of SEQ ID NO: 1215, amino acid residues 18-502 of SEQ ID NO: 1216, amino acid residues 23-512 of SEQ ID NO: 1218, or amino acid residues 18-502 of SEQ ID NO: 1219, or

the amino acid sequence of said sALP of said first polypeptide comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 1205, or at least 95% sequence identity to SEQ ID NO: 1205, or at least 99% sequence identity to SEQ ID NO: 1205.

86. The composition of claim 83 or 85, wherein A and/or B of said first polypeptide are absent.

87. The composition of any one of claims 83-86, wherein A or B of said first polypeptide comprises a fragment crystallizable region (Fc).

88. The composition of any one of claims 83-87, wherein A or B of said first polypeptide comprises  $I_n$ , and wherein I represents an aspartic acid or a glutamic acid and  $n=10$  to 16.

89. The composition of any one of claims 83-88, wherein said first polypeptide comprises the structure C-sALP-D-Fc-G- $I_n$ -H,

C is absent or is an amino acid sequence of at least one amino acid,

D is absent or is an amino acid sequence of at least one amino acid,

G is absent or is an amino acid sequence of at least one amino acid,

H is absent or is an amino acid sequence of at least one amino acid,

I represents an aspartic acid or a glutamic acid, and  $n=10$  to 16.

90. The composition of any one of claims 83-89, wherein the amino acid sequence of said first polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 1204.

91. The composition of any one of claims 83-90, wherein said NP of said second polypeptide comprises the structure:

[N-terminal extension]-[short segment]-[ring domain]-[C-terminal extension],

wherein said ring domain comprises the amino acid sequence of SEQ ID NO: 6, amino acid residues 11-27 of SEQ ID NO: 30, or SEQ ID NO: 95, and each of said N-terminal extension, short segment, and C-terminal extension is, independently, absent or is an amino acid sequence of at least one amino acid.

92. The composition of claim 91, wherein said ring domain comprises amino acid residues 6-22 of SEQ ID NO: 126.

93. The composition of claim 92, wherein the amino acid at position 17 of SEQ ID NO: 126 is Phe, Leu, Ile, Thr, Val, Ala, Ser, Glu, Arg, Tyr, Cys, Pro, or Asp.

94. The composition of any one of claims 91-93, wherein the amino acid sequence of said N-terminal extension comprises amino acid residues 1-31 or 17-31 of SEQ ID NO: 11, KGANKK (SEQ ID NO: 314), or KGANQK (SEQ ID NO: 315).

95. The composition of any one of claims 91-94, wherein said C-terminal extension comprises the amino acid sequence of SEQ ID NOs: 117 or 118 or comprises amino acid residues 23-37 selected from any one of SEQ ID NOs: 101-116.

96. The composition of claim 91, wherein the amino acid sequence of said NP consists of SEQ ID NOs: 4 or 11, or the amino acid sequence of any one of SEQ ID NOs: 31-94, or a fragment thereof comprising at least a ring domain, or the amino acid sequence of any one of SEQ ID NOs: 13-29, 100-116, 119-125, 127-233, or 1001-1155.

97. The composition of any one of claims 83-96, wherein V and/or W of said second polypeptide are absent.

98. The composition of any one of claims 83-97, wherein V or W of said second polypeptide comprises a fragment crystallizable region (Fc).

99. The composition of any one of claims 83-98, wherein V or W of said second polypeptide comprises a glycine-rich region.

100. The composition of any one of claims 83-99, wherein V or W of said second polypeptide comprises a bone-targeting moiety.

101. The composition of any one of claims 83-100, wherein V or W of said second polypeptide comprises a cathepsin cleavage sequence.

102. The composition of any one of claims 83-101, wherein said second polypeptide comprises the structure V-NP-W,

NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B),  
each of V and W is, independently, absent or is an amino acid sequence of at least one amino acid, and

said NP comprises the amino acid sequence of any one of SEQ ID NOs: 17-29, 31-40, 42-94, 101-116, 119-122, 128-161, or 163-233, or V or W comprises the amino acid sequence of any one of SEQ ID NOs: 304-313, 322-333, or 337-391.

103. The composition of any one of claims 83-102, wherein said second polypeptide comprises the structure V-NP or NP-W,

NP is said natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), and  
each of V and W comprises, independently, the amino acid sequence of any one of SEQ ID NOs: 304-313, 322-333, or 337-391.

104. The composition of any one of claims 83-103, wherein said second polypeptide comprises the structure X-Fc-Y-NP-Z or the structure X-NP-Y-Fc-Z,

NP is said natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), and  
each of X, Y, and Z is, independently, absent or is an amino acid sequence of at least one amino acid.

105. The composition of claim 104, wherein Y comprises a glycine-rich region.
106. The composition of claim 104 or 105, wherein X is absent, Z is absent, or X and Z are both absent.
107. The composition of any one of claims 104-106, wherein X, Y, or Z comprises a bone-targeting moiety.
108. The composition of any one of claims 104-107, wherein X, Y, or Z comprises a cathepsin cleavage sequence.
109. The composition of any one of claims 83-108, wherein the amino acid sequence of said second polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 501-608.
110. The composition of claim 109, wherein the amino acid sequence of said second polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 502, 504, 506, 512, 514, 516, 530, 560, 562, 564, 572, 574, 576, 584, 586, 588, 596, 598, 600, or 608.
111. The composition of claim 110, wherein the amino acid sequence of said second polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 512.
112. The composition of any one of claims 83-111, wherein said first polypeptide and/or said second polypeptide are in dimeric form.
113. The composition of any one of claims 83-112, wherein said first polypeptide and/or said second polypeptide are glycosylated or pegylated.
114. The composition of any one of claims 83-113, wherein the composition is a pharmaceutical composition comprising a pharmaceutically acceptable excipient.
115. The composition of any one of claims 83-114, wherein said composition is lyophilized.

116. The composition of any one of claims 83-115, wherein said first polypeptide is present in a dosage between about 0.2 mg/kg to about 20 mg/kg and said second polypeptide is present in a dosage between about 0.5 mg/kg to about 500 mg/kg.

117. The composition of any one of claims 83-116, wherein the amino acid sequence of said first polypeptide comprises the amino acid sequence of SEQ ID NO: 1204 and wherein the amino acid sequence of said second polypeptide comprises the amino acid sequence of SEQ ID NOs: 504, 512, 530, or 572.

118. A method of treating a disease or a condition in a subject, said method comprising administering to said subject a therapeutically effective amount of a first polypeptide and a second polypeptide, wherein

a) said first polypeptide comprises the structure A-sALP-B, wherein

- i) sALP is the extracellular domain of an alkaline phosphatase,
- ii) A is absent or is an amino acid sequence of at least one amino acid, and
- iii) B is absent or is an amino acid sequence of at least one amino acid; and

b) said second polypeptide comprises the structure V-NP-W, wherein

- i) NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B),
- ii) V is absent or is an amino acid sequence of at least one amino acid, and
- iii) W is absent or is an amino acid sequence of at least one amino acid; and

said disease or condition is selected from the group consisting of a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, a vascular smooth muscle disorder, and a condition for elongation of bone,

thereby treating said disease or said condition in said subject.

119. The method of claim 118, wherein said first polypeptide and said second polypeptide are administered within ten days, five days, or twenty-four hours of each other.

120. The method of claim 118, wherein said first polypeptide and said second polypeptide are administered simultaneously.

121. The method of any one of claims 118-120, wherein said first polypeptide and said second polypeptide are formulated together in a composition or each separately in a composition.

122. The method of claim 121, wherein said composition is a pharmaceutical composition comprising a pharmaceutically acceptable excipient.

123. The method of claim 122, wherein said composition is lyophilized.

124. The method of any one of claims 121-123, wherein said composition is the composition of any one of claims 83-117.

125. The method of any one of claims 118-124, wherein the amino acid sequence of said first polypeptide comprises the amino acid sequence of SEQ ID NO: 1204 and wherein the amino acid sequence of said second polypeptide comprises the amino acid sequence of SEQ ID NOs: 504, 512, 530, or 572.

126. The method of any one of claims 118-125, wherein said first polypeptide is present in a dosage between about 0.2 mg/kg to about 20 mg/kg and said second polypeptide is present in a dosage between about 0.5 mg/kg to about 500 mg/kg.

127. The method of any one of claims 118-125, wherein said first polypeptide is present in a dosage between about 0.2 mg/kg to about 20 mg/kg and said second polypeptide is present in a dosage between about 10 µg/kg to about 1,000 µg/kg.

128. The method of any one of claims 118-127, wherein said first polypeptide and said second polypeptide are administered subcutaneously.

129. The method of any one of claims 118-128, wherein said first polypeptide and said second polypeptide are administered one time, two times, or three times per week.

130. The method of any one of claims 118-129, wherein said subject is human.

131. The method of any one of claims 118-130, wherein said disease is said neurocutaneous syndrome.

132. The method of claim 131, wherein said neurocutaneous syndrome is neurofibromatosis type I.

133. A kit comprising:

a) a first polypeptide comprising the structure A-sALP-B, wherein

- i) sALP is the extracellular domain of an alkaline phosphatase,
- ii) A is absent or is an amino acid sequence of at least one amino acid, and
- iii) B is absent or is an amino acid sequence of at least one amino acid; and

b) instructions for administering said first polypeptide to a patient diagnosed with or at risk of developing a neurocutaneous syndrome.

134. The kit of claim 133, further comprising:

(c) a second polypeptide comprising the structure V-NP-W, wherein

- i) NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B),
- ii) V is absent or is an amino acid sequence of at least one amino acid, and
- iii) W is absent or is an amino acid sequence of at least one amino acid.

135. A kit comprising:

a) a polypeptide comprising the structure V-NP-W, wherein

- i) NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B),
- ii) V is absent or is an amino acid sequence of at least one amino acid, and
- iii) W is absent or is an amino acid sequence of at least one amino acid; and

b) instructions for administering said polypeptide to a patient diagnosed with or at risk of developing a neurocutaneous syndrome.

136. A kit comprising:

a) a first polypeptide comprising the structure A-sALP-B, wherein

- i) sALP is the extracellular domain of an alkaline phosphatase,
- ii) A is absent or is an amino acid sequence of at least one amino acid, and
- iii) B is absent or is an amino acid sequence of at least one amino acid; and


b) a second polypeptide comprising the structure V-NP-W, wherein

- i) NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B),
- ii) V is absent or is an amino acid sequence of at least one amino acid, and
- iii) W is absent or is an amino acid sequence of at least one amino acid.


137. The kit of claim 136, wherein said first polypeptide and said second polypeptide are formulated together.

138. The kit of claim 136, wherein said first polypeptide and said second polypeptide are formulated separately and in individual dosage amount.


**FIG. 1A**  
**Nf1<sub>col2</sub><sup>-/-</sup> Osteoblasts Secrete Increased Levels of Pyrophosphate (PP<sub>i</sub>)**



**FIG. 1B**  
**Increased *Ank* Expression in *Nf1*<sub>col2</sub><sup>-/-</sup> Osteoblasts**



**FIG. 2**  
**Hypothetical Working Model for Defective Bone Matrix Mineralization in NF1<sub>col2</sub><sup>-/-</sup> Mice**









FIG. 3B


Effect of sTNALP-FcD<sub>10</sub> on Nf1<sup>col2</sup><sup>-/-</sup> Bone Marrow Stromal Cells




**FIG. 3C**  
**Effect of sTNALP-FcD<sub>10</sub> on NF1<sub>col2</sub><sup>-/-</sup> Bone Marrow Stromal Cells**




**FIG. 3D**  
**Effect of sTNALP-FcD<sub>10</sub> on Floxed NF1<sub>col2</sub><sup>-/-</sup> Bone Marrow Stromal Cells**




**FIG. 3E**  
**Effect of sTNALP-FcD<sub>10</sub> on Bone Volume in NF1<sub>col2</sub><sup>-/-</sup> Mice**




**FIG. 4A**  
**Expression of *NPR-B* Gene in *Nf1<sub>Col2</sub><sup>-/-</sup>* Mice**






P0 mice rib primary chondrocytes


**FIG. 4C**  
**Effect of NC2B on Naso-anal Length in  $Nf1_{col2}^{-/-}$  Mice**



**FIG. 4D**  
**Effect of NC2B on Tibia Length in NF1<sub>col2</sub><sup>-/-</sup> Mice**



**FIG. 4E**  
**Effect of NC2B on Growth Plates in  $Nf1_{col2}^{-/-}$  Mice**



**FIG. 5A**  
**Schematic Structure of TNALP and hsTNALP-FcD<sub>10</sub>**  
**(With and Without Signal Sequence)**




FIG. 5B  
hsTNALP-FcD<sub>10</sub> Protein Sequence  
(With and Without Signal Sequence)

sTNALP-FcD <sub>10</sub> (w/sig. seq.)	<div>MVSPFLVLAIGTCLTNSLVPEKEKDPKYWRDQAQETLKYLELQKLNTNVAKNVIMFLGDMGVSTVTAA RILKGQLHHNPGEETRLEMDKFFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCN TTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSAARDWYSDNEMPPEALSQGCKDIA YQLMH NIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKXSHFIWNRTELLTLDP HNVDYLLGLFEFGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALH EAVEMDRAIGQAAGSLTSSEDTLTVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNPGP YKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPM AHLLLHGVHEQNYVPHVMAYAACT GANLGHCAPASS<b>LL</b>KDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFCSCVMHEALHNHYTQKSLSLSPGK<b>DI</b>DDDDDDDDDD (SEQ ID NO: 1201)</div>
sTNALP-FcD <sub>10</sub> (w/o sig. seq.)	<div>LVPEKEKDPKYWRDQAQETLKYLELQKLNTNVAKNVIMFLGDMGVSTVTAAAILKGQLHHNPGEETRL EMDKFFPVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDA GKSVGIVTTTRVNHATPSAAYAHSAARDWYSDNEMPPEALSQGCKDIA YQLMHNIRIDVIMGGGRKMY PKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKXSHFIWNRTELLTLDPPHNVDYLLGLFEFGDMQY ELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAAGSLT SEDTLTVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNPGPYKVVGGERENVSMVDYA HNHYQAQSAVPLRHETHGGEDVAVFSKGPM AHLLLHGVHEQNYVPHVMAYAACTIGANLGHCAPASS<b>LL</b>KDKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALH NHYTQKSLSLSPGK<b>DI</b>DDDDDDDDDD (SEQ ID NO: 1204)</div>

FIG. 5C  
hsTNALP-Fc Protein Sequence  
(With and Without Signal Sequence)

sTNALP-Fc (w/sig. seq.)	<div>MVSPFLVLAIGTCLTNSLVPEKEKDPKYWRDQAQETLKYLELQKLNTNVAKNVIMFLGDMGVSTVTAA RILKGQLHHNPGEETRL<del>EMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCN</del> TTQGNEVTSILRWAKDAGKSVGIVTTTRVNHA TPSAAYAH SADR DWYSDNEMPPEALSQGCKDIA YQLMH NIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLD LVDTWKSFKPRYKHSHF IWNRT<del>ELLTLDP</del> HNVDYLLGLFEFGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALH EAVEMDRAIGQA GSLTSS<del>EDTLTVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNPGP</del> YKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPM<del>AHLLHGVHEQNYVPHVMAYAA</del>CI GANLGHCAPASS<del>LDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI</del>SRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFFLYSKLTVDKSR WQQGNV<del>FS</del>SCSVMH<del>EALHNHYTQKSLSLSPGK</del> (SEQ ID NO: 1220)</div>
sTNALP-Fc (w/o sig. seq.)	<div>LVPEKEKDPKYWRDQAQETLKYLELQKLNTNVAKNVIMFLGDMGVSTVTAA<del>RILKGQLHHNPGEETRL</del> EMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDA GKSVGIVTTTRVNHA TPSAAYAH SADR DWYSDNEMPPEALSQGCKDIA YQLMHNIRDIDVIMGGGRKYM YKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPM<del>AHLLHGVHEQNYVPHVMAYAA</del>CI GANLGHCAPASS<del>LDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI</del>SRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFFLYSKLTVDKSR WQQGNV<del>FS</del>SCSVMH<del>EALHNHYTQKSLSLSPGK</del> (SEQ ID NO: 1221)</div>

# FIG. 5D

## hsTNALP-FcD<sub>10</sub> DNA Sequence

atggtttcac cattcttagt actggccatt ggcacctgcc ttactaactc cttagtgcca gagaaagaga aagacccccaa gtactggcga  
 gaccaagcgc aagagacact gaaatatgcc ctggagcttc agaagctcaa caccaacgtg gctaagaatg tcatcatgtt cctgggagat  
 gggatgggtg tctccacagt gacggtgcc cgcctcctca aggttcagct ccaccacaac cctggggagg agaccaggct ggagatggac  
 aagttcccc tegtggccct ctccaagacg tacaacacca atgcccaggt cctgacagc gccggcaccg ccaccgccta cctgtgtggg  
 gtgaaggcca atgagggcac cgtggggta agcgcagcca ctgagcgttc ccggtgcaac accaccagg ggaacgaggt cacctccatc  
 ctgcgtggg ccaaggacgc tgggaaatct gtgggcatgt tgaccaccac gagagtgaac catgccacc ccagcgccgc ctacgcccc  
 tcggctgacc gggactggtg ctacagacaac gagatgcccc ctgaggcctt gagccaggc tgaaggaca tgcctacca gctcatgcat  
 aacatcaggg acattgacgt gatcatggg ggtggccgga aatacatgta cccaagaat aaaactgatg tggagtatga gagtgcagag  
 aaagccaggg gcacgaggct ggacggcctg gacctcgttg acacctggaa gagcttcaaa ccgagatata agcactccca ctcatctgg  
 aacgcacgg aactcctgac ccttgacccc cacaatgtgg actacctatt ggtctcttc gagccagggg acatgcagta cgagctgaac  
 aggaacaacg tgacggaccc gtcactctcc gagatggtgg tggtgccat ccagatcctg cggaagaacc ccaaaggctt ctcttgctg  
 gtggaaggag gcagaattga ccacgggcac catgaaggaa aagccaagca ggccctgcat gaggcgttg agatggaccg ggccatcggg  
 caggcaggca gcttgacctc ctcggaagac actctgaccg tggtcactgc ggaccattcc cactcttca catttggtgg atacacccc  
 cgtggcaact ctatctttgg tctggcccc atgctgagtg acacagacaa gaagcccttc actgccatcc tgatggcaa tgggcctggc  
 tacaaggtgg tgggcgtga acgagagaat gtctccatgg tgactatgc tcacaacaac taccaggcg agtctgctgt gccctgcgc  
 cacgagaccc acggcgggga ggaactggcc gtcttctcca agggcccat ggcgacactg ctgcacggcg tccacgagca gaactacgtc  
 cccacagtga tggcgatgc agcctgcac ggggccaacc tcggccactg tgctcctgcc agctcgtTA AGgacaaaac tcacacatgc  
 ccacogtgc cagcacctga actcctgggg ggaactcag tcttctctt cccccaaaa cccaaggaca cctcatgat ctcccgacc  
 cctgaggtca catgcgtggt ggtggactg agccacgaag accctgaggt caagttcaac tggtaactgg acggcgtgga ggtgcataat  
 gccaaagaca agccgcggga ggagcagtac ctccaacaa gccctccag ccccatcga gaaaaccatc accgtcctgc accaggactg gctgaatggc  
 aaggagtaca agtgcaaggt tccacacaa gagatgacca agaaccaggt cagcctgacc cagcctgcca aaggttcta tccagcgac  
 caggtgtaca cctgcccc atccccggag atccccggag cgggaaca actacaagac cagcctccc gtgtgact ccgacggctc ctcttctc  
 atcgccgtgg agtgggagag caatgggcag cggagcag tggcagcagg ggaactctt ctcatgctcc gtgatgcatg aggtcttgca caaccactac  
 tatagcaagc tcaccgtgga caagagcagg aaagATATCG ATGACGATGA CGATGACGAT GACGATGACT AG (SEQ ID NO: 1217)  
 acgcagaaga gcctctccct gtctccgggt

**FIG. 6**  
**Human Soluble Tissue Nonspecific Alkaline Phosphatase**  
**(hsTNALP) Protein Sequence**

hsTNALP (1-502)	<u>MVSPFLVLAIGTCLTNSLVP</u> EEKDKPKYWDRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARI LKQQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQG NEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIA YQLMHNIRDID VIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHF IWNRTTELLTLDPHNVDYLLG LFEPGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIG QAGSLTSSSEDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYNGNGPGYKVVGGERENV MVDYAHNNYQAQSAVPLRHRHETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHCAPASS (SEQ ID NO: 1202)
hsTNALP (18-502)	LVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPGEETRLEM DKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSV GIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIA YQLMHNIRDIDVIMGGGRKYMYPKNKTD VEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHF IWNRTTELLTLDPHNVDYLLGLFEPGDMQYELNRNNVT DPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAGSLTSSSEDTLTVVTA DHSVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYNGNGPGYKVVGGERENVSMVDYAHNNYQAQSAVPL RHEETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHCAPASS (SEQ ID NO: 1205)

**FIG. 7**  
**Exemplary Fc Sequence (IgG-1)**

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV  
HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV  
YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFFLYSKLTIV  
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 401)

FIG. 8

## Multiple Sequence Alignment of Tissue Nonspecific Alkaline Phosphatase (TNALP)

CLUSTAL W (1.82) multiple sequence alignment: Tissue Nonspecific Alkaline Phosphatase

```

1  MISPFLLAI  GTCFASSLVP  EKEKDPKYMR  DQAQOTLKNA  LRLQTLNTNV  AKNVIMFLGD
  Q29486|PPBT_BOVIN
  Q29486|PPBT_FELCA
  P05186|PPBT_HUMAN
  P09242|PPBT_MOUSE
  P08289|PPBT_RAT
  Q9N0V0|Q9N0V0_CANFA
  -----
  XXXXXXXXXXXX  XXXXXXXXXXXX  XXEXDPXYMR  XQAQXTLKXA  LXQLXLTNTV  XKNXIMFLGD
  Consensus

61  GMGVSTVTAA  RILKGQLHHS  PGEETKLEMD  KFPYVALSKT  YNTNAQVPDS  AGTATAYLCG
  Q29486|PPBT_BOVIN
  Q29486|PPBT_FELCA
  P05186|PPBT_HUMAN
  P09242|PPBT_MOUSE
  P08289|PPBT_RAT
  Q9N0V0|Q9N0V0_CANFA
  -----
  GMGVSTVTAT  RILKGQLHHN  PGEETRLEMD  KFPYVALSKT  YNTNAQVPDS  AGTATAYLCG
  *****
  GMGVSTVTAX  RILKGQLHHX  XGEETXLEMD  KFPXVALSKT  YNTNAQVPDS  AGTATAYLCG
  Consensus

121  VKANEGTVGV  SAATQRSQC  TTQGNEVTSI  LRWAKDAGKS  VGIVTTTRVN  HATPSASYAH
  Q29486|PPBT_BOVIN
  Q29486|PPBT_FELCA
  P05186|PPBT_HUMAN
  P09242|PPBT_MOUSE
  P08289|PPBT_RAT
  Q9N0V0|Q9N0V0_CANFA
  -----
  VKANEGTVGV  SAATQRTQC  TTQGNEVTSI  LRWAKDAGKS  VGIVTTTRVN  HATPSAAYAH
  VKANEGTVGV  SAATERSRCN  TTQGNEVTSI  LRWAKDAGKS  VGIVTTTRVN  HATPSAAYAH
  VKANEGTVGV  SAATERTRCN  TTQGNEVTSI  LRWAKDAGKS  VGIVTTTRVN  HATPSAAYAH
  VKANEGTVGV  SAATERTRCN  TTQGNEVTSI  LRWAKDAGKS  VGIVTTTRVN  HATPSAAYAH
  VKANEGTVGV  SAATQTHCN  TTQGNEVTSI  LRWAKDAGKS  VGIVTTTRVN  HATPSAAYAH
  *****
  VKANEGTVGV  SAATXRXCN  TTQGNEVTSI  LRWAKDXGKS  VGIVTTTRVN  HATPSAXYAH
  Consensus

```

FIG. 8 (cont'd)

```

181  P09487|PPBT_BOVIN      SADRDWYSDN EMPPEALSQG CKDIAYQLMY NIKDIEVIMG GGRKYMFPKN RTDVEYELDE
    Q29486|PPBT_FELCA     SADRDWYSDN EMPPEALSQG CKDIAYQLMH NVRDIEVIMG GGRKYMFPKN RTDVEYEMDE
    P05186|PPBT_HUMAN     SADRDWYSDN EMPPEALSQG CKDIAYQLMH NIRDIDVIMG GGRKYMFPKN KTDVEYESDE
    P09242|PPBT_MOUSE     SADRDWYSDN EMPPEALSQG CKDIAYQLMH NIKDIDVIMG GGRKYMFPKN RTDVEYELDE
    P08289|PPBT_RAT       SADRDWYSDN EMPPEALSQG CKDIAYQLMH NIKDIDVIMG GGRKYMFPKN RTDVEYELDE
    Q9N0V0|Q9N0V0_CANFA   SADRDWYSDN EMPPEALSQG CKDIAYQLMH NVKDIEVIMG GGRKYMFPKN RTDVEYEMDE
    Consensus            *****:***:***** **
                                SADRDWYSDN EMPPEALSQG CKDIAYQLMX NXXDIXVIMG GGRKYMFPKN XTDVEYEXDE

241  P09487|PPBT_BOVIN      KARGTRLDGL NLIDIWKSFK PKKHSHYVW NRTDLLALDP HSDVYLLGLF EPGDMQYELN
    Q29486|PPBT_FELCA     KARGTRLDGL NLVDIWKSFK PRKHSHYVW NRTELLTLDP YGVDYLLGLF EPGDMQYELN
    P05186|PPBT_HUMAN     KARGTRLDGL DLVDTWKSFK PRYKHSFIW NRTELLTLDP HNVDYLLGLF EPGDMQYELN
    P09242|PPBT_MOUSE     KARGTRLDGL DLISIWKSFK PRKHSHYVW NRTELLALDP SRVDYLLGLF EPGDMQYELN
    P08289|PPBT_RAT       KARGTRLDGL DLISIWKSFK PRKHSHYVW NRTELLALDP SRVDYLLGLF EPGDMQYELN
    Q9N0V0|Q9N0V0_CANFA   KSTGARLDGL NLIDIWKNFK PRKHSHYVW NRTELLALDP YFVDYLLGLF DPGDMQYELN
    Consensus            *:*****:*. **.* ***:***:***:*****:*****
                                KXXGXRLDGL XLXXXWXXFK PXXKHSHXXW NRTXLLXLDP XXVDYLLGLF XPGDMQYELN

301  P09487|PPBT_BOVIN      RNNATDPSLS EMVEMAIRIL NKNPKGFFLL VEGGRIDHGH HEGKAKQALH EAVEMDQAIG
    Q29486|PPBT_FELCA     RNSTTDPSLS EMVEIAIKIL SKNPKGFFLL VEGGRIDHGH HEGKAKQALH EAVEMDQAIG
    P05186|PPBT_HUMAN     RNNVTDPSLS EMVVAIQIL RKNPKGFFLL VEGGRIDHGH HEGKAKQALH EAVEMDRAIG
    P09242|PPBT_MOUSE     RNNLTDPSLS EMVEVALRIL TKNLKGFFLL VEGGRIDHGH HEGKAKQALH EAVEMDQAIG
    P08289|PPBT_RAT       RNNLTDPSLS EMVEVALRIL TKNPKGFFLL VEGGRIDHGH HEGKAKQALH EAVEMDEAIG
    Q9N0V0|Q9N0V0_CANFA   RNNVTDPSLS EMVEIAIKIL SKKPRGFFLL VEGGRIDHGH HEGKAKQALH EAVEMDRAIG
    Consensus            **.***** ***:***:***:*****:*****
                                RNXXTDPSLS EMVXXAXXIL KXXXGFFLL VEGGRIDHGH HEGKAKQALH EAVEMDXAIG

```



FIG. 9

Multiple Sequence Alignment of Alkaline Phosphatase  
(TNALP, GALP, PLALP, and IALP)

CLUSTAL 2.0.5 multiple sequence alignment									
TNALPrn	MILP-----F	LVLAIGTCLT	NSFVPEKEKD	PSYWRQQAQE	TKNALKLQK	LNTNVAKNLI	55		
TNALPmm	MISP-----F	LVLAIGTCLT	NSFVPEKERD	PSYWRQQAQE	TKNALKLQK	LNTNVAKNVI	55		
TNALPhs	MISP-----F	LVLAIGTCLT	NSLVPEKEKD	PKYWRDQAQE	TKYALELQK	LNTNVAKNVI	55		
TNALPcf	-----	-----	-----EKD	PKYWRDQAQQ	TKYALRLQN	LNTNVAKNVI	33		
TNALPfc	MISP-----F	LVLAIGTCLT	NSLVPEKEKD	PKYWRDQAQQ	TKNALRLQK	LNTNVVKNVI	55		
TNALPbt	MISP-----F	LLLAIGTCFA	SSLVPEKEKD	PKYWRDQAQQ	TKNALRLQT	LNTNVAKNVI	55		
GALPhs	MQGPWV---L	LLGLRLQLS	LGIIPVEEEN	PDFWNRQAAE	ALGAAKKLQP	AQT-AAKNLI	56		
PLALPhs	MLGPCMLLLL	LLGLRLQLS	LGIIPVEEEN	PDFWNRQAAE	ALGAAKKLQP	AQT-AAKNLI	59		
IALPhs	MQGPWV---L	LLGLRLQLS	LGVIPAFEEEN	PAFWNRQAAE	ALDAAKKLQP	IQK-VAKNLI	56		
Consensus	XXXXXXXXXX	XXXXXXXXXX	*.: * :*. :* : * : * : * : * : *	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX			
TNALPrn	MFLGDGMGVS	TVTAARILKG	QLHHNTGEET	RLEMDKFPFV	ALSKTYNTNA	QVPDSAGTAT	115		
TNALPmm	MFLGDGMGVS	TVTAARILKG	QLHHNTGEET	RLEMDKFPFV	ALSKTYNTNA	QVPDSAGTAT	115		
TNALPhs	MFLGDGMGVS	TVTAARILKG	QLHHNPGEET	RLEMDKFPFV	ALSKTYNTNA	QVPDSAGTAT	115		
TNALPcf	MFLGDGMGVS	TVTATRILKG	QLHHNPGEET	RLEMDKFPFV	ALSKTYNTNA	QVPDSAGTAT	93		
TNALPfc	MFLGDGMGVS	TVTAARILKG	QLHHNPGEET	RLEMDKFPFV	ALSKTYNTNA	QVPDSAGTAT	115		
TNALPbt	MFLGDGMGVS	TVTAARILKG	QLHSPGEET	KLEMDKFPFV	ALSKTYNTNA	QVPDSAGTAT	115		
GALPhs	IFLGDGMGVS	TVTAARILKG	QKKDKLGPEI	FLAMDRFPFV	ALSKTYSVDK	HVPDSGATAT	116		
PLALPhs	IFLGDGMGVS	TVTAARILKG	QKKDKLGPEI	FLAMDRFPFV	ALSKTYNVDR	HVPDSGATAT	119		
IALPhs	LFLGDGLGVP	TVTATRILKG	QKNGKLGPEI	PLAMDRFPYL	ALSKTYNVDR	QVPDSAAATAT	116		
Consensus	:*****:	*****	* :. * * * :*: * : * : * : * : *	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX			
	XFLGDGXGVX	TVTAXRILKG	QXXXXXXXXGXEX	XLXMDXFPXX	ALSKTYXXXX	XVPDSXXTAT			

FIG. 9 (cont'd)

TNALPrn	AYLCGVKANE	GTGVSAATE	RTRCNTTQGN	EVTSILRWAK	DAGKSVGIVT	TTRVNHATPS	175
TNALPmm	AYLCGVKANE	GTGVSAATE	RTRCNTTQGN	EVTSILRWAK	DAGKSVGIVT	TTRVNHATPS	175
TNALPhs	AYLCGVKANE	GTGVSAATE	RSRCNTTQGN	EVTSILRWAK	DAGKSVGIVT	TTRVNHATPS	175
TNALPcf	AYLCGVKANE	GTGVSAATQ	RTHCNTTQGN	EVTSILRWAK	DAGKSVGIVT	TTRVNHATPS	153
TNALPfc	AYLCGVKANE	GTGVSAATQ	RTQCNTTQGN	EVTSILRWAK	DSGKSVGIVT	TTRVNHATPS	175
TNALPbt	AYLCGVKANE	GTGVSAATQ	RSQCNTTQGN	EVTSILRWAK	DAGKSVGIVT	TTRVNHATPS	175
GALPhs	AYLCGVKGNF	QTIGLSAAAR	FNQCNTTRGN	EVISVMNRK	KAGKSVGVVT	TTRVQHASP	176
PLALPhs	AYLCGVKGNF	QTIGLSAAAR	FNQCNTTRGN	EVISVMNRK	KAGKSVGVVT	TTRVQHASP	179
IALPhs	AYLCGVKANF	QTIGLSAAAR	FNQCNTTRGN	EVISVMNRK	QAGKSVGVVT	TTRVQHASP	176
	*****.*	*:*:***:..	.:****:*	** *::.. **	.:*****:**	*****:**:	
Consensus	AYLCGVKXNX	TXGXSAAXX	XXXCNTTXGN	EVXSXXXXXAK	XXGKSVGXVT	TTRVXHAXPX	
TNALPrn	AAAYHSADRD	WYSDNEMPPE	ALSQGCKDIA	YQLMHNKIDI	DVIMGGGRKY	MYPKNRTDVE	235
TNALPmm	AAAYHSADRD	WYSDNEMPPE	ALSQGCKDIA	YQLMHNKIDI	DVIMGGGRKY	MYPKNRTDVE	235
TNALPhs	AAAYHSADRD	WYSDNEMPPE	ALSQGCKDIA	YQLMHNIRDI	DVIMGGGRKY	MYPKNKTDVE	235
TNALPcf	AAAYHSADRD	WYSDNEMPPE	ALSQGCKDIA	YQLMHNKIDI	EVIMGGGRKY	MFPKNRTDVE	213
TNALPfc	AAAYHSADRD	WYSDNEMPPE	ALSQGCKDIA	YQLMHNVRDI	EVIMGGGRKY	MFPKNRTDVE	235
TNALPbt	ASAYHSADRD	WYSDNEMPPE	ALSQGCKDIA	YQLMNYNKDI	EVIMGGGRKY	MFPKNRTDVE	235
GALPhs	GAYAHTVNRN	WYSDADVPAS	ARQEGCQDIA	TQLISNM-DI	DVILGGGRKY	MFPMTGPDPE	235
PLALPhs	GTIAHTVNRN	WYSDADVPAS	ARQEGCQDIA	TQLISNM-DI	DVILGGGRKY	MFRMTGPDPE	238
IALPhs	GTIAHTVNRN	WYSDADMPAS	ARQEGCQDIA	TQLISNM-DI	DVILGGGRKY	MFPMTGPDPE	235
	.:***:..:**	**** :*:..	* .:***:***	**:*: **	:***:*****	*: . . * *	
Consensus	XXYAHXXXRX	WYSDXXXPPX	AXXXGCKDIA	XQLXXNXXDI	XVIXGGGRKY	MXXXXXXDXE	
TNALPrn	YELDEKARGT	RLDGLDLISI	WKSFKPRHKH	SHYVWNRTTEL	LALDPS-RVD	YLLGLFEPGD	294
TNALPmm	YELDEKARGT	RLDGLDLISI	WKSFKPRHKH	SHYVWNRTTEL	LALDPS-RVD	YLLGLFEPGD	294
TNALPhs	YESDEKARGT	RLDGLDLVDT	WKSFKPRYKH	SHFIWNRTTEL	LTLDPH-NVD	YLLGLFEPGD	294
TNALPcf	YEMDEKSTGA	RLDGLNLIDI	WKNFKPRHKH	SHYVWNRTTEL	LALDPY-TVD	YLLGLDFPGD	272
TNALPfc	YEMDEKARGT	RLDGLNLVDI	WKSFKPRHKH	SHYVWNRTTEL	LTLDPY-GVD	YLLGLFEPGD	294
TNALPbt	YELDEKARGT	RLDGLNLIDI	WKSFKPKHKH	SHYVWNRTDL	LALDPH-SVD	YLLGLFEPGD	294
GALPhs	YPDDYSQGGT	RLDGKNLVQE	WL---AKHQ	ARYVWNRTTEL	LQASLDPSVT	HLMGLFEPGD	292
PLALPhs	YPDDYSQGGT	RLDGKNLVQE	WL---AKRQG	ARYVWNRTTEL	MQASLDPSVT	HLMGLFEPGD	295
IALPhs	YPADASQNGI	RLDGKNLVQE	WL---AKHQ	AWYVWNRTTEL	MQASLDQSVT	HLMGLFEPGD	292
	* * . *	**** :*:..	* .:.. : *	: : :*****:	: . *	:*:***:**:	
Consensus	YXXDXXXXGX	RLDGXXLXXX	WXXXXXXXXX	XXXXXWNRTXL	XXXXXXXVXX	XLXGLFXPGD	

[illegible]

FIG. 9 (cont'd)

TNALPrn	HEQNYIPHV	AYASCIG----	-ANLDHC	AWA	SSASSP	SPGA	LLLPLA	LFPL	RTLF-----	524
TNALPmm	HEQNYIPHV	AYASCIG----	-ANLDHC	AWA	SGSAP	SPGA	LLLPLA	VL	PTLF-----	524
TNALPhs	HEQNYVPHV	AYAACIG----	-ANLGH	CAPA	SSAGS	LAAGP	LLLALA	LYPL	SVLF-----	524
TNALPcf	HEQNYIPHV	AYAACIG----	-ANQDH	CASA	SSAGG	SPSPG	LLLLLA	LLPV	GILF-----	502
TNALPfc	HEQNYIPHV	AYAACIG----	-ANLDH	CASA	SSAGG	SPSPG	LFLLLA	LLPSL	GILF-----	524
TNALPbt	QEQNYIPHV	AYAACIG----	-ANRDH	CASA	SSSGS	SPSPG	LLLLLA	LLPL	GSLF-----	524
GALPhs	QEQTFIGHV	AFACLEPYT	ACDLAP	PRAGT	TDAAH	PGPSV	VPALLP	LLAG	TLLLLGTATA	531
PLALPhs	QEQTFIGHV	AFACLEPYT	ACDLAP	PAGT	TDAAH	PGRSV	VPALLP	LLAG	TLLLLETATA	534
IALPhs	QEQSFIGHV	AFACLEPYT	ACDLAP	PACT	TDAAH	P----	VAASLP	LLAG	TLLLLGASAA	527
Consensus	:**...***	*:*:*:	::	*:	...	:	*	::	*	
	XEQXXXXHV	AXAXCXXXXX	XXXXXX	AXX	XXXXXXXXXX	XXXXXX	XXXXLXXXXX	XXXXXX	XXLXXXXXXXXX	
TNALPrn	-	(SEQ ID NO: 1210)								
TNALPmm	-	(SEQ ID NO: 1209)								
TNALPhs	-	(SEQ ID NO: 1208)								
TNALPcf	-	(SEQ ID NO: 1211)								
TNALPfc	-	(SEQ ID NO: 1207)								
TNALPbt	-	(SEQ ID NO: 1206)								
GALPhs	P 532	(SEQ ID NO: 1213)								
PLALPhs	P 535	(SEQ ID NO: 1214)								
IALPhs	P 528	(SEQ ID NO: 1212)								
Consensus	X	(SEQ ID NO: 1215)								

**FIG. 10**  
**ALP-TNALP Consensus Sequences Excluding Pathogenic Mutations**

XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX	PXXWXXXAXX	XLXXAXXLQX	XXXXXXXXAKNXI	60
XFLGDGMGVX	TVTAXRILKG	QXXXXXXXXGXEX	XLXMDXFFPX	ALSKTYXXXX	XVPDSXXTAT	120
AYLCGVKXNX	XTXGXSAAAX	XXXCNTTXGN	EVTXXXXXAK	XXGKSVGXVT	TTRVXHAXPX	180
XXYAHXXXXX	WYSDXXXXPX	AXXXGCXDIA	XQLXXNXXDI	XVIXGGGRKY	MXXXXXXXDXE	240
YXXDXXXXGX	RLDGXXLXXX	WXXXXXXXXXX	XXXXWNRTXL	XXXXXXXXXXVX	XLXGLFXPGD	300
MXYEXXRXXX	XDPSLXEMXX	XAXXXLXXXX	XGFXLXVEGG	RIDHGHHEXX	AXXALXEXXX	360
XDXAIXXAGX	XTSXXDTLXX	VTADHSHVFX	FGGYXXRGXS	IFGLAPXXXX	XDXXKXTXXL	420
YGNPGYXXX	XGXRXXVXXX	XXXXXXXXYXXQ	XAVPLXXETH	XGEDVAVFXX	GPXAHLXHGV	480
XEQXXXXHVM	AXAXCXXXXX	XXXXXXXXAXX	XXXXXXXXXXXX	XXXXLXXXXX	XXLXXXXXXXX	540
					X	541

(SEQ ID NO: 1218)

**FIG. 11**  
**TNALP Consensus Sequences Excluding Pathogenic Mutations**

MIXPFLXLAI	GTCXXXSXVP	EKEXDPXYWR	XQAQXTLKXA	LXLQXLNTNV	AKNXIMFLGD	60
GMGVSTVTAX	RILKGQLHHX	XGEETXLEMD	KFPXVALSKT	YNTNAQVPDS	AGTATAYLCG	120
VKANEGTVGV	SAATXRXXCN	TTQNEVTSI	LRWAKDXGKS	VGIVTTTRVN	HATPSAXYAH	180
SADRDWYSDN	EMPPEALSQG	CKDIAYQLMX	NXXDIXVIMG	GGRKYMXPKN	XTDVEYEXDE	240
KXXGXRLDGL	XLXXXWKXFK	PXXKHSXXXW	NRTXLLXLDP	XXVDYLLGLF	XPGDMQYELN	300
RNXXTDPSLS	EMVXXAXXIL	XXXXXGFFLL	VEGGRIDHGH	HEGKAKQALH	EAVEMDXAIG	360
XAGXXTSXXD	TLTXVVTADHS	HVFTFGGYTP	RGNSIFGLAP	MXSDTDKKPF	TXILYGNPGP	420
YKVVXGEREN	VSMVDYAHNN	YQAQSAVPLR	HETHGGEDVA	VFXKGPMAHL	LHGVXEQNYX	480
PHVMAYAXCI	GANXXHCAXA	XSXXXXXXGX	LXLXAXXXX	XXLF		524

(SEQ ID NO: 1219)

FIG. 12  
Multiple Sequence Alignment of Natriuretic Peptides

Human ANP	-----SLRRSS	CFGGRMDRIGAQSGGLGC	NSFRY-----	(SEQ ID NO: 1)
Human urodilatin	TAPRSLRRSS	CFGGRMDRIGAQSGGLGC	NSFRY-----	(SEQ ID NO: 2)
Human BNP	-SPKMVQSGG	CFGRKMDRISSSSGLGCKVLRH-----		(SEQ ID NO: 3)
Human CNP22	-----GLSKG	CFGLKLDRIGSMGSLGC	-----	(SEQ ID NO: 4)
DNP	-----EVKYDP	CFGHKIDRINHVSNLGCP	SLRDPNAPSTSA	(SEQ ID NO: 5)
	*** ::***. *.***			
CONSENSUS SEQUENCE		CFGXXXDRIXXXSXLGC		(SEQ ID NO: 6)

**FIG. 13**  
**Sequences of Human CNP53, CNP22, and CNP (ring only)**

Human CNP53	DLRVDTKSRAAWARLLQEHFNARKYKGANKKGLSKG	<b>CFGLKLDRI GSM SGLGC</b>	(SEQ ID NO: 11)
Human CNP22	-----GLSKG	<b>CFGLKLDRI GSM SGLGC</b>	(SEQ ID NO: 4)
Human CNP (ring only)	-----	<b>CFGLKLDRI GSM SGLGC</b>	(SEQ ID NO: 12)

FIG. 14

Multiple Sequence Alignment of C-Type Natriuretic Peptides from Various Species

Human	-----GLSKG <b>CFGLKLDRI</b> GSMSGLGC	(SEQ ID NO: 4)
Bovine	-----GLSKG <b>CFGLKLDRI</b> GSMSGLGC	(SEQ ID NO: 13)
Sheep	-----GLSKG <b>CFGLKLDRI</b> GSMSGLGC	(SEQ ID NO: 14)
Mouse	-----GLSKG <b>CFGLKLDRI</b> GSMSGLGC	(SEQ ID NO: 15)
Pig	-----GLSKG <b>CFGLKLDRI</b> GSMSGLGC	(SEQ ID NO: 16)
Micrurus fulvius fulvius	GLAKEALGDG <b>CFGLKLDRI</b> GTSSGLGC	(SEQ ID NO: 17)
Taeniopygia guttata	-----G <b>CFGLKLDRI</b> GTFSGLGC	(SEQ ID NO: 18)
Chicken	-----GLSR <b>SCF</b> GVKLDRI <b>GSMSGLGC</b>	(SEQ ID NO: 19)
Rana catesbeiana	-----SRG <b>CF</b> GVKLDRI <b>GA</b> FSGLGC	(SEQ ID NO: 20)
Eel	-----GWNRG <b>CF</b> GLKLDRI <b>GSLSGLGC</b>	(SEQ ID NO: 21)
Trout	-----GWNRG <b>CF</b> GLKLDRI <b>GSMSGLGC</b>	(SEQ ID NO: 22)
Ornithorhynchus anatinus	-----GLSKG <b>CFGLKLDRI</b> GSTSGLC	(SEQ ID NO: 23)
Trimeresurus flavoviridis	-----KG <b>CF</b> GHKLDRI <b>GSTSGLC</b>	(SEQ ID NO: 24)
Polypterus endlicheri	-----SKG <b>CF</b> GLKLDRI <b>GSISGLGC</b>	(SEQ ID NO: 25)
Xenopus laevis	-----LSKG <b>CF</b> GLKLDRI <b>GVVSGLC</b>	(SEQ ID NO: 26)
Oryzias latipes	-----G <b>CF</b> GMKMDRI <b>GSISGLGC</b>	(SEQ ID NO: 27)
Tetraodon nigroviridis	-----G <b>CF</b> GMKIDRI <b>GSISGLGC</b>	(SEQ ID NO: 28)
Pseudechis australis	-----SKIGDG <b>CF</b> GLPLDHI <b>GSVSGLC</b>	(SEQ ID NO: 29)
CONSENSUS SEQUENCE	XXXXXXX <b>XXXXXCF</b> GX <b>XXDXIGXXSGLGC</b> *** :*:*** *****	(SEQ ID NO: 30)

## FIG. 15A

## Multiple Alignment of C-Type Natriuretic Peptides from Various Species

```

sp|Q8AYR5|ANFC2_ORYLA      ---MAVCSSSS-----LILLTVFLSVAVETRP--SSDRDE----- 30
sp|Q805D5|ANFC2_TAKRU      ---MAASSSSF-----VPLVLLFLAIPVEPRP--SMTRDE----- 30
sp|Q76KW6|ANFC_ACITR       ---MSISSSSSSSSSSSSCLLLISLMLLAASCQGRPDLQHRNH----- 40
sp|Q61839|ANFC_MOUSE       ---MHLSQLI-----ACALLLALLSLRPSEAKPGTP----- 28
tr|Q544K5|Q544K5_MOUSE     ---MHLSQLI-----ACALLLALLSLRPSEAKPGTP----- 28
tr|Q8VHG9|Q8VHG9_NOTAL     ---MHLSQLI-----ACALLLALLSLRPSEAKPGTP----- 28
sp|P55207|ANFC_RAT         ---MHLSQLI-----ACALLLALLSLRPSEAKPGTP----- 28
sp|P55206|ANFC_BOVIN       ---MHLSQLL-----ACALLLALLSLRPSEAKPGAP----- 28
sp|P56283|ANFC_SHEEP       ---MHLSQLL-----ACALLSLLSLRPSEAKPGAP----- 28
sp|P18104|ANFC_PIG         ---MHLSQLL-----ACALLLTLLSLRPSEAKPGAP----- 28
sp|P23582|ANFC_HUMAN       ---MHLSQLL-----ACALLLTLLSLRPSEAKPGAP----- 28
sp|P84715|ANF39_ORNAN      ---MHLSHLL-----AWALLLTLLSLR--AEAKPPSPQ----- 28
tr|Q9QZ96|Q9QZ96_CAVPO     -----
sp|Q80017|ANFC4_ORYLA      ---MNLISYLV-----ACGLLVTFLLSDK--MDAQPLTPAQ----- 29
sp|Q805D3|ANFC4_TAKRU      ---MNLISYLV-----ACGLMITLLSVR--MGAKPLSQAQ----- 29
tr|C1BXI5|C1BXI5_ESOLU     ---MNISYLV-----ACGLMITLLSVR--SGAKPLTAAQ----- 29
tr|D2KXA5|D2KXA5_ANGJA     ---MNVSQLM-----VCGLLMALFSFS--TEAKSLIPAQ----- 29
tr|Q1XGY7|Q1XGY7_ACTI     ---MNISHLV-----ACGLLVALLTVT--MEAKPLTQSQ----- 29
sp|P40756|ANFD_RANCA       ---MHFCHIV-----CWGLVLAVLYLR--TEAKPVAQAH----- 29
sp|P0C7P5|BNP_TRIFL       ---MFVSRLA-----ASGLLLLALLLALSLDGKPVHQS KPGR----- 33
sp|P0C7P6|BNP_TRIGA       ---MFVSRLA-----ASGLLLLALLLALSLDGKPVQE--KPGR----- 32
sp|Q6LEM5|BNP1_BOTJA       ---MVL SRLA-----ASGLLLLALLLALSVDGKPVQQWAQS----- 32
sp|Q9PW56|BNP2_BOTJA       ---MVL SRLA-----ASGLLLLALLLALSVDGKPVQQWAQGG----- 33
sp|P68515|BNP_BOTIN       ---MVL SRLA-----ASGLLLLALLLALSVDGKPVQQWAQGG----- 33
sp|Q90Y12|BNP_CRODU       ---MFVSRLA-----ASGLLLLALLLAVSLDGKPLQQWS----- 30
sp|Q2PE51|BNP_CRODO       ---MFVSRLA-----ASGLLLLALLLAVSLDGKPLQQWS----- 30
sp|B0VXV8|BNP_SISCA       ---MFVSRLA-----ASGLLLLALLLAVSLDGKPVQQWS----- 30
sp|Q27J49|BNP_LACMU       ---MFVSRLA-----ASGLLLLALLLAVSLDGKPVQQWSH----- 31
sp|P01021|BNP_AGKHA       ---MFVSRLA-----ASGLLLLALMALSLDGKPVQQWSQGRPPGPPI 39
sp|Q09GK2|VNP_PHIOL       ---MVASRLA-----AGGLLLLALLLALALDGKPAPP--QP----- 30
tr|D1MZV3|D1MZV3_RHATT     ---MFASRLA-----ALG LLLLALV---LDGKPAPPPQP----- 28
tr|Q7T1M4|Q7T1M4_BOTJR     ---HEKPSRSG-----AKSAAVGA KLAASSDSAADECSSGRK----- 34
tr|Q402A2|Q402A2_PETMA     -----
tr|Q402A3|Q402A3_LAMJA     ---MKLQLLMMV-----VVVGSWTF LG---VGAKPLT SYELYD----- 32
tr|Q402A1|Q402A1_9PETR     ---MRRQVLVMV-----VMVVVMVMSGKSVTAKPVASYELLD----- 35
sp|P21805|ANFC_CHICK      -----
tr|A9CDT6|A9CDT6_CHICK     ---MKLLFC-----PGFFLLLIVSQKQAMAKPIS----- 26
sp|P20968|ANFC_RANCA       ---MSYKRGTC-----LGFIMLLMVSHHHTKGKPLS----- 28
sp|P55208|ANFC_TRISC       ---MSGQTSFY-----CGLLVLLLIQAQ---ARPRS----- 25
sp|P23259|ANFC_SCYCA       -----RPRS----- 4
sp|P41319|ANFC_SQUAC       ---MSGHTSFY-----CGLLLLLLIQVQ---ARPR----- 25
tr|Q2MH72|Q2MH72_9CHON     ---MSGNTNFY-----CGLVLLLLLLQVQ---GRPRS----- 25
tr|Q2MH73|Q2MH73_9CHON     ---MSGNTNFY-----CGLVLLLLLLQVQ---GRPRS----- 25
tr|Q2MH71|Q2MH71_9CHON     ---MSGNTNFY-----CGLVLLLLLLQVQ---GRPRS----- 25
tr|Q2MH74|Q2MH74_DASAK     ---MSGNTNFY-----CGLVLLLLLLQVQ---GRPRS----- 25
tr|Q2PF87|Q2PF87_CALMI     ---MNAHVSFP-----CGLMLLLLLIQVQVQ---ARPRTG----- 28
sp|Q80018|ANFC3_ORYLA      ---MSLRAF-----MLCVCLLLQSVG---ARPAS----- 23
tr|Q4ADV1|Q4ADV1_ORYLA     ---MSLRAF-----MLCVCLLLQSVG---ARPAS----- 23
sp|Q805D4|ANFC3_TAKRU      ---MSLNLPGY-----ALFFILLVASSG---AKPAP----- 25
tr|C0H7B0|C0H7B0_SALSA     ---MKMISNIQFF-----CLTALVLLNLVG---ANPMS----- 27
tr|C1BWD1|C1BWD1_ESOLU     ---MISNIQFC-----CLSVLVLLNLVG---AKPVS----- 25
tr|D2KXA3|D2KXA3_ANGJA     ---MISNITIY-----CISLLFLNLVG---GKPVS----- 25
tr|B3DJJ2|B3DJJ2_DANRE     ---MIANISVF-----CVSSDLLNLVG---AKPVS----- 25
tr|Q1XGY8|Q1XGY8_ACTI     ---MVSRLTVY-----CALFIIVLSQVS---AKPVS----- 25
sp|Q8AXR2|ANFC2_ONCMY      ---ML--YPA-----LLCAALLLIAPLIGHTEGRTL YSPD----- 30
sp|Q8AXR3|ANFC1_ONCMY      ---ML--YPA-----LLCAALLLIAPLIGHTEGRTL HPSD----- 30
tr|C1BKS8|C1BKS8_OSMO      ---ML--CPV-----LLCATLVLLPPELSEGRALHPSPE----- 30
tr|Q805E7|Q805E7_OREMO     ---ML--CPV-----LLCAALLLLTPLEITEARALHPSPD----- 30
tr|C3KH23|C3KH23_ANOFI     ---ML--CPV-----LLCATLLLLTPLEITEARALHPPD----- 30
sp|Q8AYR6|ANFC1_ORYLA      ---ML--CPV-----LLCATLLLLTPFEVTEARALHPSAD----- 30
sp|Q805D6|ANFC1_TAKRU      ---ML--CPA-----LLCAALLLLTPVEITDARALQQPSD----- 30
sp|P18145|ANFC_ANGJA       ---MM--CKA-----LVFAVLLLAVPLERADSRALRTPVD----- 30
tr|Q1XGY9|Q1XGY9_ACTI     ---MMGSCSAPLLTGHRILCLFLLMASSLSPIHSRAFRSPP----- 38
tr|A9CDT5|A9CDT5_CHICK     MLGLPA-----WPCSLFLLLVLLSASVQAMSSSGQR----- 31

```

**FIG. 15B****Multiple Alignment of C-Type Natriuretic Peptides from Various Species**

```

sp|Q8AYR5|ANFC2_ORYLA -----
sp|Q805D5|ANFC2_TAKRU -----
sp|Q76KW6|ANFC_ACITR -----
sp|Q61839|ANFC_MOUSE -----
tr|Q544K5|Q544K5_MOUSE -----
tr|Q8VHG9|Q8VHG9_NOTAL -----
sp|P55207|ANFC_RAT -----
sp|P55206|ANFC_BOVIN -----
sp|P56283|ANFC_SHEEP -----
sp|P18104|ANFC_PIG -----
sp|P23582|ANFC_HUMAN -----
sp|P84715|ANF39_ORNAN -----
tr|Q9QZ96|Q9QZ96_CAVPO -----
sp|Q800I7|ANFC4_ORYLA -----
sp|Q805D3|ANFC4_TAKRU -----
tr|C1BXI5|C1BXI5_ESOLU -----
tr|D2KXA5|D2KXA5_ANGJA -----
tr|Q1XGY7|Q1XGY7_9ACTI -----
sp|P40756|ANFD_RANCA -----
sp|P0C7P5|BNP_TRIFL -----SPPIS----- 38
sp|P0C7P6|BNP_TRIGA -----SPPISPLLVP-----PPPPPHWPPP- 53
sp|Q6LEM5|BNP1_BOTJA -----WP--GNIPPLKVQQWAQGGWPRPGPEIPPLTVQQWAQN- 69
sp|Q9PW56|BNP2_BOTJA -----WPRPGPEIPPLKVQQWAQGGWPRPGPEIPPLTVQQWAQN- 72
sp|P68515|BNP_BOTIN -----WPRPGPEIPPLKVQQWAQGGWPRPGPEIPPLTVQQWAQN- 72
sp|Q90Y12|BNP_CRODU -----QRWP--- 34
sp|Q2PE51|BNP_CRODO -----QRWP--- 34
sp|B0VXV8|BNP_SISCA -----QNWPG-- 35
sp|Q27J49|BNP_LACMU -----KGWPPERQIPPLVVQWSQKPWP-PGHHIPPVVQEWPP-- 69
sp|P01021|BNP_AGKHA PRLVVQWSQGLPPGPPIPRLVVQWSQG-LP-PGPPIPPLVVQWSQGL 87
sp|Q09GK2|VNP_PHIOL -----
tr|D1MZV3|D1MZV3_RHATT -----
tr|Q7T1M4|Q7T1M4_BOTJR -----GEPPG- 39
tr|Q402A2|Q402A2_PETMA -----
tr|Q402A3|Q402A3_LAMJA -----
tr|Q402A1|Q402A1_9PETR -----
sp|P21805|ANFC_CHICK -----
tr|A9CDT6|A9CDT6_CHICK -----
sp|P20968|ANFC_RANCA -----
sp|P55208|ANFC_TRISC -----
sp|P23259|ANFC_SCYCA -----
sp|P41319|ANFC_SQUAC -----
tr|Q2MH72|Q2MH72_9CHON -----
tr|Q2MH73|Q2MH73_9CHON -----
tr|Q2MH71|Q2MH71_9CHON -----
tr|Q2MH74|Q2MH74_DASAK -----
tr|Q2PF87|Q2PF87_CALMI -----
sp|Q800I8|ANFC3_ORYLA -----
tr|Q4ADV1|Q4ADV1_ORYLA -----
sp|Q805D4|ANFC3_TAKRU -----
tr|C0H7B0|C0H7B0_SALSA -----
tr|C1BWD1|C1BWD1_ESOLU -----
tr|D2KXA3|D2KXA3_ANGJA -----
tr|B3DJJ2|B3DJJ2_DANRE -----
tr|Q1XGY8|Q1XGY8_9ACTI -----
sp|Q8AXR2|ANFC2_ONCMY -----
sp|Q8AXR3|ANFC1_ONCMY -----
tr|C1BKS8|C1BKS8_OSMMO -----
tr|Q805E7|Q805E7_OREMO -----
tr|C3KH23|C3KH23_ANOFI -----
sp|Q8AYR6|ANFC1_ORYLA -----
sp|Q805D6|ANFC1_TAKRU -----
sp|P18145|ANFC_ANGJA -----
tr|Q1XGY9|Q1XGY9_9ACTI -----
tr|A9CDT5|A9CDT5_CHICK -----

```

**FIG. 15C****Multiple Alignment of C-Type Natriuretic Peptides from Various Species**

sp Q8AYR5 ANFC2_ORYLA	-----	
sp Q805D5 ANFC2_TAKRU	-----	
sp Q76KW6 ANFC_ACITR	-----	
sp Q61839 ANFC_MOUSE	-----	
tr Q544K5 Q544K5_MOUSE	-----	
tr Q8VHG9 Q8VHG9_NOTAL	-----	
sp P55207 ANFC_RAT	-----	
sp P55206 ANFC_BOVIN	-----	
sp P56283 ANFC_SHEEP	-----	
sp P18104 ANFC_PIG	-----	
sp P23582 ANFC_HUMAN	-----	
sp P84715 ANF39_ORNAN	-----	
tr Q9QZ96 Q9QZ96_CAVPO	-----	
sp Q800I7 ANFC4_ORYLA	-----	
sp Q805D3 ANFC4_TAKRU	-----	
tr C1BXI5 C1BXI5_ESOLU	-----	
tr D2KXA5 D2KXA5_ANGJA	-----	
tr Q1XGY7 Q1XGY7_9ACTI	-----	
sp P40756 ANFD_RANCA	-----	
sp P0C7P5 BNP_TRIFL	-----PLSAQQWMPEGRPPHP--IPPLSVQQWSQGRP-----	68
sp P0C7P6 BNP_TRIGA	---HHIPPLSVQKFPPGKPTHPHHIPPLEVQQWSQGGP-----	89
sp Q6LEM5 BNP1_BOTJA	WPHPQIPPLTVQQWAQ-GRAPGPP-IPPLTVQQWAQGRAPHPPIPPAPLQ	117
sp Q9PW56 BNP2_BOTJA	WPHPQIPPLTVQQWAQWGRPPGPP-IPPLTVQQWAQARPPHPPIPPAPLQ	121
sp P68515 BNP_BOTIN	WPHPQIPPLTVQQWAQLGPPPRPQ-IPPLEVQQWAQGRAPHPPIPPAPLQ	121
sp Q90Y12 BNP_CRODU	-----HLE-IPPLVVQNWK-----	47
sp Q2PE51 BNP_CRODO	-----HLE-IPPLVVQNWK-----	47
sp B0VXV8 BNP_SISCA	---PKVPPLVVQQWSQN--WPHPQ-IPPLVVQNWK-----	64
sp Q27J49 BNP_LACMU	--GHHIPPLVVQQWSQKKWPPGHH-IPPLVVQKWDP-----	102
sp P01021 BNP_AGKHA	PPRPKIPPLVVQQWSQG-LPPRPK-IPPLVVQKWDP-----	121
sp Q09GK2 VNP_PHIOL	-----	
tr D1MZV3 D1MZV3_RHATT	-----	
tr Q7T1M4 Q7T1M4_BOTJR	---PIIPPLTVQQWAQAR-PPHP-IPPAPLQKWAPVQK-----	73
tr Q402A2 Q402A2_PETMA	-----	
tr Q402A3 Q402A3_LAMJA	-----	
tr Q402A1 Q402A1_9PETR	-----	
sp P21805 ANFC_CHICK	-----	
tr A9CDT6 A9CDT6_CHICK	-----	
sp P20968 ANFC_RANCA	-----	
sp P55208 ANFC_TRISC	-----	
sp P23259 ANFC_SCYCA	-----	
sp P41319 ANFC_SQUAC	-----	
tr Q2MH72 Q2MH72_9CHON	-----	
tr Q2MH73 Q2MH73_9CHON	-----	
tr Q2MH71 Q2MH71_9CHON	-----	
tr Q2MH74 Q2MH74_DASAK	-----	
tr Q2PF87 Q2PF87_CALMI	-----	
sp Q800I8 ANFC3_ORYLA	-----	
tr Q4ADV1 Q4ADV1_ORYLA	-----	
sp Q805D4 ANFC3_TAKRU	-----	
tr C0H7B0 C0H7B0_SALSA	-----	
tr C1BWD1 C1BWD1_ESOLU	-----	
tr D2KXA3 D2KXA3_ANGJA	-----	
tr B3DJJ2 B3DJJ2_DANRE	-----	
tr Q1XGY8 Q1XGY8_9ACTI	-----	
sp Q8AXR2 ANFC2_ONCMY	-----	
sp Q8AXR3 ANFC1_ONCMY	-----	
tr C1BKS8 C1BKS8_OSMMO	-----	
tr Q805E7 Q805E7_OREMO	-----	
tr C3KH23 C3KH23_ANOFI	-----	
sp Q8AYR6 ANFC1_ORYLA	-----	
sp Q805D6 ANFC1_TAKRU	-----	
sp P18145 ANFC_ANGJA	-----	
tr Q1XGY9 Q1XGY9_9ACTI	-----	
tr A9CDT5 A9CDT5_CHICK	-----	

## FIG. 15D

## Multiple Alignment of C-Type Natriuretic Peptides from Various Species

sp Q8AYR5 ANFC2_ORYLA	-----EQVLKSLFGPHLTSL-----	IL	47
sp Q805D5 ANFC2_TAKRU	-----AQVLRALFGARLSSI-----	IS	47
sp Q76KW6 ANFC_ACITR	-----KSQLAGLFGAEVAAL-----	LE	57
sp Q61839 ANFC_MOUSE	-----PKVPRTPPGEELADS-----	QAAG	47
tr Q544K5 Q544K5_MOUSE	-----PKVPRTPPGEELADS-----	QAAG	47
tr Q8VHG9 Q8VHG9_NOTAL	-----PKVPRTPPGEELADS-----	QAAG	47
sp P55207 ANFC_RAT	-----PKVPRTPPGEELAEP-----	QAAG	47
sp P55206 ANFC_BOVIN	-----PKVPRTSPGEEVAEP-----	QAAG	47
sp P56283 ANFC_SHEEP	-----PKVPRTPPGEEVAEP-----	QAAG	47
sp P18104 ANFC_PIG	-----PKVPRTPPGEEVAEP-----	QAAG	47
sp P23582 ANFC_HUMAN	-----PKVPRTPPAEELAEP-----	QAAG	47
sp P84715 ANF39_ORNAN	-----PQVPRSP-GDEASEA-----	VAAN	46
tr Q9QZ96 Q9QZ96_CAVPO	-----		
sp Q80017 ANFC4_ORYLA	-----QKSLRSLLGEELEAF-----	LESG	48
sp Q805D3 ANFC4_TAKRU	-----QKSFRLSLGEELEAF-----	LESE	48
tr C1BXI5 C1BXI5_ESOLU	-----QKSLRNLLGEELESEF-----	LASG	48
tr D2KXA5 D2KXA5_ANGJA	-----EKSLRNLLGEELESEY-----	LASG	48
tr Q1XGY7 Q1XGY7_ACTI	-----QKSLRNLLGEELESAI-----	LTSD	48
sp P40756 ANFD_RANCA	-----QKSLRALLGEELEAI-----	LVSG	48
sp P0C7P5 BNP_TRIFL	---RSEVPPVVVQPHESPAGGTTAFREELSPG-----	PEAASG	103
sp P0C7P6 BNP_TRIGA	---RSEL---VQPHESPAGGTTAFREELSLG-----	PEAASG	120
sp Q6LEM5 BNP1_BOTJA	KWAPLQKWAPLLQPHESPASGTTALREELSLG-----	PEAASG	155
sp Q9PW56 BNP2_BOTJA	KWAPVQKWAPLLQPHESPASGTTALREELSLG-----	PEAASG	159
sp P68515 BNP_BOTIN	KWAPVQKWAPLLQPHESPASGTTALREELSLG-----	PEAASG	159
sp Q90Y12 BNP_CRODU	-----SPTQLQARESAPAGGTTALREELSLG-----	PEAALD	78
sp Q2PE51 BNP_CRODO	-----SPTQLQARESAPAGGTTALREELSLG-----	PEAALD	78
sp B0VXV8 BNP_SISCA	-----SPTQLQPRESPAGGTTALREELSLG-----	PDAALD	95
sp Q27J49 BNP_LACMU	---PPI-SPPLLPKPHESPAGGTTALREELSLG-----	PEAALD	136
sp P01021 BNP_AGKHA	---PPVSPPLLPKPHESPAGGTTALREELSLG-----	PEAASG	156
sp Q09GK2 VNP_PHIOL	-----LRKAPAGGTTAWRRELTEQ-----	PEGASR	55
tr D1MZV3 D1MZV3_RHATT	-----LRKAPAGGTTALQRQLTEQQQQQQ-----	QAEQSSG	59
tr Q7T1M4 Q7T1M4_BOTJR	-WAPVQKWAPLLQPHESPAGGTTALREELSLG-----	PEAASG	110
tr Q402A2 Q402A2_PETMA	-----SGSEPWEGG-FLPRVSSSSSSSSG-----	EVEPLAE	30
tr Q402A3 Q402A3_LAMJA	-----DAGSEPWEGG-FLPRISSSSSSSS-----	AERLAD	60
tr Q402A1 Q402A1_9PETR	-----DTNSEPWEGGSLPSLPSQEGED-----	SHPLS-	63
sp P21805 ANFC_CHICK	-----		
tr A9CDT6 A9CDT6_CHICK	-----SLQSLSMLLDEE-----	L	39
sp P20968 ANFC_RANCA	-----SLQNLRLLEDN-----	F	41
sp P55208 ANFC_TRISC	-----DDSLQTLRLLEDE-----	Y	40
sp P23259 ANFC_SCYCA	-----DDSLQTLRLLEDE-----	Y	19
sp P41319 ANFC_SQUAC	-----DDSLQVLSRLLEDE-----	Y	40
tr Q2MH72 Q2MH72_9CHON	-----DDSLQALTRLLEDE-----	Y	40
tr Q2MH73 Q2MH73_9CHON	-----DDSLQALTRLLEDE-----	Y	40
tr Q2MH71 Q2MH71_9CHON	-----DDSLQALTRLLEDE-----	Y	40
tr Q2MH74 Q2MH74_DASAK	-----DDSLQALTRLLEDE-----	Y	40
tr Q2PF87 Q2PF87_CALMI	-----VDSLQILSRLEDE-----	Y	43
sp Q80018 ANFC3_ORYLA	-----ELQNLRL--		32
tr Q4ADV1 Q4ADV1_ORYLA	-----ELQNLRL--		32
sp Q805D4 ANFC3_TAKRU	-----DLQILEPPLSSLEEQQEEMQEEVQEKVQEQQEEVQ		59
tr C0H7B0 C0H7B0_SALSA	-----NLQSLKQLLEEE-----	SH	41
tr C1BWD1 C1BWD1_ESOLU	-----NLQSLKEFLEE-----	SN	38
tr D2KXA3 D2KXA3_ANGJA	-----SLQSLKELLEEE-----	SN	39
tr B3DJJ2 B3DJJ2_DANRE	-----SLQSLKQLLEDE-----	VN	39
tr Q1XGY8 Q1XGY8_ACTI	-----SLQSFAQLLEDE-----	SN	39
sp Q8AXR2 ANFC2_ONCMY	-----AIQFVEQFLDR-----	YN	43
sp Q8AXR3 ANFC1_ONCMY	-----AIQFVEQFLDR-----	YN	43
tr C1BKS8 C1BKS8_OSMMO	-----GLQFVEQFLER-----	CT	43
tr Q805E7 Q805E7_OREMO	-----AVQFVEQFLER-----	YN	43
tr C3KH23 C3KH23_ANOFI	-----AVQFMEQFLER-----	YN	43
sp Q8AYR6 ANFC1_ORYLA	-----AVQFVEQFLDR-----	YN	43
sp Q805D6 ANFC1_TAKRU	-----AAQFMEQFLER-----	YN	43
sp P18145 ANFC_ANGJA	-----AIQFVEQFLEH-----	YN	43
tr Q1XGY9 Q1XGY9_ACTI	-----LQFLSTLLEKE-----	YG	51
tr A9CDT5 A9CDT5_CHICK	-----LQVLLSLLPS-----	DS	44

## FIG. 15E

## Multiple Alignment of C-Type Natriuretic Peptides from Various Species

```

sp|Q8AYR5|ANFC2_ORYLA      APPTSND--TEGSSGSPEPP-----TPSEAPVLIH-- 76
sp|Q805D5|ANFC2_TAKRU      TPVNTDDI--AELLPRRPGPPR-----SFGASPGALRGLTR-- 81
sp|Q76KW6|ANFC_ACITR       DAGAADGSSGEEAALSQRAPPS-----IRALHPRSGRLGLRDD 95
sp|Q61839|ANFC_MOUSE      GNQKKGDKTPGSGGANLKGDRS-----RLLRDRLR 76
tr|Q544K5|Q544K5_MOUSE    GNQKKGDKTPGSGGANLKGDRS-----RLLRDRLR 76
tr|Q8VHG9|Q8VHG9_NOTAL    GNQKKGDKTPGGGGANLKGDRSRLKGDTPGGGGANLKGDRSRLLRDLR 97
sp|P55207|ANFC_RAT        GNQKKGDKTPGGGGANLKGDRS-----RLLRDRLR 76
sp|P55206|ANFC_BOVIN      GGQKKGDKTPGGGGANLKDDRS-----RLLRDRLR 76
sp|P56283|ANFC_SHEEP      GGQKKGDKTPGGGGANLKDDRS-----RLLRDRLR 76
sp|P18104|ANFC_PIG        GGQKKGDKTPGGGGANLKGDRS-----RLLRDRLR 76
sp|P23582|ANFC_HUMAN      GGQKKGDKAPGGGGANLKGDRS-----RLLRDRLR 76
sp|P84715|ANF39_ORNAN     GGKKKGDKKP-----KGDRP-----RLLRELR 68
tr|Q9QZ96|Q9QZ96_CAVPO   -----
sp|Q80017|ANFC4_ORYLA     ENENRLDDVRSRM-----RLLRDRLR 68
sp|Q805D3|ANFC4_TAKRU     EKERRLDAVRSRL-----RLLRDRLR 68
tr|C1BXI5|C1BXI5_ESOLU    ERERRLDIVRSRV-----RLLRDRLR 68
tr|D2KXA5|D2KXA5_ANGJA    ERERNLESARS-----RLLRDRLR 66
tr|Q1XGY7|Q1XGY7_ACTI    EQESGSENLRSA-----RLLRDRLR 68
sp|P40756|ANFD_RANCA      ERGERSIDPKTRA-----RLLRDIR 68
sp|P0C7P5|BNP_TRIFL      -----PAAPHRLPKSKG-----ASATS-AASRPMRDRLR 130
sp|P0C7P6|BNP_TRIGA      -----PAAPQRLPKRKG-----ASATS-AASRSMRDRLR 147
sp|Q6LEM5|BNP1_BOTJA      VPSAGAEVGRSGSK-APAAPHRLSKSKG-----AAAT-----RPMRDRLR 193
sp|Q9PW56|BNP2_BOTJA      VPSAGAEVGRSGSK-APAAPHRLSKSKG-----AAATS-AASRPMRDRLR 201
sp|P68515|BNP_BOTIN      VPSAGAEVGRSGSK-APAAPHRLSKSKG-----AAATS-AASRPMRDRLR 201
sp|Q90Y12|BNP_CRODU      TPPAGPDGGRSGSKAAAAAPQRLSKSKG-----ASATS-AASR---DLR 118
sp|Q2PE51|BNP_CRODO      TPPAGPDGGRSGSKAAAAAPQRLSKSKG-----ASATS-AASR---DLR 118
sp|B0VXV8|BNP_SISCA      TPPAGPDVGRSGSK-AAAAPQRLSKSKG-----ASATS-TASRPMRDRLR 137
sp|Q27J49|BNP_LACMU      TPPAGPDVGRSGSK-APAAPHRLPKSKG-----ASATS-AASRPMRDRLR 178
sp|P01021|BNP_AGKHA      PAAAGADGGRSGSK-APAALHRLSKSKG-----ASATSASASRPMRDRLR 199
sp|Q09GK2|VNP_PHIOL      PAAGGGGGGRSGSKAANAAPTAPKSKG-----AAAAAAAARLMDRLR 100
tr|D1MZV3|D1MZV3_RHATT    PAAGGGGG--RSGSKTANAAPTAPKSKG-----AAASAASRLLRDLR 99
tr|Q7T1M4|Q7T1M4_BOTJR    VPSAGAEGRARLEGARCTPSAVEEQRGG-----GDLGGVAADAGLAPRR 155
tr|Q402A2|Q402A2_PETMA    VTATGGVSGGVSGVLGGTPWVGPRGHQ-----RPSRGLA 65
tr|Q402A3|Q402A3_LAMJA    ATVTR-HGGGGGGGGDDGTSWELPQGGPG-----PPRSSRGLA 97
tr|Q402A1|Q402A1_9PETR    -----AEGG-----PWERGSGPQ-----RSSRGIG 83
tr|P21805|ANFC_CHICK     -----
tr|A9CDT6|A9CDT6_CHICK    QHPLVSEERDREQDGSIPVGAF-----DQEDAEFQWTRNTRD----- 76
sp|P20968|ANFC_RANCA      ERSFGSDEADQQL---VPTDSL-----DQLDPELQWNKNRLE----- 75
sp|P55208|ANFC_TRISC      GHYLPDELNNEAQEMSPAASLPEFNADQSDLELPWDRESRE----- 82
sp|P23259|ANFC_SCYCA      GHYLPDELNNEAEEMSPAASLPELNADQSDLELPWERESRE----- 61
sp|P41319|ANFC_SQUAC      GHFN-SEELNNEAQEISPAASLPDLNTDQSDLELPWDRESRE----- 81
tr|Q2MH72|Q2MH72_9CHON    GQYFTTEDLNNEAPEIPPAASLPDLNTDQSDLDLSWDRESRE----- 82
tr|Q2MH73|Q2MH73_9CHON    GQYFTTEDLNNEAPEIPPAASLPDLNTDQSDLDLSWDRESRE----- 82
tr|Q2MH71|Q2MH71_9CHON    GQYFTSEDLNNEAPEIPPAASLPDLNTDQPDFDLSDWDRESRE----- 82
tr|Q2MH74|Q2MH74_DASAK    GQYFTSEDLNNEAPEMSPAASLPDLNTEQSETDLPWDRESRE----- 82
tr|Q2PF87|Q2PF87_CALMI    GPYLSSEDSMEAEASRAGTLRDLNLDQADMDDLWDRDARD----- 85
sp|Q80018|ANFC3_ORYLA     ---QDQLSSTEHPPEE---DRLD---RTREEPQLGG----- 58
tr|Q4ADV1|Q4ADV1_ORYLA    ---QDQLSSTEHPPEE---DRLD---RTREEPQLGG----- 58
sp|Q805D4|ANFC3_TAKRU     EKVQEQEQEEVQEQEEVQEQE-----EQQEEVQERGRGTGDVLLRAQLD 104
tr|C0H7B0|C0H7B0_SALSA    VPHYASDEMVGDKDLNTEN-----IAEEVPPWDSER----- 75
tr|C1BWD1|C1BWD1_ESOLU    VPYYGSESEVDDKDLNTEKEA-----FTGEVVPWLTEDR----- 74
tr|D2KXA3|D2KXA3_ANGJA    APYLDSEAEVQKEMNAENAA-----FTKASLHSDWPNSR----- 75
tr|B3DJJ2|B3DJJ2_DANRE    KPFEESQESVMEQKDATAEKSA-----LDERAEQLWESDAR----- 75
tr|Q1XGY8|Q1XGY8_ACTI    HPYVSDDDTRGGLDVSAEIA-----DDSEADIPWNHNRDL----- 77
sp|Q8AXR2|ANFC2_ONCMY     DLT--LDDLLENLVSSQPEEPSS-----AFTSGVKIAEYPKW 77
sp|Q8AXR3|ANFC1_ONCMY     DLT--LDDLLENLVSSQPEEPSS-----AFTSGVKVAYEYPKW 77
tr|C1BKS8|C1BKS8_OSMO    DLLN-LDDLLENAGSNQPEEPS-----DYANGVKVAYEYPKW 77
tr|Q805E7|Q805E7_OREMO    DLLT-LDDLLENMLNSQAEQES-----TLSSGSKAVEYPKW 77
tr|C3KH23|C3KH23_ANOFI    DLLT-LDDLLENLNSQPEEQS-----TFSSGVKAAEYPKW 77
sp|Q8AYR6|ANFC1_ORYLA     DLLT-LDDLLENLNTQPEEQS-----TLSSGVKTAIEYPKW 77
sp|Q805D6|ANFC1_TAKRU    DLLT-LDDLLENMLNSHPEDQS-----NLSS-SKADEYPKW 76
tr|P18145|ANFC_ANGJA      DLLN-IDDLLENQTDQLESPO-----PLSSGLKVAEYPKW 77
tr|Q1XGY9|Q1XGY9_ACTI    NLQSGPVNIHNVSSSEQYEDPQ-----PWADVSSVSKEQI 86
tr|A9CDT5|A9CDT5_CHICK    ESMPAEEDMKEGSSSEPQLLSP-----PLPLPSRAR----- 76

```

## FIG. 15F

## Multiple Alignment of C-Type Natriuretic Peptides from Various Species

```

sp|Q8AYR5|ANFC2_ORYLA      -----GDRGTASQILRSFLRQRE-----KTRRWG--RKPMVAG- 107
sp|Q805D5|ANFC2_TAKRU      -----GSEG-GSRFLLDFLQQQS-----KTTRRG--RSSMVGG- 111
sp|Q76KW6|ANFC_ACITR      LEAEPPAENKPRRLKDFMSSR-----KMFRGR--TKMKQQG- 131
sp|Q61839|ANFC_MOUSE      VDTKSR---AAWARLLHEHPN-----ARKYKG--GNKKGLS- 107
tr|Q544K5|Q544K5_MOUSE    VDTKSR---AAWARLLHEHPN-----ARKYKG--GNKKGLS- 107
tr|Q8VHG9|Q8VHG9_NOTAL    VDTKSR---AAWARLLHEHPN-----ARKNKG--GNKKGLS- 128
sp|P55207|ANFC_RAT        VDTKSR---AAWARLLHEHPN-----ARKYKG--GNKKGLS- 107
sp|P55206|ANFC_BOVIN      VDTKSR---AAWTRLLEHPN-----ARKYKG--GNKKGLS- 107
sp|P56283|ANFC_SHEEP      VDTKSR---AAWTRLLEHPN-----ARKYKG--GNKKGLS- 107
sp|P18104|ANFC_PIG        VDTKSR---AAWARLLHEHPN-----ARKYKG--GNKKGLS- 107
sp|P23582|ANFC_HUMAN      VDTKSR---AAWARLLQEHNP-----ARKYKG--ANKKGLS- 107
sp|P84715|ANF39_ORNAN     LDTRSRGSRGVWTRLHDHPN-----PRKYKP--ANKKGLS- 102
tr|Q9QZ96|Q9QZ96_CAVPO    -----N-----ARKYKG--GNKKGLS- 14
sp|Q80017|ANFC4_ORYLA     VDTRAR---GMWARLLNDQPA-----SRRHKS--GSKKGGST 100
sp|Q805D3|ANFC4_TAKRU     MDTRAR---GVWARLLNDQPV-----PRRHKT--GIKKGGS- 99
tr|C1BXI5|C1BXI5_ESOLU    MDTRAK---GMWARLLNDQPN-----ARRHKQ--NSKKGTV- 99
tr|D2KXA5|D2KXA5_ANGJA    LNTRAR---GMWSRIMNDQPA-----SRKQKT--GVKKGAST 98
tr|Q1XGY7|Q1XGY7_ACTI     LDIRAK---AAWARLLNDHPN-----PRKSKG--INKKGLS- 99
sp|P40756|ANFD_RANCA      ADTRSR---AAWTRLLEHPN-----SRKIKG--INKKGTS- 99
sp|P0C7P5|BNP_TRIFL      TDGKQERQKWG--RMVQPDHHAAPGGGGGGGGG--ARRMKG--LAKKAMG- 174
sp|P0C7P6|BNP_TRIGA      ADGKQARQKWG--RMVQPDHHAAPGGGGGGGGG--ARRLKG--LAKKAVG- 191
sp|Q6LEM5|BNP1_BOTJA      PDGKQARQNWG--RMAHHDHHAAGGGGGGGGG--ARRLKG--LAKKGAA- 237
sp|Q9PW56|BNP2_BOTJA      PDGKQARQNWG--RMVHHDHHAAGGGGGGGGG--ARRLKG--LAKKGAA- 246
sp|P68515|BNP_BOTIN       PDGKQARQNWG--RMVHHDHHAAGGGGGGGGG--ARRLKG--LAKKGAA- 246
sp|Q90Y12|BNP_CRODU       TDGKQARQNWG--RLVSPDHHSAGGGGGGGGG--ARRLKG--LAKKRAG- 162
sp|Q2PE51|BNP_CRODO       TDGKQARQNWG--RLVSPDHHSAGGGGGGGGG--ARRLKG--LAKKRAG- 162
sp|B0VXV8|BNP_SISCA       TDGKQARQNWG--RMLNPDHHSAPGGGGGGGG--ARRLKG--LAKKRAG- 182
sp|Q27J49|BNP_LACMU       TDGKQARQNWG--RMMNPDHHAAGGGGGGGGG--ARRLKG--LAKKRVG- 220
sp|P01021|BNP_AGKHA       PDGKQARQNWA--RMVNPDHHAAGGCCCGGGGGG--ARRLKG--LVKKGVA- 244
sp|Q09GK2|VNP_PHIOL       PDSKQARAAGW--RMVHPEHHAGGGGGGGGG--ASRRKG--VAKKGLG- 145
tr|D1MZV3|D1MZV3_RHATT    PDGKQSRAAWG--RMVHPEHHAGGGGGGGGG--SRRLKG--LPKKGLG- 142
tr|Q7T1M4|Q7T1M4_BOTJR    QAGAAELGPDGAPRPPRPPRSGRRAAAAAAERGARRLKG--LAKKGAA- 202
tr|Q402A2|Q402A2_PETMA     EGGSQVSG-GVWQRLFNDFVSN-----QRRFRG--RTKKKGK- 99
tr|Q402A3|Q402A3_LAMJA     EGGSQVSG-GVWQRLFNDFVSN-----QRRFRG--RTKKKGK- 131
tr|Q402A1|Q402A1_9PETR    -GGSQVSG-EVWQRLFNDFVSN-----QRRFRG--RTKKKGK- 116
sp|P21805|ANFC_CHICK      -----GLS- 3
tr|A9CDT6|A9CDT6_CHICK    QPASTSTADSDVQRILSDLLGL-----PQRYQN--RSKKGLS- 111
sp|P20968|ANFC_RANCA      QGDSPHVNEMTLQQLLNDPVG-----SRRYRQ--RNKKGYS- 110
sp|P55208|ANFC_TRISC      IGGRPFRQEAVLARLLKDLN-----PLRFRG--RSKKGPS- 117
sp|P23259|ANFC_SCYCA      IGGRPFRQEAVLARLLKDLN-----PLRFRG--RSKKGPS- 96
sp|P41319|ANFC_SQUAC      IGGRSFRQEALLARLLKDLN-----PLRFKG--RSKKGPS- 116
tr|Q2MH72|Q2MH72_9CHON    IASR-----PILARILKDLN-----PLRFRG--RSKKGPS- 112
tr|Q2MH73|Q2MH73_9CHON    IASR-----PILARILKDLN-----PLRFRG--RSKKGPS- 112
tr|Q2MH71|Q2MH71_9CHON    IASR-----PILARILKDLN-----PLRFRG--RSKKGPS- 112
tr|Q2MH74|Q2MH74_DASAK     IASR-----PILARILKDLN-----PLRFRG--RSKKGPS- 112
tr|Q2PF87|Q2PF87_CALMI     IGGRSFQHDGLLLRLKDLTIS-----PLRFNG--RSKKGPS- 120
sp|Q80018|ANFC3_ORYLA     SSSREAADESALTRLFADLLRT-----SKRSWG--RYKKGGM- 93
tr|Q4ADV1|Q4ADV1_ORYLA     SSSREAADESALTRLFADLLRT-----SKRSWG--RYKKGGM- 93
sp|Q805D4|ANFC3_TAKRU     SSTWALQKDDVLMRLFKDLLRT-----SKRSRS--RYKKGGL- 139
tr|C0H7B0|C0H7B0_SALSA    --NSALTGKEDVIARLLNDIMT-----PKRSWS--RFKKGGL- 109
tr|C1BWD1|C1BWD1_ESOLU    --SALTGENAVARLLSDIMTT-----PKRSWG--RFKKGGM- 107
tr|D2KXA3|D2KXA3_ANGJA    -DAALSSNENALVRLNDILSS-----SKRSWS--RFKKGGL- 109
tr|B3DJJ2|B3DJJ2_DANRE    -NSALAGKYGMFERLLGDLST-----SKRSWS--RFKKGDL- 109
tr|Q1XGY8|Q1XGY8_ACTI     -QHRQAAHSSRMILKLDILTS-----SGRSWD--REKKSGL- 111
sp|Q8AXR2|ANFC2_ONCMY      ADIP-AQGDSTWLRLKGTLAN-----QKRAVT--DRSRRGWN- 112
sp|Q8AXR3|ANFC1_ONCMY      ADIP-AQGDSTWLRLKGTLAN-----QKRAVM--DRSRRGWN- 112
tr|C1BKS8|C1BKS8_OSMO     ADLPAAQEDSAWLRLKAALAN-----QKRAEP--DRSRRAWN- 113
tr|Q805E7|Q805E7_OREMO     ADAQTQPE--TPWLRLKKGALAN-----QKRAEP--DRSRRGWN- 112
tr|C3KH23|C3KH23_ANOFI     ADAQTQAE--TPWLRLKKGAVAN-----QKRAEP--DRSRRGWN- 112
sp|Q8AYR6|ANFC1_ORYLA     ADLQTQPE--TPWFLRLKGTALN-----QKRAEP--DRSRRGWN- 112
sp|Q805D6|ANFC1_TAKRU     AEAD----TPWLRLKKGALAN-----QKRAEP--DRSRRGWN- 107
sp|P18145|ANFC_ANGJA      VDVPSOND-NTWFRLRGALAN-----RKRALP--DRAKRGWN- 112
tr|Q1XGY9|Q1XGY9_ACTI     GDEPPANE-NALYLLLRRAAAN-----RTWISA--DRVKKAWS- 121
tr|A9CDT5|A9CDT5_CHICK    -----AAHPLLWRKALAS-----RKRALSGDWAOKAVP- 104

```

## FIG. 15G

## Multiple Alignment of C-Type Natriuretic Peptides from Various Species

sp Q8AYR5 ANFC2_ORYLA	---GG	CFGMKMDRIGSISGLGC	126 (SEQ ID NO: 31)
sp Q805D5 ANFC2_TAKRU	---RG	CFGMKIDRIGSISGLGC	130 (SEQ ID NO: 32)
sp Q76KW6 ANFC_ACITR	---RG	CFGMKLDRIIGSMSGLGC	150 (SEQ ID NO: 33)
sp Q61839 ANFC_MOUSE	---KG	CFGLKLDRIIGSMSGLGC	126 (SEQ ID NO: 34)
tr Q544K5 Q544K5_MOUSE	---KG	CFGLKLDRIIGSMSGLGC	126 (SEQ ID NO: 35)
tr Q8VHG9 Q8VHG9_NOTAL	---KG	CFGLKLDRIIGSMSGLGC	147 (SEQ ID NO: 36)
sp P55207 ANFC_RAT	---KG	CFGLKLDRIIGSMSGLGC	126 (SEQ ID NO: 37)
sp P55206 ANFC_BOVIN	---KG	CFGLKLDRIIGSMSGLGC	126 (SEQ ID NO: 38)
sp P56283 ANFC_SHEEP	---KG	CFGLKLDRIIGSMSGLGC	126 (SEQ ID NO: 39)
sp P18104 ANFC_PIG	---KG	CFGLKLDRIIGSMSGLGC	126 (SEQ ID NO: 40)
sp P23582 ANFC_HUMAN	---KG	CFGLKLDRIIGSMSGLGC	126 (SEQ ID NO: 41)
sp P84715 ANF39_ORNAN	---KG	CFGLKLDRIIGSTSGGLGC	121 (SEQ ID NO: 42)
tr Q9QZ96 Q9QZ96_CAVPO	---KG	CFGLKLDRIIGSMSGLGC	33 (SEQ ID NO: 43)
sp Q800I7 ANFC4_ORYLA	-SRSG	CFGHKMDRIGTISGMGC	121 (SEQ ID NO: 44)
sp Q805D3 ANFC4_TAKRU	-SRSG	CFGHKMDRIGTISGMGC	120 (SEQ ID NO: 45)
tr C1BXI5 C1BXI5_ESOLU	-PRSG	CFGQKLDRIIGTSLGMGC	121 (SEQ ID NO: 46)
tr D2KXA5 D2KXA5_ANGJA	PARGG	CFGHKLDRIISTSLGMGC	120 (SEQ ID NO: 47)
tr Q1XGY7 Q1XGY7_9ACTI	---KG	CFGLKLDRIIGSMSGLGC	118 (SEQ ID NO: 48)
sp P40756 ANFD_RANCA	---KG	CFGLKLDRIIGAMSGLGC	118 (SEQ ID NO: 49)
sp P0C7P5 BNP_TRIFL	---KG	CFGHKLDRIIGSTSGGLGC	193 (SEQ ID NO: 50)
sp P0C7P6 BNP_TRIGA	---KG	CFGLPLDRIIGSMSGMGC	210 (SEQ ID NO: 51)
sp Q6LEM5 BNP1_BOTJA	---KG	CFGLKLDRIIGTMSGGLGC	256 (SEQ ID NO: 52)
sp Q9PW56 BNP2_BOTJA	---KG	CFGLKVDRIIGTMSGGLGC	265 (SEQ ID NO: 53)
sp P68515 BNP_BOTIN	---KG	CFGLKLDRIIGTMSGGLGC	265 (SEQ ID NO: 54)
sp Q90Y12 BNP_CRODU	---NG	CFGLKLDRIIGSMSGLGC	181 (SEQ ID NO: 55)
sp Q2PE51 BNP_CRODO	---NG	CFGLKLDRIIGSMSGLGC	181 (SEQ ID NO: 56)
sp B0VXV8 BNP_SISCA	---SG	CFGLKLDRIIGSMSGLGC	201 (SEQ ID NO: 57)
sp Q27J49 BNP_LACMU	---DG	CFGLKLDRIIGSMSGLGC	239 (SEQ ID NO: 58)
sp P01021 BNP_AKHA	---KG	CFGLKLDRIIGTMSGGLGC	263 (SEQ ID NO: 59)
sp Q09GK2 VNP_PHIOL	---KG	CFGLKLDRIIGSMSGLGC	164 (SEQ ID NO: 60)
tr D1MZV3 D1MZV3_RHATT	---SG	CFGLKLDRIIGSMSGLGC	161 (SEQ ID NO: 61)
tr Q7T1M4 Q7T1M4_BOTJR	---KG	CFGLKLDRIIGTMSGGLGC	221 (SEQ ID NO: 62)
tr Q402A2 Q402A2_PETMA	----	CFGVKLDRIIGSMSGLGC	116 (SEQ ID NO: 63)
tr Q402A3 Q402A3_LAMJA	----	CFGVKLDRIIGSMSGLGC	148 (SEQ ID NO: 64)
tr Q402A1 Q402A1_9PETR	----	CFGVKLDRIIGSMSGLGC	133 (SEQ ID NO: 65)
sp P21805 ANFC_CHICK	---RS	CFGVKLDRIIGSMSGLGC	22 (SEQ ID NO: 66)
tr A9CDT6 A9CDT6_CHICK	---RS	CFGVKLDRIIGSMSGLGC	130 (SEQ ID NO: 67)
sp P20968 ANFC_RANCA	---RG	CFGVKLDRIIGAFSGLGC	129 (SEQ ID NO: 68)
sp P55208 ANFC_TRISC	---RG	CFGVKLDRIIGAMSGLGC	136 (SEQ ID NO: 69)
sp P23259 ANFC_SCYCA	---RG	CFGVKLDRIIGAMSGLGC	115 (SEQ ID NO: 70)
sp P41319 ANFC_SQUAC	---RS	CFGLKLDRIIGAMSGLGC	135 (SEQ ID NO: 71)
tr Q2MH72 Q2MH72_9CHON	---RG	CFGVKLDRIIGAMSGLGC	131 (SEQ ID NO: 72)
tr Q2MH73 Q2MH73_9CHON	---RG	CFGVKLDRIIGAMSGLGC	131 (SEQ ID NO: 73)
tr Q2MH71 Q2MH71_9CHON	---RG	CFGVKLDRIIGAMSGLGC	131 (SEQ ID NO: 74)
tr Q2MH74 Q2MH74_DASAK	---RG	CFGVKLDRIIGAMSGLGC	131 (SEQ ID NO: 75)
tr Q2PF87 Q2PF87_CALMI	---RG	CFGVKLDRIIGAMSGLGC	139 (SEQ ID NO: 76)
sp Q800I8 ANFC3_ORYLA	---RS	CFGVRLERIGSFSGGLGC	112 (SEQ ID NO: 77)
tr Q4ADV1 Q4ADV1_ORYLA	---RS	CFGVRLERIGSFSGGLGC	112 (SEQ ID NO: 78)
sp Q805D4 ANFC3_TAKRU	---RS	CFGVRLARIGSFSGGLGC	158 (SEQ ID NO: 79)
tr C0H7B0 C0H7B0_SALSA	---RS	CFGVRLERIGSFSGGLGC	128 (SEQ ID NO: 80)
tr C1BWD1 C1BWD1_ESOLU	---RS	CFGVRLERIGSFSGGLGC	126 (SEQ ID NO: 81)
tr D2KXA3 D2KXA3_ANGJA	---RS	CFGVRLERIGSFSGGLGC	128 (SEQ ID NO: 82)
tr B3DJJ2 B3DJJ2_DANRE	---RS	CFGVRLERIGSFSGGLGC	128 (SEQ ID NO: 83)
tr Q1XGY8 Q1XGY8_9ACTI	---RS	CFGVRLDRIIGSMSGLGC	130 (SEQ ID NO: 84)
sp Q8AXR2 ANFC2_ONCMY	---RG	CFGLKLDRIIGSMSGLGC	131 (SEQ ID NO: 85)
sp Q8AXR3 ANFC1_ONCMY	---RG	CFGLKLDRIIGSMSGLGC	131 (SEQ ID NO: 86)
tr C1BKS8 C1BKS8_OSMMO	---RG	CFGLKLDRIIGSMSGLGC	132 (SEQ ID NO: 87)
tr Q805E7 Q805E7_OREMO	---RG	CFGLKLDRIIGSMSGLGC	131 (SEQ ID NO: 88)
tr C3KH23 C3KH23_ANOFI	---RG	CFGLKLDRIIGSMSGLGC	131 (SEQ ID NO: 89)
sp Q8AYR6 ANFC1_ORYLA	---RG	CFGLKLDRIIGSMSGLGC	131 (SEQ ID NO: 90)
sp Q805D6 ANFC1_TAKRU	---RG	CFGLKLDRIIGSMSGLGC	126 (SEQ ID NO: 91)
sp P18145 ANFC_ANGJA	---RG	CFGLKLDRIIGSLSGGLGC	131 (SEQ ID NO: 92)
tr Q1XGY9 Q1XGY9_9ACTI	---KG	CFGLKLDRIIGSISGLGC	140 (SEQ ID NO: 93)
tr A9CDT5 A9CDT5_CHICK	---RG	CFGLKMDRIIGAFSGLGC	123 (SEQ ID NO: 94)
CONSENSUS SEQUENCE	*** : * : * : *	CFGXXXXRXXXXSGXGC	(SEQ ID NO: 95)

**FIG. 16**  
**Schematic Structure of Natriuretic Peptide**



## Schematic Structures of Exemplary Fc-NP or NP-Fc Fusion Proteins

FIG. 17A




FIG. 17B




FIG. 17C




FIG. 17D




FIG. 17E




FIG. 18A

NC2st Protein Sequence (With Signal Sequence)

Sequence:

10 20 30 40 50 60  
MGVHECPAWL WLLLSLLSLW PGAYAAWSH PQFEQSGGG GENLYFQGGD KTHTCPPCPA

70 80 90 100 110 120  
PELLGGPSVF LFPPKPKDTL MISRTPEVC VVDVSHEDP EVKFNWYVDG VEVHNAKTKP

130 140 150 160 170 180  
REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL

190 200 210 220 230 240  
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY KTTPPVLDSD GSFFLYSKLT

250 260 270 280 290 300  
VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGKGGGG SGGGGSGGGG SGGLSKGCFG

310  
LKLDRIQSMG GLGC

(SED ID NO: 501)

Number of amino acids: 314  
Molecular weight of monomer: 34053.5

- 1-25 = Signal peptide
- 26-27 = Linker
- 28-35 = Strep-tag II
- 36-41 = Linker
- 42-47 = Tobacco etch virus protease cleavage sequence
- 48-49 = Linker
- 50-276 = Fc domain of human IgG1
- 277-292 = Glycine-rich linker
- 293-314 = C-type natriuretic peptide

**FIG. 18B****NC2st Protein Sequence (Without Signal Sequence)**

NC2st (w/o sig. seq.) ASWSHPQFEQSGGGGGENLYFQGGDKTHTCPPCPAPELLGGPSVFLFPPKPD~~TL~~MISRTPEVTCVVVDVSHE  
DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ  
PREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKS  
RWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGGSGGGSGGGSGGLSKGCFGLKLDRI~~GSMSGGLGC~~  
(SEQ ID NO: 502)

# FIG. 18C

## NC2st DNA Sequence

ATGGGCGTGACGAGTGTCTGCTGGCTGTGGCTGCTGTGAGCCTGCTGTCTGTGGCCCTGGCGCCTACGCCGCCCTCTTGGAGC  
CACCCCCAGTTTGAGCAGTCTGGCGCGGAGGAGCGAGAACCTGTACTTTCAGGGCGGCGACAAGACCCACACACCTGTCCCCCTTGT  
CCTGCCCCCTGAGCTGCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCAAGCCCAAGGACACCCCTGATGATCAGCCGGACCCCCGAA  
GTGACCTGCGTGGTGGTGGACGTGTCCACGAGGACCCCTGAAGTGAAGTTCAATTGTTACGTGGACGGCGTGGAGGTGCACAACGCC  
AAGACCAAGCCCCGGGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTGCACCCAGGACTGGCTGAACGGC  
AAAGAGTACAAAGTGCAAGTCTCCAACAAGGCCCTGCCTGCCCCCATCGAGAAAACCATCAGCAAGGCCAAGGCCAGCCAGAGAA  
CCCCAGGTGTACACCCCTGCCCCCAGCCGGGAGGAAATGACCAAGAACCCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCC  
AGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAACCCCCCTGTGCTGGACAGCGACGGAAGC  
TTCCTCCTGTACTCCAAACTGACCGTGGACAAGCCGGTGGCAGCAGGCAACGTGTTTCACTGACGTGACGTGATGCACGAGGCCCTG  
CACAAACCACTACACCCAGAAGTCCCTGAGCCTGTCTCCTGGCAAGGGCGGAGGGGGAAGTGGAGCGGAGGAAGCGGGGGAGGCGGA  
AGCGGCGGACTGAGCAAGGGCTGCTTCGGCCCTGAAGCTGGACCCGGATCGGCAGCATGAGCGGCCCTGGGCTGCTGA (SEQ ID NO:  
801)

FIG. 19A  
NC2B Protein Sequences

NC2B (w/sig. seq.)	<div>MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH</div> <div>EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG</div> <div>QPREPQVYTTLPSSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSGGSFFLYSKLTVDK</div> <div>SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGGGGGGGGGLSKGCFGLKLDRI GSM SGLGC</div> <div>(SEQ ID NO: 503)</div>
NC2B (w/o sig. seq.)	<div>DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE</div> <div>EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTTLPSSREEMTKNQVSLT</div> <div>CLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSGGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQK</div> <div>SLSLSPGKGGGGGGGGGGGGLSKGCFGLKLDRI GSM SGLGC (SEQ ID NO: 504)</div>
D10-NC2 (w/sig. seq.)	<div>MGVHECPAWLWLLLSLLSLWPGAYADDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE</div> <div>VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP</div> <div>IEKTISKAKGQPREPQVYTTLPSSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSGSF</div> <div>FLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPGKGGGGGGGGGGGGLSKGCFGLKLDRI</div> <div>GSM SGLGC (SEQ ID NO: 607)</div>
D10-NC2 (w/o sig. seq.)	<div>DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE</div> <div>VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTTLPSSRE</div> <div>EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSGGSFFLYSKLTVDKSRWQQGNVSCSVMH</div> <div>EALHNHYTQKSLSLSPGKGGGGGGGGGGGGLSKGCFGLKLDRI GSM SGLGC (SEQ ID NO: 608)</div>

**FIG. 19B**  
**NC2B DNA Sequence**

ATGGGCGTGCAAGAGTGTCTGCTGGCTGTGGCTGTGCTGAGCCCTGCTGTCTCTGTGGCCCTACGCCGACAAAGACCCAC  
ACCTGTCCCCCTTGTCCTGCCCCCTGAGCTGCTGGCGGACCCAGCGTGTTCCTGTTCCCCCAAGCCCAAGGACACCCCTGATGATC  
AGCCGGACCCCCGAAGTGACCTGCGTGGTGGACGTGTCCACAGGACCCCTGAAGTGAAGTTCAATTGGTACGTGGACGGCGTG  
GAGGTGCACAAACGCCAAGACCAAGCCCCGGAGGAACAGTACAACAGCACCTACCGGTGGTGTCCGTGCTGACCGTGTGCACCCAG  
GACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTCTCCAACAAGGCCCTGCCCTGCCCCCATCGAGAAAACCATCAGCAAAGGCCAAG  
GGCCAGCCAGAGAACCCAGGTGTACCCCTGCCCCCAGCCGGGAGGAAATGACCAAGAACCAAGGTGTCCCTGACCTGCCCTGGTG  
AAGGGCTTCTACCCCAAGCGATATCGCCGTGGAGTGGAGAGCAACGGCCAGCCCTGAGAACAACTACAAAGACCCACCCCTGTGCTG  
GACAGCGACGGCAGCTTCTTCCTGTACTCCAAACTGACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTGTTTCAGCTGCAGCGTG  
ATGCACGAGGCCCTGCACAACCACTACACCCAGAGTCCCTGAGCCTGTCTCCTGGCAAGGCGGAGGGGGAAGTGGAGCGGGAGGA  
AGCGGGGAGGCGGAAGCGGCGGACTGAGCAAGGGGTGCTTTCGGCCTGAAGCTGGACCGGATCGGCAGCATGAGCGGCCCTGGGCTGC  
TGA (SEQ ID NO: 802)

NC2B-34  
(w/o sig. seq.)

DKTHTCP CPAPELLGGPSVFLFPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKKPRE  
EQNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT  
CLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK  
**SLSLSPGK** GGGGGSGGGSGGGGGSGGGGGSGGGGGGLSKCCFGLKLDRIGSM\$GLGC (SEQ ID  
NO: 510)

**FIG. 20B**  
**NC2B-22 DNA Sequence**

ATGGGCGTGACGAGTGTCTGCTGCCCTGGCTGTGGCTGTGCTGAGCCCTGCTGTCTCTGTGGCCCTACGCCGACAAAGACCCAC  
ACCTGTCCCCCTTGTCCTGCCCTGAGCTGCTGGCGGACCCAGCGTGTTCCTGTTCCCCCAAGCCCAAGGACACCCCTGATGATC  
AGCCGGACCCCGAAGTGACCTGCGTGGTGGACGTGTCCACAGGACCCCTGAAGTCAATTGGTACGTGGACGGCGTG  
GAGGTGCACAAACGCCAAGACCAAGCCCCGGAGGAACAGTACAACAGCACCTACCGGTGGTGTCCGTGCTGACCGTGTGCACCCAG  
GACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTCTCCAACAAGGCCCTGCCCTGCCCCCATCGAGAAAACCATCAGCAAAGGCCAAG  
GGCAGCCCCAGAGAACCCAGGTGTACCCCTGCCCCCCAGCCGGGAGGAAATGACCAAGAACCAAGGTGTCCCTGACCTGCCCTGGTG  
AAGGGCTTCTACCCCAAGCGATATCGCCGTGGAGTGGAGAGCAACGGCCAGCCCTGAGAACAACTACAAAGACCCACCCCTGTGCTG  
GACAGCGACGGCAGCTTCTTCCTGTACTCCAAACTGACCCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTGTTTCAGCTGCAGCGTG  
ATGCACGAGGCCCTGCACAACCACTACACCCAGAGTCCCTGAGCCTGTCTCCTGGCAAGGCGGAGGGGGAAGTGGAGCGGGAGGA  
AGCGGGGAGGCGGAAGCGGAGCGGAGGATCTGGCGGCGGACTGAGCAAGGGCTGCTTCGGCCCTGAAGCTGGACCGGATCGGCAGC  
ATGAGCGGCCCTGGGCTGCTGA (SEQ ID NO: 803)

**FIG. 20C**  
**NC2B-28 DNA Sequence**

ATGGGCGTGACGAGTGTCTGCTGGCTGTGGCTGTGCTGAGCCTGTCTCTGTGGCCTGGCGCCTACGCCGACAAAGACCCAC  
ACCTGTCCCCCTTGTCCTGCCCCCTGAGCTGCTGGCGGACCCAGCGTGTTCCTGTTCCCCCAAGCCCAAGGACACCCCTGATGATC  
AGCCGGACCCCCGAAGTGACCTGCGTGGTGGACGTGTCCACAGGACCCCTGAAGTCAATTGGTACGTGGACGGCGTG  
GAGGTGCACAAACGCCAAGACCAAGCCCCGGAGGAACAGTACAACAGCACCTACCGGTGGTGTCCGTGCTGACCGTGTGCACCCAG  
GACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTCTCCAACAAGGCCCTGCCCTGCCCCCATCGAGAAAACCATCAGCAAAGGCCAAG  
GGCAGCCCCAGAGAACCCAGGTGTACCCCTGCCCCCCAGCCGGGAGGAAATGACCAAGAACCCAGGTGTCCCTGACCTGCCCTGGTG  
AAGGGCTTCTACCCCAAGCGATATCGCCGTGGAGTGGAGAGCAACGGCCAGCCTGAGAACAACTACAAAGACCCACCCCTGTGCTG  
GACAGCGACGGCAGCTTCTTCCTGTACTCCAACCTGACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTGTTTCAGCTGCAGCGTG  
ATGCACGAGGCCCTGCACAACCACTACACCCAGAGTCCCTGAGCCTGTCTCCTGGCAAGGCGGAGGGGGAAGTGGAGCGGGAGGA  
AGCGGGGAGGCGGAAGCGGAGCGGAGGATCTGGCGGCGGAGGAAGTGGCGGAGGCGGACTGAGCAAGGGGCTGCTTCGGCCTGAAG  
CTGGACCCGGATCGGCAGCATGAGCGGCCCTGGGCTGCTGA (SEQ ID NO: 804)

**FIG. 20D**  
**NC2B-34 DNA Sequence**

ATGGGCGTGACGAGTGTCTGCTGGCTGTGGCTGTGCTGAGCCTGTCTCTGTGGCCTGGCGCCTACGCCGACAAAGACCCAC  
ACCTGTCCCCCTTGTCCTGCCCCCTGAGCTGCTGGCGGACCCAGCGTGTTCCTGTTCCCCCAAGCCCAAGGACACCCCTGATGATC  
AGCCGGACCCCCGAAGTGACCTGCGTGGTGGACGTGTCCACAGGACCCCTGAAGTCAATTGGTACGTGGACGGCGTG  
GAGGTGCACAAACGCCAAGACCAAGCCCCGGAGGAACAGTACAACAGCACCTACCGGTGGTGTCCGTGCTGACCGTGTGCACCCAG  
GACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTCTCCAACAAGGCCCTGCCCTGCCCCCATCGAGAAAACCATCAGCAAAGGCCAAG  
GGCCAGCCAGAGAACCCAGGTGTACCCCTGCCCCCCAGCCGGGAGGAAATGACCAAGAACCAAGGTGTCCCTGACCTGCCCTGGTG  
AAGGGCTTCTACCCCAAGCGATATCGCCGTGGAGTGGAGAGCAACGGCCAGCCTGAGAACAACTACAAAGACCCACCCCTGTGCTG  
GACAGCGACGGCAGCTTCTTCCTGTACTCCAACCTGACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTGTTCAAGCTGCAGCGTG  
ATGCACGAGGCCCTGCACAACCACTACACCCAGAGTCCCTGAGCCTGTCTCCTGGCAAGGCGGAGGGGGAAGTGGAGCGGGAGGA  
AGCGGGGAGGCGGAAGCGGAGCGGAGGATCTGGCGGCGGAGGAAGTGGCGGAGGCGGAGCGGCGGAGGGGAGGACTGAGCAAG  
GGCTGCTTCGGCCTGAAGCTGGACCCGGATCGGCAGCATGAGCGGCCTGGGCTGCTGA (SEQ ID NO: 805)

FIG. 21

NC2 Variants

NC2-KGANKK (w/sig. seq.)	MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQOQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGGSGGGSGKANKKGLSKGCGGLKLDRI GSM SGLGC (SEQ ID NO: 511)
NC2-KGANKK (w/o sig. seq.)	DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMEALHNHYTQK SLSLSPGKGGGGSGGGSGKANKKGLSKGCGGLKLDRI GSM SGLGC (SEQ ID NO: 512)
NC2-KGANQK (w/sig. seq.)	MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQOQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGGSGGGSGKANKQKGLSKGCGGLKLDRI GSM SGLGC (SEQ ID NO: 513)
NC2-KGANQK (w/o sig. seq.)	DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMEALHNHYTQK SLSLSPGKGGGGSGGGSGKANKQKGLSKGCGGLKLDRI GSM SGLGC (SEQ ID NO: 514)

FIG. 22

NC2 Variants

NC2-CNP53mut2  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGSPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG  
QPREPQVYTTLPSSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDK  
SRWQQGNVSCSVMHEALHNNHYTQKSLSPGKGGGDLQVDTQSQAAWAQLLQEHFNAQQYKGANKKGLSKGC  
FGILKLDRIGMSGGLGC (SEQ ID NO: 515)

NC2-CNP53mut2  
(w/o sig. seq.)

DKTHTCPPCPAPELLGSPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTTLPSSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNNHYTQK  
SLSLSPGKGGGDLQVDTQSQAAWAQLLQEHFNAQQYKGANKKGLSKGCGFGLKLDRIGMSGGLGC (SEQ ID  
NO: 516)

FIG. 23

Fc-CNP53 Constructs

Fc-CNP53-A  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG  
QPREPQVYTTLPDSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQOGNVFSCSMHEALHNHYTQKSLSLSPGKGGGDLRVDTKSRAAWARLLQEHHPNARKYKGANKGLSKGC  
EGLKLDRI<sup>517</sup>GSASGLGC (SEQ ID NO: 517)

Fc-CNP53-A  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTTLPDSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQK  
SLSLSPGKGGGDLRVDTKSRAAWARLLQEHHPNARKYKGANKGLSKGCFLKLDRI<sup>518</sup>GSASGLGC (SEQ ID  
NO: 518)

Fc-CNP53-AAA  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG  
QPREPQVYTTLPDSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQOGNVFSCSMHEALHNHYTQKSLSLSPGKGGGDLRVDTKSRAAWARLLQEHHPNARKYKGANAAGLSKGC  
EGLKLDRI<sup>519</sup>GSASGLGC (SEQ ID NO: 519)

Fc-CNP53-AAA  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTTLPDSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQK  
SLSLSPGKGGGDLRVDTKSRAAWARLLQEHHPNARKYKGANAAGLSKGCFLKLDRI<sup>520</sup>GSASGLGC (SEQ ID  
NO: 520)

FIG. 24  
NP Multiple Sequence Alignment and CDNP Constructs

Human ANP	SLRRSSCFGGRMDRIGAQSGLGNCNSFRY	(SEQ ID NO: 1)
Rat ANP	SLRRSSCFGGRIDRIGAQSGLGNCNSFRY	(SEQ ID NO: 96)
Urodilatin	TAPRSLRRSSCFGGRMDRIGAQSGLGNCNSFRY	(SEQ ID NO: 2)
Human BNP	SPKMVQSGGCFGRKMDRISSSSSGLGCKVLRRH	(SEQ ID NO: 3)
Rat BNP	SQDSAFRIQERLRNSKMAHSSSCFQGKIDRIGAVSRGLGCDGLRLF	(SEQ ID NO: 97)
Pig BNP	SPKTMRDSSGCFGRRIDRIGSLGSLGNCNVLRRY	(SEQ ID NO: 98)
DNP	EVKYDPFCFCHKIDRINHVSNLGCPSLRDRPRNPAPSTSA	(SEQ ID NO: 5)
TNP-C	SDSKIINGCGFGLDRIGSVSGLGNCNRIQNPPKFSGE	(SEQ ID NO: 99)
CDNP	GLSKGCGFGLKIDRIGSMSGLGCPSLRDRPRNPAPSTSA	(SEQ ID NO: 100)
	*** : *** * . *** :	
CDNP-N1 (C7)	GLSKGCGFGLKIDRIGSMSGLGNCNSLRDRPRNPAPSTSA	(SEQ ID NO: 101)
CDNP-G1 (C8)	GLSKGCGFGLKIDRIGSMSGLGCGSLRDRPRNPAPSTSA	(SEQ ID NO: 102)
CDNP-H1 (C9)	GLSKGCGFGLKIDRIGSMSGLGCHSLRDRPRNPAPSTSA	(SEQ ID NO: 103)
CDNP-K1	GLSKGCGFGLKIDRIGSMSGLGCKSLRDRPRNPAPSTSA	(SEQ ID NO: 104)
CDNP-Z1 (Z=hydroxyproline)	GLSKGCGFGLKIDRIGSMSGLGCGZSLRDRPRNPAPSTSA	(SEQ ID NO: 105)
CDNP-S3	GLSKGCGFGLKIDRIGSMSGLGCPSSRDPRNPAPSTSA	(SEQ ID NO: 106)
CDNP-A4	GLSKGCGFGLKIDRIGSMSGLGCPSLADPRNPAPSTSA	(SEQ ID NO: 107)
CDNP-A5	GLSKGCGFGLKIDRIGSMSGLGCPSLRAPRNPAPSTSA	(SEQ ID NO: 108)
CDNP-S3A4 (C12)	GLSKGCGFGLKIDRIGSMSGLGCPSSADPRNPAPSTSA	(SEQ ID NO: 109)
CDNP-A4A5	GLSKGCGFGLKIDRIGSMSGLGCPSLAAPRNPAPSTSA	(SEQ ID NO: 110)
CDNP-S3A5 (C11)	GLSKGCGFGLKIDRIGSMSGLGCPSSRAPRNPAPSTSA	(SEQ ID NO: 111)
CDNP-(A17)S3A5	GLSKGCGFGLKIDRIGSASGLGCPSSRAPRNPAPSTSA	(SEQ ID NO: 112)
CDNP-S3A4A5 (C10)	GLSKGCGFGLKIDRIGSMSGLGCPSSAAPRNPAPSTSA	(SEQ ID NO: 113)
CDNP-(A17)S3A4A5	GLSKGCGFGLKIDRIGSASGLGCPSSAAPRNPAPSTSA	(SEQ ID NO: 114)
CDNP-S3A4A5R6 (C13)	GLSKGCGFGLKIDRIGSMSGLGCPSSAARRNPAPSTSA	(SEQ ID NO: 115)
CDNP-S3A4A5S7 (C14)	GLSKGCGFGLKIDRIGSMSGLGCPSSAAPSPNPAPSTSA	(SEQ ID NO: 116)
DNP TAIL	PSLRDRPRNPAPSTSA	(SEQ ID NO: 117)
CONSENSUS SEQUENCE FOR DNP C-TERMINAL TAIL	XSXXXXXPNPAPSTSA	(SEQ ID NO: 118)

## FIG. 25A

## Exemplary Constructs Having N-terminal NP fused to C-terminal Fc Domain

CNP-16AAlinker-Fc-His<sub>10</sub>  
(NC1) GLSKGCFGLKLDRI<sup>10</sup>GSM<sup>10</sup>SLGCGGGGGGGGGGGGSGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDG

GSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQKSLSLSPGKGGENLYFQGSHHHHHHHHHH (SEQ ID NO: 521)

CNP-6AAlinker-Fc-His<sub>10</sub>  
(NC3) GLSKGCFGLKLDRI<sup>10</sup>GSM<sup>10</sup>SLGCGGGGGGGGGGSGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQKSLSLSPGKGGENLYFQGSHHHHHHHHHH (SEQ ID NO: 522)

CNP-6AAlinker-Fc

GLSKGCFGLKLDRI<sup>10</sup>GSM<sup>10</sup>SLGCGGGGGGGGGGSGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 523)

CDNP-Fc

GLSKGCFGLKLDRI<sup>10</sup>GSM<sup>10</sup>SLGCP<sup>10</sup>SLRDP<sup>10</sup>RNP<sup>10</sup>AP<sup>10</sup>ST<sup>10</sup>ADK<sup>10</sup>THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 524)

CDNP-A17saa-Fc

GLSKGCFGLKLDRI<sup>10</sup>GSA<sup>10</sup>SLGCP<sup>10</sup>SSA<sup>10</sup>AP<sup>10</sup>RNP<sup>10</sup>AP<sup>10</sup>ST<sup>10</sup>ADK<sup>10</sup>THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 525)

CDNP-A17sra-Fc

GLSKGCFGLKLDRI<sup>10</sup>GSA<sup>10</sup>SLGCP<sup>10</sup>SSRA<sup>10</sup>AP<sup>10</sup>RNP<sup>10</sup>AP<sup>10</sup>ST<sup>10</sup>ADK<sup>10</sup>THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 526)

**FIG. 25B**  
**NC1 DNA Sequence**

ATGGGCGTGACGAGTGTCTGCTGGCTGTGGCTGTGCTGAGCCTGTCTGTGGCCTGGCGCCTACGCCGGCCTGAGCAAAG  
GGCTGCTTCGGCCTGAAGCTGGACCGGATCGGCAGCATGTCTGGCCTGGCTGTGGCGGAGGATCTGGCGCGGAGGAAGTGGC  
GGAGGGCAGCGGCGATAAGACCCACACCTGTCCCCCTTGTCTGCCCCTGAGCTGTGGGGGACCCAGCGTGTCTCTGTTCCTCC  
CCAAAGCCCCAAGGACACCCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCTGGTGGTGTGCCACGAGGACCCCTGAAGTG  
AAGTTCAATTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAACAGTACAACAGCACCTACCGGGTG  
GTGTCCGTGCTGACCGTGTGCAACGAGGACTGGCTGAACGGCAAAAGATACAAGTGCAGGTCTCCAACAAGGCCCTGCCCTGCCCCC  
ATCGAGAAAAACCATCAGCAAGGCCAAGGCCAGCCAGAGAACCCAGGTGTACACCTGCCCCAGCCGGAGGAAATGACCAAG  
AACCAGGTGTCCCTGACCTGCCCTGGTGAAGGGCTTCTACCCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAAC  
AACTACAAGACCACCCCCTGTGTGTGACAGCGACGGCAGCTTCTTCTGTACTCCAAACTGACCGTGGACAAAGAGCCGGTGGCAG  
CAGGGCAACGTTTTCAGCTGCAGCGTGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAAGTCCCTGAGCCTGTCTCTGGCAAAG  
GGCGGCGAGAACCTGTACTTTCAGGGCAGCCACCACCATCACCATCATCACTGA (SEQ ID NO: 806)

**FIG. 26**  
**Human CNP22 and Point Mutations at Position 17**

CNP22	GLSKGCFGLKLDRI <sup>4</sup> GSMSG <sup>4</sup> LG <sup>4</sup> C	(SEQ ID NO: 4)
CNP-F17 (C15)	GLSKGCFGLKLDRI <sup>4</sup> GSF <sup>4</sup> SG <sup>4</sup> LG <sup>4</sup> C	(SEQ ID NO: 119)
CNP-L17 (C16)	GLSKGCFGLKLDRI <sup>4</sup> GS <sup>4</sup> I <sup>4</sup> SG <sup>4</sup> LG <sup>4</sup> C	(SEQ ID NO: 120)
CNP-I17 (C17)	GLSKGCFGLKLDRI <sup>4</sup> GS <sup>4</sup> I <sup>4</sup> SG <sup>4</sup> LG <sup>4</sup> C	(SEQ ID NO: 121)
CNP-T17 (C18)	GLSKGCFGLKLDRI <sup>4</sup> GS <sup>4</sup> T <sup>4</sup> SG <sup>4</sup> LG <sup>4</sup> C	(SEQ ID NO: 122)
CNP-V17 (C19)	GLSKGCFGLKLDRI <sup>4</sup> GS <sup>4</sup> V <sup>4</sup> SG <sup>4</sup> LG <sup>4</sup> C	(SEQ ID NO: 123)
CNP-A17 (C1)	GLSKGCFGLKLDRI <sup>4</sup> GS <sup>4</sup> A <sup>4</sup> SG <sup>4</sup> LG <sup>4</sup> C	(SEQ ID NO: 124)
CNP-S17	GLSKGCFGLKLDRI <sup>4</sup> GS <sup>4</sup> S <sup>4</sup> SG <sup>4</sup> LG <sup>4</sup> C	(SEQ ID NO: 125)
CNP-E17	GLSKGCFGLKLDRI <sup>4</sup> GS <sup>4</sup> E <sup>4</sup> SG <sup>4</sup> LG <sup>4</sup> C	(SEQ ID NO: 156)
CNP-R17	GLSKGCFGLKLDRI <sup>4</sup> GS <sup>4</sup> R <sup>4</sup> SG <sup>4</sup> LG <sup>4</sup> C	(SEQ ID NO: 157)
CNP-Y17	GLSKGCFGLKLDRI <sup>4</sup> GS <sup>4</sup> Y <sup>4</sup> SG <sup>4</sup> LG <sup>4</sup> C	(SEQ ID NO: 158)
CONSENSUS:	GLSKGCFGLKLDRI <sup>4</sup> GS <sup>4</sup> X <sup>4</sup> SG <sup>4</sup> LG <sup>4</sup> C	(SEQ ID NO: 126)



**FIG. 28A**  
**Additional CNP Variants**

GDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1001)
PDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1002)
MDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1003)
DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1004)
LRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1005)
RVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1006)
VDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1007)
DTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1008)
TKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1009)
KSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1010)
SRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1011)
RAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1012)
AAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1013)
AWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1014)
WARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1015)
ARLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1016)
RLLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1017)
LLQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1018)
LQEHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1019)
EHPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1020)
HPNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1021)
PNARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1022)
NARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1023)
ARKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1024)
RKYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1025)
KYKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1026)
YKGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1027)
KGANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1028)
GANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1029)
ANKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1030)
NKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1031)

FIG. 28B

KKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1032)
KGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1033)
LSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1034)
SKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1035)
KGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1036)
GCFLKLDRI GSM SGLGC	(SEQ ID NO: 1037)
QEHPNARKYKGANKKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1038)
PQEHPNARKYKGANKKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1039)
MQEHPNARKYKGANKKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1040)
GQEHPNARKYKGANKKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1041)
GQEHPNARKYKGANKPKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1042)
GQEHPNARKYKGANKQGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1043)
GQEHPNARKYKGANKQQLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1044)
GQEHPNARKYKGANKPKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1045)
GQEHPNARKYKGANKKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1046)
PGQEHPNARKYKGANKKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1047)
MGQEHPNARKYKGANKKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1048)
GANRRGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1049)
GANRRGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1050)
PGANRRGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1051)
MGANRRGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1052)
GHKSEVAHRFKGANKKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1053)
GHKSEVAHRFKGANKKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1054)
PGHKSEVAHRFKGANKKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1055)
MGHKSEVAHRFKGANKKKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1056)
RGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1057)
ERGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1058)
GANQQGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1059)
GANRRGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1060)
GANPRGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1061)
GANSSGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1062)

FIG. 28C

	GANPRGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1063)
	GANRRGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1064)
	GANQQGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1065)
	GANS SGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1066)
	AAWARLLQEHNPAGLSKCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1067)
	AAWARLLQEHPNARGLSKCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1068)
	DLRVDTKSRAAWARGLSKCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1069)
	GQEHNPARKYKGANPKGSLKCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1070)
	GQEHNPARKYKGANQKGLSKCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1071)
	GLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1072)
	ERGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1073)
	RGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1074)
	GLSRGCFGLRLDRI GSM SGLGC	(SEQ ID NO: 1075)
	GLSKGCXGLKLDRI GSM SGLGC	(SEQ ID NO: 1076)
	GLSKGCXGLKLDRI GSM SGLGC	(SEQ ID NO: 1077)
	RLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1078)
	ELSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1079)
	GLSKRCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1080)
	GLSKQCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1081)
	GLSKSCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1082)
	GLSKGCFGLKLDRI SSMSGLGC	(SEQ ID NO: 1083)
	GLSKGCFGLKLDRI NSMSGLGC	(SEQ ID NO: 1084)
	GLSKGCFGLKLDRI RSMSGLGC	(SEQ ID NO: 1085)
	GLSKGCFGLKLDRI XSMSGLGC	(SEQ ID NO: 1086)
	GLSKGCFGLKLDRI GSM SSSLGC	(SEQ ID NO: 1087)
	GLSKGCFGLKLDRI GSM SRLGC	(SEQ ID NO: 1088)
	GLSKGCFGLKLDRI GSM SNLGC	(SEQ ID NO: 1089)
	GLSKGCFGLKLDRI GSM SGLSC	(SEQ ID NO: 1090)
	GLSKGCFGLKLDRI GSM SGLTC	(SEQ ID NO: 1091)
	GLSKGCFGLKLDRI GSM SGLRC	(SEQ ID NO: 1092)
	GLSKGCXFGLKLDRI GSM SGLGC	(SEQ ID NO: 1093)

(X: D-Phe)

(X: 3-amino-2-phenylpropionic acid)

(X: Cit)

(X: [CH<sub>2</sub>NH]bond)

FIG. 28D

(X: N-Me-Phe)	GLSKGCXGLKLDRI GSM SGLGC	(SEQ ID NO: 1094)
(X: t-Bu-Gly)	GLSKGCFXLKLDRI GSM SGLGC	(SEQ ID NO: 1095)
(X: NHCH <sub>2</sub> CH (Ph) CO)	GLSKGCXGLKLDRI GSM SGLGC	(SEQ ID NO: 1096)
	GQPREPQVYTLPPSGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1097)
	GERAFKAWAVARLSQGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1098)
	GQHKDDNPNLPRGANPRGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1099)
	GHHSEQHHPHGANQQGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1100)
	GAHHPHEHDTHGANGQQGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1101)
	FGIPMDRIGRNPRGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1102)
	GKRTGQYKLGSKTGPKGLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1103)
	SPKMVQSGGCFGLKLDRI GSM SGLGCKVLRH	(SEQ ID NO: 1104)
	GQPREPQVYTGANQQGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1105)
	GVPQVSTGTGANQQGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1106)
	GQPSSSQSTGANQQGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1107)
	GSTGQWHSESGANQQGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1108)
	GQTHSSGTQSGANQQGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1109)
	GSSSSSSSSSGANQQGLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1110)
(X <sub>1</sub> : [CH <sub>2</sub> NH] bond; X <sub>2</sub> and X <sub>3</sub> : N-Me-Leu)	GLSKGCX <sub>1</sub> FGX <sub>2</sub> KLDRI GSM SGX <sub>3</sub> GC	(SEQ ID NO: 1111)
(X <sub>1</sub> and X <sub>2</sub> : N-Me-Leu)	GLSKGCFGX <sub>1</sub> KLDRI GSM SGX <sub>2</sub> GC	(SEQ ID NO: 1112)
(X <sub>1</sub> , X <sub>2</sub> , and X <sub>3</sub> : N-Me-Leu)	GLSKGCFGX <sub>1</sub> KX <sub>2</sub> DRIGSM SGX <sub>3</sub> GC	(SEQ ID NO: 1113)
(X <sub>1</sub> and X <sub>2</sub> : N-Me-Leu)	GLSKGCFGX <sub>1</sub> KX <sub>2</sub> DRIGSM SGLGC	(SEQ ID NO: 1114)
	GLSRGCYGLKLDRI GSM SGLGC	(SEQ ID NO: 1115)
	GLSRGCFVLKLDRI GSM SGLGC	(SEQ ID NO: 1116)
	GLSRGCFSLKLDRI GSM SGLGC	(SEQ ID NO: 1117)
	GLSRGCFTLKLDRI GSM SGLGC	(SEQ ID NO: 1118)
	GLSRGCFGTKLDRI GSM SGLGC	(SEQ ID NO: 1119)
	GLSRGCFGLKLDRI RSM SGLGC	(SEQ ID NO: 1120)
(X: Cit)	GLSRGCFGLKLDRI XSM SGLGC	(SEQ ID NO: 1121)
	GLSRGCFGLKLDRI GSV SGLGC	(SEQ ID NO: 1122)
	GLSRGCFGLKLDRI GSM SVGC	(SEQ ID NO: 1123)
(X: t-Bu-Ala)	GLSRGCFGLKLDRI GSM SGXGC	(SEQ ID NO: 1124)

**FIG. 28E**

(X: pentanoic acid)	ELSEGCFLKLDRI GSM SGLGC	(SEQ ID NO: 1125)
(X: heptanoic acid)	XELSEGCFLKLDRI GSM SGLGC	(SEQ ID NO: 1126)
(X: pentanoic acid)	XELSEGCFLKLDRI GSM SGLGC	(SEQ ID NO: 1127)
(X: heptanoic acid)	XELSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1128)
(X: Cit)	XELSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1129)
	GLSKGCFGLXLDRI GSM SGLGC	(SEQ ID NO: 1130)
	GLSKGCFGLQLDRI GSM SGLGC	(SEQ ID NO: 1131)
	GLSKGCFGLRLDRI GSM SGLGC	(SEQ ID NO: 1132)
	GLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1133)
	GLSKGCFGLKLDRI SSMSGLGC	(SEQ ID NO: 1134)
(all D-amino acids)	GLSKGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1135)
(X: N-Me-Leu)	GLSKGCFGXKLDRI GSM SGLGC	(SEQ ID NO: 1136)
(X: N-Me-Leu)	GLSKGCFGLKXLDRI GSM SGLGC	(SEQ ID NO: 1137)
(X: N-Me-Leu)	GLSKGCFGLKLDRI GSM SGXGC	(SEQ ID NO: 1138)
(X: 3,4-dichloro-Phe)	GLSGGCXGLKLDRI GSM SGLGC	(SEQ ID NO: 1139)
(X: 3-Me-Phe)	GLSGGCXGLKLDRI GSM SGLGC	(SEQ ID NO: 1140)
	GLSRSCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1141)
	GLSRRCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1142)
	GLSGGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1143)
	GLSGGCFGLSLDRI GSM SGLGC	(SEQ ID NO: 1144)
	GLSRGCFGLKLDRI GQM SGLGC	(SEQ ID NO: 1145)
	GLSRGCFGLKLDRI GSM SGLGC	(SEQ ID NO: 1146)
	GLSRGCFGLKLDRI GSM SSLGC	(SEQ ID NO: 1147)
	GLSRGCFGLKLDRI GSM SRLGC	(SEQ ID NO: 1148)
	GLSRGCFGLKLDRI GSM SGRGC	(SEQ ID NO: 1149)
	GLSRGCFGLKLDRI GSM SGLSC	(SEQ ID NO: 1150)
	GLSRGCFGLKLDRI GSM SGLTC	(SEQ ID NO: 1151)
	GLSRGCFGLKLDRI GSM SGLRC	(SEQ ID NO: 1152)
(X: D-Phe)	GLSKGCXGLKLDRI GSM SGLGC	(SEQ ID NO: 1153)
(X: 3-Cl-Phe)	GLSKGCXGLKLDRI GSM SGLGC	(SEQ ID NO: 1154)
	RSSCFGGRI SRIGACFFFFF	(SEQ ID NO: 1155)



**FIG. 30**  
**CNP variants having Point Mutations at Position 17**

CNP-X17	GLSKG <b>CFGLKLD</b> RIGSX <b>SGLGC</b>	(SEQ ID NO: 126)
CNP-F17	GLSKG <b>CFGLKLD</b> RIGSF <b>SGLGC</b>	(SEQ ID NO: 119)
CNP-L17	GLSKG <b>CFGLKLD</b> RIGSL <b>SGLGC</b>	(SEQ ID NO: 120)
CNP-I17	GLSKG <b>CFGLKLD</b> RIGSI <b>SGLGC</b>	(SEQ ID NO: 121)
CNP-T17	GLSKG <b>CFGLKLD</b> RIGST <b>SGLGC</b>	(SEQ ID NO: 122)
CNP-E17	GLSKG <b>CFGLKLD</b> RIGSE <b>SGLGC</b>	(SEQ ID NO: 156)
CNP-R17	GLSKG <b>CFGLKLD</b> RIGSR <b>SGLGC</b>	(SEQ ID NO: 157)
CNP-Y17	GLSKG <b>CFGLKLD</b> RIGSY <b>SGLGC</b>	(SEQ ID NO: 158)
CNP-C17	GLSKG <b>CFGLKLD</b> RIGSC <b>SGLGC</b>	(SEQ ID NO: 159)
CNP-P17	GLSKG <b>CFGLKLD</b> RIGSP <b>SGLGC</b>	(SEQ ID NO: 160)
CNP-D17	GLSKG <b>CFGLKLD</b> RIGSD <b>SGLGC</b>	(SEQ ID NO: 161)
CNP37-X17	QEHPNARKYKGANKKGLSKG <b>CFGLKLD</b> RIGSX <b>SGLGC</b>	(SEQ ID NO: 162)
CNP37-F17	QEHPNARKYKGANKKGLSKG <b>CFGLKLD</b> RIGSF <b>SGLGC</b>	(SEQ ID NO: 163)
CNP37-L17	QEHPNARKYKGANKKGLSKG <b>CFGLKLD</b> RIGSL <b>SGLGC</b>	(SEQ ID NO: 164)
CNP37-I17	QEHPNARKYKGANKKGLSKG <b>CFGLKLD</b> RIGSI <b>SGLGC</b>	(SEQ ID NO: 165)
CNP37-T17	QEHPNARKYKGANKKGLSKG <b>CFGLKLD</b> RIGST <b>SGLGC</b>	(SEQ ID NO: 166)
CNP37-E17	QEHPNARKYKGANKKGLSKG <b>CFGLKLD</b> RIGSE <b>SGLGC</b>	(SEQ ID NO: 167)
CNP37-R17	QEHPNARKYKGANKKGLSKG <b>CFGLKLD</b> RIGSR <b>SGLGC</b>	(SEQ ID NO: 168)
CNP37-Y17	QEHPNARKYKGANKKGLSKG <b>CFGLKLD</b> RIGSY <b>SGLGC</b>	(SEQ ID NO: 169)
CNP37-C17	QEHPNARKYKGANKKGLSKG <b>CFGLKLD</b> RIGSC <b>SGLGC</b>	(SEQ ID NO: 170)
CNP37-P17	QEHPNARKYKGANKKGLSKG <b>CFGLKLD</b> RIGSP <b>SGLGC</b>	(SEQ ID NO: 171)
CNP37-D17	QEHPNARKYKGANKKGLSKG <b>CFGLKLD</b> RIGSD <b>SGLGC</b>	(SEQ ID NO: 172)

**FIG. 31A**  
**Additional CNP variants having Point Mutations at Position 17**

KA1-X17	<u>HGPQQEHPN</u> ARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 173)
KA2-X17	SGGGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 174)
KA3-X17	GGGHGPQGEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 175)
KA4-X17	GGSGGGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 176)
KA5-X17	SGGGSGGGSGGGKGANCKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 177)
KA6-X17	<u>HGPQQEHPN</u> ARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 178)
KA7-X17	GGSGGGSGGGSGGGKGANCKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 179)
KA8-X17	GGGHGPQGEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 180)
KB1-X17	<u>HKLRGQEHPN</u> ARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 181)
KB2-X17	GGGHKLRGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 182)
KB3-X17	<u>HKLRGSGGGSGGGKGANCKKGLSKGCFGLKLDRIGSXSLGC</u>	(SEQ ID NO: 183)
KB4-X17	<u>GGGHKLRGSGGGSGGGKGANCKKGLSKGCFGLKLDRIGSXSLGC</u>	(SEQ ID NO: 184)
PGCNP37-X17	PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 185)
KA1 (E6)-X17	EEEEEEHGPQQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 186)
KA2 (E6)-X17	EEEEEEHGPQQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 187)
KA3 (E6)-X17	EEEEEEGGGHGPQGEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 188)
KA4 (E6)-X17	EEEEEEGGSGGGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 189)
KA5 (E6)-X17	EEEEEEHGPQQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 190)
KA6 (E6)-X17	EEEEEEHGPQQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 191)
KA7 (E6)-X17	EEEEEEGGSGGGSGGGKGANCKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 192)
KA8 (E6)-X17	EEEEEEGGGHGPQGEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 193)
KB1 (E6)-X17	EEEEEEHGPQQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 194)
KB2 (E6)-X17	EEEEEEGGGHKLRGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 195)
KB3 (E6)-X17	EEEEEEHGPQQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 196)
KB4 (E6)-X17	EEEEEEGGGHKLRGSGGGSGGGKGANCKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 197)
E6PGCNP37-X17	EEEEEEHGPQQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 198)

FIG. 31B

## Additional CNP variants having Point Mutations at Position 17

C1 (E6) -X17	EEEEEESSGGGSGGGGGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 199)
C2 (E6) -X17	EEEEEEASTSPANPQPAASSPGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 200)
C3 (E6) -X17	EEEEEEPSAAPQPNAPSTSAGLSKGCFFGLKLDRIGSXSLGC	(SEQ ID NO: 201)
C4 (E6) -X17	EEEEEESSGGGSGGGKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 202)
C5 (E6) -X17	EEEEEESSGGGSGGGQGANQQGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 203)
C6 (E6) -X17	EEEEEESSGGGSGGGKGANQKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 204)
C7 (E6) -X17	EEEEEESSGGGSGGGKGANQKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 205)
C8 (E6) -X17	EEEEEESSGGGSGGGQGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 206)
C9 (E6) -X17	EEEEEESSGGGSGGGKGANQQGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 207)
C10 (E6) -X17	EEEEEESSGGGSGGGQGANQKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 208)
C11 (E6) -X17	EEEEEESSGGGSGGGQGANQKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 209)
D6CNP37-X17	DDDDDDQEHPNARKYKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 210)
C1 (D6) -X17	DDDDDDSSGGGSGGGGGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 211)
C2 (D6) -X17	DDDDDDASTSPANPQPAASSGGLSKGCFFGLKLDRIGSXSLGC	(SEQ ID NO: 212)
C3 (D6) -X17	DDDDDDGSSAAPQPNAPSTSAGLSKGCFFGLKLDRIGSXSLGC	(SEQ ID NO: 213)
C4 (D6) -X17	DDDDDDSSGGGSGGGKGANKKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 214)
C5 (D6) -X17	DDDDDDSSGGGSGGGQGANQQGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 215)
C6 (D6) -X17	DDDDDDSSGGGSGGGKGANQKGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 216)
D6-14AAlinker-CNP-X17	DDDDDDSSGGGSGGGGGLSKGCFGLKLDRIGSXSLGC	(SEQ ID NO: 217)
CNP-14AAlinker-D6-X17	GLSKGCFGLKLDRIGSXSLCGGGSGGGGGDDDD	(SEQ ID NO: 218)
CNP-Nterm1-X17	GSSAAPRPNAPSTSAGLSKGCFFGLKLDRIGSXSLGC	(SEQ ID NO: 219)
CNP-Nterm2-X17	ASTSPANPRPAASSGGLSKGCFFGLKLDRIGSXSLGC	(SEQ ID NO: 220)

**FIG. 32**  
**CNP variants having M17L**

KA1 (E6) -L17	EEEEEEHGPQGGQEHHPNARKYKGANKKKGLSKG <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 221)
KA2 (E6) -L17	EEEEEESSGGGGQEHHPNARKYKGANKKKGLSKG <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 222)
KA3 (E6) -L17	EEEEEEGGGGHGPQGGQEHHPNARKYKGANKKKGLSKG <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 223)
KA4 (E6) -L17	EEEEEEGGGGSGGGQEHHPNARKYKGANKKKGLSKG <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 224)
KA5 (E6) -L17	EEEEEESSGGGGSGGGSGGGGKGAN <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 225)
KA6 (E6) -L17	EEEEEEHGPQGGGGSGGGGKGAN <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 226)
KA7 (E6) -L17	EEEEEEGGGGSGGGSGGGGKGAN <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 227)
KA8 (E6) -L17	EEEEEEGGGGHGPQGGGGSGGGGKGAN <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 228)
KB1 (E6) -L17	EEEEEEHKLRGQEHHPNARKYKGANKKKGLSKG <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 229)
KB2 (E6) -L17	EEEEEEGGGCHKLRGQEHHPNARKYKGANKKKGLSKG <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 230)
KB3 (E6) -L17	EEEEEEHKLRGSGGGSGGGGKGAN <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 231)
KB4 (E6) -L17	EEEEEEGGGCHKLRGSGGGSGGGGKGAN <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 232)
E6PGCNP37-L17	EEEEEPGGQEHHPNARKYKGANKKKGLSKG <b>CFGLKLDRI</b> GSLSGLGC	(SEQ ID NO: 233)

**FIG. 33A**  
**NC2st-X17 and NC2B-X17 Protein Sequences**

NC2st-X17 (w/ sig. seq.)	<p> <b>MGVHECPAWLWLLLSLWPGAYAA</b><b>SWSH</b><b>PQFEQSGGGG</b><b>ENLYFQGGDKTHTCPPCPAPELLGGPSVFLFPP</b>  <b>PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK</b>  <b>EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN</b>  <b>YKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPGKGGGGGGGGGGGGGG</b>  <b>GLSKGCFGLKLDRIGSXSLGC</b> (SEQ ID NO: 527)                 </p>
NC2st-X17 (w/o sig. seq.)	<p> <b>ASW</b><b>SH</b><b>PQFEQSGGGG</b><b>ENLYFQGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH</b>  <b>DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ</b>  <b>PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSGSFFLYSKLTVDKS</b>  <b>RWQQGNVSCSVMHEALHNHYTQKSLSLSPGKGGGGGGGGGGGGGGGLSKGCFGLKLDRIGSXSLGC</b>                      (SEQ ID NO: 528)                 </p>
NC2B-X17 (w/sig. seq.)	<p> <b>MGVHECPAWLWLLLSLWPGAYADKTH</b><b>TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH</b>  <b>EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG</b>  <b>QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSGSFFLYSKLTVDK</b>  <b>SRWQQGNVSCSVMHEALHNHYTQKSLSLSPGKGGGGGGGGGGGGGGGLSKGCFGLKLDRIGSXSLGC</b>                      (SEQ ID NO: 529)                 </p>
NC2B-X17 (w/o sig. seq.)	<p> <b>DKTH</b><b>TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE</b>  <b>EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT</b>  <b>CLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQK</b>  <b>SLSLSPGKGGGGGGGGGGGGGGGLSKGCFGLKLDRIGSXSLGC</b> (SEQ ID NO: 530)                 </p>

NC2B-34-X17  
(w/o sig. seq.)

[illegible]

FIG. 33C  
NC2-X17 Variants

NC2-KGANKK-X17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFCSCVMHEALHNNHYTQKSLSPGKGGGSGGGSGKANKKGLSKGCFGLKLDRIGSXSLGCG  
(SEQ ID NO: 537)

NC2-KGANKK-X17  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNNHYTQK  
SLSPGKGGGSGGGSGKANKKGLSKGCFGLKLDRIGSXSLGCG (SEQ ID NO: 538)

NC2-KGANQK-X17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFCSCVMHEALHNNHYTQKSLSPGKGGGSGGGSGKANKKGLSKGCFGLKLDRIGSXSLGCG  
(SEQ ID NO: 539)

NC2-KGANQK-X17  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNNHYTQK  
SLSPGKGGGSGGGSGKANKKGLSKGCFGLKLDRIGSXSLGCG (SEQ ID NO: 540)

NC2-CNP53mut2-X17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFCSCVMHEALHNNHYTQKSLSPGKGGGDLQVDTQSQAAWAQLLQEHHPNAQQYKGANKKGLSKGC  
FGLKLDRIGSXSLGCG (SEQ ID NO: 541)

NC2-CNP53mut2-X17  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNNHYTQK  
SLSPGKGGGDLQVDTQSQAAWAQLLQEHHPNAQQYKGANKKGLSKGCFGLKLDRIGSXSLGCG (SEQ ID  
NO: 542)

FIG. 33D

Fc-CNP53-X17 Constructs

Fc-CNP53-X17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQOGNVFSCSVMHREALHNHYTQKSLSLSPGKGGGDLRVDITKSRAAWARLLQEHHPNARKYKGANKGLSKGC  
EGLKLDRIGSXSGLG (SEQ ID NO: 543)

Fc-CNP53-X17  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMHREALHNHYTQK  
SLSLSPGKGGGDLRVDITKSRAAWARLLQEHHPNARKYKGANKGLSKGCFGLKLDRIGSXSGLG (SEQ ID  
NO: 544)

Fc-CNP53-AA-X17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQOGNVFSCSVMHREALHNHYTQKSLSLSPGKGGGDLRVDITKSRAAWARLLQEHHPNARKYKGANAAGLSKGC  
EGLKLDRIGSXSGLG (SEQ ID NO: 545)

Fc-CNP53-AA-X17  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMHREALHNHYTQK  
SLSLSPGKGGGDLRVDITKSRAAWARLLQEHHPNARKYKGANAAGLSKGCFGLKLDRIGSXSGLG (SEQ ID  
NO: 546)

FIG. 33E

Constructs Having N-terminal NP-X17 fused to C-terminal Fc Domain

CNP-X17-16AAlinker-Fc-His <sub>10</sub> (NC1)	GLSKGCFGLKLDRIGSXSLGCGGGGGGGGGSGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQKSLSLSPGKGGENLYFQGSHHHHHHHHH (SEQ ID NO: 547)
CNP-X17-6AAlinker-Fc-His <sub>10</sub> (NC3)	GLSKGCFGLKLDRIGSXSLGCGGGGGSGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQKSLSLSPGKGGENLYFQGSHHHHHHHHH (SEQ ID NO: 548)
CNP-X17-6AAlinker-Fc	GLSKGCFGLKLDRIGSXSLGCGGGGGSGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 549)
CDNP-X17-Fc	GLSKGCFGLKLDRIGSXSLGCPSLRDRPNAPSTISADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 550)
CDNP-X17-saa-Fc	GLSKGCFGLKLDRIGSXSLGCPSSAARPNAPSTISADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 551)
CDNP-X17-sra-Fc	GLSKGCFGLKLDRIGSXSLGCPSSRAPRPNAPSTISADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 552)

# FIG. 34A NC2 Variants

NC2-KGANKK  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIIGMSGLGC  
(SEQ ID NO: 511)

NC2-KGANKK  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQK  
SLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIIGMSGLGC (SEQ ID NO: 512)

NC2-KGANQK  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIIGMSGLGC  
(SEQ ID NO: 513)

NC2-KGANQK  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQK  
SLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIIGMSGLGC (SEQ ID NO: 514)

NC2-CNP53mut2  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGDLQVDTQSQAAWAQLLQEHHPNAQQYKGANKKGLSKGC  
FGLKLDRIIGMSGLGC (SEQ ID NO: 515)

NC2-CNP53mut2  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQK  
SLSLSPGKGGGDLQVDTQSQAAWAQLLQEHHPNAQQYKGANKKGLSKGCFGLKLDRIIGMSGLGC (SEQ ID  
NO: 516)

FIG. 34B  
D10-NC2 Variants

D10-NC2-KGANKK  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDKTHTCPPCPAPELLGSPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVSCSVMHEALHNYHTQKSLSLSPGKGGGGGGGSKGANKKGLSKGCFGLKLDRI  
GSMGSLGC (SEQ ID NO: 553)

D10-NC2-KGANKK  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGSPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMH  
EALHNYHTQKSLSLSPGKGGGGGGGSKGANKKGLSKGCFGLKLDRI GMSMGLGC (SEQ ID NO: 554)

D10-NC2-KGANQK  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDKTHTCPPCPAPELLGSPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVSCSVMHEALHNYHTQKSLSLSPGKGGGGGGGSKGANQKGLSKGCFGLKLDRI  
GSMGSLGC (SEQ ID NO: 555)

D10-NC2-KGANQK  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGSPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMH  
EALHNYHTQKSLSLSPGKGGGGGGGSKGANQKGLSKGCFGLKLDRI GMSMGLGC (SEQ ID NO: 556)

D10-NC2-CNP53mut2  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDKTHTCPPCPAPELLGSPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVSCSVMHEALHNYHTQKSLSLSPGKGGDDLQVDTQSQAAWAQLLEHPNAQQYKQ  
ANKKGLSKGCFGLKLDRI GMSMGLGC (SEQ ID NO: 557)

D10-NC2-CNP53mut2  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGSPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMH  
EALHNYHTQKSLSLSPGKGGDDLQVDTQSQAAWAQLLEHPNAQQYKGANQKGLSKGCFGLKLDRI GMSMGLG  
C (SEQ ID NO: 558)

FIG. 34C  
NC2-F17 Variants

NC2-KGANKK-F17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADKTHTCPAPELLGGPSVFLFPPKPCDTLMSRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTSISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGSGFFLYSKLTVDK  
SRWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIGSFSGLGC  
(SEQ ID NO: 559)

NC2-KGANKK-F17  
(w/o sig. seq.)

DKTHTCPAPELLGGPSVFLFPPKPCDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTSISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGSGFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQK  
SLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIGSFSGLGC (SEQ ID NO: 560)

NC2-KGANQK-F17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADKTHTCPAPELLGGPSVFLFPPKPCDTLMSRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTSISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGSGFFLYSKLTVDK  
SRWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIGSFSGLGC  
(SEQ ID NO: 561)

NC2-KGANQK-F17  
(w/o sig. seq.)

DKTHTCPAPELLGGPSVFLFPPKPCDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTSISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGSGFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQK  
SLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIGSFSGLGC (SEQ ID NO: 562)

NC2-CNP53mut2-F17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADKTHTCPAPELLGGPSVFLFPPKPCDTLMSRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTSISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGSGFFLYSKLTVDK  
SRWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGDLQVDTQSQAAWAQLLQEHPNAQQYKGANKKGLSKG  
CFGLKLDRIGSFSGLGC (SEQ ID NO: 563)

NC2-CNP53mut2-F17  
(w/o sig. seq.)

DKTHTCPAPELLGGPSVFLFPPKPCDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTSISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGSGFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQK  
SLSLSPGKGGGDLQVDTQSQAAWAQLLQEHPNAQQYKGANKKGLSKGCFGLKLDRIGSFSGLGC (SEQ ID  
NO: 564)

**FIG. 34D**  
**D10-NC2-F17 Variants**

D10-NC2-KGANKK-F17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCFGLKLDRI  
GSFSGLG (SEQ ID NO: 565)

D10-NC2-KGANKK-F17  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMH  
EALHNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCFGLKLDRI (SEQ ID NO: 566)

D10-NC2-KGANQK-F17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCFGLKLDRI  
GSFSGLG (SEQ ID NO: 567)

D10-NC2-KGANQK-F17  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMH  
EALHNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCFGLKLDRI (SEQ ID NO: 568)

D10-NC2-CNP53mut2-F17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPGKGGDDLQVDTQSQAAWAQLLEHPNAQQYK  
ANKKGLSKGCFGLKLDRI (SEQ ID NO: 569)

D10-NC2-CNP53mut2-F17  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMH  
EALHNHYTQKSLSLSPGKGGDDLQVDTQSQAAWAQLLEHPNAQQYKANGKGLSKGCFGLKLDRI (SEQ ID NO: 570)

FIG. 34E  
NC2-L17 Variants

NC2-KGANKK-L17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCGFLKLDRIGSLSGLGC  
(SEQ ID NO: 571)

NC2-KGANKK-L17  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQK  
SLSLSPGKGGGGGGGSGKANGKGLSKGCGFLKLDRIGSLSGLGC (SEQ ID NO: 572)

NC2-KGANQK-L17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCGFLKLDRIGSLSGLGC  
(SEQ ID NO: 573)

NC2-KGANQK-L17  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQK  
SLSLSPGKGGGGGGGSGKANGKGLSKGCGFLKLDRIGSLSGLGC (SEQ ID NO: 574)

NC2-CNP53mut2-L17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGDLQVDTSQAAWAQLLEHPNAQQYKGANKKGLSKGCGFLKLDRIGSLSGLGC  
(SEQ ID NO: 575)

NC2-CNP53mut2-L17  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQK  
SLSLSPGKGGGDLQVDTSQAAWAQLLEHPNAQQYKGANKKGLSKGCGFLKLDRIGSLSGLGC (SEQ ID  
NO: 576)

**FIG. 34F**  
**D10-NC2-L17 Variants**

D10-NC2-KGANKK-L17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVFCSCVMHEALHNNHYTEQKSLSPGKGGGGGGGSGKGGKGLSKGCFGLKLDRI  
GSLSLGLGC (SEQ ID NO: 577)

D10-NC2-KGANKK-L17  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMH  
EALHNNHYTEQKSLSPGKGGGGGGGSGKGGKGLSKGCFGLKLDRI GSLSLGLGC (SEQ ID NO: 578)

D10-NC2-KGANQK-L17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVFCSCVMHEALHNNHYTEQKSLSPGKGGGGGGGSGKGGKGLSKGCFGLKLDRI  
GSLSLGLGC (SEQ ID NO: 579)

D10-NC2-KGANQK-L17  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMH  
EALHNNHYTEQKSLSPGKGGGGGGGSGKGGKGLSKGCFGLKLDRI GSLSLGLGC (SEQ ID NO: 580)

D10-NC2-CNP53mut2-L17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVFCSCVMHEALHNNHYTEQKSLSPGKGGGDLQVDTQSAAWAQLLEHPNAQQYK  
ANKKGLSKGCFGLKLDRI GSLSLGLGC (SEQ ID NO: 581)

D10-NC2-CNP53mut2-L17  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMH  
EALHNNHYTEQKSLSPGKGGGDLQVDTQSAAWAQLLEHPNAQQYKGGKGLSKGCFGLKLDRI GSLSLGLG  
C (SEQ ID NO: 582)

FIG. 34G  
NC2-R17 Variants

NC2-KGANKK-R17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIIGRSGLGC  
(SEQ ID NO: 583)

NC2-KGANKK-R17  
(w/o sig. seq.)

DKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQK  
SLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIIGRSGLGC (SEQ ID NO: 584)

NC2-KGANQK-R17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIIGRSGLGC  
(SEQ ID NO: 585)

NC2-KGANQK-R17  
(w/o sig. seq.)

DKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQK  
SLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIIGRSGLGC (SEQ ID NO: 586)

NC2-CNP53mut2-R17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPGAYADKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFSCSVMEALHNHYTQKSLSLSPGKGGGDLQVDTQSQAAWAQLLEHPNAQQYKGANKKGLSKG  
FGLKLDRIIGRSGLGC (SEQ ID NO: 587)

NC2-CNP53mut2-R17  
(w/o sig. seq.)

DKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQK  
SLSLSPGKGGGDLQVDTQSQAAWAQLLEHPNAQQYKGANKKGLSKGCFGLKLDRIIGRSGLGC (SEQ ID  
NO: 588)

# FIG. 34H D10-NC2-R17 Variants

D10-NC2-KGANKK-R17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVFCSCVMHEALHNNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCFGLKLDRI  
GSRSLGCG (SEQ ID NO: 589)

D10-NC2-KGANKK-R17  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMH  
EALHNNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCFGLKLDRI GSRSLGCG (SEQ ID NO: 590)

D10-NC2-KGANQK-R17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVFCSCVMHEALHNNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCFGLKLDRI  
GSRSLGCG (SEQ ID NO: 591)

D10-NC2-KGANQK-R17  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMH  
EALHNNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCFGLKLDRI GSRSLGCG (SEQ ID NO: 592)

D10-NC2-CNP53mut2-R17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVFCSCVMHEALHNNHYTQKSLSLSPGKGGDDLQVDIQSQAAWAQLLEHPNAQQYK  
ANKKGLSKGCFGLKLDRI GSRSLGCG (SEQ ID NO: 593)

D10-NC2-CNP53mut2-R17  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMH  
EALHNNHYTQKSLSLSPGKGGDDLQVDIQSQAAWAQLLEHPNAQQYKANGKGLSKGCFGLKLDRI GSRSLG  
C (SEQ ID NO: 594)

**FIG. 34I**  
**NC2-Y17 Variants**

NC2-KGANKK-Y17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIQSYSLGCG  
(SEQ ID NO: 595)

NC2-KGANKK-Y17  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQGNVFSCSVMHEALHNHYTQK  
SLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIQSYSLGCG (SEQ ID NO: 596)

NC2-KGANQK-Y17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIQSYSLGCG  
(SEQ ID NO: 597)

NC2-KGANQK-Y17  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQGNVFSCSVMHEALHNHYTQK  
SLSLSPGKGGGGSGGSGKANKKGLSKGCFGLKLDRIQSYSLGCG (SEQ ID NO: 598)

NC2-CNP53mut2-Y17  
(w/sig. seq.)

MGVHECPAWLWLLLSLLSLWPAYADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH  
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKG  
QPREPQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK  
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGDLQVDTQSQAAWAQLLQEHHPNAQQYKGANKKGLSKG  
FGLKLDRIQSYSLGCG (SEQ ID NO: 599)

NC2-CNP53mut2-Y17  
(w/o sig. seq.)

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE  
EQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSREEMTKNQVSLT  
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQGNVFSCSVMHEALHNHYTQK  
SLSLSPGKGGGDLQVDTQSQAAWAQLLQEHHPNAQQYKGANKKGLSKGCFGLKLDRIQSYSLGCG (SEQ ID  
NO: 600)

**FIG. 34J**  
**D10-NC2-Y17 Variants**

D10-NC2-KGANKK-Y17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVSCSVMHEALHNNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCFGLKLDRI  
GSYSGLG (SEQ ID NO: 601)

D10-NC2-KGANKK-Y17  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMH  
EALHNNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCFGLKLDRI (SEQ ID NO: 602)

D10-NC2-KGANQK-Y17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVSCSVMHEALHNNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCFGLKLDRI  
GSYSGLG (SEQ ID NO: 603)

D10-NC2-KGANQK-Y17  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMH  
EALHNNHYTQKSLSLSPGKGGGGGGGSGKANGKGLSKGCFGLKLDRI (SEQ ID NO: 604)

D10-NC2-CNP53mut2-Y17  
(w/sig. seq.)

MGVHECPAWLWLLLSLSLWPGAYADDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE  
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP  
IEKTIISKAKGQPRPEQVYITLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF  
FLYSKLTVDKSRWQQGNVSCSVMHEALHNNHYTQKSLSLSPGKGGDDLQVDTQSQAAWAQQLLEHPNAQQYK  
ANKKGLSKGCFGLKLDRI (SEQ ID NO: 605)

D10-NC2-CNP53mut2-Y17  
(w/o sig. seq.)

DDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTIISKAKGQPRPEQVYITLPPSRE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMH  
EALHNNHYTQKSLSLSPGKGGDDLQVDTQSQAAWAQQLLEHPNAQQYKANGKGLSKGCFGLKLDRI (SEQ ID NO: 606)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 12/39004

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 39/00; A61K 38/00; A61P 13/06; C12N 9/16 (2012.01)

USPC - 424/134.1; 514/12.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
USPC: 424/134.1; 514/12.1Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
USPC: 435/196; 424/134.1; 514/12.1  
(keyword limited; terms below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PubWEST (PGPB,USPT,USOC,EPAB,JPAB); Google; PubMed

Search terms: alkaline phosphatase, ALP, sALP, TNALP, neurocutaneous, neurofibromatosis, extracellular, bone, skeletal, mineralization, natriuretic peptide, NPR-B, SEQ ID NOs:1204, 1216, 1205, 572

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2010/0184680 A1 (BEVEC) 22 July 2010 (22.07.2010) para [0007], [0116], [0141]-[0142], [0201]	25
---		---
A		26
Y	US 2010/0297119 A1 (CRINE et al.) 25 November 2010 (25.11.2010) para [0040], [0064], [0089], [0117], [0163], [0176]; SEQ ID NOs:4-6	1-5
Y	RAMACHANDRAN et al. Treatment of an anabolic bone deficiency in neurofibromatosis with bone morphogenetic proteins and its potential application for congenital pseudoarthrosis of the tibia. J. Bone Joint Surg. Br. (2009), Vol. 91-B, No. Supp. I, abstract 137; entire abstract	1-5
A	US 7,803,769 B2 (SULLIVAN et al.) 28 September 2010 (28.09.2010) SEQ ID NO:83	26

☐ Further documents are listed in the continuation of Box C.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

24 October 2012 (24.10.2012)

Date of mailing of the international search report

02 NOV 2012

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300  
PCT OSP: 571-272-7774

Continuation of Box III - observations where unity of invention is lacking:

Group II+: claims 25-31 and 37, drawn to a method of treating a neurocutaneous syndrome in a subject, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising:

(a) a polypeptide comprising the structure V-NP-W; and

(b) a pharmaceutically acceptable excipient,

wherein NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), V is absent or is an amino acid sequence of at least one amino acid, and W is absent or is an amino acid sequence of at least one amino acid, thereby treating said syndrome in said subject. The first invention is restricted to SEQ ID NO: 504 (Claims 25 and 26). Should an additional fee(s) be paid, Applicant is invited to elect an additional sequence(s) to be searched. The exact claims searched will depend on Applicant's election.

Group III: claims 83-86 and 118-123, drawn to a composition comprising a first polypeptide and a second polypeptide, wherein

a) said first polypeptide comprises the structure A-sALP-B, wherein

i) sALP is the extracellular domain of an alkaline phosphatase,

ii) A is absent or is an amino acid sequence of at least one amino acid, and

iii) B is absent or is an amino acid sequence of at least one amino acid; and

b) said second polypeptide comprises the structure V-NP-W, wherein

i) NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B),

ii) V is absent or is an amino acid sequence of at least one amino acid, and

iii) W is absent or is an amino acid sequence of at least one amino acid.

The inventions listed as Groups I through III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions of Groups I-II+ do not include the inventive concept of a composition comprising a first polypeptide A-sALP-B and a second polypeptide V-NP-W, as required by Group III.

The inventions of Group I do not include the inventive concept of a polypeptide comprising the structure V-NP-W, as required by Group II+.

The inventions of Group II+ do not include the inventive concept of a polypeptide comprising the structure A-sALP-B, as required by Group I.

The inventions of Groups I and II+ share the technical feature of a method of treating a neurocutaneous syndrome in a subject, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a therapeutic polypeptide. However, this shared technical feature does not represent a contribution over prior art as being anticipated by US 2010/0184680 A1 (Bevec). Bevec discloses Claim 25, a method of treating a neurocutaneous syndrome in a subject (para [0141], neurocutaneous melanosis), said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition (para [0201]) comprising:

(a) a polypeptide comprising the structure V-NP-W; wherein NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), V is absent and W is absent (para [0007]), and

(b) a pharmaceutically acceptable excipient (para [0142]), thereby treating said syndrome in said subject (para [0116]). As said composition was known in the art at the time of the invention, this cannot be considered a special technical feature that would otherwise unify the groups.

The inventions of Groups I and III share the technical feature of a polypeptide comprises the structure A-sALP-B, wherein i) sALP is the extracellular domain of an alkaline phosphatase, ii) A is absent or is an amino acid sequence of at least one amino acid, and iii) B is absent or is an amino acid sequence of at least one amino acid. However, this shared technical feature does not represent a contribution over prior art as being anticipated by US 2010/0297119 A1 to Crine et al. (hereafter 'Crine'). Crine teaches a polypeptide comprises the structure A-sALP-B, wherein i) sALP is the extracellular domain of an alkaline phosphatase, ii) A is absent, and iii) B is an amino acid sequence of at least one amino acid (Fig. 1C, hsTNALP-FcD10 w/o signal peptide). As said composition was known in the art at the time of the invention, this cannot be considered a special technical feature that would otherwise unify the groups.

The inventions of Groups II+ and III share the technical feature of a polypeptide comprises the structure V-NP-W, wherein i) NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), ii) V is absent or is an amino acid sequence of at least one amino acid, and iii) W is absent or is an amino acid sequence of at least one amino acid. However, this shared technical feature does not represent a contribution over prior art as being anticipated by Bevec. Bevec discloses a polypeptide comprising the structure V-NP-W; wherein NP is a natriuretic peptide that is an agonist of natriuretic peptide receptor B (NPR-B), V is absent and W is absent (para [0007]). As said composition was known in the art at the time of the invention, this cannot be considered a special technical feature that would otherwise unify the groups.

Groups I through III therefore lack unity under PCT Rule 13 because they do not share a same or corresponding special technical feature.